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PREFACE
The findings of the World Drug Report 2013 deliver 
important lessons for the forthcoming high-level review 
of the commitments that countries reaffirmed in 2009 on 
the measures for drug control. These measures are laid out 
in the Political Declaration and Plan of Action on 
International Cooperation towards an Integrated and 
Balanced Strategy to Counter the World Drug Problem. 
At the global level, there has been an increase in the 
production and misuse of new psychoactive substances, 
that is, substances that are not under international control. 
The manufacture and use of substances that are under 
international control remain largely stable as compared 
with 2009, although trends in drug supply and demand 
have been unequal across regions and countries and across 
drug types. Member States that are party to the three 
international drug control Conventions, which were 
adopted to protect the health and welfare of mankind, 
remain committed to the drug control system. Evidence 
shows that while the system may not have eliminated the 
drug problem, it continues to ensure that it does not 
escalate to unmanageable proportions. 
We have to admit that, globally, the demand for drugs has 
not been substantially reduced and that some challenges 
exist in the implementation of the drug control system, in 
the violence generated by trafficking in illicit drugs, in the 
fast evolving nature of new psychoactive substances, and 
in those national legislative measures which may result in 
a violation of human rights. The real issue is not to amend 
the Conventions, but to implement them according to 
their underlying spirit. 
While intensified competition in trafficking in cocaine has 
led to growing levels of violence in Central America, the 
problem will not be resolved if drugs are legalized. 
Organized crime is highly adaptive. It will simply move to 
other businesses that are equally profitable and violent.
Countering the drug problem in full compliance with 
human rights standards requires an emphasis on the 
underlying spirit of the existing drug Conventions, which 
is about health. Advocacy for a stronger health perspective 
and an interconnected re-balancing of drug control efforts 
must take place. As experience has shown, neither supply 
reduction nor demand reduction on their own are able to 
solve the problem. For this reason, a more balanced 
approach in dealing with the drug problem is a necessity. 
This includes more serious efforts on prevention and 
treatment, not only in terms of political statements, but 
also in terms of funds dedicated for these purposes.
This year’s World Drug Report shows the extent of the 
problem associated with new psychoactive substances and 
the deadly impact they can have on their users. The issue 
of new psychoactive substances is one that the international 
community will review at the high-level session of the 
Commission on Narcotic Drugs in 2014. As is the case 
with traditional drugs, international action against these 
substances must focus on addressing both supply and 
demand. The paucity of knowledge on the adverse impacts 
and risks to public health and safety, coupled with the fact 
that new psychoactive substances are not under 
international control, underscores the importance of 
innovative prevention measures and sharing of good 
practices between countries.
The multitude of new psychoactive substances and the 
speed with which they have emerged in all regions of the 
world is one of the most notable trends in drug markets 
over the past five years. While the existing international 
control system is equipped to deal with the emergence of 
new substances that pose a threat to public health, it is 
currently required to provide a response commensurate 
with the unprecedented fast evolving nature of the 
phenomenon of new psychoactive substances. Some 
countries have adopted innovative approaches to curb the 
rise of these substances, but the global nature of the 
problem requires a response based on international 
cooperation and universal coverage. Such a response should 
make use of all the relevant provisions of the existing 
international drug Conventions. In addition, in 
strengthening the international control system, a systematic 
evaluation of the appropriateness of some of the innovative 
approaches at the national level should be encouraged. 
The detection and identification of emerging substances 
is a fundamental step in assessing the potential health risks 
of new psychoactive substances and, as such, scientific, 
epidemiological, forensic and toxicological information on 
these substances needs to be collected, updated and 
disseminated. As requested by the Commission on Narcotic 
Drugs in its resolution 56/4 on enhancing international 
cooperation in the identification and reporting of new 
psychoactive substances, the United Nations Office on 
Drugs and Crime (UNODC) is ready to assist the 
international community by building a global early 
warning mechanism that will provide Governments with 
the necessary information on new psychoactive substances, 
particularly scientific data that are essential in the 
development and implementation of evidence-based 
responses. 
As we approach 2014 and the withdrawal of international 
forces from Afghanistan, that country requires concerted 
efforts on the part of the international community. The 
United Nations, and particularly UNODC, will need to 
provide far greater assistance to bring counter-narcotic 
programmes into the mainstream of social and economic 
development strategies so as to successfully curb the current 
cultivation and production of opium and the worrying 
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high use of opiates among the Afghan population. 
UNODC is working to achieve this through its country 
programme, one of its largest in the world, as well as its 
integrated regional programme for Afghanistan and 
neighbouring countries. 
The trends in new emerging routes for trafficking of drugs 
and in the production of illicit substances indicate that the 
continent of Africa is increasingly becoming vulnerable to 
the drug trade and organized crime, although data from 
the African region is scarce. While this may further fuel 
political and economic instability in many countries in the 
region, it can also lead to an increase in the local availability 
and consumption of illicit substances. This, therefore, 
requires the international community to invest in evidence-
informed interventions for the prevention of drug use, the 
treatment of drug dependence, the successful interdiction 
of illicit substances and the suppression of organized crime. 
The international community also needs to make the 
necessary resources available to monitor the drug situation 
in Africa.
Regarding people who inject drugs and who live with HIV, 
the World Drug Report 2013 shows that there have been 
some improvements. Those countries which implemented 
a comprehensive set of HIV interventions were able to 
achieve a reduction in high-risk behaviours and in the 
transmission of HIV and other blood-borne infections. 
This holds the promise that countries can achieve the 
targets set out in the 2009 Political Declaration and Plan 
of Action by implementing and expanding prevention and 
treatment services for people who inject drugs. However, 
there is still an immense task ahead to achieve the 
commitment made by the General Assembly in the 2011 
Political Declaration on HIV and AIDS: Intensifying Our 
Efforts to Eliminate HIV and AIDS, which sets out the 
target of reducing new HIV infections by 50 per cent 
among people who inject drugs. This warrants significant 
scaling up of evidence-based HIV interventions in countries 
where the epidemic is driven by injecting drug use.
Illicit drugs continue to jeopardize the health and welfare 
of people throughout the world. They represent a clear 
threat to the stability and security of entire regions and to 
economic and social development. In so many ways, illicit 
drugs, crime and development are bound to each other. 
Drug dependence is often exacerbated by low social and 
economic development, and drug trafficking, along with 
many other forms of transnational organized crime, 
undermines human development. We must break this 
destructive cycle in order to protect the right of people to 
a healthy way of life and to promote sustainable economic 
growth and greater security and stability. It is, therefore, 
important that drugs are addressed when developing the 
post-2015 development agenda.
Yury Fedotov
Executive Director
United Nations Office on Drugs and Crime
vW
O
R
L
D
 D
R
U
G
 R
E
P
O
R
T
 2
01
3
CONTENTS
PREFACE     iii 
EXPLANATORY NOTES  vii 
EXECUTIVE SUMMARY  ix
1. RECENT STATISTICS AND TREND ANALYSIS OF ILLICIT DRUG MARKETS
A. Extent of illicit drug use and health consequences  1
B. Overview of trends related to drug supply indicators, by drug type and region 17
C. Cannabis market  24
D. Illicit opiate market  30
E. Cocaine market  37
F. The market for amphetamine-type stimulants 49 
G. Conclusion   57
2. NEW PSYCHOACTIVE SUBSTANCES
A. Introduction   59
B. New psychoactive  substances: concepts and definitions  60
C. The recent emergence and spread of new psychoactive substances 67
D. Conclusions and future course of action 113 
ANNEX I     i
Maps and tables on drug demand
ANNEX II     vii
Maps and tables on drug supply
ANNEX III
Regional groupings   xv
GLOSSARY     xvii
Editorial and production team
The World Drug Report 2013 was produced under the supervision of 
Sandeep Chawla, UNODC Deputy Executive Director and Director, 
Division for Policy Analysis and Public Affairs 
Core team
Research and Trend Analysis Branch
Angela Me, Suzanne Kunnen, Kristina Kuttnig and Jaya Mohan. 
Laboratory and Scientific Section
Justice Tettey, Beate Hammond, Sabrina Levissianos and Kristal Pineros.
Statistics and Surveys Section
Coen Bussink, Philip Davis, Yuliya Lyamzina, Kamran Niaz, Preethi Perera,
Umidjon Rahmonberdiev, Martin Raithelhuber, Ali Saadeddin, Janie Shelton
Antoine Vella and Irmgard Zeiler.
Studies and Threat Analysis Section
Anja Korenblik and Thomas Pietschmann.
The report also benefited from the work and expertise of many other 
UNODC staff members in Vienna and around the world.
vii
W
O
R
L
D
 D
R
U
G
 R
E
P
O
R
T
 2
01
3
EXPLANATORY NOTES
The following abbreviations have been used in this Report:
AIDS acquired immunodeficiency syndrome
ATS amphetamine-type stimulant
BZP N-benzylpiperazine
CICAD Inter-American Drug Abuse Control 
Commission (Organization of Ameri-
can States)
mCPP m-chlorophenylpiperazine
DEA Drug Enforcement Administration 
(United States of America)
EMCDDA European Monitoring Centre for Drugs 
and Drug Addiction
Europol European Police Office
GDP gross domestic product
ha hectare
HIV human immunodeficiency virus
INTERPOL International Criminal Police 
Organization
LSD lysergic acid diethylamide
MDA methylenedioxyamphetamine
MDE methylenedioxyethylamphetamine
MDMA methylenedioxymethamphetamine
3,4-MDP-2-P 3,4-methylenedioxyphenyl-2-pro-
panone
MDPV methylenedioxypyrovalerone
4-MMC 4-methylmethcathinone
NPS new psychoactive substance
P-2-P 1-phenyl-2-propanone
PMK piperonyl methyl ketone
THC tetrahydrocannabinol
WHO World Health Organization
The boundaries and names shown and the designations 
used on maps do not imply official endorsement or accept-
ance by the United Nations. A dotted line represents 
approximately the line of control in Jammu and Kashmir 
agreed upon by India and Pakistan. The final status of 
Jammu and Kashmir has not yet been agreed upon by the 
parties. Disputed boundaries (China/India) are represented 
by cross hatch due to the difficulty of showing sufficient 
detail. 
The designations employed and the presentation of the 
material in this publication do not imply the expression 
of any opinion whatsoever on the part of the Secretariat 
of the United Nations concerning the legal status of any 
country, territory, city or area or of its authorities, or con-
cerning the delimitation of its frontiers or boundaries.
Countries and areas are referred to by the names that were 
in official use at the time the relevant data were collected.
All references to Kosovo in the present publication should 
be understood to be in compliance with Security Council 
resolution 1244 (1999).
Since there is some scientific and legal ambiguity about 
the distinctions between “drug use”, “drug misuse” and 
“drug abuse”, the neutral terms “drug use” and “drug con-
sumption” are used in this report.
The data on population used in this report are from: 
United Nations, Department of Economic and Social 
Affairs, Population Division, World Population Prospects: 
The 2010 Revision. Available from http://esa.un.org/wpp.
References to dollars ($) are to United States dollars, unless 
otherwise stated.
References to “tons” are to metric tons, unless otherwise 
stated.
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The World Drug Report presents a comprehensive over-
view of the latest developments in drug markets. It covers 
production, trafficking, consumption and related health 
consequences. Chapter 1 of this year’s report examines the 
global situation and the latest trends in the different drug 
markets and the extent of illicit drug use, as well as the 
related health impact.
Chapter 2 addresses the phenomenon of new psychoactive 
substances (NPS), which can have deadly consequences 
for their users but are hard to control, with dynamic, fast-
mutating producers and “product lines” which have 
emerged over the past decade.
The global picture
Global drug use situation remains stable
On the whole, the global drug use situation has remained 
stable. While there has been some increase in the estimated 
total number of users of any illicit substance, estimates 
show that the number of drug users with dependence or 
drug use disorders has remained stable. The increase in the 
annually estimated number of users is, to a large extent, a 
reflection of an increase in the world population. 
However, polydrug use, especially the combination of pre-
scription drugs and illicit substances, continues to be a 
concern. The misuse of sedatives and tranquillizers is of 
particular concern, with more than 60 per cent of the 
countries covered in the report ranking such substances as 
among the first three misused types of substances. 
The increasing number of NPS appearing on the market 
has also become a major public health concern, not only 
because of increasing use but also because of the lack of 
scientific research and understanding of their adverse 
effects.
Injecting drug use and HIV remain a 
public health concern
New data reveal that the prevalence of people who inject 
drugs and those who inject drugs and are also living with 
HIV in 2011 was lower than previously estimated: 14.0 
million people between the ages of 15 and 64 are estimated 
to be injecting drugs, while 1.6 million people who inject 
drugs are living with HIV. This reflects a 12 per cent 
decline in the number of people who inject drugs and a 
46 per cent decline in the number of people who inject 
drugs that are living with HIV since the 2008 estimates. 
In 2011, the number of drug-related deaths was estimated 
at 211,000. Most of those deaths were among the younger 
population of users and were, to a large extent, preventable. 
Opioids remained the most commonly reported group of 
substances involved in drug-related deaths. There contin-
ues to be a major gap in the delivery of treatment services 
for drug dependence: only an estimated one in six problem 
drug users had received treatment in the preceding year.
Maritime trafficking poses challenge  
to authorities 
Given the large quantities of licit substances that make 
their way across oceans and continents every day, in con-
tainers and even small boats, maritime trafficking poses a 
particularly knotty challenge for the authorities. 
East and West Africa seem to be gaining in prominence 
with regard to routes for maritime trafficking. A new mari-
time route going southwards from Afghanistan via ports 
in the Islamic Republic of Iran or Pakistan is increasingly 
being used by traffickers to reach consumer markets 
through East and West African ports. Since 2009, seizures 
of heroin have risen sharply in Africa, especially in East 
Africa, where they increased almost 10-fold. 
Experience has shown that a maritime seizure is consist-
ently more likely to be larger than a seizure involving trans-
port by road or rail. In fact, although maritime seizures 
constitute no more than 11 per cent of all cases across all 
drug categories globally, each maritime seizure was on aver-
age almost 30 times larger than seized consignments traf-
ficked by air. Targeted interdiction efforts by the authorities 
would enable them to seize larger quantities of drugs being 
trafficked over water.
New drug trafficking routes
Traffickers are increasingly looking for new routes to sup-
plement the old ones: new land routes for heroin smuggling 
seem to be emerging, e.g. in addition to the established 
Balkan and northern routes, heroin is trafficked southward 
from Afghanistan via the Islamic Republic of Iran or Paki-
stan,  leading through the Middle East via Iraq. While the 
Balkan trafficking route remains the most popular one, a 
decrease in the amount of heroin being trafficked on this 
route has been noted.
Moreover, Afghan opiates seem to be emerging as compe-
tition to opiates produced and consumed in the East and 
South-East Asia subregion, as seizures made in countries 
of that region show.
While it is clear that the African continent is becoming 
increasingly important and vulnerable in terms of the pro-
liferation of trafficking routes, the availability of data is 
very limited. In order to effectively monitor this worrying 
trend, there is an urgent need to improve the data collec-
tion and analysis capacity of countries in the region.
Cocaine seizures in Colombia indicate that the Atlantic 
route may be gaining in prominence as compared with the 
Pacific route in maritime trafficking; linguistic ties appear 
to play a role in cocaine trafficking from South America 
EXECUTIVE SUMMARY
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to Europe via Brazil, Portugal and lusophone countries in 
Africa. The cocaine market seems to be expanding towards 
the emerging economies in Asia.
Overall trends across drug categories
Opiates
Trends with regard to the production and consumption of 
opiates witnessed some major shifts. 
The limited available data suggest that opioid use (prescrip-
tion opioids, heroin and opium) has gone up in parts of 
Asia (East and South-East Asia, as well as Central and West 
Asia) and Africa since 2009. 
Use of opiates (heroin and opium), on the other hand, 
remains stable (around 16.5 million people, or 0.4 per cent 
of the population aged 15-64), although a high prevalence 
for opiate use has been reported from South-West and 
Central Asia, Eastern and South-Eastern Europe and North 
America. 
In Europe specifically, there are indications that heroin use 
is declining, due to a number of factors, including an aging 
user population in treatment and increased interdiction of 
supply. Nevertheless, non-medical use of prescription opi-
oids continues to be reported from some parts of Europe.
Production-wise, Afghanistan retained its position as the 
lead producer and cultivator of opium globally (74 per 
cent of global illicit opium production in 2012). While 
the global area under poppy cultivation rose by 15 per cent 
in 2012, driven largely by increases in Afghanistan and 
Myanmar, global opium production fell by almost 30 per 
cent, to less than 5,000 tons in 2012, mainly as a result of 
poor yields in Afghanistan. Mexico remained the largest 
producer of opium in the Americas. 
It appears that opium production in the Lao People’s Dem-
ocratic Republic and Myanmar may not be able to meet 
the demand posed by the increasing number of heroin 
users in some parts of Asia. 
While seizures of morphine and heroin increased globally 
in 2011, declines were noted in specific regions and coun-
tries, including Turkey and Western and Central Europe.
Cocaine
The global area under coca cultivation amounted to 
155,600 ha in 2011, almost unchanged from a year earlier 
but 14 per cent lower than in 2007 and 30 per cent less 
than in 2000. Estimates of the amounts of cocaine manu-
factured, expressed in quantities of 100 per cent pure 
cocaine, ranged from 776 to 1,051 tons in 2011, largely 
unchanged from a year earlier. The world’s largest cocaine 
seizures (not adjusted for purity) continue to be reported 
from Colombia (200 tons) and the United States (94 tons). 
However, there has been an indication in recent years that 
the cocaine market has been shifting to several regions 
which have not been associated previously with either traf-
ficking or use. Significant increases have been noted in Asia, 
Oceania and Central and South America and the Carib-
bean. In Central America, intensified competition in traf-
ficking of cocaine has led to growing levels of violence.
Cocaine has long been perceived as a drug for the affluent. 
There is some evidence which, though inconclusive, 
suggests that this perception may not be entirely ground-
less, all other factors being equal. Nonetheless, the extent 
of its use is not always led by the wallet. There are examples 
of wealthy countries with low prevalence rates, and 
vice-versa.
Arguably, parts of East and South-East Asia run a higher 
risk of expansion of cocaine use (although from very low 
levels). Seizures in Hong Kong, China, rose dramatically, 
to almost 600 kg in 2010, and had exceeded 800 kg by 
2011. This can be attributed to several factors, often linked 
to the glamour associated with its use and the emergence 
of more affluent sections of society. In the case of Latin 
America, in contrast, most of the increase appears to be 
linked to “spill-over” effects, as cocaine is widely available 
and relatively cheap owing to the proximity to producing 
countries. 
In North America, seizures and prevalence have declined 
considerably since 2006 (with the exception of a rebound 
in seizures in 2011). Between 2006 and 2011, cocaine use 
among the general population in the United States fell by 
40 per cent, which is partly linked to less production in 
Colombia, law enforcement intervention and inter-cartel 
violence.
While, earlier, North America and Central/Western Europe 
dominated the cocaine market, today they account for 
approximately one half of users globally, a reflection of the 
fact that use seems to have stabilized in Europe and 
declined in North America.
In Oceania, on the other hand, cocaine seizures reached 
new highs in 2010 and 2011 (1.9 and 1.8 tons, respec-
tively, up from 290 kg in 2009). The annual prevalence 
rate for cocaine use in Australia for the population aged 
14 years or older more than doubled from 1.0 per cent in 
2004 to 2.1 per cent of the adult population in 2010; that 
figure is higher than the European average and exceeds the 
corresponding prevalence rates in the United States. 
Amphetamine-type stimulants
There are signs that the market for amphetamine-type 
stimulants (ATS) is expanding: seizures and consumption 
levels are increasing, manufacture seems to be spreading 
and new markets are developing.
The use of ATS, excluding “ecstasy”, remains widespread 
globally, and appears to be increasing in most regions. In 
2011, an estimated 0.7 per cent of the global population 
aged 15-64, or 33.8 million people, had used ATS in the 
preceding year. The prevalence of “ecstasy” in 2011 (19.4 
million, or 0.4 per cent of the population) was lower than 
in 2009.
W
O
R
L
D
 D
R
U
G
 R
E
P
O
R
T
 2
01
3
xiExecutive summary
While use is steady in the traditional markets of North 
America and Oceania, there seems to be an increase in the 
market in Asia’s developed economies, notably in East and 
South-East Asia, and there is also an emerging market in 
Africa, an assessment that is borne out by increasing diver-
sions of precursors, seizures and methamphetamine manu-
facture. The estimated annual prevalence of ATS use in 
the region is higher than the global average.
At the global level, seizures have risen to a new high: 123 
tons in 2011, a 66 per cent rise compared with 2010 (74 
tons) and a doubling since 2005 (60 tons). Mexico clocked 
the largest amount of methamphetamine seized, more than 
doubling, from 13 tons to 31 tons, within the space of a 
year, thus surpassing the United States for the first time. 
Methamphetamine continues to be the mainstay of the 
ATS business; it accounted for 71 per cent of global ATS 
seizures in 2011. Methamphetamine pills remain the pre-
dominant ATS in East and South-East Asia where 122.8 
million pills were seized in 2011, although this was a 9 per 
cent decline compared with 2010 (134.4 million pills). 
Seizures of crystalline methamphetamine, however, 
increased to 8.8 tons, the highest level during the past five 
years, indicating that the substance is an imminent threat. 
Methamphetamine manufacture seems to be spreading as 
well: new locations were uncovered, inter alia, in Poland 
and the Russian Federation. There is also an indication of 
increased manufacturing activity in Central America and 
an increase in the influence of Mexican drug trafficking 
organizations in the synthetic drugs market within the 
region.
Figures for amphetamine seizures have also gone up, par-
ticularly in the Middle East, where the drug is available 
largely in pill form, marketed as “captagon” pills and con-
sisting largely of amphetamine. 
Europe and the United States reported almost the same 
number of amphetamine laboratories (58 versus 57) in 
2011, with the total number remaining fairly stable com-
pared with 2010. 
While “ecstasy” use has been declining globally, it seems 
to be increasing in Europe. In ascending order, Europe, 
North America and Oceania remain the three regions with 
a prevalence of “ecstasy” use that is above the global 
average.
Cannabis
Providing a global picture of levels of cannabis cultivation 
and production remains a difficult task: although cannabis 
is produced in practically every country in the world, its 
cultivation is largely localized and, more often than not, 
feeds local markets. 
Cannabis remains the most widely used illicit substance. 
There was a minor increase in the prevalence of cannabis 
users (180.6 million or 3.9 per cent of the population aged 
15-64) as compared with previous estimates in 2009.
The areas of cannabis eradicated increased in the United 
States, possibly indicating an increase in the area under 
cultivation. Cultivation also seems to have gone up in the 
Americas as a whole. In South America, reported cannabis 
herb seizures rose by 46 per cent in 2011. 
In Europe, seizures of cannabis herb increased, while sei-
zures of cannabis resin (“hashish”) went down. This may 
indicate that domestically produced cannabis continues to 
replace imported resin, mainly from Morocco. The pro-
duction of cannabis resin seems to have stabilized and even 
declined in its main producing countries, i.e. Afghanistan 
and Morocco.
Many countries in Africa reported seizures of cannabis 
herb, with Nigeria reporting the largest quantities seized 
in the region. 
In Europe, cannabis is generally cultivated outdoors in 
countries with favourable climatic conditions. In countries 
with less favourable climatic conditions, such as Belgium 
and the Netherlands, a larger number of indoor plants are 
found. It is difficult to compile an accurate picture of cul-
tivation and eradication, as this varies widely across coun-
tries and climatic zones. Plant density fluctuates wildly, 
depending on the cultivation method (indoor or outdoor) 
and environmental factors.
New psychoactive substances
While new harmful substances have been emerging with 
unfailing regularity on the drug scene, the international 
drug control system is floundering, for the first time, under 
the speed and creativity of the phenomenon known as new 
psychoactive substances (NPS).
The number of NPS reported by Member States to 
UNODC rose from 166 at the end of 2009 to 251 by 
mid-2012, an increase of more than 50 per cent. For the 
first time, the number of NPS actually exceeded the total 
number of substances under international control (234). 
NPS are substances of abuse, either in a pure form or a 
preparation, that are not controlled by international drug 
conventions, but which may pose a public health threat. 
In this context, the term “new” does not necessarily refer 
to new inventions but to substances that have newly 
become available in specific markets. In general, NPS is 
an umbrella term for unregulated (new) psychoactive sub-
stances or products intended to mimic the effects of con-
trolled drugs.
Member States have responded to this challenge using a 
variety of methods within their legislative frameworks, by 
attempting to put single substances or their analogues 
under control. 
It has generally been observed that, when a NPS is con-
trolled or scheduled, its  use declines shortly thereafter, 
which has a positive impact on health-related consequences 
and deaths related to the substance, although the “substi-
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tution effect” has inhibited any in-depth research on the 
long-term impact of NPS scheduling. There are of course, 
instances when scheduling or controlling a NPS has had 
little or no impact. Generally, the following kinds of 
impacts have been observed after the scheduling of a NPS:
(a) The substance remains on the market, but its use de-
clines immediately. Examples include mephedrone in 
the United Kingdom of Great Britain and Northern 
Ireland, BZP in New Zealand, “legal highs” in Poland, 
mephedrone in Australia and MDPV in the United 
States of America; 
(b)  Use of the substance declines after a longer interval, 
maybe a year or more (e.g. ketamine in the United 
States); 
(c) Scheduling has little or no immediate impact on the 
use of the substance, e.g. 3,4-methylenedioxy-N-
methylamphetamine (MDMA), commonly known as 
“ecstasy”, in the United States and other countries. 
Further, there are cases of NPS disappearing from the 
market. This has also been the case with the majority of 
the substances controlled under the 1961 Convention and 
the 1971 Convention. Of the 234 substances currently 
under international control, only a few dozen are still being 
misused, and the bulk of the misuse is concentrated in a 
dozen such substances.
It is obvious that legislations to control NPS are not a “one 
size fits all” solution, and there are always exceptions to 
the rule. However, a holistic approach which involves a 
number of factors — prevention and treatment, legal 
status, improving precursor controls and cracking down 
on trafficking rings — has to be applied to tackle the 
situation. 
There is a lack of long-term data which would provide a 
much-needed perspective: no sooner is one substance 
scheduled, than another one replaces it, thus making it 
difficult to study the long-term impact of a substance on 
usage and its health effects.
The problem of NPS is a hydra-headed one in that manu-
facturers produce new variants to escape the new legal 
frameworks that are constantly being developed to control 
known substances. These substances include  synthetic 
and plant-based psychoactive substances, and have rapidly 
spread in widely dispersed markets. Until mid-2012, the 
majority of the identified NPS were synthetic cannabinoids 
(23 per cent), phenethylamines (23 per cent) and synthetic 
cathinones (18 per cent), followed by tryptamines (10 per 
cent), plant-based substances (8 per cent) and piperazines 
(5 per cent). The single most widespread substances were 
JWH-018 and JWH-073 among the synthetic cannabi-
noids; mephedrone, MDPV and methylone among the 
synthetic cathinones; and m-chlorophenylpiperazine 
(mCPP), N-benzylpiperazine (BZP) and 1-(3-trifluoro-
methylphenyl)piperazine (TFMPP) among the pipera-
zines. Plant-based substances included mostly kratom, khat 
and Salvia divinorum. 
What makes NPS especially dangerous and problematic is 
the general perception surrounding them. They have often 
been marketed as “legal highs”, implying that they are safe 
to consume and use, while the truth may be quite differ-
ent. In order to mislead the authorities, suppliers have also 
marketed and advertised their products aggressively and 
sold them under the names of relatively harmless everyday 
products such as room fresheners, bath salts, herbal 
incenses and even plant fertilizers. 
Countries in nearly all regions have reported the emergence 
of NPS. The 2008-2012 period in particular saw the emer-
gence of synthetic cannabinoids and synthetic cathinones, 
while the number of countries reporting new phenethyl-
amines, ketamine and piperazines declined (as compared 
with the period prior to 2008).
Origin and manufacture
While most widespread in Europe and North America, 
NPS seem to originate nowadays primarily in Asia (East 
and South Asia), notably in countries known for their 
advanced chemical and pharmaceutical industries. Domes-
tic manufacture has also been reported by countries in 
Europe, the Americas and Asia. Nonetheless, the overall 
pattern is one of transregional trafficking which deviates 
from the clandestine manufacture of controlled psycho-
tropic substances such as ATS, which typically occurs 
within the same region as where the consumers are located. 
Role of technology
The Internet seems to play an important role in the busi-
ness of NPS: 88 per cent of countries responding to a 
UNODC survey said that the Internet served as a key 
source for the supply in their markets. At the same time, 
a Eurobarometer survey found that just 7 per cent of young 
consumers of NPS in Europe (age 15-24) used the Internet 
to actually purchase such substances, indicating that, while 
the import and wholesale business in such substances may 
be increasingly conducted via the Internet, the end con-
sumer still retains a preference for more traditional retail 
and distribution channels. 
Spread of new psychoactive  
substances at the regional level
With its early warning system, comprising 27 European 
Union countries and Croatia, Norway and Turkey, Europe 
has the most advanced regional system in place to deal with 
emerging NPS. Through the early warning system, formal 
notification was provided for a total of 236 new substances 
during the 2005-2012 period, equivalent to more than 90 
per cent of all substances found globally and reported to 
UNODC (251). The number of identified NPS in the 
European Union rose from 14 in 2005 to 236 by the end 
of 2012. 
NPS seem to constitute a significant market segment 
already. Close to 5 per cent of people aged 15-24 have 
already experimented with NPS in the European Union, 
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which is equivalent to one-fifth of the numbers who have 
tried cannabis and close to around half of the number who 
have used drugs other than cannabis. While cannabis use 
has clearly declined among adolescents and young people 
in Europe over the past decade, and the use of drugs other 
than cannabis has remained largely stable, the use of NPS 
has gone up. 
Within Europe, Eurobarometer data for 2011 suggest that 
five countries account for almost three-quarters of all users 
of NPS: United Kingdom (23 per cent of the European 
Union total), followed by Poland (17 per cent), France (14 
per cent), Germany (12 per cent) and Spain (8 per cent). 
The United Kingdom is also the country that identified 
the most NPS in the European Union (30 per cent of the 
total during the 2005-2010 period). 
The United States identified the largest number of NPS 
worldwide: for 2012 as a whole, a total of 158 NPS were 
identified, i.e. twice as many as in the European Union 
(73). The most frequently reported substances were 
synthetic cannabinoids (51 in 2012, up from 2 in 2009) 
and synthetic cathinones (31 in 2012, up from 4 in 2009). 
Both have a serious negative impact on health. Excluding 
cannabis, use of NPS among students is more widespread 
than the use of any other drug, owing primarily to syn-
thetic cannabinoids as contained in Spice or similar herbal 
mixtures. Use of NPS among youth in the United States 
appears to be more than twice as widespread as in the 
European Union. 
In Canada, authorities identified 59 NPS over the first two 
quarters of 2012, i.e. almost as many as in the United 
States. Most of the substances were synthetic cathinones 
(18), synthetic cannabinoids (16) and phenethylamines 
(11). In a national school survey, widespread use was 
reported among tenth-grade students for Salvia divinorum 
(lifetime prevalence of 5.8 per cent), jimson weed or 
Datura (2.6 per cent), a hallucinogenic plant, and ketamine 
(1.6 per cent).
NPS are also making inroads in the countries of Latin 
America, even though, generally speaking, levels of misuse 
of such substances in the region are lower than in North 
America or Europe. Reported substances included keta-
mine and plant-based substances, notably Salvia divino-
rum, followed by piperazines, synthetic cathinones, 
phenethylamines and, to a lesser extent, synthetic cannabi-
noids. Brazil also reported the emergence of mephedrone 
and of DMMA (a phenethylamine) in its market; Chile 
reported the emergence of Salvia divinorum and 
tryptamine; Costa Rica reported the emergence of BZP 
and TFMPP, two piperazines. 
For many years, New Zealand has played a key role in the 
market for piperazines, notably BZP. A large number of 
NPS are also found in Australia, similar to the situation in 
Europe and North America. Overall, 44 NPS were identi-
fied during the first two quarters of 2012 in the Oceania 
region, equivalent to one quarter of all such substances 
identified worldwide. Australia identified 33 NPS during 
the first two quarters of 2012, led by synthetic cathinones 
(13) and phenethylamines (8).
According to the UNODC survey undertaken in 2012, 
the second-largest number of countries reporting the emer-
gence of NPS was in Asia. The emergence of such sub-
stances was reported from a number of countries and areas, 
mostly in East and South-East Asia (Brunei Darussalam; 
China; Hong Kong, China; Indonesia; Japan; Philippines; 
Singapore; Thailand; Viet Nam), as well as in the Middle 
East (Bahrain, Israel, Jordan, Oman, Saudi Arabia and 
United Arab Emirates). 
Hong Kong, China, reported the emergence of a number 
of synthetic cannabinoids (such as JWH-018) and synthetic 
cathinones (4-methylethcathinone and butylone). Indone-
sia informed UNODC of the emergence of BZP. Singapore 
saw the emergence of a number of synthetic cannabinoids 
(including JWH-018) and synthetic cathinones 
(3-fluromethcathinone and 4-methylecathinone). Oman 
witnessed the emergence of synthetic cannabinoids (JWH-
018). Japan reported the emergence of phenethylamines, 
synthetic cathinones, piperazines, ketamine, synthetic can-
nabinoids and plant-based substances. 
The two main NPS in Asia in terms of consumption are 
ketamine and kratom, mostly affecting the countries of 
East and South-East Asia. Ketamine pills have been sold 
for several years as a substitute for “ecstasy” (and sometimes 
even as “ecstasy”). In addition, large-scale traditional con-
sumption of khat is present in Western Asia, notably in 
Yemen. 
In total, 7 African countries (Angola, Cape Verde, Egypt, 
Ghana, South Africa, Togo and Zimbabwe) reported the 
emergence of NPS to UNODC. Egypt reported not only 
the emergence of plant-based substances (Salvia divinorum) 
but also the emergence of synthetic cannabinoids, keta-
mine, piperazines (BZP) and other substances (2-diphe-
nylmethylpiperidine (2-DPMP) and 4-benzylpiperidine). 
Nonetheless, the overall problems related to the production 
and consumption of NPS appear to be less pronounced 
in Africa. There are, however, a number of traditionally 
used substances (such as khat or ibogaine) that fall under 
the category of NPS and that, in terms of their spread, 
may cause serious health problems and other social 
consequences. 
The road ahead
Scheduling or controlling a substance is a lengthy — and 
costly — process, especially as it is the authorities who bear 
the onus of proof. Additionally, controlling an ever-larger 
number of substances, affecting police, customs, forensic 
laboratories, import/export authorities and the health 
authorities, among others, may stretch some Member 
States beyond their capacities. 
Alternative systems, such as the establishment of “early 
warning systems” for NPS, “emergency scheduling”, “ana-
xiv WORLD DRUG REPORT 2013 
logue scheduling”, “generic scheduling”, application of the 
“medicines law” and other creative approaches, all have 
their pros and cons. Most have improved the situation and 
have taught valuable lessons in planning for future control 
regimes. However, what is missing is coordination at the 
global level so that drug dealers cannot simply exploit loop-
holes, both within regions and even within countries.
The establishment of a global early warning system is 
needed to inform Member States of emerging substances 
and to support them in their response to this complex and 
changing phenomenon.1 While the international drug con-
trol conventions offer the possibility of scheduling new 
substances, the sheer rapidity of emerging NPS makes this 
a very challenging undertaking. What is needed is an 
understanding and sharing of methods and lessons learned 
in regional responses to the situation involving NPS before 
exploring the setting up of a global response to the 
problem. 
1 In its resolution 56/4 of 15 March 2013, the Commission on Narcotic 
Drugs encouraged the United Nations Office on Drugs and Crime 
“to share and exchange ideas, efforts, good practices and experiences 
in adopting effective responses to address the unique challenges posed 
by new psychoactive substances, which may include, among other 
national responses, new laws, regulations and restrictions”.
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11RECENT STATISTICS AND TREND ANALYSIS  OF ILLICIT DRUG MARKETS
A. EXTENT OF ILLICIT DRUG USE 
AND HEALTH CONSEQUENCES
Extent of drug use
In 2011, between 167 and 315 million people aged 15–64 
were estimated to have used an illicit substance in the pre-
ceding year. This corresponds to between 3.6 and 6.9 per 
cent of the adult population. The prevalence of illicit drug 
use and the numbers of problem drug users — those with 
drug use disorders or dependence – have remained stable.1 
Since 2009, the prevalence of cannabis, opioids, and opi-
ates use has gone up, while the prevalence of use of cocaine, 
amphetamine-type stimulants and “ecstasy”-group sub-
stances appears to have followed a declining trend between 
2009 and 2011.2 Nevertheless, since 2008 there has been 
an overall 18 per cent increase in the estimated total 
number of people who had used an illicit substance in the 
preceding year, which to some extent reflects both an 
increase in the global population and a slight increase in 
the prevalence of illicit drug use. A series of maps are pre-
sented in Annex I showing the prevalence of drug use 
among the population aged 15-64 for cannabis, ampheta-
mies, opioids, opiates, cocaine and ecstasy.  In addition, a 
table is included providing estimates of the prevalence and 
total number of users for each drug type at the global, 
regional and subregional levels.
Cannabis 
Cannabis use has increased globally, particularly in Asia 
since 2009. Although epidemiological data is not available, 
1 The number of problem drug users is driven mainly by the estimated 
number of cocaine and opiate users and therefore reflects the overall 
stable trends in the use of those drugs.
experts from the region report a perceived increase in use. 
The regions with a prevalence of cannabis use that is higher 
than the global average continue to be West and Central 
Africa (12.4 per cent), Oceania (essentially Australia and 
New Zealand, 10.9 per cent), North America (10.7 per 
cent) and Western and Central Europe (7.6 per cent). Can-
nabis use in North America and in most parts of Western 
and Central Europe is considered to be stable or 
declining.
2 Changes in the prevalence of different drugs may be an artefact owing 
to revised estimates within regions and subregions that may impact the 
global prevalence of the drugs.
Fig. 1. Trends in drug use, 2006-2011
Fig. 2. Trends in the prevalence of different 
drugs, 2009-2011
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Amphetamine-type stimulants 
Use of ATS, excluding “ecstasy”, remains widespread glob-
ally, and appears to be increasing. Although prevalence 
estimates are not available from Asia and Africa, experts 
from these regions continue to report a perceived increase 
in the use of ATS. While the use of ATS was already a 
problem in East and South-East Asia, there are reports of 
increasing diversion of precursor chemicals, as well as 
increased seizures and manufacture of methamphetamine, 
combined with an increase in its use. Current data from 
the drug use survey in Pakistan, for instance supports this 
assessment. Use of ATS is emerging in Pakistan, with a 
reported annual prevalence of 0.1 per cent among the gen-
eral population.3 High levels of ATS use are reported in 
Oceania (2.1 per cent in Australia and New Zealand), Cen-
tral and North America (1.3 per cent each) and Africa (0.9 
per cent), while the estimated annual prevalence of ATS 
use in Asia (0.7 per cent) is comparable with the global 
average.
Opioids
The use of opioids (heroin, opium and prescription opi-
oids) has increased in Asia since 2009, particularly in East, 
South-East, Central and South-West Asia. While reliable 
data do not exist for most parts of Africa, experts report 
an increase in the use of opioids there. North America 3.9 
per cent), Oceania (3.0 per cent), the Near and Middle 
East/South-West Asia (1.9 per cent) and East and South-
Eastern Europe (1.2 per cent) show a prevalence of opioid 
use that is higher than the global average. The use of opi-
ates (heroin and opium) has remained stable in some 
regions, nevertheless, a high prevalence is reported in the 
Near and Middle East/South-West Asia (1.2 per cent), 
primarily in Afghanistan, Iran (Islamic Republic of ) and 
Pakistan, as well as Central Asia (0.8 per cent), Eastern 
and South-Eastern Europe (0.8 per cent), North America 
(0.5 per cent) and West and Central Africa (0.4 per cent). 
Cocaine
The two major markets for cocaine, North America and 
Western and Central Europe, registered a decrease in 
cocaine use between 2010 and 2011, with annual preva-
lence among the adult population in Western and Central 
Europe decreasing from 1.3 per cent in 2010 to 1.2 per 
cent in 2011, and from 1.6 per cent to 1.5 per cent in 
North America. While cocaine use in many South Ameri-
can countries has decreased or remained stable, there has 
been a substantial increase in Brazil that is obvious enough 
to be reflected in the regional prevalence rate for 2011. 
Australia has also reported an increase in cocaine use. 
3 United Nations Office on Drugs and Crime and Pakistan, Ministry 
of Narcotics Control, “Drug use in Pakistan 2013: technical summary 
report” (March 2013). 
“Ecstasy”
Overall, use of “ecstasy” (i.e., methylenedioxymetham-
phetamine (MDMA)) has been declining, although it 
seems to be increasing in Europe. The three regions with 
a high prevalence of “ecstasy” use continue to be Oceania 
(2.9 per cent), North America (0.9 per cent) and Europe 
(0.7 per cent). Use continues to be associated with young 
people and recreational and nightlife settings in urban cen-
tres. For example, of the 2 million past-year users of 
“ecstasy” in Europe, 1.5 million were between 15 and 34 
years of age.4 
Non-medical use of prescription 
drugs
While global estimates of non-medical use of prescription 
drugs are not available, such use remains a major public 
health concern. The misuse or non-medical use of tran-
quillizers and sedatives such as benzodiazepines and bar-
biturates remains high and, at times, higher than that of 
many illicit substances. Along with the single use of tran-
quillizers (e.g. benzodiazepines), their use is commonly 
observed among polydrug users, especially among users of 
heroin who use benzodiazepines to enhance its effects, as 
well as those on methadone medication.5 Benzodiazepines 
are also often cited among the other substances reported 
in both fatal and non-fatal overdose cases among opioid 
users.6 
The misuse of tranquillizers and sedatives is spread across 
all regions. Among the 103 countries that have provided 
information on the non-medical use of such substances 
through the annual report questionnaire, nearly 60 per 
cent ranked them as among the three most misused types 
of substances in their country, while nearly 15 per cent of 
countries7 ranked them as the most commonly used sub-
stances. In countries with data on the annual prevalence 
of tranquillizers, prevalence varied between 0.4 per cent in 
England and Wales and 12.9 per cent in Estonia. 
The misuse of prescription opioids is also increasingly 
being reported from different regions. Tramadol is an 
opioid painkiller that is not under international control, 
whose misuse is being reported from many countries in 
Africa, the Middle East, Asia (including China) and the 
4 European Monitoring Centre for Drugs and Drug Addiction, Annual 
Report 2012: The State of the Drugs Problem in Europe (Luxembourg, 
Publications Office of the European Union, 2012).
5 M. Backmund and others, “Co-consumption of benzodiazepines 
in heroin users, methadone- substituted and codeine-substituted 
patients”, Journal of Addictive Diseases, vol. 24, No. 4 (2006), pp. 
17-29.
6 P. Oliver, R. Forrest and J. Keen, “Benzodiazepines and cocaine as risk 
factors in fatal opioid overdoses” (London, National Treatment Agency 
for Substance Misuse, April 2007.
7 Algeria, Bulgaria, Burkina Faso, Estonia, Honduras, Hungary, Italy, 
Netherlands, Nicaragua, Peru, Poland, Romania, Serbia and Venezuela 
(Bolivarian Republic of ).
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Pacific Islands. In many countries, the most common 
sources of prescription drugs are friends and relatives who 
have been prescribed them by a physician.8 The sale of 
counterfeit prescription drugs through black markets and 
loosely controlled pharmacies in developing countries is 
quite common, while unregulated Internet pharmacies are 
fast becoming a common source.9 
New psychoactive substances
NPS have become a major concern, not only because of 
their increasing use but also because of the lack of scientific 
research and understanding of their adverse effects (see 
chapter 2). 
Apart from these new substances, several countries10 have 
also reported the misuse of cough medicines containing 
codeine and simple cough suppressants such as dex-
tromethorphan. Dextromethorphan was included for pre-
review by the Expert Committee on Drug Dependence at 
its thirty-fifth meeting, in 2012.11 The misuse of dex-
tromethorphan is quite common among adolescents and 
8 United Nations Office on Drugs and Crime, The Non-medical Use of 
Prescription Drugs: Policy Direction Issues (Vienna, 2011).
9 Report of the International Narcotics Control Board for 2012 (United 
Nations publication, Sales No. E.13.XI.1).
10 Including Australia, Bangladesh, Canada, Germany, Indonesia, Nige-
ria, Pakistan, the Republic of Korea, the United States, Sweden and 
Hong Kong, China.
11 World Health Organization, “Dextromethorphan: pre-review report”, 
prepared for the thirty-fifth meeting of the Expert Committee on 
Drug Dependence, held in Hammamet, Tunisia, from 4 to 8 June 
2012.
young adults. For instance, in the United States of Amer-
ica, the annual prevalence of non-medical use of cough 
syrups among students in eighth, tenth and twelfth grades 
was reported as 2.7 per cent, 5.5 per cent and 5.3 per 
cent, respectively.12 When cough syrup containing dex-
tromethorphan is taken in quantities higher than the rec-
ommended dosages, the dextromethorphan acts as a 
“dissociative hallucinogen”, producing effects similar to 
those created by other hallucinogens such as ketamine and 
phencyclidine.13 
Extent of health consequences of  
drug use
Injecting drug use
Updating the previous global estimates, the United Nations 
Office on Drugs and Crime (UNODC) estimates that in 
2011 a total of 14.0 million (range: 11.2 million to 22.0 
million) people injected drugs worldwide, which corre-
sponds to 0.31 per cent (range: 0.24-0.48 per cent) of the 
population aged 15-64.14 The current global estimates are 
lower than the previous ones of 15.9 million people, and 
primarily reflect the fact that many countries have revised 
their earlier estimates downward, based on behavioural 
surveillance data. However, many countries have also 
reported an increase in the prevalence of injecting drug use 
and in the number of people who inject drugs. 
Changes over time in national, regional and global esti-
mates of injecting drug use may result from a number of 
factors, such as improvements in the methodology or cov-
erage of behavioural surveillance (e.g., Georgia, Italy and 
South Africa), additional countries undertaking behav-
ioural surveillance for the first time (Kenya and Seychelles) 
or changes in patterns of drug use, including injecting drug 
use (Australia and Brazil). Such factors have contributed 
to the overall reduced global estimates of people who inject 
drugs. Notable increases in the estimated number of people 
who inject drugs have been reported from Pakistan, the 
Russian Federation and Viet Nam, while countries report-
ing a considerable reduction include Brazil, Indonesia, 
South Africa, Thailand and the United States. 
At a regional level, a high prevalence of injecting drug use 
is found in Eastern and South-Eastern Europe (1.3 per 
cent of the population aged 15-64), where the percentage 
of people who inject drugs is four times greater than the 
global average and which alone accounts for 21 per cent 
of the total number of people who inject drugs globally. 
A high prevalence rate for injecting drug use is also noted 
in Central Asia (1.3 per cent), which has a rate of more 
12 Lloyd D. Johnston and others, Monitoring the Future: National Results 
on Adolescent Drug Use—Overview of Key Findings, 2011 (Ann Arbor, 
Michigan, University of Michigan, Institute for Social Research, 
2012).
13 World Health Organization, “Dextromethorphan: pre-review report”.
14 This estimate is based on information provided by 83 countries that 
together account for 81 per cent of the global population aged 15-64.
Fig. 3. Annual prevalence of non medical use 
of tranquillizers and sedatives among 
the general population in high- 
prevalence countries
Source: United Nations Office on Drugs and Crime, data from the 
annual report questionnaire (2007-2011).
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Table 1. Estimated number and prevalence of people who inject drugs among the general  
population aged 15-64, 2011
Sources: United Nations Office on Drugs and Crime, data from the annual report questionnaire; progress reports of the Joint United 
Nations Programme on HIV/AIDS (UNAIDS) on the global AIDS response (various years); the Reference Group to the United Nations on 
HIV and Injecting Drug Use; estimates based on United Nations Office on Drugs and Crime data; and national Government reports.
Region Subregion Injecting drug users
Estimated number Prevalence (%)
Low Best High Low Best High
AFRICA 304,925 997,574 6,608,038 0.05 0.17 1.12
AMERICA 2,908,787 3,427,561 4,019,041 0.47 0.55 0.64
North America 1,935,144 2,006,470 2,101,572 0.63 0.65 0.68
Latin America and the Caribbean 973,643 1,421,091 1,917,468 0.31 0.45 0.61
ASIA 4,328,212 5,692,005 7,031,647 0.16 0.20 0.25
Central Asia and Transcaucasia 659,582 699,191 758,421 1.25 1.33 1.44
East and South-East Asia 2,959,863 3,786,472 4,677,484 0.19 0.25 0.30
Near and Middle East/ 
South-West Asia 462,269 952,948 1,334,013 0.17 0.36 0.50
South Asia 246,498 253,394 261,729 0.03 0.03 0.03
EUROPE 3,553,859 3,777,948 4,156,492 0.64 0.68 0.75
Eastern/South-Eastern Europe 2,821,599 2,907,484 2,987,155 1.23 1.26 1.30
Western/Central Europe 732,260 870,464 1,169,337 0.23 0.27 0.36
OCEANIA 118,628 128,005 158,919 0.49 0.53 0.66
GLOBAL 11,214,411 14,023,092 21,974,136 0.24 0.31 0.48
Fig. 4. Changes in the prevalence of people 
who inject drugs use among the adult 
population aged 15-64, 2008-2011
Source: UNODC and Reference Group to the United Nations on 
HIV and Injecting Drug Use.
Note: A ratio of 1.0 indicates no change in the estimates. Chart shows 
countries where the prevalence of injecting drug use has at least either 
doubled (ratio is 2.0 or greater) or halved (ratio is 0.5 or less). Changes in 
prevalence may reflect improved reporting on prevalence estimates, as well 
as changes in injecting behaviour.
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Fig. 5. Changes in the number of people who 
inject drugs among the adult  
population aged 15-64, 2008-2011
Source: UNODC and Reference Group to the United Nations on 
HIV and Injecting Drug Use.
Note: Changes may reflect improved reporting on prevalence estimates, as 
well as changes in injecting behaviour.
Brazil
South Africa
Italy
Indonesia
Thailand
Kenya
Australia
Georgia
Spain
Malaysia
Ukraine
Nepal
Kazakhstan
Afghanistan
Argentina
Belarus
Viet Nam
Pakistan
Russian 
Federation
Moldova (Republic of)
United
States
-600,000 -400,000 -200,000 0 200,000 400,000 600,000
Increase in numberDecrease in number
 A. Extent of illicit drug use and health consequences
W
O
R
L
D
 D
R
U
G
 R
E
P
O
R
T
 2
01
3
5
than four times the global average. Injecting drug use also 
remains a serious public health concern in a number of 
countries in East and South-East Asia, with the region 
accounting for 27 per cent of the global total. South Asia 
has the lowest level of injecting drug use (0.03 per cent, 
mostly as a result of the low prevalence rate reported in 
India), considerably lower than that of any other region.
Countries and areas with the highest rates of injecting drug 
use – more than 3.5 times the global average — are Azer-
baijan (5.2 per cent), Seychelles (2.3 per cent), the Russian 
Federation (2.3 per cent), Estonia (1.5 per cent), Georgia 
(1.3 per cent), Canada (1.3 per cent), the Republic of 
Moldova (1.2 per cent), Puerto Rico (1.15 per cent), Latvia 
(1.15 per cent) and Belarus (1.11 per cent). China, the 
Russian Federation and the United States are the countries 
with the largest numbers of people who inject drugs. Com-
bined, they account for an estimated 46 per cent, or nearly 
one in two, people who inject drugs globally. 
HIV among people who inject drugs 
Of the estimated 14.0 million (range: 11.2 million to 22.0 
million) people who inject drugs worldwide, UNODC 
estimates that 1.6 million (range: 1.2 million to 3.9 mil-
lion) are living with HIV. That represents a global preva-
lence of HIV of 11.5 per cent among people who inject 
drugs.15 
15 The estimate is based on the reporting of the HIV prevalence rate 
among people who inject drugs from 106 countries.
Along with the estimates of the total number of people 
who inject drugs, the global total and prevalence rates of 
people who inject drugs living with HIV for 2011 is also 
lower than the estimated 3 million (18.9 per cent preva-
lence among people who inject drugs) previously presented 
by the Reference Group to the United Nations on HIV 
and Injecting Drug Use for 2008. These reduced estimates 
are in large part a result of the availability of more reliable 
information on HIV prevalence among people who inject 
drugs. 
The total number of people who inject drugs and are living 
with HIV in a particular region is a function of three vari-
ables: the prevalence of HIV among people who inject 
drugs; the prevalence of people who inject drugs; and the 
total population in the region aged 15-64. These variables 
are depicted in figure 8. 
There is relatively little regional variation in the prevalence 
of HIV among people who inject drugs, especially in com-
parison with the variation observed in the prevalence of 
people who inject drugs. The one exception is Oceania 
(based on data from Australia and New Zealand), where 
the prevalence of HIV among people who inject drugs is 
noticeably lower than in all other regions. Overall, the 
Russian Federation, the United States and China account 
for one half (46 per cent) of the global number of people 
who inject drugs that are living with HIV (21 per cent, 15 
per cent and 10 per cent, respectively).
Table 2. People who inject drugs living with HIV, 2011
Source: United Nations Office on Drugs and Crime, data from the annual report questionnaire; progress reports of the Joint United 
Nations Programme on HIV/AIDS (UNAIDS) on the global AIDS response (various years); the Reference Group to the United Nations on 
HIV and Injecting Drug Use; estimates based on United Nations Office on Drugs and Crime data; and national Government reports.
Region Subregion HIV among injecting drug users
Estimated number Prevalence (%) 
Best estimate
Low Best High
AFRICA 36,506 117,502 1,837,542 11.8
AMERICA 222,053 369,445 560,134 10.8
North America 159,836 270,749 383,041 13.5
Latin America and the Caribbean 62,217 98,696 177,093 6.9
ASIA 440,559 637,271 928,476 11.2
Central Asia and Transcaucasia 54,858 59,193 71,352 8.5
East and South-East Asia 256,396 328,101 519,982 8.7
Near and Middle East/South-West Asia 108,539 228,765 315,430 24.0
South Asia 20,767 21,212 21,712 8.4
EUROPE 466,243 492,054 532,304 13.0
Eastern/South-Eastern Europe 419,715 433,836 448,183 14.9
Western/Central Europe 46,528 58,217 84,120 6.7
OCEANIA 1,095 1,308 1,635 1.0
GLOBAL 1,166,456 1,617,580 3,860,091 11.5
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Map 1. Prevalence of people who inject drugs among the general population aged 15-64, 2011 or  
latest year available
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Map 2. Prevalence of HIV among people who inject drugs, 2011 or latest year available
Source: United Nations Office on Drugs and Crime, data from the annual report questionnaire; progress reports of the Joint United 
Nations Programme on HIV/AIDS (UNAIDS) on the global AIDS response (various years); the Reference Group to the United Nations on 
HIV and Injecting Drug Use; estimates based on United Nations Office on Drugs and Crime data; and national Government reports.
Note: The boundaries shown on this map do not imply official endorsement or acceptance by the United Nations. Dashed lines represent undetermined 
boundaries. Dotted line represents approximately the Line of Control in Jammu and Kashmir agreed upon by India and Pakistan. The final status of Jammu 
and Kashmir has not yet been agreed upon by the parties. The final boundary between the Sudan and South Sudan has not yet been determined.
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Fig. 6. Changes in the prevalence of HIV 
among people who inject drugs,  
2008-2011
Source: UNODC and Reference Group to the United Nations on 
HIV and Injecting Drug Use.
Note: Ratio of latest to previous Reference Group estimates of the preva-
lence of HIV among injecting drug users. A ratio of 1.0 indicates no change 
in the estimates. Chart shows countries where the prevalence of HIV 
among injecting drug users has either at least doubled (ratio is 2.0 or 
greater) or halved (ratio is 0.5 or less). Changes may reflect improved 
reporting on prevalence estimates as well as changes in injecting behaviour 
and HIV infection.
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Fig. 7. Changes in the number of people who 
inject drugs living with HIV from 2008 
to 2011
Source: UNODC and Reference Group to the United Nations on 
HIV and Injecting Drug Use.
Note: Calculation based on 2011 adult population. Changes may reflect 
improved reporting on prevalence estimates, as well as changes in injecting 
behaviour and HIV infection.
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The region with the highest prevalence of HIV among 
people who inject drugs is the Near and Middle East/
South-West Asia (24 per cent). This is driven primarily by 
high rates of HIV among people who inject drugs in Paki-
stan (37.0 per cent) and Iran (Islamic Republic of ) (15.1 
per cent). Almost 30 per cent of the global population who 
inject drugs and are living with HIV, however, are in East-
ern and South-Eastern Europe. Similar to Pakistan, 
Ukraine has a large population of people who inject drugs, 
with a very high prevalence of HIV (22.0 per cent).
International data show that rates of HIV prevalence are 
much higher among prison inmates than the general popu-
lation.16 From the annual report questionnaire, the 
reported prevalence rate of HIV in the prison population 
varies from 0.2 per cent in Hungary to 15 per cent in Kyr-
gyzstan; these rates are between 2 and 37 times higher than 
in the general adult population.
Hepatitis among people who inject 
drugs
Another major global public health concern is hepatitis C, 
which can lead to liver diseases such as cirrhosis and cancer. 
Infection with the hepatitis C virus (HCV) is highly preva-
lent among people who inject drugs. UNODC estimates 
that the global prevalence of HCV among people who 
16 United Nations Office on Drugs and Crime, International Labour 
Organization, United Nations Development Programme and World 
Health Organization, policy brief on “HIV prevention, treatment and 
care in prisons and other closed settings: a comprehensive package of 
interventions” (2012).
inject drugs is 51.0 per cent, meaning that 7.2 million 
people who inject drugs were living with HCV in 2011.17 
The largest numbers of people who inject drugs and are 
living with HCV are found in East and South-East Asia, 
Eastern and South-Eastern Europe and North America. 
The highest HCV prevalence rates among people who 
inject drugs in countries with predominantly large num-
bers of people who inject drugs (more than 100,000 to 
help ensure that a stable prevalence can be determined) are 
mostly located in North America and East and South-East 
Asia: Mexico (96.0 per cent), Viet Nam (74.1 per cent), 
United States (73.4 per cent), Canada (69.1 per cent), 
Malaysia (67.1 per cent), China (67.0 per cent) and 
Ukraine (67.0 per cent).
The global prevalence of the hepatitis B virus (HBV) in 
2011 among people who inject drugs is estimated at 8.4 
per cent, or 1.2 million people, based on reporting from 
63 countries. The highest prevalence of HBV among 
people who inject drugs is found in the Near and Middle 
East/South West Asia (22.5 per cent) and Western and 
Central Europe (19.2 per cent).
As is the case for other infectious diseases, such as tuber-
culosis and HIV, the prevalence of hepatitis and, in par-
ticular, hepatitis C, is very high among the prison 
17 The estimate is based on reporting from 78 countries.
Fig. 9. Estimated number of people who inject drugs, and number of people who inject drugs living 
with hepatitis B and hepatitis C
Source: United Nations Office on Drugs and Crime, data from the annual report questionnaire and national Government reports.
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Fig. 10. Primary drug of concern for people in treatment, by region (2011 or latest year available) 
Source: United Nations Office on Drugs and Crime, data from the annual report questionnaire, supplemented by national Government 
reports.
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Drug treatment: costs and benefits
There are different treatment modalities available in different countries, and studies have shown that treatment interven-
tions can have great benefits. Long-term drug treatment may, on average, save money, and result in a host of other 
benefits. Data demonstrate that the benefits of treatment vary according to the drug of choice and the severity of depend-
ence. In a meta-analysis of over 34 randomized controlled trials, cognitive behavioural therapy was found to have the 
largest effect on cannabis dependence, followed by opioid dependence and polysubstance dependence.a Cognitive 
behavioural therapy has also been shown to be effective against substance abuse occurring in tandem with suicidal 
thoughts in adolescents.b Opiate substitution therapy has also proven to increase the probability of survival, owing to a 
lower rate of suicide attempts, diminished likelihood of HIV transmission and reduced participation in crime. A com-
parison of involvement in criminal activity, pre- and post-treatment, shows a significant drop after therapy for a variety 
of criminal behaviours. In a study of over 23,000 people who inject drugs, the incidence of HIV was 54 per cent lower 
among those who had received methadone maintenance therapy compared with those who did not. Additional benefits 
to society include lower rates of driving under the influence of drugs or alcohol, and higher employment among treated 
users. In the United States, one year of methadone maintenance treatment for opioid dependence costs approximately 
$4,700, whereas one year of imprisonment costs approximately $24,000. The weight of evidence shows enormous ben-
efits, both in dollars saved and improved quality of life.
a R. K. McHugh, B. A. Hearon and M. W. Otto, “Cognitive-behavioural therapy for substance use disorders”, Psychiatric Clinics of North America, vol. 33, 
No. 3 (2010), pp. 511-525.
b C. Esposito-Smythers and others, “Treatment of co-occurring substance abuse and suicidality among adolescents: a randomized trial”, Journal of Con-
sulting and Clinical Psychology, vol. 79, No. 6 (2011), pp. 728-739.
Sources: United States, Department of Health and Human Services, National Institute on Drug Abuse, Principles of Drug Addiction 
Treatment: A Research-based Guide, 3rd ed., NIH publication No. 12-4180 (2012); J. Kimber and others, “Survival and cessation in 
injecting drug users: prospective observational study of outcomes and effect of opiate substitution treatment”, British Medical Journal, 
vol. 341, No. 7764 (17 July 2010), p.135 L. Cottler and others, “Predictors of high rates of suicidal ideation among drug users”, Jour-
nal of Nervous and Mental Disease, vol. 193, No. 7 (2005), pp. 431-437; M. A. Ilgen and others, “Substance use-disorder treatment 
and a decline in attempted suicide during and after treatment”, Journal of Studies on Alcohol and Drugs, vol. 68, No. 4 (2007), pp. 
503-509; M. Jofre-Bonet and J. L. Sindelar, “Drug treatment as a crime fighting tool”, Journal of Mental Health Policy and Economics, 
vol. 4, No. 4 (2001), pp. 175-178; 
A. Healey and others, “Criminal outcomes and costs of treatment services for injecting and non-injecting heroin users: evidence from 
a national prospective cohort survey”, Journal of Health Services Research and Policy, vol. 8, No. 3 (2003), pp. 134-141; I. Sheerin and 
others, “Reduction in crime by drug users on a methadone maintenance therapy programme in New Zealand”, New Zealand Medical 
Journal, vol. 117, No. 1190 (12 March 2004); G. J. MacArthur and others, “Opiate substitution therapy and HIV transmission in 
people who inject drugs: systematic review and meta-analysis”, British Medical Journal, vol. 345, No. 7879 (20 October 2012); G. 
D’Onofrio and others, “A brief intervention reduces hazardous and harmful drinking in emergency department patients”, Annals of 
Emergency Medicine, vol. 60, No. 2 (2012), pp. 181-192; and M. Bilban, A. Kastelic and L. M. Zaletel-Kragelj, “Ability to work and 
employability of patients in opioid substitution treatment programs in Slovenia”, Croatian Medical Journal, vol. 49, No. 6 (2008), pp. 
842-852.
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population: more than 10 per cent in most cases and up 
to 42 per cent in Finland and 45 per cent in New 
Zealand.
Problem drug use as reflected by the 
demand for treatment
It is estimated that approximately one in six problem drug 
users18 globally receives treatment for drug use disorders 
or dependence each year. However, there is a greater than 
six fold variation between the regions. Africa, in particular, 
stands out, with only one in 18 problem drug users access-
ing treatment services, predominantly for treatment related 
to cannabis use disorders. In Latin America and the Carib-
bean and Eastern and South-Eastern Europe, approxi-
mately one in 11 problem drug users accesses treatment 
services, well below the global average. Conversely, in 
North America, each year an estimated one in three prob-
lem drug users receives treatment interventions. To a cer-
tain extent, these regional differences reflect varying 
reporting systems for treatment demand,19 but they also 
undoubtedly demonstrate the wide disparity in the avail-
ability and accessibility of drug dependance treatment ser-
vices in different regions.
Drug-related deaths
Drug-related deaths show the extreme harm that can result 
from drug use. These deaths are invariably premature, 
occurring at a relatively younger age. For example, accord-
ing to the European Monitoring Centre for Drugs and 
Drug Addiction (EMCDDA), the mean age for drug-
related deaths for countries in Europe varies from 26 to 
18 Those who regularly use opiates, cocaine or amphetamines, are people 
who inject drugs or are diagnosed with dependence or substance use 
disorders.
19 Member States may report treatment episodes rather than persons 
in treatment, include only inpatient services or provide data that is 
geographically limited (e.g. for only the capital city).
44 years, and such deaths can largely be prevented.
UNODC estimates that there were between 102,000 and 
247,000 drug-related deaths in 2011, corresponding to a 
mortality rate of between 22.3 and 54.0 deaths per million 
population aged 15-64. This represents between 0.54 per 
cent and 1.3 per cent of mortality from all causes globally 
among those aged 15-64.20 The extent of drug-related 
deaths has essentially remained unchanged globally and 
within regions.
Regional trends in drug use
Africa
Africa remains a region with minimal systematic informa-
tion available on either the extent of or patterns or trends 
related to drug use. Nevertheless, estimates from Africa 
indicate a high prevalence of cannabis use (7.5 per cent, 
or nearly double the global average), which is particularly 
high in West Africa. The use of ATS (0.9 per cent), cocaine 
(0.4 per cent) and opiates (0.3 per cent) remains compa-
rable with the global average.
The use of opioids is perceived to be increasing signifi-
cantly in Africa, with experts in the region also reporting 
an increase. Many countries also reported an increase in 
use of cannabis, ATS and cocaine in 2011. Cocaine use in 
particular is perceived to be increasing in the Western 
coastal countries and is considered to be linked with the 
trafficking of cocaine into and through the region. A recent 
study in the Dakar region of Senegal indicated that, while 
heroin use had declined since 2000, consumption of crack 
20 According to World Population Prospects: The 2010 Revision (United 
Nations, Department of Economic and Social Affairs), an average of 
18.94 million deaths will occur each year for those aged 15-64 from 
all causes of mortality during the period 2010-2015.
Table 3. Estimated number of drug-related deaths and mortality rates per million population aged 
15-64 for 2011
Source: United Nations Office on Drugs and Crime, data from the annual reports questionnaire, the Inter-American Drug Abuse Control 
Commission (CICAD) and the European Monitoring Centre for Drugs and Drug Addiction, Louisa Degenhardt and others, “Illicit drug 
use”, in Comparative Quantification of Health Risks: Global and Regional Burden of Disease Attributable to Selected Major Risk Factors, 
vol. 1, M. Ezaati and others, eds. (Geneva, World Health Organization, 2004). Data for Africa have been adjusted to reflect the 2011 
population. The wide range in the estimates for Asia reflects the low level of reporting from countries in the region. The best estimate for 
Asia is towards the upper end of the range, because a small number of highly populated countries report a relatively high mortality rate, 
which produces a high regional average.
 Region Number of drug-related deaths Mortality rate per million aged 15-64
Estimate Lower estimate Upper estimate Estimate Lower estimate Upper estimate
 Africa  36,435  17,336  55,533 61.9 29.4 94.3
 North America  47,813  47,813  47,813 155.8 155.8 155.8
 Latin America and the Caribbean  4,756  3,613  8,097 15.0 11.4 25.6
 Asia  104,116  16,125  118,443 37.3 5.8 42.4
 Western and Central Europe  8,087  8,087  8,087 24.9 24.9 24.9
 Eastern and South-Eastern Europe  7,382  7,382  7,382 32.1 32.1 32.1
 Oceania  1,957  1,685  1,980 80.8 69.6 81.8
 Global  210,546  102,040  247,336 45.9 22.3 54.0
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cocaine had increased, and that currently between 70 per 
cent and 80 per cent of crack users were also using hero-
in.21 Similarly, heroin trafficking through the coastal 
regions of East Africa is believed to have caused an increase 
in heroin and injecting drug use. In a behavioural surveil-
lance study among people who inject drugs in Seychelles, 
heroin was the most commonly injected substance; other 
substances commonly used by injectors included cannabis 
and alcohol.22 In Kenya, heroin was the primary drug used 
by people who inject drugs, while polydrug use of cannabis 
 
21 Gilles Raguin and others, “Drug use and HIV in West Africa: a 
neglected epidemic”, Tropical Medicine and International Health, vol. 
16, No. 9 (2011), pp. 1131-1133.
22 Seychelles, Ministry of Health, “Injecting drug use in the Seychelles, 
2011: integrated biological and behavioural surveillance study, round 
1” (2011).
and flunitrazepam was also commonly reported among 
those injecting drugs.23 
In Nigeria, cannabis remains the most commonly used 
substance, but opioid use is also perceived to be increasing. 
The misuse of prescription opioids such as pentazocine 
and codeine-containing cough syrups is considered to be 
particularly problematic.24 South Africa reported an 
increase in the use of heroin, methamphetamine and meth-
cathinone, while cocaine use remained stable. Treatment 
facilities across the country reported that heroin use was a 
growing concern. Polydrug use was also reported as a 
common phenomenon among drug users in treatment, 
e.g. the use of cannabis and methaqualone among meth-
amphetamine users and methamphetamine among heroin 
users, as was the use of benzodiazepines, narcotic analgesics 
and codeine-containing preparations.25 
In North Africa, recent information on drug use is avail-
able from Algeria and Morocco. While the overall preva-
lence of different drugs is low in Algeria (use of any illicit 
drug was reported among 1.15 per cent of the adult popu-
lation), an increase in the misuse of cannabis and tran-
quilizers and sedatives has been reported, while the use of 
opioids and ATS is considered stable. However, an increase 
in injecting ATS was reported.26 In Morocco, use of can-
23 “Rapid situational assessment of HIV prevalence and related risky 
behaviours among people who inject drugs in Nairobi and coast prov-
inces of Kenya”, in Most-At-Risk Populations: Unveiling New Evidence 
for Accelerated Programming (Kenya, Ministry of Health, National 
AIDS and STI Control Programme, March 2012).
24 Information provided by Nigeria in the annual report questionnaire 
(2012).
25 Siphokazi Dada and others, “Monitoring alcohol and drug abuse 
trends in South Africa (July 1996-June 2011): phase 30”, SACENDU 
Research Brief, vol. 14, No. 2 (2011).
26 Information provided by Algeria and Morocco in the annual report 
questionnaire (2012).
Fig. 11. Cumulative unweighted average of  
perceived trends in drug use in Africa 
by drug type
Source: United Nations Office on Drugs and Crime, data from the 
annual report questionnaire.
Drug-related deaths in the United 
Kingdom of Great Britain and 
Northern Ireland
Within the United Kingdom, data from England and 
Wales show that drug misusea was responsible for 10 per 
cent of deaths from all causes for those aged 20-39 in 
2011.b Heroin and morphine accounted for most of the 
deaths, but between 2010 and 2011 the number of 
deaths associated with these two drugs declined by 25 
per cent, from 791 to 596. This decline might have been 
associated with the heroin “drought” experienced in the 
United Kingdom starting in 2010. However, over the 
same time period, the number of deaths related to the 
use of methadone, reportedly mixed with benzodiaz-
epines and/or alcohol, increased by 37 per cent, from 
355 to 486.c A similar situation was observed in Scot-
land, where there was a 19 per cent decline in the number 
of deaths involving heroin and morphine, from 254 in 
2010 to 206 in 2011, with a simultaneous 58 per cent 
increase in the number of deaths associated with metha-
done, from 174 in 2010 to 275 deaths in 2011.d Across 
the United Kingdom, the involvement of multiple sub-
stances implicated in drug-related deaths, notably the 
use of opiates/opioid analgesics, benzodiazepines and 
alcohol, has been noted,e highlighting the increased risk 
associated with polydrug use.
a The definition of this indicator is (a) deaths where the underlying 
cause is drug abuse or drug dependence or (b) deaths where the under-
lying cause is drug poisoning and where any of the substances con-
trolled under the Misuse of Drugs Act 1971 are involved.
b Based on data from the United Kingdom, Office for National Statis-
tics, “Deaths relating to drug poisoning in England and Wales, 2011”, 
Statistical Bulletin (August 2012).
c Ibid.
d Drug-related Deaths in Scotland in 2011 (National Records of Scot-
land, August 2012).
e Hamid Ghodse and others, Drug-related Deaths in the UK: Annual 
Report 2012 (International Centre for Drug Policy, St. George’s, Univer-
sity of London, London, 2013).
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nabis and ATS was reported as stable, while the use of 
cocaine and opiates had increased. 
The Americas
In the Americas, a high prevalence of most illicit drugs, 
essentially driven by estimates in North America, was 
observed, with the prevalence of cannabis (7.9 per cent) 
and cocaine (1.3 per cent) being particularly high in the 
region.
North America
In North America, the annual prevalence of all illicit drugs 
has remained stable and, except for opiate use, is at levels 
much higher than the global average. 
Overall, use of illicit drugs in the United States has 
remained stable, at an estimated 14.9 per cent of the popu-
lation aged 12 years and older in 2011, compared with 
15.3 per cent in 2010.27 Prevalence of cannabis use has 
also remained stable, though at high levels: 11.5 per cent 
27 United States, Department of Health and Human Services, Substance 
Abuse and Mental Health Services Administration, Results from the 
2011 National Survey on Drug Use and Health: Summary of National 
Findings, NSDUH Series H-44, HHS Publication No. SMA 12-4713 
(Rockville, Maryland, 2012).
in 2011, compared with 11.6 per cent in 2010 among the 
population aged 12 years and older. Cannabis use has con-
tinued to increase among high-school students. In 2011, 
an estimated 1 in 15 high-school seniors was a daily or 
near-daily user of cannabis. Synthetic marijuana, otherwise 
known as Spice or K2, was assessed for the first time; 
approximately 11.4 per cent of high school students 
reported its use in the previous year. The overall prevalence 
of non-medical use of psychotherapeutics (pain relievers, 
tranquilizers and sedatives, and stimulants) among persons 
12 years or older in the past year also declined, from 6.3 
per cent in 2010 to 5.7 per cent in 2011. Similarly, a 
decline was observed in the use of inhalants, cocaine, pre-
scription painkillers, amphetamine and tranquillizers 
among high-school students. While the prevalence of 
“ecstasy” use in 2011 remained stable among the general 
population, past-year use of “ecstasy” increased among 
twelfth graders and declined slightly for eighth and tenth 
graders. 
In Canada, the reported use of cannabis in the past year 
among the population aged 15 years and older declined 
from 10.7 per cent in 2010 to 9.1 per cent in 2011.28 The 
28 Information provided by Canada in the annual report questionnaire 
(2011). It is reported that, with high sampling variability and a coef-
Driving under the influence of drugs
Worldwide, road traffic injuries are the second most common cause of death for persons between 5 and 29 years of age; 
90 per cent of those deaths occur in low- to middle-income countries. The World Health Organization estimates that 
1.2 million people die annually from traffic-related injuries and predicts that, by 2030, traffic accidents will be the fifth 
leading cause of death. Driving under the influence of drugs or alcohol is a powerful predictor of traffic-related deaths; 
it becomes particularly risky when the two are combined. 
While the prevalence rate for driving under the influence of drugs is not known in many parts of the world, recent stud-
ies from Brazil, Europe and the United States indicate that it may be more common than previously thought. 
In the United States in 2011, 3.4 per cent of those aged 12 and older, or 9.4 million people, reported driving under the 
influence of illicit drugs. Estimates from the United States indicate that approximately 66 per cent of drivers who test 
positive for illicit drugs also have alcohol in their system, thereby increasing their risk of causing a fatal traffic accident.
In Brazil, a cross-sectional study of 3,398 drivers found that 4.6 per cent of them tested positive for some illicit substance. 
Of those who tested positive, 39 per cent tested positive for cocaine, 32 per cent for tetrahydrocannabinol (THC) (can-
nabis), 16 per cent for amphetamines and 14 per cent for benzodiazepines. In another study in Brazil, drug testing on 
patients who were admitted to the emergency room after traffic accidents showed that such patients were more likely to 
have cannabis in their system than alcohol. 
In Europe, in a sample of 50,000 randomly tested drivers from 13 countries, approximately 1.9 per cent of drivers tested 
positive for an illicit substance: traces of THC were detected in 1.3 per cent, cocaine in 0.4 per cent, amphetamines in 
0.08 per cent and illicit opioids in 0.07 per cent. Additionally, benzodiazepines were found in 0.9 per cent and medical 
opioids among 0.35 per cent of European drivers. Among the general driving population, illicit drugs were detected 
mainly among young male drivers, and at all times of the day, but mostly at the weekends.
Sources: M. Peden and others, eds., World Report on Road Traffic Injury Prevention (Geneva, World Health Organization, 2004); 
United States, Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Results from 
the 2011 National Survey on Drug Use and Health: Summary of National Findings, NSDUH Series H-44, HHS Publication No. SMA 
12-4713 (Rockville, Maryland, 2012); Substance Abuse and Mental Health Services Administration, “The NSDUH report: state esti-
mates of drunk and drugged driving” (Rockville, Maryland, 2012); European Monitoring Centre for Drugs and Drug Addiction, Driving 
Under the Influence of Drugs, Alcohol and Medicines in Europe: Findings from the DRUID Project (Luxembourg, Publications Office of 
the European Union, 2012); and Flavio Pechansky, Paulina do Carmo Arruda Vieira Duarte and Raquel Brandini De Boni, Use of Alco-
hol and Other Drugs on Brazilian Roads and Other Studies (Porto Alegre, National Secretariat for Drugs Policies, September 2010).
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Fig. 13. Trends in drug use in selected South 
American countries
A. Chile
Source: Chile, Consejo Nacional para el Control de Estupefa-
cientes (CONACE), Ministerio del Interior y Seguridad Pública, 
Noveno Estudio Nacional De Drogas en Población General, 2010 
(Santiago, June 2011).
use of other substances, including opioids, cocaine and 
methamphetamine, was reported as stable. The use of the 
psychoactive plant Salvia divinorum among young people 
in Canada remains of concern.
For Mexico, new estimates for 2011, as well as expert per-
ception, indicate a slight increase since 2008 in the use of 
cocaine (from 0.4 per cent in 2008 to 0.5 per cent in 2011) 
and ATS (0.1 per cent to 0.2 per cent). There was also 
some increase in the use of cannabis and opioids, while 
use of tranquillizers and sedatives was perceived to be 
stable.29 
South America, Central America and  
the Caribbean
The annual prevalence of cocaine use in South America 
(1.3 per cent of the adult population) is comparable to 
levels in North America, while it remains much higher 
than the global average in Central America (0.6 per cent) 
and the Caribbean (0.7 per cent).
Cocaine use has increased significantly in Brazil, Costa 
Rica and, to lesser extent, Peru while no change in its use 
was reported in Argentina. The use of cannabis in South 
America is higher (5.7 per cent) than the global average, 
but lower in Central America and Caribbean (2.6 and 2.8 
per cent respectively). In South America and Central 
ficient of variation between 16.7 per cent and 33.3 per cent, the esti-
mates of amphetamine, “ecstasy” and lysergic acid diethylamide (LSD) 
should be interpreted with caution. Since the coefficient of variation 
was greater than 33.3 per cent and/or the number of observations was 
less than six, the past-year estimates for opioids, tranquillizers and 
sedatives, and Salvia divinorum are suppressed and not reported.
29 Information provided by Mexico in the annual report questionnaire 
(2011).
Fig. 12. Trends in annual prevalence of drug 
use among the population 12 years and 
older in the United States, 2000-2011 
Source: United States, Department of Health and Human Services, 
Substance Abuse and Mental Health Services Administration,  
Results from the 2011 National Survey on Drug Use and Health: 
Summary of National Findings, NSDUH Series H-44, HHS Publica-
tion No. SMA 12-4713 (Rockville, Maryland, 2012).
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Source: Uruguay, Junta Nacional de Drogas, Observatorio Uru-
guayo de Drogas, Quinta Encuesta Nacional en Hogares sobre 
Consumo de Drogas: Informe de Investigación (May 2012).
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America the use of  opioids (0.3 and 0.2 per cent, respec-
tively) and Ecstasy (0.1 per cent each) also remain well 
below the global average. While opiates use remains low, 
countries such as Colombia report that heroin use is 
becoming increasingly common among certain age groups 
and socio-economic classes.30
Asia
Reliable estimates of the prevalence of different drugs are 
available for only a few countries in Asia. Overall, drug use 
in the region remains at low levels. While the annual preva-
lence rate of use of ATS ranges between 0.2 and 1.2 per 
cent of the adult population, and that of opioids between 
0.3 and 0.5 per cent, the annual prevalence rates for the 
use of cannabis (1.0–3.1 per cent), “ecstasy” (0.1–0.7 per 
cent) and cocaine (0.05 per cent) are considerably lower 
than the global average. In absolute numbers, however, 
Asia is home to an estimated one quarter to 40 per cent of 
all illicit drug users worldwide, as well as 60 per cent of 
opiate users and between 30 and 60 per cent of ATS users. 
Recent data available from Pakistan and China indicate an 
increase in the use of opiates, as well as of ATS. A new 
survey on drug use, conducted in Pakistan in 2012, 
reported cannabis as the most commonly used drug, with 
an annual prevalence of 3.6 per cent, followed by prescrip-
tion opioids (1.5 per cent) and tranquillizers and sedatives 
(1.4 per cent). Opiate use (0.9 per cent), though high, 
remained at levels lower than in Afghanistan and Iran 
(Islamic Republic of ). Most of the opiate use was linked 
to heroin (0.7 per cent) and, to a lesser extent, opium (0.3 
per cent). Use of ATS (0.1 per cent) and cocaine (0.01 per 
cent) appeared to be low but emerging.
Opioid use remains high in China, with the number of 
registered heroin users increasing each year: there were 1.24 
million in 2011, compared with 1.06 million in 2010. The 
number and proportion of registered users of ATS are also 
increasing (38 per cent of all registered users in 2012, com-
pared with 28 per cent in 2010). In addition, there has 
been a major increase in the number of drug users regis-
tered for use of other substances, such as ketamine. In 
2012, more than 7 per cent of registered drug users were 
using ketamine. 
The first-ever national survey on drug use in the Maldives 
was conducted in 2011/12. Cannabis was found to be the 
most commonly used substance, followed by opiates 
(annual prevalence of 2.5 per cent and 1.54 per cent, 
respectively, of the adult population). The use of prescrip-
tion opioids, cocaine, ATS, sedatives and tranquillizers 
though, appeared to be less common.31 
30 Ministerio de Salud y Protección Social - República de Colombia, 
Preventing the Spread of Heroin Consumption in the Americas: the 
Colombian Experience". 51st Regular Session of CICADA/OAS, May 
2012
31 United Nations Office on Drugs and Crime, National Drug Use 
Survey: Maldives — 2011/2012 (2013).
In Asia, experts from East and South-East Asia reported 
higher levels of ATS use in 2011. Ketamine use also 
remained widespread in some countries in the region, and 
was reported in Brunei Darussalam, China, Indonesia, 
Malaysia and Singapore. 
In Central Asia and Transcaucasia, use of opioids, especially 
heroin and opium, remains of primary concern, with 
annual prevalence estimated at 0.9 per cent of the adult 
population. Azerbaijan (1.5%), Georgia (1.36%) and 
Kazakhstan (1%) are the countries with considerably high 
levels of opioid use in the region. There is limited infor-
mation available from the Near and Middle East/South-
West Asia. While the use of ATS is the primary concern 
among the Gulf countries, misuse of narcotic analgesics, 
especially tramadol, is reported as an emerging concern, 
with some countries also reporting tramadol-related deaths.
Europe
In Europe, cannabis remains the most commonly used of 
illicit substance, with an annual prevalence of 5.6 per cent, 
followed by cocaine (0.8 per cent), opioids (0.7 per cent) 
and ATS (0.5 per cent).
In Western and Central Europe, there are indications, 
based on prevalence estimates, that the use of most illicit 
substances is declining or stabilizing at high levels. Con-
cerns remain, however, about the replacement of heroin 
with prescription opioids, the partial replacement of meth-
amphetamine by amphetamine, particularly in the north 
of Europe, and the continual increase in the introduction 
and use of NPS.
Fig. 14. Trends in registered drug users and 
proportion of registered drug users in 
China, 2000-2011
Source: Information provided by China in the annual report ques-
tionnaire, and annual reports on drug control in China published 
by the Office of the National Narcotics Control Commission of 
China. 
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Western and Central Europe
Except for the use of ATS (annual prevalence of 0.7 per 
cent), the use of all illicit substances in Western and Cen-
tral Europe remains higher than the global average. The 
annual prevalence of cannabis use is estimated at 7.6 per 
cent of the adult population, with declining or stable trends 
observed in most countries, except in Estonia and Finland, 
where the rates of cannabis use show no sign of levelling 
off.32 The annual prevalence of cocaine use (1.2 per cent) 
in Western and Central Europe is nearly three times the 
32 European Monitoring Centre for Drugs and Drug Addiction, Annual 
Report 2012: The State of the Drugs Problem in Europe.
Table 4. Annual prevalence of cocaine use in 
high-prevalence countries in Europe
UNODC Annual Report Questionnaire; European Monitoring 
Centre for Drugs and Drug Addiction, Statistical Bulletin 2012.
Denmark 0.9 (2010) 1.4 (2008)
Ireland 1.5 (2011) 1.7 (2007)
Spain 2.3 (2011) 2.7 (2009)
England and Wales 2.2 (2011) 2.2 (2010)
Fig. 15. Drug use trends in selected countries 
in Europe
A. Germany
Source: A. Pabst and others, “Substanzkonsum und substanzbezo-
gene Störungen: Ergebnisse des Epidemiologischen Suchtsurveys 
2009”, Sucht — Zeitschrift für Wissenschaft und Praxis, vol. 56, 
No. 5 (2010), pp. 327-336; L. Kraus and others, “Kurzbericht Epi-
demiologischer Suchtsurvey 2009: Tabellenband — Prävalenz der 
Medikamenteneinnahme und problematischen Medikamentenge-
brauchs nach Geschlecht und Alter im Jahr 2009” (Munich, Insti-
tut für Therapieforschung, 2010).
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B. Spain
Source: European Monitoring Centre for Drugs and Drug Addic-
tion, Statistical Bulletin 2012 (available from www.emcdda.europa.
eu/stats12); United Nations Office on Drugs and Crime, informa-
tion provided by Spain in the annual report questionnaire. 
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global average, but has been reported as showing a stabiliz-
ing or downward trend. Countries with a high prevalence 
of cocaine use observed a decline or stabilization in its use 
compared with the previous survey.
The latest school survey of 15- and 16-year-olds in the 
European Union also indicates evidence of a reduction or 
stabilization in the use of all major substances. However, 
polydrug use among school students remains of concern, 
with nearly 9 per cent of students reporting use of two or 
more substances. Cannabis use has remained stable overall 
among school students in Europe since 2007 (17 per cent 
lifetime prevalence); its use has increased significantly in 
11 countries and declined in 5 others. The Czech Repub-
lic, France and Monaco are the only European countries 
with a higher lifetime prevalence of cannabis use among 
15- and 16-year-olds (42 per cent, 37 per cent and 39 per 
cent, respectively) than the United States (35 per cent). 
Overall, in Western and Central Europe, the prevalence of 
use of “ecstasy” and ATS has remained stable (0.8 per cent 
and 0.7 per cent, respectively). While methamphetamine 
use was previously limited to only the Czech Republic and 
Slovakia, sporadic reports of methamphetamine smoking 
and availability of crystal methamphetamine have been 
reported, notably in the Baltic States and northern Europe, 
while low levels of use and availability for these substances 
were also reported from the United Kingdom and 
Germany.
While over 1 million people are currently estimated to have 
used opioids — in particular, by injecting heroin — there 
are signs of a decline in its use, with 60 per cent (710,000) 
of estimated problem opioid users currently receiving sub-
stitution and maintenance therapy. Also, injecting practices 
are  on the decline among new heroin users: only one third 
(36 per cent) of those entering treatment for heroin-related 
problems reported injecting as the main method of use.
Indicators from some European Union member States also 
show that heroin has become less available in recent years, 
and that in some countries it has been replaced by sub-
stances such as fentanyl and buprenorphine. This has been 
the situation mostly in Estonia and Finland, with sporadic 
or low levels of activities related to fentanyl use reported 
from countries such as Greece, Italy and the United King-
dom.33 In Estonia, the annual prevalence of fentanyl use 
in 2008 was reported as 0.1 per cent, while it was 1.1 per 
cent among males aged 15-24. Among drug users regis-
tered in treatment, three quarters (76 per cent) were there 
for fentanyl use. Fentanyl has also been described as 
endemic among people who inject drugs in Estonia.34 
There is limited data on fentanyl use in other European 
countries, but there have been time-limited “outbreaks” of 
the injection of fentanyl in Bulgaria and Slovakia. Similarly, 
Finland, Germany and Sweden have reported localized 
increases in the use of fentanyl and fentanyl-related deaths 
in recent years.35 
The number of people using substances such as gamma-
hydroxybutyric acid (GHB), gamma-butyrolactone (GBL), 
ketamine and, more recently, mephedrone is still relatively 
low in most European countries, but high levels of use are 
found in some subpopulations (such as “clubbers”), and it 
appears that such substances have the potential for 
more widespread diffusion. A European survey of youth 
attitudes, in which more than 12,000 young people aged 
15-24 were interviewed, estimated that 5 per cent of the 
respondents had used at least one new psychoactive sub-
stance at some point.36  There have also been reports of 
health problems linked with these substances, including 
dependence among chronic users, and some unexpected 
conditions, such as bladder disease and urinary tract symp-
toms in ketamine users.37,38 
Eastern and South-Eastern Europe
Except for the prevalence of opioid use (usually heroin), 
which is estimated to be 1.2 per cent of the adult popula-
tion, the use of other illicit substances in Eastern and 
South-Eastern Europe is quite low compared with global 
levels. While there is limited new information from the 
subregion, Belarus has reported an increase in opioid use, 
with 68 per cent of opioid users injecting mostly locally 
33 European Monitoring Centre for Drugs and Drug Addiction, Annual 
Report 2012: The State of the Drugs Problem in Europe.
34 European Monitoring Centre for Drugs and Drug Addiction, “Fenta-
nyl in Europe: EMCDDA Trendspotter study” (Luxembourg, Publica-
tions Office of the European Union, 2012).
35 European Monitoring Centre for Drugs and Drug Addiction, Annual 
Report 2012: The State of the Drugs Problem in Europe.
36 European Monitoring Centre for Drugs and Drug Addiction, Annual 
Report 2012: The State of the Drugs Problem in Europe.
37   Ibid.
38 R. Pal and others, “Ketamine is associated with lower urinary tract 
signs and symptoms”, Drug and Alcohol Dependence (forthcoming).
Fig. 16. Trends in cannabis use in European 
countries that reported a significant 
change among school students
Source: The European School Survey Project on Alcohol and Other Drugs 
(ESPAD) Report: Substance Use among Students in 36 European Countries 
(Stockholm, Swedish Council for Information on Alcohol and Other Drugs, 
2012).Note: Data for Denmark compares 2003 and 2011.
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made preparations of opium such as “kompot” or 
“cherniashka”,39 and recent trends in the country indicate 
an increase in the number of people injecting, as well as 
in the number of injecting practices, and HIV prevalence 
among those who inject drugs.40 
In the Russian Federation, decreased availability of heroin 
has led to its partial replacement with local and readily 
available substances such as acetylated opium, as in Bela-
rus, and with desomorphine, a homemade preparation 
made from over-the-counter preparations containing 
codeine.41 
Oceania
The prevalence of the use of most illicit substances remains 
quite high in the Oceania region - essentially Australia and 
New Zealand - while quantitative data for the Pacific island 
States remains limited.42 High prevalence rates are reported 
for the use of cannabis (10.9 per cent), opioids (3.0 per 
cent), “ecstasy” (2.9 per cent), ATS (2.1 per cent) and 
cocaine (1.5 per cent).
In a new development in Australia, there has been a 
decrease in the use of “ecstasy” among police detainees. 
Only 5 per cent of police detainees in 2010 and 2011 
39 “Kompot” is a crude preparation from poppy straw, while “cherni-
ashka” is made by mixing locally grown opium poppy with acetic 
anhydride.
40 Information provided by Belarus in the annual report questionnaire 
(2011).
41 Information provided by the Russian Federation in the annual report 
questionnaire (2011).
42 The United Nations Office on Drugs and Crime conducted a work-
shop, held in Suva, Fiji, from 16 to 19 October 2012 and supported 
by the Government of Australia, in which national experts reported 
that cannabis use was quite widespread in Pacific island States and that 
the non-medical use of prescription drugs such as tramadol, benzodi-
azepines and other sedatives was reported to be common among some 
segments of the population. While there are reports of trafficking of 
cocaine from isolated places in Pacific island States, there is reportedly 
negligible use among the local population. Similarly, there are indica-
tions of local manufacturing of ATS, for instance in Fiji, but negligible 
use reported among the local population.
reported using “ecstasy”, half the percentage who reported 
such use in 2009. Prior to 2012, an increasing interest in 
synthetic cannabis products was reported.43 In New Zea-
land, GHB/GBL is reported to be sold with methampheta-
mine “as a package to help users with the comedown effects 
of methamphetamine”.44 
B. OVERVIEW OF TRENDS 
RELATED TO DRUG SUPPLY 
INDICATORS, BY DRUG TYPE 
AND REGION
A number of emerging trends have been observed in terms 
of trafficking of certain types of drugs, as well as the devel-
opment of new markets and modes of transport across all 
drug types.
Oceania is the only region that has shown a clear increas-
ing trend in seizures across drug categories; the picture for 
the rest of the world is more complex.
Another noteworthy phenomenon is that the two classes 
of stimulants cocaine and ATS, instead of competing, seem 
to be complementary in nature, fuelling demand for each 
other instead of cutting into it. This relationship does not 
exist for any other pair among the four major drug classes.
There are indications of new markets for cocaine, although 
the available data indicates an overall decline in the market 
for cocaine at the global level. The picture for opiates is 
mixed, with increased levels of aggregate seizures of heroin 
and morphine recorded, alongside reduced levels of seizures 
of opium close to the major source country of Afghanistan, 
and declines in seizures of heroin in some of the major 
consumer markets. 
With regard to trafficking, maritime seizures are where the 
quantities lie. Based on reported data for 1997-2011, each 
maritime seizure was on average almost 30 times larger 
than consignments seized while being trafficked by air, and 
almost four times larger than those trafficked by road and 
rail, suggesting the need for greater vigilance in this area. 
A more comprehensive look at the various drug categories 
follows.
Cocaine
The available global indicators for the cocaine market sug-
gest that, at a global level, the availability of cocaine has 
declined, or at least stabilized, in recent years. In contrast 
with the market for other drugs, the cocaine market is 
characterized by the fact that not only are the source coun-
tries circumscribed within a relatively small area in South 
43 Information provided by Australia in the annual report questionnaire 
(2011).
44 Information provided by New Zealand in the annual report question-
naire (2011).
Fig. 17. Trends in drug use in Australia,  
1991-2010
Source: Australia, National Campaign against Drug Abuse Social 
Issues Survey reports for the years 1991 and 1993); and National 
Drug Strategy Household Survey reports for the years 1995, 1998, 
2001, 2004, 2007 and 2010.
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America, but also, until recently, cocaine consumption has 
been concentrated in specific parts of the globe. Hence, it 
is plausible that trafficking patterns converged to create 
certain distinct patterns and routes which were best suited 
to supply those limited consumer markets.
Consequently, with respect to cocaine specifically, the 
attention of the global community and the efforts to reduce 
and measure drug supply and demand may have focused 
on these well-known routes and markets. More recently, 
there are indications of emerging cocaine consumption in 
countries previously not associated with this phenomenon, 
and it cannot be excluded that the available indicators do 
not yet fully reflect the extent of global cocaine demand 
and supply. 
In any case, it is clear that regions like Asia and Africa, 
which together account for the majority of the world’s 
population, and where cocaine use has until recently been 
relatively low and continues to be largely limited to certain 
subregions, harbour the potential for a significant demand-
driven expansion of the cocaine market.
Amphetamine-type stimulants 
Seizures of ATS, which showed a remarkable increase in 
2011, point to a continued expansion in the global market 
for these substances. Seizures, mainly of methampheta-
mine, have increased steadily and substantially in the estab-
lished producing and consumer regions of North America 
and East and South-East Asia. Despite recent fluctuations, 
seizures remain high in the Near and Middle East/South-
West Asia, mainly in the form of captagon tablets contain-
ing amphetamine and caffeine. In 2011, quantities of ATS 
seized rebounded in Western and Central Europe, follow-
ing a decreasing trend from 2007 to 2010. Moreover, sei-
zures of amphetamine in Eastern Europe, while still limited 
in comparison with global figures, rose to a level signifi-
cantly higher than those reached previously. Seizures in 
Oceania, also rebounded from 2009 to 2011.
Cannabis
Cannabis herb continues to be produced, trafficked and 
consumed in large quantities in all regions. North America 
accounted for more than half of global seizures of cannabis 
herb, owing mainly to the quantities seized by Mexico and 
the United States. Large quantities are also seized in South 
America and Africa. Afghanistan and Morocco remain the 
foremost source countries for cannabis resin. Seizures of 
cannabis resin continue to be concentrated in Western and 
Central Europe, North Africa, and the Near and Middle 
East/South-West Asia. 
The mixed market of Western and Central Europe, which 
is a major consumer market for cannabis resin originating 
in Morocco, but which is also affected by the production 
and consumption of cannabis herb, has shown signs of 
gravitating towards more and better quality cannabis herb 
produced with enhanced techniques (such as indoor cul-
tivation) within the same subregion and trafficked on more 
localized routes.
In recent years, seizure totals for Western and Central 
Europe showed an increase in the case of cannabis herb 
and a decrease in the case of cannabis resin. Data on the 
content of tetrahydrocannabinol (THC), the psychoactive 
ingredient in cannabis, also suggest that the average 
potency (purity) of cannabis herb currently available in 
Europe is comparable to that of cannabis resin, which in 
the past used to be a significantly more potent alternative 
to cannabis herb.45 
Opiates
Afghanistan remains by far the largest source country for 
opiates worldwide. In recent years, Afghanistan registered 
several high annual production levels, notably in the peak 
year of 2007, but also in 2008 and 2011, with a decrease 
between 2007 and 2010 and between 2011 and 2012. As 
of 2011, aggregate global seizures of morphine and heroin 
had increased by approximately one half over a period of 
three years, in spite of the decreasing trend in production 
over the period 2007-2010. Declines in heroin seizures 
were observed, however, in specific regions and countries, 
notably Turkey (in 2010 and 2011), Eastern Europe and 
Central Asia and the Transcaucasian countries (in 2009, 
2010 and 2011), and Western and Central Europe (in 
2010). The general picture, in terms of seizure quantities, 
45 Based on cannabis potency reported by countries to UNODC through 
the Annual Report Questionnaire.
Fig. 18. Trend in main indicators of drug supply 
and drug supply reduction, 2003-2011
Source: UNODC, data from the annual report questionnaire and 
other official sources and International Crop Monitoring Pro-
gramme (cultivation).
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in the Near and Middle East/South-West Asia was mixed 
and rather erratic, with an increase in heroin seizures in 
the Islamic Republic of Iran in 2010 followed by a decrease 
in 2011, a decline in opium seizures in the same country 
in 2010 and 2011, continuing increases in heroin seizures 
in Pakistan and a spike in 2011 in morphine seizures in 
Afghanistan.
Assuming these fluctuations are, at least in part, a conse-
quence of law enforcement activities, and excluding from 
the aggregate the Near and Middle East/South-West Asia 
subregion, as well as those regions or subregions whose 
supply cannot be assumed to be predominantly sourced 
from Afghanistan (i.e. the Americas, Africa, East, South 
and South-East Asia and Oceania), a clear decline can be 
observed, starting gradually in 2009 and becoming sharper 
in 2010 and 2011. The one-year delay between the onset 
of the decline in production and that of seizures was also 
observed in the case of the dramatic drop in production 
in 2001, and can be linked to the duration of the various 
stages in the production and trafficking chain, including 
processing into heroin and trafficking, before heroin 
reaches destination and transit countries. However, pro-
duction levels are far from the only factor that influences 
trends related to seizure levels.
Overall trends across drug classes
An interesting feature can be observed when comparing, 
subregion by subregion, recent trends with regard to sei-
Fig. 19. Breakdown of global heroin seizures in 
comparison with opium production in 
Afghanistan, 1998-2012a
Source: UNODC, data from the annual report questionnaire and 
other official sources and International Crop Monitoring Pro-
gramme (cultivation).
a For 2012, comprehensive seizure data were unavailable.
b Western, Central, Eastern and South-Eastern Europe and Central Asia and 
Transcaucasian countries.
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zures of cocaine and ATS, which both consist of stimulant 
substances. Although by no means conclusive, there are 
indications that these two classes of stimulants are com-
plementary rather than competitive products; in other 
words, an increase in demand for one comes together with, 
and possibly even fuels, the demand for the other, rather 
than replacing it. This is substantiated by the fact that, 
while significant increases occurred for both drug classes 
in parallel in several subregions (East Africa, Eastern 
Europe, East and South-East Asia, Oceania and South 
Asia), the tendency for a subregion to register a significant 
increase in one of the two and a decrease in the other was 
very limited. A similar relationship cannot be observed 
when comparing any of the other pairs among the four 
major drug classes.
A comparison of total quantities of drug seizures between 
the 2010-2011 biennium and the preceding one shows 
Oceania as the only region with a clear dominant (increas-
ing) trend across the four different drug classes. This may 
be due to a considerable extent to renewed vigour in drug 
supply reduction efforts, in addition to any changes in the 
trafficked volumes for certain drug types. A rather similar 
pattern, but in the opposite direction, appears to hold for 
Europe, but the picture is not as clear, as seizures of cocaine 
increased slightly and seizures of ATS actually rebounded 
in 2011. 
Asia registered an increase in all drug classes with the excep-
tion of cannabis, most notably in the case of cocaine, which 
is significant in terms of the growth rate and also in view 
of the size of the population. In the Americas, the excep-
tion to the increasing trend was the well-established cocaine 
market. The available seizure data for Africa was not com-
prehensive, but a comparison of the totals excluding South-
ern Africa reveals an increase for seizures of heroin and 
ATS. 
Modes of transportation
While cases involving maritime trafficking are the least 
common among cases involving the three modes of trans-
portation of road and rail, maritime and air,46 the fre-
quency distribution of seizure cases by weight of seizure 
reveals that a maritime seizure is consistently the most 
likely to be a large seizure (from10 kg onwards).
When individual drug seizure cases (of all drug types) 
reported to UNODC are broken down into the three dif-
ferent modes of transportation mentioned above, cases of 
maritime trafficking constitute only 11 per cent of cases 
in spite of the fact that they consistently account for a sig-
nificant proportion of the quantity seized. Indeed, at 
46 This breakdown excludes cases in which the mode of transportation 
was unknown, not applicable or specified as “other”. In particular, 
seizures involving mail (which could be transported by air, sea or land) 
and seizures of drugs in storage are excluded.
Fig. 21. Recent trends in drug seizures, by drug 
type and region (2010-2011 totals as a 
percentage of 2008-2009 totals)
Source: UNODC, data from the annual report questionnaire and 
other official sources 
aDue to a lack of available data, the subregion of Southern Africa is 
excluded from the calculation of the trends for Africa.
Fig. 22. Distribution of mode of transportationa 
of individual drug seizure cases  
reported to UNODC, 1997-2011
Source: United Nations Office on Drugs and Crime, individual drug 
seizure database.
a Excludes cases in which the mode of transportation was unknown, not 
applicable or specified as “other”.
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approximately 330 kg, the average quantity seized in a 
single maritime seizure is by far the highest among the 
three modes of transportation. Seized drugs trafficked by 
air account for more than a third of cases, but for the small-
est average quantity per case. 
In terms of maximizing the impact of seizures on the 
flow and availability of illicit drugs, this may warrant an 
intensified focus of interdiction efforts on maritime 
trafficking.
Examining different drug types separately, cases of mari-
time trafficking comprise a limited percentage of the total 
number of seizures in each of the drug categories A notable 
contrast is seizures of cannabis resin made by Spain, most 
of which (93 per cent over the period 2007-2011, exclud-
ing cases in which the mode of transportation was not 
specified, not applicable or specified as “other”) were cat-
egorized as commercial maritime seizures. These seizures 
reflect trafficking of cannabis resin from Morocco on sea 
vessels to Spain, which constitutes a major consumer 
market for cannabis resin in itself but is also used as a gate-
way to the broader market of Western and Central Europe.
Seizures made by air account for a majority of seized con-
signments of cocaine and heroin, and slightly less than a 
majority of seizures in the case of ATS (see figure 25). In 
contrast, only about 3 per cent of seized consignments of 
cannabis herb are made as the drugs are being transported 
by air, with the difference being made up by seizures of 
consignments being transported by road and rail. This may 
be due to the more localized nature of trafficking patterns 
for cannabis herb, which is produced nearly everywhere in 
the world, with the result that demand can often be met 
by local supply.
Fig. 23. Average quantity seized in indi-
vidual seizure cases, by mode of 
transportation,a 1997-2011  
(kilograms)
Source: United Nations Office on Drugs and Crime, individual 
drug seizure database.
a Excludes cases in which the mode of transportation was unknown, not 
applicable or specified as “other”
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Fig. 24. Frequency distributions of quantitiesa 
seized in reported individual drug sei-
zure cases, 1997-2011, by mode of 
transportation
Source: United Nations Office on Drugs and Crime, individual drug 
seizure database.
a Quantities of less than 100 grams are excluded.
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Fig. 25. Distribution of number of individual 
drug seizures by drug type and mode  
of transportation,a 2007-2011
Source: United Nations Office on Drugs and Crime, individual drug 
seizure database. 
a Excludes cases where the mode of transportation was unknown, not 
applicable or specified as “other”.
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Fig. 26. Distribution of significant cannabis  
resin seizures reported by Spain, by 
mode of transportation,a 2007-2011
Source: United Nations Office on Drugs and Crime, individual 
drug seizure database.
a Excludes cases in which the mode of transportation was unknown, not 
applicable or specified as “other”.
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Trafficking hubs
Pakistan, which has long been an important hub for heroin 
trafficking for a number of geographic reasons,47 may be 
seeing the development of other routes and modes of trans-
portation, including maritime shipping. 
While a significant proportion of individual drug seizures 
reported by Pakistan, and the majority of heroin seizures, 
continue to be accounted for by air traffic, the destinations 
for trafficking by air have undergone significant shifts over 
time. While West and Central Africa accounted for the 
dominant portion in 2001, East and South-East Asia took 
over that role around 2006. By 2011, the proportion 
intended for West and Central Africa had declined to 4 
per cent. This does not imply that the importance of this 
subregion declined, but may be an indication that traffick-
ing by air directly from Pakistan to West Africa has been 
47 The country shares a long border with Afghanistan and affords several 
advantages for traffickers from a logistical aspect, including a long 
coast granting access to the Indian Ocean, flexible options for air travel 
to key destinations and strong ties with the United Kingdom.
supplanted by other methods of transportation, including 
maritime shipments. 
The rather abrupt increase in the share of East and South-
East Asia marked the first inroads made by traffickers of 
Afghan-sourced heroin into consumer markets, notably 
China, previously supplied predominantly by heroin from 
South-East Asia. By 2011, Europe and the Gulf region had 
also gained prominence.48 The United Kingdom reported 
a substantial rise in seizures of heroin trafficked directly 
from Pakistan, which accounted for nearly two thirds of 
heroin seized at the border (including airports and sea-
ports) in late 2010 and early 2011. However, it was unclear 
whether this reflected a shift in the market of the United 
Kingdom or improved intelligence flows.
In 2010, 2011 and 2012, in contrast with earlier years, 
Pakistan reported several large maritime seizures of heroin, 
intended mainly for West Africa and Europe (see figure 
29).
One possible factor driving this apparent change may be 
the disruption of the flow of heroin along the well-estab-
lished Balkan route, which goes through Iran (Islamic 
Republic of ) and Turkey. This may have spurred the devel-
opment of alternative maritime routes which use Africa 
and some Gulf States as staging posts for trafficking to the 
European market. A concomitant reason could possibly 
be reduced demand from the European market and a con-
sequent search for new routes and new consumer markets 
to supplant the declining share of Europe. In any case, the 
significance of  this statistic should be seen in perspective, 
as it could also be a reflection of changes in law enforce-
ment strategy; moreover, the increasing trend in the quan-
tity seized in maritime cases by Pakistan is based on a 
limited number of seizure cases. 
48 Includes Bahrain, Kuwait, Qatar, Oman, Saudi Arabia and the United 
Arab Emirates. However, not all of these countries appear as a destina-
tion in each of the following years: 2001, 2006 and 2011.
Fig. 28. Intended destinationsa of consignments trafficked by air seized in Pakistan (all drugs), 2001, 
2006 and 2011
Source: United Nations Office on Drugs and Crime, individual drug seizure database.
a Excludes cases in which the destination was Pakistan itself or was not specified.
b Includes Bahrain, Kuwait, Qatar, Oman, Saudi Arabia and the United Arab Emirates. 
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East Africa has long been known to function as a point of 
entry for heroin entering the African continent, intended 
most notably for South Africa and trafficked through coun-
tries on the East African and Southern African coast.49 
Some indicators suggest that this role may be assuming 
increasing importance and expanding to other drug types 
and other destinations. Comparing seizure totals for the 
2010-2011 biennium with the preceding one reveals an 
increase in each of the drug categories, which may reflect 
increased trafficking into and through this subregion. 
However, given the limited coverage of data in this subre-
gion and the fact that the data are driven by the quantities 
seized in a small number of countries, the possibility that 
these increases are partly the result of intensified law 
enforcement efforts cannot be excluded.
According to Kenyan authorities,50 Kenya was a transit 
country for heroin trafficked to Europe and the United 
States. The heroin could be traced back to both India and 
Pakistan, was observed to enter Kenya by sea and air and 
was re-exported to other markets, either directly to Europe 
or via West Africa. Ethiopia was identified as a transit 
country for heroin in 2011 by both Nigeria and Thailand, 
the latter of which has had its heroin market supplied 
mainly from South-East and South-West Asia via more 
direct routes.
49 See, for example, country report by South Africa, presented at the 
Seventeenth Meeting of Heads of National Drug Law Enforcement 
Agencies, Africa, Nairobi, 17-21 September 2007.
50 Country report by Kenya, presented at the Twenty-second Meeting 
of Heads of National Drug Law Enforcement Agencies, Africa, Accra, 
25-29 June 2012.
In the past, West Africa has been identified as a significant 
trafficking hub for cocaine and heroin. More recently, there 
have been indications of emerging manufacture of ATS in 
West Africa. According to Nigerian authorities,51 two 
methamphetamine laboratories were dismantled in the 
country between January 2011 and June 2012. Reports 
51 Country report by Nigeria, presented at the Twenty-second Meeting 
of Heads of National Drug Law Enforcement Agencies, Africa, Accra, 
25-29 June 2012.
Fig. 29. Total quantity seized in individual  
maritime heroin seizures reported by  
Pakistan, 2005-2012a
Source: United Nations Office on Drugs and Crime, individual drug 
seizure database.
a Data for 2012 refers to the first quarter (January to March) only.
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West Africa remains vulnerable
West Africa continues to be a region of particular con-
cern in the global drug phenomenon; it is facing the 
threat of organized crime, including drug trafficking, 
which may in turn have a spillover effect on the extent of 
drug use.
There is evidence that, by 2000, significant numbers of 
consignments of heroin originating in Afghanistan were 
being trafficked via Pakistan to West and Central Africa, 
mainly by air. In many cases, heroin was further traf-
ficked to other consumer markets. By 2007, West Africa 
had assumed an important role as a hub for cocaine on 
its way from South America to Western and Central 
Europe. In the case of both cocaine and heroin, traffick-
ing activities may have contributed to a supply-driven 
increase in use, notably in Nigeria, where the annual 
prevalence rate is believed to be significantly higher than 
the global average. The number of cocaine users in West 
and Central Africa is estimated at 1.6 million (past-year 
use). Owing to the paucity of data, however, the uncer-
tainty regarding this number is particularly pronounced, 
with a corresponding range of 570,000 to 2.4 million 
cocaine users. Nevertheless the prevalence rate in this 
subregion is likely significantly higher than the global 
average.
Beginning in mid-2009, high-purity crystalline metham-
phetamine originating in various West African countries 
started being seized in East Asia, with Japan, Malaysia, 
the Republic of Korea and Thailand being some of the 
main destination countries. Moreover, since 2011, five 
methamphetamine laboratories have been seized in Nige-
ria, pointing to a possible growing dimension of the 
problem. The profitability of the trade, coupled with low 
awareness of the end products of ATS and their precur-
sors and the relative simplicity of the manufacturing 
processes, are some of the main reasons why West Africa 
remains vulnerable to the manufacture and trafficking of 
ATS. 
Illicit drug traffic may potentially undermine progress 
made in African countries in the area of safety, stability, 
governance and socioeconomic development. Most 
countries in the region do not possess the required tech-
nical and financial means to respond effectively to the 
problems of illicit cultivation, manufacture and drug use.
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from Thailand and Uganda also indicate trafficking of 
amphetamine from West Africa via Ethiopia, raising the 
possibility of a parallel flow of drugs between East and 
West Africa: heroin going west and amphetamine going 
east. 
Other important transit countries include the Netherlands 
(for various drugs) and Brazil (for cocaine). Specifically for 
maritime trafficking, the Netherlands was also important 
as a country of provenance, although the transition from 
land to maritime transportation may not always occur at 
a seaport in the Netherlands. Ecuador emerges as an impor-
tant hub in South America for maritime trafficking of 
cocaine.
C. CANNABIS MARKET
Cannabis is produced in virtually every country of the 
world, making it the most widely illicitly produced and 
consumed drug plant. Tables and maps with country data 
on cannabis cultivation, production and seizures can be 
found in Annex II.
The cannabis plant yields two main products: cannabis 
herb and cannabis resin. Cannabis herb, the dried flower 
buds of the female cannabis plant, is not only consumed 
in almost all countries of the world, it is produced in most 
of them, too. The more protracted processing of the com-
pressed resin glands of the cannabis plant into cannabis 
resin is confined to far fewer countries, most of which are 
located in North Africa, the Near and Middle East and 
South-West Asia.52 
It is difficult to estimate global levels of cannabis cultiva-
tion and production: its cultivation is largely of a localized 
nature, and it is often consumed in the country of produc-
tion. Cannabis herb is increasingly cultivated in its main 
user markets in the Americas and Europe. The bulk of 
cannabis resin originates in Afghanistan and Morocco; 
there is evidence of stabilization or even a decrease in pro-
duction in these countries.
Global cannabis cultivation and  
production
The localized and often small-scale nature of cannabis cul-
tivation and production makes it very difficult to estimate 
them at the global level.53 Likewise, few countries estimate 
the extent of cannabis cultivation and production; in gen-
eral, data on cannabis are scarce in many regions.
52 World Drug Report 2012 (United Nations publication, Sales No. E.12.
XI.1).
53 In the World Drug Report 2009 (United Nations publication, Sales 
No. E.09.XI.12), it was estimated that the global production of can-
nabis herb ranged from 13,300 to 66,100 tons and the production of 
cannabis resin from 2,200 to 9,900 tons. The calculations were based 
on the minimum and maximum levels from reported cultivation and 
production, seizures and prevalence rates. In 2011, these indicators 
did not show significant changes that would justify an update of the 
production estimates, taking into account the large minimum and 
maximum levels.
The largest areas under cultivation or areas eradicated were 
reported by Afghanistan54 (12,000 ha under cultivation), 
Mexico (12,000 ha under cultivation and 13,430 ha eradi-
cated), and Morocco (47,500 ha under cultivation after 
eradication). Some countries also provided information 
on the number of plants or number of sites eradicated. 
Relating the number of plants to the size of an area is dif-
ficult as plant density can vary significantly, depending on 
the cultivation method and on environmental factors. 
Therefore, comparing plant eradication with eradicated 
area is difficult. An update of information available can-
nabis cultivation and production, as well as eradication, 
can be found in Annex II.
With regard to outdoor cultivation, the United States 
reported the largest number of plants eradicated (9.9 mil-
lion), followed by the Philippines (4 million), Tajikistan 
(2.1 million) and Indonesia (1.8 million). With regard to 
indoor cultivation, by far the largest number of plants was 
eradicated by Netherlands (1.8 million), a major supplier 
of cannabis herb to the European market, the United States 
(0.47 million) and Belgium (0.3 million), to where a large 
portion of European cannabis herb production has shifted 
in recent years.55
Ukraine reported the largest number of eradicated outdoor 
sites (98,000), followed by the United States (23,622) and 
New Zealand (2,131). New Zealand, a country with high 
levels of cannabis use, reported a very large number of 
eradicated outdoor sites when compared with plants eradi-
cated, which indicates a small average size of grow sites: 
the number of plants per outdoor site was 55, a much 
smaller average size than in, for example, the Philippines 
(30,663 plants per site). 
The Netherlands reported the dismantling of 5,435 indoor 
cultivation sites. This number is comparable to the number 
of sites eradicated in previous years. The United States 
reported the dismantling of 4,721 indoor sites and a much 
smaller number of plants per site (98) than the Netherlands 
(335). The number of plants per indoor site in Belgium 
was reported as 349, which was about the same as in the 
Netherlands.
In countries with a favourable climate for outdoor cultiva-
tion (e.g. Australia and Italy), the vast majority of plants 
eradicated were on outdoor sites, while the opposite was 
true for countries such as Belgium, Hungary and the Neth-
erlands, which have less favourable climatic conditions.
54 Information from the cannabis survey conducted by the United 
Nations Office on Drugs and Crime and Afghanistan in Afghanistan 
in 2011.
55 See, for example, European Monitoring Centre for Drugs and Drug 
Addiction, Cannabis Production and Markets in Europe, EMCDDA 
Insights Series No. 12 (Luxembourg, Office for Official Publications 
of the European Union, 2012).
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Cannabis resin production: a look at 
the two main source countries
In 2011, the main countries mentioned as a source country 
of cannabis resin by countries in which seizures of cannabis 
resin took place continued to be Morocco, followed by 
Afghanistan and, to a lesser extent, India, Lebanon and 
Pakistan (Pakistan assessed that all resin seized in its terri-
tory originated in Afghanistan). Such data must be treated 
carefully as they do not distinguish between transit coun-
tries and countries of origin, but the data do suggest that 
Afghanistan and Morocco are the two main source coun-
tries for cannabis resin.
Annex II shows a map with the geographical distribution 
of countries mentioning Afghanistan or Morocco as a 
source country for cannabis resin between 2009 and 2011, 
and thus may reflect the main markets for Afghan and 
Moroccan cannabis resin. Morocco was named as a source 
of trafficked cannabis resin by 17 different countries, 11 
of which were in Western and Central Europe, where 
Morocco seems to remain the main source of cannabis 
resin. Afghanistan, on the other hand, was named as a 
source country for seized cannabis resin by its neighbour-
ing countries and by countries further north. Countries in 
the Near and Middle East and in Europe also named 
Afghanistan as a source of cannabis resin.
The global distribution of cannabis resin seizures reflects 
the main source countries as well. During the period 2000-
2011, global seizures of cannabis resin were dominated 
by Spain, which is the main entry point to Europe for 
Moroccan cannabis resin. In 2011, Spain accounted for 
34 per cent of global seizures, Pakistan for 18 per cent and 
Morocco for 12 per cent. 
Morocco: indications of a decrease  
in production
Data reported by the Government of Morocco point to an 
overall decrease in the production of cannabis resin since 
the period 2003-2005, when UNODC and the Govern-
ment conducted joint surveys (in the most recent UNODC 
cannabis survey on Morocco, from 2005, the total area 
under illicit cannabis cultivation was estimated at 72,500 
hectares). In 2011, the estimates provided by the Govern-
ment did not change compared with those provided in 
2010.
The reported decrease in production is substantiated by a 
decrease in seizures of both resin and kif (a dried form of 
cannabis that can be processed into cannabis resin) in the 
country. In 2011, 138 tons of kif were seized, which was 
less than in 2009 (223 tons) and 2010 (186 tons). Seizures 
of cannabis resin by Moroccan authorities increased 
slightly, from 119 tons in 2010 to 126 tons in 2011, but 
that followed a large decline from a peak of 188 tons in 
2009. In 2010, Moroccan authorities attributed the decline 
in seizures to increased law enforcement efforts to counter 
cultivation within the country and to counter trafficking 
along the country’s borders.
Likewise, the quantities of cannabis resin seized in Spain 
fell for the third consecutive year and Spanish authorities 
noted that the quantities seized had been decreasing over-
all. In 2011, seizures amounted to 356 tons (compared to 
384 tons in 2010 and 445 tons in 2009). 
Afghanistan: signs of stabilization
In 2011, the Government of Afghanistan and UNODC 
jointly carried out the third survey on cannabis cultivation 
Fig. 30. Main source countries of cannabis 
resin, as reported by Member States, 
2002-2011
Source: UNODC, data from the annual report questionnaire and 
other official sources. 
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Fig. 31. Cannabis resin seizures, global total 
and selected countries, 2000-2011 
Source: UNODC, data from the annual report questionnaire and 
other official sources.
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in Afghanistan. The survey found that cultivation of can-
nabis plant and production of cannabis resin in Afghani-
stan appeared stable, and that there was no evidence of a 
substantive change in comparison with the previous can-
nabis surveys, which had taken place in 2009 and 2010. 
Cannabis in Afghanistan is a very attractive cash crop. 
However, the volume of cannabis cultivated is much lower 
than that of opium poppy (12,000 hectares of cannabis 
were cultivated in 2011, compared with 131,000 hectares 
of opium poppy), and it is cultivated less frequently: the 
majority of farmers who grow it do so every other year, 
and some even less often. The cultivation of cannabis in 
Afghanistan thus appears to be self-limiting.56 However, 
since strong links exist between opium poppy and cannabis 
cultivation57 and since there is a large pool of farmers who 
occasionally cultivate cannabis on a commercial basis, there 
may be significant potential for the substitution of can-
nabis for opium poppy, if opium poppy cultivation were 
to become less attractive.
Cannabis herb: increasing cultivation 
in the main markets
The region with the largest reported share of seizures of 
cannabis herb is by far North America, with the bulk of 
global seizures taking place in the United States and 
Mexico. North America accounted for 69 per cent of global 
herb seizures in 2011.
In Latin America and the Caribbean, the region with the 
second largest amount of seizures, most countries observed 
an increase in seizures, with Bolivia (Plurinational State 
of ), Colombia and Paraguay reporting an increase of more 
than 100 per cent when comparing the period 2002-2006 
with the period 2007-2011. Data are scarce for many Afri-
can countries; however, seizures in West, Central and 
Southern Africa have been decreasing over the past decade. 
There have been increased seizures of cannabis herb in 
North Africa. Other regions present a mixed picture (see 
Annex II).
Domestic cultivation in the United States 
on the rise
In 2011, the United States reported that the availability of 
cannabis herb may have increased. The United States 
attributes this increase to sustained high levels of produc-
tion in Mexico – the primary foreign source of the United 
States cannabis supply – and increased domestic cannabis 
cultivation.58
56 United Nations Office on Drugs and Crime and Afghanistan, Ministry 
of Counter-Narcotics, Survey of Commercial Cannabis Cultivation and 
Production 2011 (September 2012). Available from www.unodc.org/
documents/crop-monitoring/Afghanistan/2011_Afghanistan_Can-
nabis_Survey_Report_w_cover_small.pdf.
57 To a large extent, farmers who cultivate cannabis in summer also cul-
tivate opium poppy in winter.
58 United States, Department of Justice, National Drug Intelligence 
Center, National Drug Threat Assessment 2011 (August 2011).
Since 2002, seizures in both Mexico and the United States 
have followed an upward trend, with a combined total of 
3,033 tons seized in 2002 and 3,944 tons seized in 2011 
(the total amounts seized reached their highest level – 
4,655 tons – in 2010). In 2009, the amount seized in the 
United States exceeded the amount seized by the Mexican 
authorities for the first time.
The United States reported that high and increasing levels 
of domestic eradication could indicate increased domestic 
production, which is driven by high profitability and 
demand.59 This is similar to what is observed in Europe, 
where domestically produced cannabis products seem to 
be increasingly replacing imported cannabis products.
In the United States, eradication of domestic indoor can-
nabis plants increased from 213,000 in 2002 to 462,000 
in 2010; the number of domestic outdoor cannabis plants 
eradicated more than tripled over the same period, from 
3,129,000 in 2002 to 9,867,000 in 2010.60
59 United States, Department of Justice, National Drug Intelligence 
60 United States, Executive Office of the President, Office of National 
Drug Control Policy, National Drug Control Strategy: Data Supplement 
2012 (Washington, D.C., 2012).
Fig. 32. Cannabis herb seizures in Mexico and 
the United States, 2002-2011
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Fig. 33. Number of domestic indoor cannabis 
plants and sites eradicated in the  
United States, 2002-2010
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The number of domestic outdoor cannabis sites eradicated 
showed a different trend – there was an overall decrease 
until 2008, after which it increased again slightly. The 
decrease in the number of outdoor sites eradicated together 
with the strong increase in the number of plants eradicated 
indicates a larger average size of the sites that were eradi-
cated. This could be an indication of intensive production 
(i.e. larger plantations with more plants) and/or a concen-
tration of law enforcement efforts on very large grow sites. 
The average size of eradicated indoor sites has not changed 
significantly, indicating that most large-scale cultivation 
occurs outdoors.
Rest of the world: increased seizures in 
Latin America and the Caribbean and a 
continuing trend towards domestically 
produced cannabis herb in Europe
Most countries in Latin America and the Caribbean have 
registered increases in seizures of cannabis herb in recent 
years. Three countries in Latin America (Brazil, Colombia 
and Paraguay) seized significant quantities of cannabis herb 
in 2011. 
In Brazil, the number of seizure cases was roughly the same 
in 2010 and 2011 (885 and 878 cases, respectively), but 
the total amount of cannabis herb seized rose from 155 
tons in 2010 to 174 tons in 2011, which was the third 
consecutive increase.
In Colombia, the number of seizures increased from 
38,876 in 2010 to 41,291 in 2011, and the amount seized 
rose for the third consecutive year, from 209 tons in 2009 
to 255 tons in 2010 and 321 tons in 2011. Whether this 
Map 3. Cannabis plant eradication in the United States of America between the periods 2005-2007 
and 2008-2010 
Source: UNODC, data from the annual report questionnaire and other official sources.  
Fig. 34. Number of domestic outdoor canna-
bis plants and sites eradicated in the 
United States, 2002-2010
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is the result of increased levels of production or increased 
law enforcement efforts is not clear.
In Paraguay, seizures of cannabis herb more than doubled, 
from 84 tons in 2009 to 171 tons in 2011 (no data are 
available for 2010).
In Europe, the trend towards increased seizures of cannabis 
herb and decreased seizures of cannabis resin continued, 
which may be an indication of imported resin being 
increasingly replaced by domestically produced cannabis. 
Cannabis resin seizures in the whole region decreased from 
566 tons in 2010 to 503 tons in 2011. This was mainly 
the result of reduced seizures in Spain (decrease of 28 tons), 
Portugal (decrease of 20 tons) and Turkey (decrease of 8 
tons). Cannabis herb seizures increased by 12 per cent, 
from 164 tons in 2010 to 184 tons in 2011.
Nearly all countries in Africa reported the cultivation and 
seizure of cannabis herb. Nigeria continued to seize the 
largest quantities of cannabis herb in the region, with 139 
tons seized between July 2011 and April 2012.61 The 
second largest annual seizure totals were in Egypt, whose 
authorities reported seizing 73 tons of cannabis herb in 
61 Information contained in the country report by Nigeria presented at 
the Twenty-second Meeting of Heads of National Drug Law Enforce-
ment Agencies, Africa, Accra, 25-29 June 2012.
2011, down from 107 tons in 2010. Seizures of cannabis 
herb in Mozambique increased from 3 tons in 2010 to 32 
tons in 2011, and authorities in Burkina Faso reported 
seizures of 33 tons of cannabis herb in 2011, nearly double 
the 17 tons seized in 2009.
Fig. 35. Cannabis herb and cannabis resin  
seizures in Europe, 2002-2012
Source: UNODC, data from the annual report questionnaire and 
other official sources. 
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Marijuana in the United States of America
As of February 2013, 18 states of the United States of America, as well as the District of Columbia, have passed laws 
allowing marijuana to be used for a variety of medical conditions.a
Many of these states have in place, or are developing, programmes or provisions to regulate the use of medical marijuana 
by approved patients, as well as the cultivation, sale and possession of marijuana.b Under the programmes of some states, 
patients may be assisted by so-called caregivers, who are persons authorized to help patients grow, acquire and use the 
drug.c
In 2012, voters in two states—Colorado and Washington state—also passed initiatives legalizing the sale and recreational 
use of marijuana by adults, aged 21 years and older.
It is important to note that none of these state marijuana laws changes the fact that producing, selling or possessing 
marijuana continues to be an offence under United States Federal law.d The position of the United States Federal Gov-
ernment is that marijuana should be subjected to the same rigorous clinical trials and scientific scrutiny that are applied 
to all other new medications.e
Medical marijuana laws were passed separately on a state-by-state basis; a wide range of different policies regulating 
marijuana use exist. Nevada, for example, allows the possession of 1 ounce (28 grams) of usable marijuana, three mature 
and four immature plants.f Oregon permits patients to possess up to 24 ounces (672 grams) of usable marijuana and six 
mature plants.g Though most states that have decriminalized medical marijuana have also provided legal protections for 
its users, the majority of these laws have not established mechanisms for dispensing the drug or for regulating its quality 
and safety.
The definitions of what qualifies patients for medical marijuana can vary greatly among these states. New Mexico, for 
instance, permits the use of medical marijuana only for a limited set of conditions (including cancer, glaucoma, HIV/
AIDS, epilepsy, multiple sclerosis, spinal cord damage and terminal illness).h California, on the other hand, has an 
extensive list that includes general ailments such as migraines, severe or chronic pain and “any other illness for which 
marijuana provides relief ”.i
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Data on numbers of and trends among medical marijuana patients are limited by the absence of a standard method of 
collecting and disseminating data. Many states have a mandatory registration system of patients; in California, the most 
populous United States state, registration is voluntary. Only some states, such as Colorado,j provide detailed statistics 
online. 
A recent studyk examined a number of state medical marijuana registries as of June 2011 (in states with mandatory 
registration only) and highlighted some key information about those enrolled in medical marijuana programmes. The 
study concluded that the majority of persons registered appeared to be young, male and registered for chronic pain. There 
was a significant difference between states in the proportion of the adult population registered for medical marijuana, 
ranging from 4.1 per cent (Montana) to 0.07 per cent (Vermont). Possible explanations given for these differences were 
differences in disease burden, social acceptance of marijuana and ease of marijuana registration and acquisition. The 
study was limited by a lack of or limited data from several states.
There is an ongoing discussion on the impact of medical marijuana laws on overall levels of marijuana use and on risk 
perception of consumption. Several articles on that topic are listed below. 
Further reading
Sunil K. Aggarwal and others, “Medicinal use of cannabis in the United States: historical perspectives, current trends, 
and future directions”, Journal of Opioid Management, vol. 5, No. 3 (2009), pp. 153-168. 
Magdalena Cerdá and others, “Medical marijuana laws in 50 states: investigating the relationship between state legaliza-
tion of medical marijuana and marijuana use, abuse and dependence”, Drug and Alcohol Dependence, vol. 120, No. 1 
(2012), pp. 22-27.
Dennis M. Gorman and Charles Huber, Jr., “Do medical cannabis laws encourage cannabis use?”, International Journal 
of Drug Policy, vol. 18, No. 3 (2007), pp. 160-167.
Sam Harper, Erin C. Strumpf and Jay S. Kaufman, “Do medical marijuana laws increase marijuana use? Replication 
study and extension”, Annals of Epidemiology, vol. 22, No. 3 (2012), pp. 207-212.
Shereen Khatapoush and Denise Hallfors, "‘Sending the wrong message’: did medical marijuana legalization in Califor-
nia change attitudes about and use of marijuana?", Journal of Drug Issues, vol. 34, No. 4 (2004), pp. 751-770.
Robin Room and others, Cannabis Policy: Moving Beyond Stalemate (Oxford, Oxford University Press, 2010).
a See www.whitehouse.gov/ondcp/state-laws-related-to-marijuana (accessed February 2013).
b Mark Eddy, Medical Marijuana: Review and Analysis of Federal and State Policies, Congressional Research Service Report for Congress (2 April  
2010). Available from http://assets.opencrs.com/rpts/RL33211_20100402.pdf.
c Ibid.
d See www.whitehouse.gov/ondcp/state-laws-related-to-marijuana (accessed February 2013).
e See www.whitehouse.gov/ondcp/frequently-asked-questions-and-facts-about-marijuana#opposed (accessed February 2013).
f Nevada Revised Statutes (NRS), chapter 453A, “Medical use of marijuana” (http://leg.state.nv.us/NRS/NRS-453A.html).
g Oregon, Senate Bill (SB) 161 (www.leg.state.or.us/07reg/measures/sb0100.dir/sb0161.en.html).
h New Mexico, Medical Cannabis Program (http://nmhealth.org/mcp (accessed February 2013).
i California, Proposition 215 (http://vote96.sos.ca.gov/bp/215text.htm (accessed February 2013)).
j See www.colorado.gov/cs/Satellite/CDPHE-CHEIS/CBON/1251593017044 (accessed February 2013).
k Daniel W. Bowles, “Persons registered for medical marijuana in the United States”, Journal of Palliative Medicine, vol. 15, No. 1 (2012), pp. 9-11.
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D. ILLICIT OPIATE MARKET
Overview
Afghanistan maintained its position as the lead producer 
and cultivator of opium globally. With a global total of over 
236,000 hectares under cultivation, illicit cultivation of 
opium poppy reached peak levels in 2012, surpassing the 
10-year high recorded in 2007. This was mainly the result 
of increases in Afghanistan and Myanmar (the two main 
producers). A preliminary assessment of opium poppy cul-
tivation trends in Afghanistan in 2013 revealed that such 
cultivation is likely to increase in the main opium growing 
regions, which would be the third consecutive increase since 
2010.62 Mexico remained the largest grower of opium 
poppy in the Americas. An overview of global potential 
production of opium and manufacture of heroin, as well 
as country data on opium poppy cultivation and eradica-
tion and opium production can be found in Annex II.
The fluctuations which characterized opium production 
in Afghanistan in recent years, also affected Europe, the 
main market for opiates. Heroin use decreased in Western 
and Central Europe, which can be ascribed to a change in 
the structure of the market, which has seen decreased 
supply, increased law enforcement activity and an ageing 
user population, combined with an increase in the avail-
ability of treatment. However, the same does not apply to 
the non-medical use of prescription opioids. 
There are indications that more Afghan opiates are being 
62 United Nations Office on Drugs and Crime and Afghanistan, Ministry 
of Counter-Narcotics, “Afghanistan: opium risk assessment 2013” 
(April 2013).
trafficked on routes other than the Balkan route (which 
goes through Iran (Islamic Republic of ) and Turkey to 
Europe) and the northern route (through Central Asia and 
the Russian Federation). As these other routes go south-
ward from Afghanistan, either through Pakistan or through 
Iran (Islamic Republic of ), they are known collectively as 
the “southern route”. 
East Africa may be developing into a hub for onward traf-
ficking, with maritime trafficking playing an increasingly 
important role compared with trafficking by air and cou-
rier. A relatively new route has developed through the 
Middle East via Iraq, while a stronger flow of Afghan opi-
ates towards East and South-East Asia has been observed. 
These markets have traditionally been supplied by opiates 
from within the subregion. 
Continued inconsistency in the information available from 
the Americas on opiate production and flows makes an 
analysis of the situation difficult – while Mexico has the 
greater potential production of opium, it is Colombia that 
is reported as the main supplier of heroin to the United 
States. The Canadian market seems to be supplied by pro-
ducers from Asia. 
Typically, opium is converted into heroin in or close to the 
countries where opium poppy is cultivated and, by and 
large, seizure patterns reflect this. However, opium poppy 
eradication and opium and morphine seizures are reported 
in a wide range of countries other than the main opium-
producing countries, albeit usually in comparatively small 
ÇÇÇÇÇÇ
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Seizures
Only opium
Only morphine
Both opium and morphine
No data available or no ARQ received
Map 4. Opium and morphine seizures between 2007 and 2011
Source: UNODC Annual Reports Questionnaire supplemented by other sources.
Note: The boundaries shown on this map do not imply official endorsement or acceptance by the United Nations. Dashed lines represent undetermined 
boundaries. The dotted line represents approximately the Line of Control in Jammu and Kashmir agreed upon by India and Pakistan. The final status of 
Jammu and Kashmir has not yet been agreed upon by the parties. The final boundary between the Sudan and South Sudan has not yet been determined.
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quantities. This phenomenon should be investigated further 
in order to improve understanding of the global scope of 
the opiates market.
Revision of opium production  
estimates in Afghanistan for the 
period 2006-2009
UNODC has undertaken an exercise to improve the qual-
ity of data on opium production in Afghanistan, a process 
that has also led to a re-examination of the estimates for 
the period 2006-2009, which were consequently revised 
downwards.
Survey work and its supervision in the field have become 
increasingly difficult, in part owing to the deteriorating 
security situation in the main opium poppy-growing areas 
in the south of Afghanistan, coupled with a dramatic 
increase in poppy cultivation and the size of the area sur-
veyed after 2005. It has become more and more difficult 
for surveyors to comply with the opium yield survey pro-
tocol, which is designed for data collection on the ground.
UNODC sought expert advice and undertook an extensive 
study that led to the development of statistical tests for 
gauging the reliability of opium yield survey data.63 After 
successfully establishing procedures for quality control, 
opium yield data for the period 2006-2009, a particularly 
challenging period, were reviewed, which resulted in a 
downward revision of the yield estimates and a correspond-
ing decrease in the opium production estimates. The revi-
sion did not, however, have an impact on production 
trends in those years, nor did it change Afghanistan’s posi-
tion as the world’s leading producer of opium.64
Despite the downward revision, the level of opium pro-
duction in Afghanistan in 2007, 2008 and 2011 can be 
considered to be exceptionally high. Years with relatively 
low levels of production, such as 2009, 2010 and 2012, 
reduced the assumed “overproduction” in those years. 
This could explain why farm-gate opium prices in Afghani-
stan rose rapidly after mid-2009 (the first year with a com-
paratively low harvest after several years of record 
production), from only $64 per kilogram to $169 per kilo-
gram after the 2010 harvest failed, owing to weather con-
ditions and plant disease. After a relatively high level of 
opium production in 2011, prices went down but remained 
at a much higher level than before 2010, as the 2012 
opium harvest turned out to be below average. In 2012, 
due to a combination of disease of opium poppy and 
adverse weather conditions, opium production in Afghani-
stan was estimated at only 3,700 tons, 36% less than in 
2011. 
63 See United Nations Office on Drugs and Crime and Afghanistan, 
Ministry of Counter-Narcotics, Afghanistan: Opium Survey 2011 
(December 2011), pp. 95-97.
64 For a detailed description of the revision see United Nations Office on 
Drugs and Crime and Afghanistan, Ministry of Counter-Narcotics, 
Afghanistan: Opium Survey 2012 (May 2013), chapter 7.3.
However, production fluctuations alone do not explain 
why opium prices rebounded so strongly after 2010 and 
remained at a high level of about $200 per kilogram, even 
after a relatively good harvest in 2011. Other factors, such 
as changes in trafficking flow, demand or law enforcement, 
are likely to have played a role, and need to be further 
investigated. 
Effect of fluctuations in global opiate 
production on major markets
Structural changes in the European  
heroin market
The fluctuation in Afghan opium production affected the 
European market, which has seen decreased supply, owing 
in part to successful law enforcement activity, as well as to 
changes in trafficking flows. Heroin seizures have also 
decreased in Europe since 2009. In Western and Central 
Europe, greater access to treatment and alternatives to 
heroin, along with relatively smaller numbers of new 
heroin users, have contributed to a change in the structure 
of the European heroin market. While the decreased heroin 
supply also affected Eastern and South-Eastern Europe, 
structural changes on the demand side to the extent 
observed in Western and Central Europe were not reported 
in those subregions.
Increased law enforcement activity, as reflected in the fig-
ures for global heroin seizures, also affected the supply to 
Europe, where heroin seizures declined by 28 per cent in 
2011 to 16 tons, only half the amount seized in 2008 (29 
tons). A decline was also noticed in heroin seizures in the 
Islamic Republic of Iran (by 15 per cent to 23 tons) and 
Fig. 36. Opium production estimates in  
Afghanistan before and after revision, 
and farm-gate prices of dry opium, 
2004 to 2012
Source: United Nations Office on Drugs and Crime and Afghani-
stan, Ministry of Counter-Narcotics, Afghanistan: Opium Survey 
2011 (December 2011), pp. 95-97.
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Purity-adjusted retail price in the United States ($
per pure gram)
Purity-adjusted retail price, weighted average, 12
countries in West and Central Europe ($ per pure
gram)
Turkey (by 43 per cent to 7 tons) in 2011, two countries 
on the Balkan route through which Afghan opiates reach 
Europe. 
Interestingly, heroin seizures had already started to decline 
in 2010 in Turkey and South-East Europe, despite the fact 
that they are further along the trafficking route than the 
Islamic Republic of Iran.
EMCDDA argues that the decline in seizures reported in 
Turkey and the European Union in 2010 and 2011 could 
be a result of changes in both trafficking flows and law 
enforcement activity.65
The assumption that changes in production levels and in 
law enforcement activity did indeed lead to changes in the 
volume of drug flow is also supported by purity figures 
from Western and Central European countries. In Ger-
many, for example, a clear decline in heroin purity was 
seen: it was 34.1 per cent at the wholesale level in 2010, 
having increased steadily from 36.5 per cent in 2005 to 
60.3 per cent in 2009.66 The retail level followed a similar 
pattern from 2005, but reflected the decline in purity one 
year later, when it fell from 25 per cent in 2010 to only 11 
per cent in 2011. Such drops in purity are often associated 
with the diminished availability of the drug in user mar-
kets: traffickers cut the drug with more adulterants or cut-
ting agents to maintain their previous sales volumes. 
65 European Monitoring Centre for Drugs and Drug Addiction and 
European Police Office, EU Drug Markets Report: A Strategic Analysis 
(Luxembourg, Publications Office of the European Union, 2013), p. 
30.
66 Tim Pfeiffer-Gerschel and others, 2012 National Report to the 
EMCDDA by the Reitox National Focal Point: Germany – New Devel-
opments, Trends and In-Depth Information on Selected Issues (Deutsche 
Beobachtungsstelle für Drogen und Drogensucht, 2012), p. 190.
Changes on the demand side have also contributed to a 
lesser flow of opiates towards Europe. Drug treatment and 
use indicators suggest that the heroin market, particularly 
in Western and Central Europe, is undergoing a structural 
change. Heroin users have a relatively high level of service 
contact and access to opioid substitution therapy or alter-
natives to heroin.67 These alternative substances may also 
be obtained illicitly. In Estonia, for example, heroin users 
are reported to be using illicit synthetic opioids (fentanyl). 
Greece, Italy, Latvia, the Russian Federation, Slovakia and 
Switzerland all reported seizures of 1 kg or more of pre-
scription and other opioids in 2011,68 indicating that this 
phenomenon is not restricted to Western and Central 
Europe.
All these factors – substitution strategies, treatment and 
low levels of new use – represent a combination of long-
term structural changes in the user population and short-
term adaptive use strategies. They shed some light on how 
the heroin user population, particularly in Western and 
Central Europe, could react to supply fluctuations and a 
reduced flow of opiates into the region. The heroin seizures 
reported for 2011 in Western and Central Europe, which 
are at about the 2010 level, indicate that these changes and 
strategies, however, may not necessarily continue. 
67 European Monitoring Centre for Drugs and Drug Addiction, Annual 
Report 2012: The State of the Drugs Problem in Europe, p. 73.
68 Annual report questionnaire replies for 2011.
Fig. 37. Heroin seizures worldwide, in Europe 
and in selected countries, 2002-2011 
(Tons) 
Source: UNODC, data from annual report questionnaire and other 
official sources.
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Fig. 38. Heroin retail prices in the United  
States and Western and Central  
Europe, 2003-2011
Source: United Nations Office on Drugs and Crime, data from the 
annual report questionnaire; Europol; and the United States Office 
of National Drug Control Policy.
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The northern route, which is used mainly to supply the 
heroin market in Central Asia and the Russian Federation, 
reflects a different pattern. Overall, heroin seizures in Cen-
tral Asia have been declining since the first decade of the 
twenty-first century, from an annual average of 5 tons per 
year during the period 2002-2006 to only 3 tons during 
the period 2007-2011, while demand in Central Asia and 
the Russian Federation is thought to be stable or increas-
ing. The small peak in seizures in 2008 seems to reflect the 
high opium production in Afghanistan in that and the 
preceding year but did not change the overall declining 
trend. The link between production in Afghanistan and 
seizure levels in Central Asia is not evident and other fac-
tors are assumed to have played a role. 
Changing patterns: increase in  
maritime trafficking to Africa
A strong increase in heroin seizures has been observed in 
Africa, especially in East Africa, since 2009. The amount 
of heroin seized in East, West and Central Africa remains 
small compared with those in other regions, but from 
2009, they increased over fivefold. The vast majority of 
these seizures were made at sea borders or ports or on the 
open sea, which points to increased maritime trafficking 
of Afghan opiates towards Africa. Data on recent seizures 
made at sea borders, at ports or at sea suggest that large 
volumes are trafficked along this route: in a single case in 
April 2011, 202 kg of heroin was seized in Benin69 as part 
of a controlled delivery operation conducted by the Gov-
ernments of Benin and Pakistan and, in January 2012, 210 
kg of heroin that had been trafficked via a maritime route 
was seized in the United Republic of Tanzania.70
69 United Nations Office on Drugs and Crime, Paris Pact Drug Situation 
Report: Trafficking in Opiates Originating in Afghanistan (March 2013).
70 Annual report questionnaire.
Data from heroin seizures reported in East Africa between 
2010 and 2012 suggest that heroin is trafficked towards 
the sea borders and ports of Kenya and the United Repub-
lic of Tanzania. Later on, it is transported towards South 
Africa by road. Anecdotal information reveals that traffick-
ers use a number of vessels to traffic opiates from ports in 
Iran (Islamic Republic of ) and Pakistan to Africa. Dhows 
and, to a lesser extent, containers are used to reach East 
Africa, while containers are used more to reach West Africa, 
particularly Benin and Nigeria.
Emerging routes through the Middle East
Iraq and the Middle East may be emerging as new traf-
ficking routes: an increasing number of countries are 
reporting seizures of heroin sourced from Afghanistan. 
Whether that also indicates an increase in heroin abuse in 
the region remains to be seen. It is also noteworthy that 
between 2006 and 2011, most Pakistani traffickers arrested 
in Pakistan were headed for destinations in the Gulf States 
or in China, Malaysia and Thailand.
There are reports that strengthened law enforcement coun-
termeasures on the border between the Islamic Republic 
of Iran and Turkey might have led to new trafficking routes 
emerging in Iraq.71 In 2011, Turkish law enforcement 
authorities reported three operations linked to heroin traf-
ficking through the north of Iraq that resulted in seizures 
of 550 kg of the drug.72 Both heroin and opium are traf-
ficked through Iraq. Canadian authorities reported seizures 
71 Report of the Subcommission on Illicit Drug Traffic and Related 
Matters in the Near and Middle East on its forty-seventh session, 
held in Antalya, Turkey, from 19 to 23 November 2012 (UNODC/
SUBCOM/47/5).
72 “The new patterns of drug trafficking in Turkey”, presentation pre-
pared by the Turkish Central Narcotics Division for the international 
conference entitled “Criminal drug organizations: situation in EU with 
special focus on the Balkans”, Ohrid, the former Yugoslav Republic of 
Macedonia, October 2012.
Fig. 39. Heroin seizures in Europe, 2002-2011 
Source: UNODC, data from annual report questionnaire and other 
official sources.
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Fig. 40. Heroin seizures in Central Asia by 
country, 2002-2011
Source: UNODC, data from annual report questionnaire and other 
official sources.
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Map 5. Locations of reported heroin seizures in Africa for the period 2010-2012
Source: UNODC data from the individual seizures database and UNODC Regional Office for Central Asia, mapping of drug seizures online.
Note: The boundaries shown on this map do not imply official endorsement or acceptance by the United Nations. The final boundary between the Sudan 
and South Sudan has not yet been determined.
of opium trafficked by air from Iraq to Canada during the 
period 2009-2012, including a single 10 kg shipment 
hidden in car parts.73
Many countries in the Middle East, including Saudi Arabia 
and the Syrian Arab Republic, have reported increases in 
opiate seizures to UNODC. Heroin seizures reported by 
the Syrian Arab Republic were, on average, over 80 kg 
during the period 2007 to 2011, compared with only 14 
kg in the preceding five-year period; the quantity of heroin 
seized in Saudi Arabia has also increased since 2007, from 
an average of 1 kg during the period 2002-2007 to 41 kg 
73 Canada Border Services Agency, “CBSA finds 10 kilos of suspected 
opium concealed in steel gear”, 24 February 2012 (www.cbsa-asfc.
gc.ca/media/prosecutions-poursuites/tor/2012-02-24-eng.html).
in 2008, 56 kg in 2010 and 111 kg in 2011.74 Lack of data 
makes it difficult to define whether these increases imply 
an increase in heroin use in the region, or whether traffick-
ers are seeking alternative routes (notably to Europe). 
Finally, large shipments of heroin being trafficked in con-
tainers have been seized in the United Arab Emirates, 
which is a key node with major ports in Dubai, Khawr 
Fakkan and Abu Dhabi. Trade flow through harbours in 
the country may be exploited by drug traffickers for their 
illicit trade. In 2011, Dubai authorities seized 130 kg of 
heroin en route from Pakistan.75
74 UNODC annual report questionnaire.
75 United Nations Office on Drugs and Crime and World Customs 
Organization, “UNODC-WCO Container Control Programme: year-
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Against the trend? The heroin market in 
East and South-East Asia 
The pattern of heroin seizures in East and South-East Asia 
is quite different to that in Europe. The number of regis-
tered heroin users in China is increasing and it appears that 
opium production in the Lao People’s Democratic Republic 
and Myanmar is unable to meet demand. This would indi-
cate that other sources, possibly Afghanistan, are supplying 
the country with opiates.
Seizure trends in China generally follow opium production 
trends in South-East Asia. Heroin seizures in China 
reached their lowest levels in 2007 and 2008, which ties 
in with the low levels of opium production seen in the Lao 
People’s Democratic Republic and Myanmar during the 
period 2005-2006 (factoring in the one-year time lag 
between the production and seizure of the drug). Subse-
quently, heroin seizures rose again, following increases in 
opium production in South-East Asia. However, the 
number of registered heroin users was much higher than 
in the first half of the decade, when production levels and 
seizure levels in South-East Asia were much lower. This 
could indicate the growing importance of other source 
regions for the Chinese opiate market, in particular 
Afghanistan, which registered record harvests in some years 
when opium production in South-East Asia was low. 
This indicates a diversification of source regions and thus 
trafficking routes, which include maritime and courier 
routes, possibly taking advantage of growing licit trade 
flows between China and South-West Asia.76 China reports 
end report 2011”, p. 11 (available from www.unodc.org/documents/
toc/CCP_Year_End_Report_2011.pdf ).
76 For more information on this issue, see United Nations Office on 
Drugs and Crime, Misuse of Licit Trade for Opiate Trafficking in Western 
and Central Asia: A Threat Assessment (October 2012). More research is 
needed to get a better understanding of misuse of licit trade for drug 
Malaysia as the second leading country, after Myanmar, 
from which drugs enter the country, and lists Afghanistan 
as the second leading source country for opiates entering 
the country. As the opium production areas in Myanmar 
border China and there is little need to resort to other traf-
ficking routes, it is not unlikely that Afghan opiates enter 
China through regional hubs in Malaysia and Thailand via 
couriers; this is confirmed by statistics from Malaysia and 
Pakistan.77
trafficking in China and South-East Asia.
77 Annual report questionnaire replies submitted by Malaysia and Paki-
stan for 2011.
Fig. 41. Heroin seizures in Africa, 2002-2011
Source: UNODC, data from annual report questionnaire and other 
official sources and the World Customs Organization.
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Fig. 42. Opium production in South-East Asia 
and heroin seizures and use in China, 
2002-2011
Source: UNODC, data from annual report questionnaire and other 
official sources.
Fig. 43. Heroin seizures in selected countries 
in South-East Asia and Oceania, 2006-
2011 (Kilograms)
Source: UNODC, data from annual report questionnaire and other 
official sources.
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The rising levels of heroin seizures in several countries in 
South-East Asia and Oceania supports the assumption of 
a growing opiate flow through these regions to known 
consumer markets such as China and Australia. Owing to 
a lack of drug use statistics in many South-East Asian coun-
tries, it is difficult to assess whether and how this develop-
ment affects opiate use in those countries. 
Problems identifying opiate flows  
in the Americas
All countries in the Americas, except Canada, are supplied 
by heroin produced in the region. According to Govern-
ment reports, the Canadian heroin market is supplied by 
heroin originating in Asia, mainly Afghanistan. Middle 
Eastern and Asian organized criminal groups both within 
Canada and abroad continued to be involved in the smug-
gling of heroin intended for Canada.78
The available information on heroin production in Colom-
bia and Mexico, two important supply countries for the 
United States market, is inconsistent and does not fully 
explain the heroin supply situation in the region, given 
that the potential cultivation is greater in Mexico, while 
the United States reports Colombia as its main supplier.79 
There is insufficient information about the role played by 
heroin originating in Afghanistan for the United States 
market. 
In Colombia, between 2007 and 2011, 4 tons of heroin 
of unknown purity was seized, while potential production 
amounted to 6 tons of pure heroin. In 2010, the amount 
78 Annual report questionnaire replies submitted by Canada for 2011.
79 Annual report questionnaire replies submitted by the United States for 
2011.
of heroin (of unknown quality) seized was even larger than 
the amount of potential production in the country. Allow-
ing for lower purity of the seized heroin, this would indi-
cate a very high seizure rate, which would leave only a small 
amount of heroin for local consumption and export. 
Though, with an annual prevalence of only 0.02 per cent 
among those aged 15-64 years, opiates are not widely used 
in the country, and the number of estimated opiate users 
is around 6,000. 
Official data show a strong decline in opium and heroin 
production in Colombia over the period 1998-2007 and 
further declines to 2011. However, heroin prices did not 
increase. Nominal prices for heroin at the wholesale level 
were lower in 2011 in both dollars and Colombian pesos, 
than they were five years before, suggesting that the supply 
of heroin did not drastically diminish. 
In comparison, in Mexico, potential heroin production is 
estimated to be 30 times higher than in Colombia, and 
heroin seizures reached the Colombian level in 2011. 
Despite this, and while acknowledging the growing impor-
tance of Mexico as a supply country for heroin reaching 
its market, the United States – on the basis of information 
from its Heroin Signature Program – continues to consider 
Colombia the primary source of heroin in the country,80 
although heroin from South-West Asia continues to be 
available. The United States estimates poppy cultivation 
 
 
80 Levamisole and tetramisole were mentioned as cutting agents used 
in heroin available in the United States (annual report questionnaire 
replies submitted by the United States for 2011). These substances are 
known to be used in cocaine manufacture in Colombia, where they are 
added to export-ready cocaine in clandestine laboratories.
Fig. 44. Potential heroin production in  
Colombia and seizures in Colombia  
and Mexico, 2007-2011
Source: UNODC, data from annual report questionnaire and other 
official sources and Illicit Crop Monitoring Programme. 
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Fig. 45. Colombia, annual wholesale price  
of heroin, 2007 to 2011
Source: United Nations Office on Drugs and Crime and Colombia, 
Colombia: Coca Cultivation Survey 2011 (June 2012). 
0
5,000
10,000
15,000
20,000
25,000
W
h
o
le
sa
le
 p
ri
ce
 o
f 
h
er
o
in
(p
er
 k
ilo
g
ra
m
)
Heroin (wholesale),
Colombian pesos per
kg (thousands)
 22,294  19,560  21,422  20,421  19,101 
Heroin (wholesale),
United States dollars
per kg
 10,780  9,950  9,993  10,786  10,348 
2007 2008 2009 2010 2011
E. Cocaine market 37
W
O
R
L
D
 D
R
U
G
 R
E
P
O
R
T
 2
01
3
in Mexico at 12,000 hectares,81 with a correspondingly 
higher potential production of heroin.82
It is unclear how Colombia, given its much lower potential 
production, could supply larger amounts to the United 
States market than Mexico. This points to heroin produc-
tion in Colombia having a greater degree of importance 
than that reflected in the available potential production 
estimates, and/or different interpretations could be drawn 
from the United States Heroin Signature Program, since 
“investigative reporting suggests that heroin producers in 
Mexico maybe using Colombian processing techniques”.83
E. COCAINE MARKET 
Global trends in the main supply 
indicators
Most indicators, including cultivation of coca bush, manu-
facture of cocaine, seizures of cocaine and prevalence esti-
mates in the major consumer countries, suggest that in 
recent years the cocaine market has, on the whole, been 
declining. This finding primarily reflects the situation in 
North America, where the cocaine market declined signifi-
cantly over the period 2006-2012, and, to a lesser extent, 
in Western and Central Europe, where the cocaine market 
appears to have stabilized following many years of growth. 
In contrast, over the past decade the prevalence of cocaine 
use appears to have increased in several regions with large 
populations, notably South America, but also, to a lesser 
extent, Africa and Asia. Globally, this has resulted in a shift 
in the demand for cocaine. Moreover, several regions not 
previously associated with large-scale use of or trafficking 
in cocaine have shown signs of emerging as markets for 
cocaine. There is no certainty that cocaine use will remain 
concentrated in the Americas, Europe and Oceania. In 
Africa and Asia, which account for the majority of the 
world’s population, the prevalence rate of cocaine use, 
while still low, holds the potential to grow. In the long 
term, the growth in global population maybe a major driv-
ing force in setting the trend for global demand.
Cultivation, production and manufacture 
of cocaine
Global illicit cultivation of coca bush in 2011 remained at 
around the same level as in 2010. Despite the uncertainty 
in estimates of cocaine manufacture, the same can be 
assumed for global cocaine manufacture. An overview of 
81 International Narcotics Control Strategy Report, vol. 1, Drug and Chemi-
cal Control.
82 The Government of Mexico does not validate the estimates provided 
by the United States of America, as they are not part of its official 
figures and it does not have information on the methodology used 
to calculate them. The Government of Mexico is in the process of 
implementing a monitoring system in collaboration with UNODC to 
estimate illicit cultivation and production.
83 National Drug Intelligence Center of the U.S. Department of Justice. 
2011 National Drug Threat Assessment, p.27.
global illicit cultivation of coca bush, potential production 
of coca leaf and potential manufacture of cocaine can be 
found in Annex II.
After several years of increases since 2005, the Plurinational 
State of Bolivia saw a decrease in coca bush cultivation of 
12 per cent in 2011. The decrease took place in all three 
growing areas (the Yungas of La Paz, the Cochabamba 
Tropics (Chapare) and Apolo) and was attributed to efforts 
by the Government to eradicate coca bushes, specifically 
in national parks and other areas where the Government 
prohibits coca bush cultivation, and to achieve a reduction 
of such cultivation through so-called rationalization − a 
voluntary reduction negotiated with coca farmers in areas 
where national laws allow and regulate coca bush 
cultivation. 
Colombia and Peru, on the other hand, experienced small 
increases in the area under coca bush cultivation. However, 
the small nominal increase in area in Colombia should be 
interpreted with caution, as a determination of whether 
the 2011 figure was statistically different from 2010 cannot 
be made under the applied methodology. In Colombia, 
cocaine manufacture was estimated to be slightly lower in 
2011 than in 2010, as the per-hectare yield decreased from 
4.6 tons of fresh coca leaf per year in 2010 to 4.2 tons in 
2011 and, as a result, total production of fresh coca leaf 
decreased by 14 per cent to 263,800 tons in 2011. 
For the first time, an estimate of coca bush cultivation in 
Peru with the reference date of 31 December is presented 
to improve the comparability of cultivation figures among 
countries.84 This estimate takes into account eradication 
that happened after the acquisition of satellite imagery, the 
main data source for the coca area estimate, and the end 
of the survey year. It represents the net area under coca 
bush cultivation on 31 December in Peru (62,500 ha) and 
is lower than the estimates interpreted from satellite 
imagery collected in the preceding months (64,400 ha). 
Since the net area under coca bush cultivation on 31 
December is a concept also used by Colombia, this devel-
opment improves the comparability of estimates between 
the two countries. However, for comparisons with past 
years the previously published estimated area interpreted 
from satellite imagery was used for the global coca bush 
cultivation estimate to maintain consistency in the histori-
cal series of estimates. 
A comparison of the long-term trends in cultivation of 
coca bush and manufacture of cocaine suggests that the 
noticeable decline in the total area under cultivation that 
occurred between 2001 and 2003, which essentially deter-
mined a transition between two relatively stable periods 
(before and after 2002), was offset by an increase in effi-
ciency in the manufacturing chain from coca bush to 
cocaine hydrochloride. Indeed, while the estimated total 
84 For a discussion of different area concepts and the effect of eradication 
on comparability see World Drug Report 2012, pp. 41 and 42.
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area under cultivation in 2011 stood at three quarters of 
the level in 1990, the quantity of cocaine manufactured 
in 2011 was at least as high as the level in 1990 based on 
the lower estimate, with the higher estimate being equiva-
lent to an increase of slightly more than a third. The cul-
tivation and manufacture estimates imply an average 
overall yield of 4.2 kg of cocaine per hectare of coca bush 
over the period 1990-2001, and an average range of 5.1-
6.8 kg per hectare over the period 2009-2011.
Global trends in the main  
demand indicators
The latest estimates by UNODC indicate that 17 million 
people used cocaine at least once in the past year, equiva-
lent to 0.37 per cent of the global population aged 15-64 
(as of 2011). For an extended period, global demand for 
cocaine was dominated by two major consumer markets: 
North America and Western and Central Europe. Today, 
these two markets together are estimated to account for 
approximately one half of cocaine users globally. The extent 
of cocaine use appears to have been contained recently in 
both of these well-established markets. However, a com-
parison of the currently estimated number of cocaine users 
with users for the period 2004-2005 (see World Drug 
Report 2006, United Nations publication, Sales No. E.06.
XI.10), based on the information available to UNODC at 
Fig. 46. Comparison of long-term trends in coca bush cultivation and cocaine manufacture,  
1990-2011
Source: UNODC international crop monitoring programme.
a As of 2005, new conversion factors have been applied for Colombia. Although the transition may have been gradual, UNODC believes that the new fac-
tors reflect real improvements in efficiency in the manufacture of cocaine in Colombia. The value for 2004, which represents a significant increase, is based 
on the old conversion factors.
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Fig. 47. Distribution of cocaine users (annual prevalence), figures for 2011 compared with figures  
for the period 2004-2005
Source: UNODC estimates.
2004-2005
7%
2%
25%
15%
49%
North America
Latin America and the Caribbean
Western and Central Europe
Eastern and South-Eastern Europe
Africa
Asia
Oceania
2011
27%
21%24%
15%
8%
North America
Latin America and the Caribbean
Western and Central Europe
Eastern and South-Eastern Europe
Africa
Asia
Oceania
E. Cocaine market 39
W
O
R
L
D
 D
R
U
G
 R
E
P
O
R
T
 2
01
3
the time, indicates a significant increase in Africa, Asia, 
Oceania, Latin America85 and the Caribbean and Eastern 
and South-Eastern Europe.26
Several factors may be contributing to the increased impor-
tance of the markets of Africa, Asia, Oceania, Latin Amer-
ica and the Caribbean and Eastern and South-Eastern 
Europe. Apart from the social, psychological and cultural 
factors that may influence the use of an illicit substance 
such as cocaine, one other factor that may influence the 
extent of cocaine use – or indeed the use of any other drug 
- is the so-called spillover effect, whereby the ready avail-
ability of a drug, relatively low prices and proximity to 
source in production and transit countries may play a role 
in driving up its use. In the case of cocaine, this may apply 
in particular to Latin America and, to a lesser extent, West 
and Central Africa. The latest UNODC estimates indicate 
that, as at 2011, Latin America, the Caribbean and Africa 
collectively account for 6.2 million users (or 36 per cent 
of the global total). 
Another factor which could determine changes in demand 
relates to the geographic distribution of the global popula-
tion. The relatively stable markets of Western and Central 
Europe and North America account for only 14 per cent 
of the global population aged 15-64, so that even a minor 
change in the prevalence rate outside these markets can 
result in a major shift in global demand. UNODC esti-
mates annual prevalence rates of 1.3 per cent for South 
America, 0.43 per cent for Africa and 0.05 per cent for 
Asia, all of which represent significant increases in com-
parison with its assessment of these rates for the period 
2004-2005 (respectively, 0.7 per cent, 0.2 per cent and 
0.01 per cent). The prevalence rates for Asia and Africa 
continue to be low compared with the established cocaine 
85 In accordance with the classification used by UNODC, Mexico is 
included with North America rather than Latin America.
markets, so the potential for further growth cannot be 
discounted.
A related factor that could drive the demand for cocaine 
(or any other drug), if all other factors remain unchanged, 
is the sheer growth in global population and the conse-
quent growth in the number of potential users. Indeed, 
given the relative stability of prevalence rates, global popu-
lation appears to be, in and of itself, a reasonable indicator 
for the number of cocaine users. However, the impact of 
this can be seen more in the absolute number of users 
rather than their geographic distribution; despite the fact 
that countries in Asia and Africa tend to have higher popu-
lation growth rates than countries in North America and 
Western and Central Europe, the proportion of the global 
population aged 15-64 in Asia and Africa together stood 
at 74 per cent in 2005 and had not yet reached 75 per cent 
by 2011. 
Annual prevalence estimates of cocaine use reflect in part 
the scale of cocaine consumption, but these figures must 
be supplemented with other information. Firstly, the avail-
ability of data from Africa and Asia is limited, in part 
because cocaine use in these regions has so far been low 
and limited to a few countries and therefore possibly has 
not been perceived as a major threat; hence the correspond-
ing levels of uncertainty are especially pronounced. Sec-
ondly, changes in the estimates may be driven partly by 
improvements in the methodology of UNODC and new 
national estimates that have become available. Thirdly, the 
average per capita consumption of cocaine by users needs 
to be determined by taking into account the significant 
variation among different countries in the prevalent culture 
and changing patterns in the use of different forms of 
86 A moderate increase in the number of users can also be seen for West-
ern and Central Europe, but it is believed that this does not reflect the 
recent, shorter-term trend.
Fig. 48. Number of people who have used cocaine in the past year, figures for 2011 compared  
with figures for the period 2004-2005
Source: UNODC estimates.
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cocaine (such as crack cocaine as opposed to cocaine salts), 
in associated modes of administration (snorting, smoking 
and injecting) and even in the nature of the consumed 
product, with reports suggesting that cocaine is increas-
ingly adulterated and cut with a variety of substances.
Cocaine use is often perceived to be more prevalent within 
the more affluent segments of society and the more afflu-
ent countries. As discussed above, the extent of cocaine use 
may be influenced by numerous factors, and wealth may 
not be foremost among them; there are several examples 
of wealthy countries with low prevalence rates and less 
wealthy countries with higher prevalence rates. Moreover, 
for certain forms of cocaine, notably some forms of cocaine 
base consumed in South America, a typical dose is signifi-
cantly less expensive than a typical dose of cocaine salt. 
Nevertheless, although these are macro-level indicators, a 
comparison of national prevalence rate estimates with gross 
domestic product (GDP) per capita suggests that, while a 
relationship between these variables is difficult to ascertain 
at a global level, within certain regional groupings, notably 
those with less established or developing consumer mar-
kets, the suggestion of a correlation between disposable 
income and cocaine use may not be entirely groundless. 
More generally, such a link may possibly be observed 
within certain groups of countries that are relatively uni-
form in terms of other relevant parameters, such as those 
of a geographic, historical and even cultural nature. If 
indeed an association between an increase in disposable 
income and the risk of cocaine use were to be demon-
strated, notwithstanding the other contributing factors, 
this would again point to Asia, with several highly popu-
lated countries registering strong and sustained economic 
performance, as a region exposed to potential increased 
cocaine use.
However, other socioeconomic aspects may also have a bear-
ing; in the case of European countries with an established 
cocaine market, for example, the human development index 
appears to be more relevant than GDP. Although the data 
is inconclusive, it suggests that further investigation of the 
relationships between illicit drug use and socioeconomic 
parameters may be warranted.
Comparing supply and demand
The long-term trend in the number of cocaine users world-
wide indicates a gradual increase, driven to a large extent 
by the growth in global population. Interestingly, despite 
fluctuations due to short-term developments in the key 
countries of Bolivia (Plurinational State of ), Colombia and 
Peru, estimates appear to show that the total quantity of 
manufactured cocaine has kept pace with demand in the 
long run. 
Short periods where the increase in manufacture appeared 
to outperform or underperform that in the number of users 
were followed by corrections in the opposite direction, so 
that the broader equilibrium between supply and demand 
was roughly maintained.
The shorter-term developments in recent years are less clear 
because of the uncertainty in recent manufacture estimates, 
connected with the introduction of alternative conversion 
factors for Bolivia (Plurinational State of ) and Peru. The 
upper estimates (which reflect the higher conversion fac-
tors) would suggest that estimates of how much cocaine 
was manufactured remained approximately in line with 
global demand, even though the trend was for declining 
levels of manufacture in the short term; if, instead, the 
lower estimates reflect reality, it would appear that global 
supply has now been below global demand for a significant 
period of time.87
87 It should be noted that this analysis reflects only the number of cocaine 
users and global cocaine manufacture estimates, and not necessarily the 
quantities consumed globally or quantities available for consumption. 
Fig. 49. Global population aged 15-64 and corresponding annual prevalence of cocaine use, 2011
Source: UNODC estimates (prevalence rates); United Nations, Department of Economic and Social Affairs, Population Division (population).
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In both South America and Central America, when seizure 
quantities and the number of cocaine users are expressed 
as a proportion of the global totals, cocaine seizures clearly 
outperform cocaine use, in keeping with the role of these 
regions as source and transit regions. In the stable and well-
established consumer markets of North America and West-
ern and Central Europe, the relationship is inverted but 
the discrepancy is moderate, with the share of cocaine use 
only slightly more than double that of cocaine seizures at 
most (in the case of Western and Central Europe). In the 
developing and possibly the emerging markets, on the 
other hand, cocaine use outperforms cocaine seizures by 
far; in other words, the amount of seized cocaine per user 
is significantly lower than in North America or Western 
and Central Europe (see figure 54).
Trends in total seizures confirm the picture of stability or 
decline in the major production, consumer and transit 
regions, with pronounced upward trends being registered 
in regions where cocaine consumption has so far been lim-
ited, notably East Africa, Eastern Europe, South Asia and 
East and South-East Asia. A strong increase was also reg-
istered in Oceania, particularly in Australia, where cocaine 
use is already significant.
These depend also on other factors such as per capita consumption, 
seizures and purity of cocaine seized. Taking these elements into 
account would require improved and detailed knowledge of the param-
eters, but would likely result in the trend being adjusted downwards, 
for both supply and demand.
A shift in cocaine use in the Americas
Large quantities of cocaine continue to be smuggled from 
South America, notably Colombia, to the United States 
and Canada, with Ecuador, Mexico and countries in Cen-
tral America as transit countries. However, the market for 
cocaine in the United States appears to have declined con-
siderably, with both seizures and annual prevalence of 
cocaine use peaking in 2006 and following a parallel 
declining trend since then, with the exception of a rebound 
in cocaine seizures in 2011. The average purity of cocaine 
seized in the United States fell significantly between 2006 
and 2009 at both the retail level (from 74 per cent to 47 
per cent, for quantities of 2 g or less) and higher up in the 
distribution chain (from 84 per cent to 71 per cent for 
quantities greater than 50 g); moreover, reduced levels were 
sustained in 2010 and 2011, with only a slight rebound 
at the retail level (in 2011, these average purity levels stood 
at 52 per cent and 71 per cent respectively). Purity-adjusted 
prices at the retail level peaked in 2009 but as of 2011 
remained higher than in the 2002-2006 period, even when 
adjusted for inflation.88
It is likely that disruptions in the chain of supply resulting 
from law enforcement intervention and other develop-
ments, such as inter-cartel violence, contributed signifi-
cantly to reducing the availability of cocaine at destination, 
with seizures moving closer to source (declining in the 
United States at around the same time as Colombia regis-
tered an increase). A breakdown of cocaine seizures in 
88 United States, Office of National Drug Control Policy, National Drug 
Control Strategy: Data Supplement 2012.
Fig. 50. Cocaine prevalence compared with 
gross domestic product (per capita), 
2009-2011
Source: UNODC (prevalence rates); and IMF (gross domestic prod-
uct per capita).
a Classification of the United Nations Department of Economic and Social 
Affairs, Statistics Division.
Fig. 51. Cocaine prevalence compared with  
human development index in European 
countries with an established  
consumer market,a 2009-2011
Source: UNODC (prevalence rates); and UNDP (human develop-
ment index).
a Denmark, France, Germany, Iceland, Ireland, Netherlands, Norway, Spain 
and Switzerland. No aggregate prevalence data were available for the 
United Kingdom.
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Colombia also suggests that the Atlantic route has gained 
in importance in comparison with the Pacific route. Sei-
zures by United States authorities along the south-west 
border increased over the period 2008-2011; in contrast, 
seizures in Mexico in 2010 and 2011 stood at approxi-
mately one fifth of the peak level of 2007.
Brazil, with its extensive land borders with all three major 
source countries for cocaine, a large population, significant 
levels of use of both cocaine salt and crack cocaine and a 
long coastline affording easy access to the Atlantic ocean 
for onward trafficking to Africa and Europe, plays an 
important role in the global cocaine market as both a des-
tination and a transit country.
In 2011, more than half of the cocaine seized in Brazil 
originated in the Plurinational State of Bolivia (54 per 
cent), followed by Peru (38 per cent) and Colombia (7.5 
Fig. 52. Comparison on long-term trends in main global cocaine supply and demand indicators,  
1990-2011
Source: UNODC international crop monitoring programme (manufacture estimates) and estimates (prevalence rates); United Nations, 
Department of Economic and Social Affairs, Population Division (population data).
a As of 2005, new conversion factors have been applied to Colombia. Although the transition may have been gradual, UNODC believes that the new factors 
reflect real improvements in efficiency in Colombia. The value for 2004, which represents a significant increase, is based on the old conversion factors.
b Direct estimates for years prior to 1996 were not available. For 1990-1995, the prevalence rate is assumed to be constant at the 1996 level.
Fig. 53. Global cocaine seizures, 2000-2011
Source: UNODC, data from annual report questionnaire and other 
official sources.
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89 The Plurinational State of Bolivia, the only 
country among the three major source countries not to 
have direct access to the open sea, identified Brazil as the 
foremost planned destination for seized cocaine.
Brazil also reported an increase in the use of cocaine in the 
89 Annual report questionnaire replies submitted by Brazil for 2011.
general population. According to a study90 conducted 
among college students in the 27 Brazilian state capitals, 
the annual prevalence of cocaine use among college stu-
dents stood at 3 per cent. The estimated prevalence of 
cocaine use among the general population is estimated at 
1.75% and is also consistent with the trend of increasing 
cocaine use in Brazil.
Brazil is also a point of transit for cocaine consignments 
trafficked to West and Central Africa and Europe, notably 
the Iberian peninsula. It appears that the linguistic and 
cultural ties with Portugal and lusophone countries in 
Africa play a role in this phenomenon, as Brazil occurs 
more frequently as a country of provenance among indi-
vidual cocaine consignments seized by Portugal than those 
reported by Spain. In the case of seizures reported by Por-
tugal, the frequency of Brazil as the country of provenance 
also rose markedly from 2008 to 2009.
Developments in Europe
In parallel with the trend in the United States, cocaine 
seizures in Western and Central Europe declined rapidly 
from the peak level of 2006, and appear to have stabilized 
at a lower level. A similar trend, starting in 2008, was seen 
in the estimated average purity of cocaine, based on price 
and purity data from 14 countries in Western and Central 
Europe. Estimations of the purity-adjusted prices in these 
countries, however, suggest that the reduction in availabil-
ity was not as pronounced as in the United States; moreo-
90 Brazil, National Secretariat for Drug Policies, 1st Nationwide Survey on 
the Use of Alcohol, Tobacco and other Drugs among College Students in the 
27 Brazilian State Capitals (Brasilia, 2010).
Fig. 55. Cocaine seizure trends, 2010/11  
compared with 2008/09, by subregion
Source: UNODC, data from annual report questionnaire and other 
official sources.
Note: Due to lack of available data, the subregion of southern Africa is not 
included.
a The decline in South-Eastern Europe is mainly due to a single large seizure 
in Romania in 2009, and may not necessarily reflect the trend in cocaine 
trafficking in South-Eastern Europe.
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Fig. 56. Annual prevalence of cocaine use and 
cocaine seizures in the United States, 
2000-2011
Source: UNODC, data from annual report questionnaire and other 
official sources.
Fig. 57. Cocaine seizures in the United States 
and Colombia, 2002-2011
Source: UNODC, data from annual report questionnaire and other 
official sources.
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ver, the purity-adjusted price in Western and Central 
Europe remains moderately higher than in the United 
States. Prevalence data from some of the major consumer 
countries in Western Europe corroborate the general pic-
ture of a decline in the cocaine market. However, other 
parts of Europe with a limited market for cocaine have 
shown signs of a possible emergence as consumer or transit 
countries.
Spain, an important transit and consumer country for 
cocaine in Europe, registered a pattern similar to that 
observed in the United States, with seizures falling steadily 
between 2006 and 2011, and the prevalence estimates for 
2009 and 2011 also showing distinct declines. Prevalence 
data for England and Wales also showed a decline from an 
annual prevalence rate of 3.0 per cent among the popula-
tion aged 16-59 in 2008/09 to 2.2 per cent in 2011/12.
Cocaine use and trafficking in Eastern and South-Eastern 
Europe has so far been limited. However, some countries 
in these regions have registered recent increases or fluctua-
tions in cocaine seizures. Turkey attributed the recent 
increase in cocaine seizures to its role as a destination coun-
try and its more recent role as a transit country. Reports 
on the provenance of cocaine in 2010 and 2011 from 
Albania, Austria, Bulgaria, Hungary, Poland, Romania, 
Serbia, Turkey and Ukraine, taken together, point to the 
possible emergence of cocaine trafficking routes overlap-
ping to some extent with the established Balkan route for 
heroin trafficking and being used to convey limited quan-
tities of cocaine to Central and Eastern Europe. 
The overlap between cocaine and heroin trafficking routes 
may begin in Turkey, or possibly also closer to the destina-
tion, such as the port of Constanta in Romania. Austria 
has concluded, based on drug seizures made in 2011, that 
10 per cent of cocaine entered its territory via the Balkan 
Fig. 58. Distribution of countries of provenance of individual seizures of cocaine-type drugs reported 
by Portugal and Spain, by number of seizures, 2007-2011
Source: UNODC, individual drug seizure database.
Note: Reporting countries are asked to provide information about the country where the drugs were obtained (or, in the case of unaccompanied shipments, 
the departure country). For the purposes of this figure, this is considered as the provenance of the drug. However, countries are also asked to provide infor-
mation on the country of origin, i.e., where the drugs were produced/manufactured. In cases where the country where the drugs were obtained is not speci-
fied, or coincides with the country that made the seizure, the country of origin is taken as the provenance. In order to reflect patterns in transnational 
trafficking, any cases where the provenance coincides with the country making the seizure, or where no information on provenance is known, are excluded.
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Fig. 59. Cocainea seizures in Western and  
Central Europe, 2000-2011
Source: UNODC, data from annual report questionnaire and other 
official sources. 
a Includes cocaine salts, base, paste and crack.
b For 2011, the quantity for the United Kingdom covers England and Wales 
only (and refers to the financial year 2011/12).
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route. According to Turkish authorities,91 certain large 
organizations in Turkey known to have been involved in 
heroin trafficking in the past have shifted their operations 
in part to cocaine smuggling. In addition to seizures made 
at airports Turkish law enforcement agencies made larger 
seizures of cocaine found in containers and maritime ves-
sels in 2011.
91 Turkish National Police, Department of Anti-Smuggling and Orga-
nized Crime, Turkish Report of Anti-Smuggling and Organized Crime, 
2011 (Ankara, March 2012).
The provenance of cocaine entering Europe along this route 
appears to vary. Frequently, cocaine transits Africa before 
reaching South-Eastern Europe, and the involvement of 
West African nationals is common. In other cases, traffick-
ers obtain cocaine directly from South America, frequently 
from Brazil. Limited but non-negligible amounts of cocaine 
have also been seized in the Syrian Arab Republic, Lebanon 
and, notably, Israel, which registered an increase in 2011; 
hence a link between this emerging route and the Near and 
Middle East cannot be excluded. 
Another area of Europe that has shown signs of a possible 
expansion of the cocaine market is that of the Baltic coun-
tries. Estonia, Latvia and Lithuania each registered a spike 
in cocaine seizures in 2010. This included significant quan-
tities being trafficked into these countries by sea. Reports 
suggest that some of the cocaine reaching the Baltic States 
is trafficked further to Eastern Europe and possibly Scan-
dinavia. Based on expert perceptions, Estonia reported 
recent increases in the use of cocaine in its own consumer 
market.
An expanded market in Oceania
Cocaine seizures in Oceania reached new highs in 2010 
and 2011, driven mainly by the quantities reported by 
Australia. In addition to the major transit countries for 
cocaine, Canada was identified by both Australia and New 
Zealand as a transit country for significant quantities of 
cocaine reaching their territories. In terms of the number 
of cases, the United Kingdom, the United States and Thai-
land were also prominent embarkation countries among 
cocaine border detections in Australia over the 2010/11 
financial year.
Australia registered increasing seizures across most drug 
types, so the upward trend may possibly be attributable to 
changes in law enforcement efforts rather than the avail-
ability of cocaine. However, the annual prevalence rate for 
Fig. 60. Cocaine retail prices in the United States and Western and Central Europe, 2003-2011
Source: Estimates based on annual report questionnaire and data from Europol and the United States Office of National Drug Control 
Policy.
Fig. 61. Annual prevalence of cocaine use and 
cocaine seizures in Spain, 1999-2011
Source: UNODC, data from annual report questionnaire and other 
official sources; annual report questionnaire and EMCDDA (preva-
lence).
a Only one prevalence estimate was available for the reference period 
2005-2006.
b Only one prevalence estimate was available for the reference period 
2007-2008.
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cocaine use among the population aged 14 and over was 
estimated at 2.1 per cent in 2010, up from 1.6 per cent in 
2007 and 1.0 per cent in 2004. This suggests that the 
cocaine consumer market in Australia has expanded, and 
there is currently no evidence to show that the increasing 
trend has stabilized.
Possibly emerging markets in Africa 
and Asia 
Overall, the use of cocaine in Africa remains limited in 
comparison with the markets in the Americas and Western 
and Central Europe. South Africa and Nigeria have both 
had a sizeable consumer market for cocaine for some time, 
and both of these countries also play a significant role as 
transit countries. By 2007, West Africa had acquired an 
important role as a transhipment hub for cocaine trafficked 
from South America to Europe. Although the importance 
of this role may have since receded, the cocaine market in 
Africa may have grown more complex. West African nation-
als remain prominent among traffickers and organized net-
works smuggling cocaine (as well as other drugs) to various 
destinations. The routes from West Africa to Europe may 
have shifted away from flights to European airports and 
the northbound maritime routes along the African coast 
that prevailed in 2007 to land trafficking routes. The avail-
ability of cocaine in West Africa and along the land traf-
ficking routes may also have fuelled an increase in cocaine 
use in West and North Africa; over the period 2009-2011, 
Algeria, Burkina Faso, Côte d‘Ivoire and Morocco each 
reported increases in cocaine use based on expert percep-
tions, and the latest changes reported by Ghana and Togo 
(relative to 2008) also indicated rising cocaine use.
The prevalence rate in Kenya, while probably still lower 
than in Nigeria or South Africa, implies a sizeable consumer 
market of its own, and there are indications that East Africa 
may have acquired increased importance as a destination 
or as a transit region. The United Republic of Tanzania 
reported seizures of 65 kg in 2010, a level which, although 
small, significantly exceeds those recorded in previous years. 
Although comprehensive data from the United Republic 
of Tanzania for 2011 were not available, the partial total 
had reached 85 kg by April 2011. It is not clear whether 
these quantities were intended for the consumer market in 
East Africa or possibly other destinations. 
The provenance of cocaine in East Africa was also not clear, 
but in addition to West Africa, the Gulf region, itself a 
region with a limited but possibly growing market, has also 
Fig. 62. Cocaine seizures in selected countries in Europe with previously limited cocaine markets 
registering recent increases or fluctuations, 2005-2011
Source: UNODC, data from annual report questionnaire and other official sources. 
a The high level of seizures in Romania in 2009 was mainly due to a single large seizure in the port of Constanta.
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emerged as a possible source. The United Arab Emirates 
and Saudi Arabia have both registered increased seizures 
of cocaine in recent years. Uganda, as well as Poland and 
Thailand, identified the United Arab Emirates as a transit 
country for seized cocaine reaching their territory in 2011, 
and Yemen identified the Comoros as a destination. Qatar 
was also identified as a transit country by Japan, which has 
in turn increased its seizures of cocaine.
Among the markets with the potential for growth in the 
extent of cocaine use, that of East and South-East Asia 
arguably presents the greatest risk of expansion. Seizures 
in Hong Kong, China, rose sharply to almost 600 kg in 
2010 and had topped 800 kg by 2011. According to 
authorities in Hong Kong, China,92 recent seizures 
included single cases of 649 kg, 567 kg and 147 kg. In 
2011, an increase of slightly more than 10 per cent was 
recorded in the number of registered cocaine users, and 
there were 11 cases of small-scale processing to obtain crack 
cocaine (probably starting from cocaine salt). The Philip-
pines has also seized relatively large quantities of cocaine 
in recent years, some of which was recovered from a ship-
ment that was likely intended for Hong Kong, China. 
Thailand, a country with a large consumer market for 
stimulants (specifically ATS) but, so far, limited cocaine 
use, also identified the Philippines among the transit coun-
tries for cocaine reaching its territory, in addition to Paki-
stan, another country which recorded uncharacteristically 
high cocaine seizures in 2010. A recent survey on drug use 
in Pakistan confirms the emergence of limited use of 
cocaine in Pakistan.93
92 Country report by Hong Kong, China, presented at the Thirty-sixth 
Meeting of Heads of National Drug Law Enforcement Agencies, Asia 
and the Pacific, Bangkok, 30 October-2 November 2012.
93 UNODC and Pakistan, “Drug use in Pakistan 2013: technical sum-
mary report”.
Despite these signs of a tentative emerging cocaine market, 
limited price data from countries in Asia does not suggest 
any significant increases in availability (although they 
would be compatible in some cases with a possible increase 
in demand), with the possible exception of Japan, where 
the typical retail price in 2011 decreased moderately 
between 2008 and 2011.
Fig. 64. Cocaine seizures in selected countries in Africa and Asia with previously limited cocaine 
markets registering recent increases or fluctuations, 2005-2011
Source: UNODC, data from annual report questionnaire and other official sources. 
a For Kenya and the United Arab Emirates, comprehensive seizure data for 2011 were not available.
b For 2011, the quantity for the United Republic of Tanzania covers January-April only.
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Central America: drug trafficking and violence
Cocaine has been trafficked through Central America for 
decades, but the importance of the region to the flow of 
cocaine increased after 2000 and again after 2006, follow-
ing an increase in drug law enforcement efforts in Mexico. 
While the cocaine flow through the region declined mark-
edly over the period 2006-2011, some of it was displaced 
to Central America, as traffickers looked for alternative 
routes, particularly along the border between Guatemala 
and Honduras. In the process, they often entered into 
cooperation with local organized criminal groups, which 
had long been engaged in a range of criminal activities, 
including drug trafficking, extortion and smuggling of 
migrants. This development appears to have intensified 
competition between local groups and to have led to grow-
ing levels of violence in some areas. 
The correlation between contested trafficking areas and 
high homicide rates is most obvious in Guatemala and 
Honduras. Some of the most violent areas lie along the 
Honduran coast, on both sides of the Guatemalan/Hon-
duran border, as well as in Guatemala along the borders 
with Belize and Mexico. 
Homicide rates by municipal area in northern Central America, 2011
 
Source: UNODC, Transnational Organized Crime in Central America and the Caribbean: A Threat Assessment (September 2012).
Homicide rates in northern Central America, 2000-2011
 
Source: UNODC Homicide  Database.
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F. THE MARKET FOR AMPHETA-
MINE-TYPE STIMULANTS 
New psychoactive substances have 
become a global phenomenon 
The range of new psychoactive substances on the markets 
for ATS is at its peak, exceeding the number of substances 
that are currently within the scope of the Single Conven-
tion on Narcotic Drugs of 1961 and the Convention on 
Psychotropic Substances of 1971. The issue of NPS is cov-
ered extensively in chapter II.
Global amphetamine-type stimulant 
seizures rise to highest level ever 
recorded
Seizures of ATS have reached new highs: 123 tons in 2011 
compared with 74 tons in 2010 , a 66 per cent rise. Sei-
zures increased across all regions, with Asia, North America 
and Europe registering dramatic increases.
The overall increase in ATS seizures is mainly due to surg-
ing methamphetamine seizures, which grew by 73 per cent 
from 51 tons in 2010 to 88 tons in 2011. The highest 
methamphetamine seizures were reported by Mexico, 
where seizures more than doubled, from 13 tons to 31 
tons, and surpassed for the first time those of the United 
States which seized 23 tons in 2011, up from 15 tons in 
2010. Seizures rose steeply in the Americas (28 tons to 54 
tons), Asia (21 tons to 32 tons) and Europe (576 kg to 2 
tons). 
Methamphetamine accounts for 71 per cent of global ATS 
seizures and, as in previous years, most of the world’s meth-
amphetamine seizures (61 per cent) are reported by coun-
tries in North America. After a significant surge in 
methamphetamine seizures in Mexico in 2010, seizures 
doubled again from 13 tons to 31 tons, making it the 
Categories of new psychoactive substances sold on the global market
Synthetic cannabinoids: These are cannabinoid receptor 
agonists which produce effects similar to those of delta-
9-tetrahydrocannabinol (THC), the principal psychoac-
tive component in cannabis. Synthetic cannabinoids are 
often laced with herbal products and sold as Spice, K2, 
Kronic, etc.
Synthetic cathinones: These are analogues and derivatives 
of the internationally controlled substance cathinone, one 
of the active components of the khat plant. They generally 
have stimulant effects and include frequently reported 
NPS such as mephedrone and methylenedioxypyrov-
alerone (MDPV). 
Ketamine: A human and veterinary anaesthetic which acts 
as a stimulant at low doses and a hallucinogen at high 
doses. It is one of the most widespread NPS in Asia.
Phenethylamines: This group contains substances related 
to amphetamine and methamphetamine, and generally 
produces stimulant effects. However, modification of these 
compounds can lead to potent hallucinogens such as 
Bromo-Dragonfly. 
Piperazines: These substances are frequently sold as 
“ecstasy” because of their central nervous system stimulant 
properties. The most commonly reported substances in 
this group are N-benzylpiperazine (BZP) and 1-(3-chloro-
phenyl)piperazine (mCPP). 
Plant-based substances: This group includes plants with 
psychoactive properties. The most frequently reported are:
Kratom (Mitragyna speciosa), a plant indigenous to 
South-East Asia that contains the alkaloid mitragy-
nine; a stimulant at low doses and sedative at high 
doses.
, a plant indigenous to forest areas in 
Oxaca, Mexico, which contains the active ingredient 
salvinorin A, a hallucinogenic substance.
Khat (Catha edulis), a plant native to the horn of 
Africa and the Arabian peninsula. The leaves of the 
plant are chewed, resulting in the release of the stimu-
lants cathinone and cathine.
Other substances: These include aminoindanes (stimu-
lants), phencyclidine-type substances (hallucinogens) and 
tryptamines (hallucinogens).
Fig. 66. Global seizures of amphetamine-type 
stimulants, 2002-2011 
Source: UNODC, data from the annual report questionnaire and 
other official sources.
a Including seized amphetamine, “ecstasy”-type substances, 
methamphetamine, non-specified amphetamine-type stimulants, 
other stimulants and prescription stimulants. For the categories of 
other stimulants and prescription stimulants, seizures reported by 
weight or volume only are included.
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country where the most methamphetamine was seized. 
East and South-East Asia also continue to make up a sig-
nificant share of the global methamphetamine market, with 
the highest seizures reported from China (10 tons in 2010 
to 14 tons in 2011), Indonesia (354 kg to 1 ton), Malaysia 
(920 kg to 1 ton) and Thailand (6 tons to 10 tons).
Methamphetamine laboratories were reported by all 
regions. Most methamphetamine laboratories continue to 
be reported by the United States, where their numbers 
quadrupled from 2,754 in 2010 to 11,116 in 2011. In 
North America, Mexico and Canada reported 159 and 35 
laboratories respectively, both showing an upward trend 
compared with 2010. In addition, 350 laboratories were 
reported by countries in Europe, most of them by the 
Czech Republic, where 338 laboratories were identified. 
To compound the situation, new methamphetamine labo-
ratories have been reported by some countries for the first 
time. The dismantling of one methamphetamine labora-
tory was reported by Belgium and four such laboratories 
were seized in the Russian Federation. Poland saw a re-
emergence of the existence of methamphetamine labora-
tories with the identification of two laboratories for the 
first time since 2007. Clandestine manufacture is also 
taking place in Oceania, with 109 methamphetamine labo-
ratories reported by New Zealand. 
Amphetamine seizures were also on the increase in 2011, 
the most significant taking place in the Near and Middle 
East and South-West Asia, from 14 tons in 2010 to 20 tons 
in 2011. As in previous years, the highest amphetamine 
seizures were registered by Saudi Arabia (11 tons), the 
Syrian Arab Republic (4 tons) and Jordan (4 tons). Total 
seizures rose by 55 per cent, from 20 tons in 2010 to 31 
tons in 2011, after having declined in 2010. Increases were 
reported by all regions. In Europe, particularly in the Rus-
sian Federation, seizures of amphetamines increased from 
142 kg in 2010 to more than 2 tons in 2011. Laboratory 
activity was reported to have increased in Belarus, where 
nine laboratories were seized in 2011 after none had been 
reported in 2010 and two in 2009. At the global level, the 
number of reported amphetamine laboratories remained 
largely stable, with 131 laboratories uncovered in 2011 
compared with 103 in 2010. Europe accounted for most 
laboratories (69 laboratories) seized worldwide. With 
regard to the Near and Middle East region, where most of 
the world’s amphetamine seizures are made, Lebanon 
reported the seizure of three laboratories manufacturing 
amphetamine base and two Captagon94 laboratories. 
94 Captagon was originally the trade name for fenetylline, a synthetic 
stimulant. Analysis of seized Captagon pills show that most contain 
amphetamine and other ingredients such as caffeine and theophylline.
Fig. 67. Countries reporting the highest meth-
amphetamine seizures, 2010-2011
Source: UNODC, data from the annual report questionnaire and 
other official sources.
Fig. 68. Methamphetamine seized worldwide 
and in North America, 2002-2011 
Source: UNODC, data from the annual report questionnaire and 
other official sources.
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zures in “powder form”, all other countries shown in this table seized 
amphetamines in pill form (mostly Captagon).
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There are indications of possible “ecstasy” manufacture in 
Mexico, with 2,500 litres of safrole, one of the principal 
precursors of MDMA, seized at an airport in 2011 and 
three shipments of safrole reported as suspicious since June 
2010.95 Large quantities of methylamine, a non-scheduled 
chemical, which can be used in the manufacture of “ecstasy” 
as well as methamphetamine, have been seized in Mexico 
with a total of 154,000 litres reportedly seized by mid-
2011.96 The number of “ecstasy” laboratories remained 
stable (39 laboratories), with the existence of “ecstasy” labo-
ratories mainly reported by Oceania, East and South-East 
Asia and North America.
With respect to seizures, the global level of “ecstasy” sei-
zures has been stable or declining since 2008. At 3.6 tons, 
compared with 3.8 tons in 2010, seizures of “ecstasy”-type 
substances decreased by 5 per cent in 2011, reflecting fewer 
seizures reported by Canada and China. However, seizures 
rose in Europe and Oceania. Most “ecstasy” was seized in 
the United States, the Netherlands and France. 
Increased seizures of crystalline 
methamphetamine in East and 
South-East Asia point to a more 
diversified market for amphetamine-
type stimulants 
Traditionally, methamphetamine pills are the most wide-
spread ATS in East and South-East Asia. In 2011, however, 
seizures of crystalline methamphetamine reached their 
95 European Monitoring Centre for Drugs and Drug Addiction and 
European Police Office, EU Drug Markets Report: A Strategic Analysis.
96 Precursors and Chemicals Frequently Used in the Illicit Manufacture of 
Narcotic Drugs and Psychotropic Substances: Report of the International 
Narcotics Control Board for 2011 on the Implementation of Article 12 of 
the United Nations Convention against Illicit Traffic in Narcotic Drugs 
and Psychotropic Substances of 1988 (United Nations publication, Sales 
No. E.12.XI.4).
highest level during the past five years, an indication that 
the ATS market has become more diversified. In 2011, a 
total of approximately 8.8 tons of crystalline methamphet-
amine were seized in the region, representing a 28 per cent 
increase over the approximately 7 tons seized in 2010. 
Record-level seizures were reported in a number of coun-
tries during the year. In 2011, more than 1 ton of crystal-
line methamphetamine was seized in Malaysia, representing 
a 39 per cent increase compared with 2010 and the highest 
total ever reported by the country. Indonesia seized more 
than 1 ton of crystalline methamphetamine in 2011, the 
highest total reported during the past five years. Seizures 
in Thailand reached a record high of more than 1 ton in 
2011, much higher than the 706 kg seized in 2010. Record 
seizures were also reported from Cambodia (19 kg) and 
Singapore (14 kg), although the amounts seized were com-
paratively low by regional standards. The largest portion 
of crystalline methamphetamine seizures continued to be 
made in China, where more than 4 tons seized in 2011 
accounted for half of the regional total. 
With respect to methamphetamine pills (“yaba”), the east-
ern Shan State in Myanmar remains a key source in the 
region. In 2011, authorities in Myanmar seized a small 
number of pill pressing machines and related equipment 
used to make methamphetamine pills from two separate 
clandestine methamphetamine manufacturing facilities.97 
However, the low number of manufacturing operations 
dismantled is inconsistent with the high amount of seizures 
made. Methamphetamine pills produced in Myanmar are 
trafficked to neighbouring countries, particularly China, 
the Lao People’s Democratic Republic and Thailand. To a 
lesser extent, methamphetamine pills are also smuggled to 
97 Presentation by the Central Committee for Drug Abuse Control of 
Myanmar at the Global Synthetics Monitoring: Analysis, Reporting 
and Trends (SMART) Programme regional workshop, Phnom Penh, 
24 and 25 July 2012.
Fig. 70. Countries reporting the highest 
“ecstasy”-type substance seizures, 
2010-2011
Source: UNODC, data from the annual report questionnaire and 
other official sources.
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Fig. 71. Crystalline methamphetamine seizures 
in East and South-East Asia, 2007-2011
Source: Based on data collected by the Drug Abuse Information 
Network for Asia and the Pacific including data for Brunei Darus-
salam, Cambodia, China, Indonesia, Japan, the Lao’s People Dem-
ocratic Republic, Malaysia, Myanmar, the Philippines, the Republic 
of Korea, Singapore, Thailand and Viet Nam.
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Bangladesh, where seizures of methamphetamine pills have 
increased, from 812,716 methamphetamine pills in 2010 
to 1,4 million methamphetamine pills in 2011. 
In 2011, seizures of methamphetamine pills remained high 
in East and South-East Asia, a total of 122.8 million meth-
amphetamine pills were seized. While this figure represents 
a 9 per cent decrease compared with the 134.4 million pills 
seized in 2010, it is 33 per cent higher than the 92.1 mil-
lion pills seized in 2009 and a five-and-a-half fold increase 
compared with the 2007 figure (22.4 million pills seized). 
In 2011, the number of pills seized in China (61.9 mil-
lion), Thailand (49.4 million), Myanmar (5.9 million) and 
the Lao People’s Democratic Republic (4.6 million) 
accounted for 98 per cent of the total seizures during the 
year (as these four countries did in 2010). The largest rela-
tive increases were reported by Cambodia (189 per cent), 
Myanmar (169 per cent) and Singapore (120 per cent), 
although the number of methamphetamine pills seized is 
low by regional standards. Viet Nam also reported a large 
increase (65 per cent) in methamphetamine pill seizures 
in 2011, with 366,000 synthetic drug pills seized, most of 
which were likely to have been methamphetamine pills. 
However, methamphetamine pill seizure data are not uni-
formly reported from Viet Nam, making year-by-year com-
parisons for that country difficult.
“Ecstasy” has been in decline in recent years, but in 2011 
“ecstasy” seizures showed an increase in Brunei Darus-
salam, Cambodia, Indonesia, Japan, Malaysia, the Philip-
pines, the Republic of Korea and Thailand. “Ecstasy” 
manufacture continues to be reported in the region, par-
ticularly in Indonesia and Malaysia. Manufacture in the 
region has consisted primarily of pill pressing and re-press-
ing operations, although some “ecstasy” production facili-
ties have been dismantled in Indonesia. Safrole-rich oils, 
which can serve as precursors in the manufacturing process, 
continue to be smuggled from Cambodia and China. 
In 2011, some 400 illicit synthetic drug manufacturing 
facilities were seized in East and South-East Asia, most of 
which were manufacturing methamphetamine. While this 
figure is lower than the number reported for 2010 (442), 
it is more than three times the number of illicit manufac-
turing facilities seized in 2007 (125). China continued to 
report high, albeit declining, levels of illicit synthetic drug 
manufacture with 357 illicit synthetic drug manufacturing 
facilities seized in 2011. It is unclear how many of these 
facilities were specifically manufacturing methampheta-
Fig. 72. Methamphetamine pill seizures by countries neighbouring Myanmar, 2009-2011
Source: Based on data collected by the Drug Abuse Information Network for Asia and the Pacific, the National Narcotics Control  
Commission of China, the Office of the Narcotics Control Board of Thailand, and the Standing Office on Drugs and Crime of Viet Nam.
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salam, Cambodia, China, Indonesia, Japan, the Lao’s People Dem-
ocratic Republic, Malaysia, Myanmar, the Philippines, the Republic 
of Korea, Singapore, Thailand and Viet Nam.
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mine. Illicit drug manufacture has expanded from the 
southern coastal areas of China to northern and central 
areas of the country; in 2011, illicit drug manufacturing 
facilities were seized in 29 of the 33 provinces, municipali-
ties and autonomous regions of China. 
Illicit laboratories were also seized in Cambodia, Indonesia, 
Malaysia, the Philippines and Thailand; these were mostly 
smaller-scale laboratories, which are mobile and can be 
more easily relocated. Malaysia also reported the seizure 
of one illicit nimetazepam (Erimin-5) manufacturing facil-
ity, a substance which is frequently sold on the illicit ATS 
market.98
Seizures of amphetamine, mostly 
Captagon, rise in the Near and 
Middle East
Near and Middle East seizures account for almost 64 per 
cent of global amphetamine seizures. Unlike any other 
region of the world, amphetamine is seized in the Near 
and Middle East in the form of Captagon pills. In 2011, 
significant increases were reported by Jordan, Kuwait, 
Qatar, Saudi Arabia and the Syrian Arab Republic. All the 
seizures were of Captagon pills. The three largest seizures 
in 2011 were made by Saudi Arabia and involved 720 kg, 
705 kg and 666 kg seized in Haditha, Saudi Arabia, at the 
land border with Jordan.99 Most amphetamine seizures are 
made in Saudi Arabia. In 2011, 11 tons were seized, which 
represents 37 per cent of global amphetamine seizures and 
58 per cent of seizures made in the Near and Middle East.
98 Nimetazepam is a benzodiazepine derivative, controlled in Schedule 
IV of the Convention on Psychotropic Substances of 1971, often 
marketed under the brand name Erimin.
99 World Customs Organization, Customs and Drugs Report 2011 (Brus-
sels, 2012).
The changing faces of illicit manufac-
ture of amphetamine-type stimulants 
Traditional precursors are being replaced with alternate 
precursors and chemically modified precursors that are not 
under international control. For the manufacture of 
amphetamines, for example, the non-scheduled bisulfite 
adduct of the essential amphetamine precursor 1-phenyl-
2-propanone (P-2-P)100 has been seized in several Euro-
pean countries in recent years in the form of a white 
powder that can be converted to form liquid P-2-P with 
relative ease. Alpha-phenylacetoacetonitrile (APAAN), a 
direct precursor of P-2-P, is a non-controlled substance 
100 P-2-P is also known as benzyl methyl ketone (BMK).
Fig. 74. “Ecstasy” seizures in East and South-
East Asia, 2007-2011 
Source: Based on data collected by the Drug Abuse Information 
Network for Asia and the Pacific, including data for Brunei Darus-
salam, Cambodia, China, Indonesia, Japan, the Lao’s People Dem-
ocratic Republic, Malaysia, Myanmar, the Philippines, the Republic 
of Korea, Singapore, Thailand and Viet Nam.
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Fig. 75. Captagon pill seizures in Jordan and 
the Syrian Arab Republic, 2005-2011
Source: UNODC, data from the annual report questionnaire and 
other official sources.
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which can easily be converted into P-2-P. APAAN was 
originally discovered in a large scale methamphetamine 
manufacturing laboratory in Malaysia in 2006 and, since 
2009, has been seized in Belgium, the Netherlands, Poland 
and Turkey. In Poland, 700 kg of APAAN were seized in 
April 2011. The Netherlands reported the seizure of several 
laboratories where APAAN was being converted to P-2-P.
Another chemical that is widely used in illicit ATS manu-
facture and which is not under international control is 
methylamine which, together with phenylacetic acid or 
P-2-P, can be used in the illicit manufacture of metham-
phetamine, or may also be used in MDMA manufacture, 
together with (3,4-MDP-2-P). In 2011, a total of 1,400 
tons of chemicals used to make methamphetamine were 
confiscated by customs authorities in Mexico. Seven sei-
zures, comprising 741 tons of methylamine, were reported 
in December 2011. Six of them were intended to be 
shipped onwards to Guatemala, which seized large volumes 
of precursor chemicals in 2011 and 2012. 
In January 2012, 195 tons of methylamine were seized in 
Mexico, marking the first attempt to traffic precursor chem-
icals from Mexico to Nicaragua and a repeated attempt of 
trafficking to Guatemala. These seizures may point to 
increased manufacturing activity in Central America and 
a rising influence of Mexican drug trafficking organizations 
in the synthetic drugs market within the region.
The increasing appearance of non-controlled “pre-precur-
sor” substances, many of which have few known legitimate 
uses other than for the manufacture of controlled precur-
sors, is expected to be a continuing trend in global seizures; 
this presents a myriad of new challenges for drug control 
authorities.
For instance, for “ecstasy” manufacture, methyl 3-[3’4’- 
(methylenedioxy)phenyl]-2-methyl glycidate (MMDMG, 
also known as PMK-glycidate) is an alternative to the inter-
nationally controlled precursor 3,4-MDP-2-P), also known 
as piperonyl methyl ketone (PMK). MMDMG, which is 
not under international control, was first detected in Aus-
tralia in 2004 and is made from piperonal, which is a pre-
cursor of 3,4-MDP-2-P. In May 2010, a small quantity of 
MMDMG was found in an “ecstasy” and methampheta-
mine laboratory in the Netherlands along with instructions 
for its conversion into 3,4-MDP-2-P for “ecstasy” manu-
facture. In October 2010, authorities in Slovakia seized 
200 kg of chemicals, which were a mixture of 3,4-MDP-
2-P, piperonal and MMDMG. In March 2011, Denmark 
seized 800 kg of MMDMG from an air cargo shipment 
that was reportedly one in a series of shipments destined 
for the Netherlands and had originated in China.101 One 
conversion laboratory, where MMDMG was being con-
verted to PMK, was seized in the Netherlands in 2011. 
MMDMG has also reportedly appeared in Belgium, Esto-
nia and Poland. 
After a decline, “ecstasy” seizures 
show a rise in 2011 in Europe
In 2011, the largest seizures of “ecstasy”-type substances 
were reported in Europe, showing an increase from 1.3 
tons in 2010 to 1.7 tons in 2011, surpassing the level of 
seizures in the Americas, which totalled 1.2 tons in 2011. 
Seizures in North America declined; in the United States 
from 1 ton in 2010 to 926 kg in 2011 and in Canada from 
529 kg in 2010 to 192 kg in 2011. At the global level, the 
United States reported the highest seizures of “ecstasy”-type 
substances with 926 kg seized in 2011, followed by Neth-
erlands with 583 kg and France with 409 kg. There were 
signs of a partial recovery of the “ecstasy” market in 2011, 
particularly in France where seizures increased from 180 
kg in 2010 to 409 kg in 2011 and in the Netherlands with 
seizures of 343 kg in 2010 and 583 kg in 2011. 
101 Precursors and Chemicals Frequently Used in the Illicit Manufacture of 
Narcotic Drugs and Psychotropic Substances: Report of the International 
Narcotics Control Board for 2011.
Table 5. Seizures of methylamine in Mexico, December 2011
Source: Mexico, Navy Secretariat, 2011.
Note: Mexico regional information: Baja California (north); Colima (south-west); Michoacán (south-west); and Sonora (north-west).
Date Seizure (tons) Arriving from Seized in Bound for 
08.12.11 205 China Michoacán 
Port of Lazaro Cardenas
Guatemala 
Port of Quetzal
09.12.11 23 Turkey Colima  
Port of Manzanillo
Guatemala 
Port of Quetzal
16.12.11 43 China Baja California Mexico 
Obregon, Sonora State
19.12.11 100 China Michoacán 
Port of Lazaro Cardenas
Guatemala 
Port of Quetzal
23.12.11 229 China Michoacán 
Port of Lazaro Cardenas
Guatemala 
Port of Quetzal
26.12.11 21 Peru Colima  
Port of Manzanillo
Guatemala 
Port of Quetzal
28.12.11 120 China Michoacán Port of Lazaro Cardenas
Guatemala 
Port of Quetzal
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Turkey has emerged as a major “ecstasy” seizing country, 
with the quantities being intercepted slowly increasing over 
the past decade, reaching a peak of 1.7 million “ecstasy” 
tablets (474 kg) in 2005. After experiencing a decline in 
subsequent years until 2009, seizures started to increase 
from 251 kg in 2010 to 370 kg in 2011. In 2011, Brazil 
reported the highest seizures of “ecstasy” since 1987 
amounting to 70 kg; in the past decade, most annual sei-
zures reported by Brazil were below 1 kg.
There has been a decline in the number of “ecstasy” labo-
ratories seized on a global level from 50 in 2009 to 43 in 
2010 and 39 in 2011. The shift in manufacturing activity 
from Europe to other regions is illustrated by the increas-
ing geographical spread; “ecstasy” manufacture was 
reported by Australia (16) Indonesia (6), Malaysia (6), the 
United States (5), Canada (4), France (1) and Belgium (1).
Pills sold as “ecstasy” frequently  
contain other substances
A large proportion of seized drugs marketed on the street 
as “ecstasy” continue to contain substances other than 
MDMA. Amphetamines, for example, are common in pills 
analysed in Luxembourg, Spain and Turkey, according to 
reports from EMCDDA and Europol.102 In most cases, 
however, these are NPS, that is, substances that are not 
controlled under the 1961 or 1971 Conventions. Keta-
mine, for example, is frequently sold as “ecstasy” in markets 
in East and South-East Asia. Many countries in Europe, 
on the other hand, report that mCPP, alone or with other 
substances, was identified in 20 per cent or more of the 
102 European Monitoring Centre for Drugs and Drug Addiction and 
European Police Office, EU Drug Markets Report: A Strategic Analysis.
pills analysed in Austria, Belgium, Croatia, the Czech 
Republic, Cyprus, Denmark, Finland, Portugal and the 
United Kingdom.
In New Zealand, 4-methylethcathinone (4-MEC) is 
reportedly the most common substance identified in pills 
sold as “ecstasy”. Forensic analysis of seizures of “ecstasy”-
type street pills and powder used in their manufacture 
seized during the dismantling of a large-scale pill manu-
facturing facility and supply ring in 2011 and a related 
facility in 2012, identified 4-MEC, 3,4-methylenedioxy-
D-pyrrolidinobutyrophenone (MDPBP), eutylone (bk-
EBDB), N-ethylamphetamine, N-ethylcathinone, BZP 
and 1-(3-trifluoromethylphenyl)piperazine (TFMPP).
For more than 15 years, the Drugs Information and Moni-
toring System in the Netherlands has carried out laboratory 
analyses of pills sold as “ecstasy” and results show the sig-
nificant developments that the “ecstasy” market has under-
gone over the years. A review of the composition of 
sampled pills over the past six years clearly indicates that 
the proportion of pills containing only MDMA-like sub-
stances increased in 2010 and 2011, from 82 per cent to 
85 per cent, after the MDMA content reached the lowest 
levels in 2008 and 2009 (70 per cent in both years), prob-
ably because the precursor chemicals for “ecstasy” were 
difficult to obtain at that time. Mirroring the trends in 
other countries of the European Union, mCPP was also 
one of the most widely reported substances in pills sold as 
“ecstasy” in the Netherlands, but the number of mentions 
declined from 2010 to 2011, from 5 to 4 per cent. The 
Fig. 77. “Ecstasy” seizures in selected  
countries, 2007-2011
Source: UNODC, data from the annual report questionnaire and 
other official sources.
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Fig. 78. Content of pills sold as “ecstasy” in 
the Netherlands, based on laboratory 
analyses, 2006-2011
Source: Netherlands Institute of Mental Health and Addiction 
(Trimbos Institute), Drugs Information and Monitoring System. 
Note: Data for 2011 are from January to June. Category “others” may 
include samples with MDMA and, for instance, caffeine and other pharma-
cologically active non-scheduled substances. In 2009 the miscellaneous cat-
egory consisted mainly of mCPP (11.60 per cent) and mephedrone (7.4 per 
cent); in 2010 and 2011 this category consisted mainly of mCPP and caf-
feine. 
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same is true for mephedrone, where the proportion 
dropped from 1 to 0.3 per cent from 2010 to 2011. The 
substance paramethoxymethamphetamine (PMMA) was 
also identified in a number of “ecstasy” pills sold in the 
Netherlands, with the presence of PMMA remaining 
largely stable (reported 29 times (1.2 per cent) in 2010 
and 23 times (0.9 per cent) in 2011). This substance has 
gained notoriety by its presumed link to several fatalities 
in Canada and Scotland (United Kingdom). The review 
conducted in the Netherlands showed the benefits of con-
tinuous laboratory analyses, which provide valuable 
insights into the dynamics of ATS markets. 
Methamphetamine trafficking from 
West Africa to East and South-East 
Asia continues
West Africa, a region not previously known for ATS, has 
gained increased prominence as a point of origin of meth-
amphetamine trafficked to East and South-East Asia. In a 
UNODC report on the ATS situation in West Africa, 
methamphetamine was shown to have been trafficked from 
Benin, Côte d’Ivoire, the Gambia, Ghana, Guinea, Mali, 
Nigeria, Senegal and Togo.103
African drug trafficking organizations, which used to traf-
fic primarily cocaine and heroin, are trafficking increasing 
amounts of methamphetamine in East and South-East 
Asia, usually by air courier and in fairly small quantities 
(between 0.5 kg and 3.0 kg). Asia is a prime location due 
to the size of its ATS market, which is one of the largest 
in the world, and due to the high prices that methampheta-
103 UNODC, West Africa: 2012 ATS Situation Report—A Report from the 
Global SMART Programme (Vienna, June 2012).
mine can command. In Japan, one kilogram of metham-
phetamine retails for at least $212,600. EMCDDA and 
Europol report that West African criminal organizations 
also use major airports in the European Union to traffic 
methamphetamine manufactured in Africa to the Asian 
markets and that they recruit couriers in the European 
Union. Australia and New Zealand have also reported the 
increasing role of West African organized criminal groups 
in trafficking of ATS and ATS precursors to Australia and 
New Zealand.
Trafficking of methamphetamine by African groups has 
been reported by Brunei Darussalam, Cambodia, China, 
Indonesia, Japan, the Lao People’s Democratic Republic, 
Malaysia, New Zealand, the Philippines, the Republic of 
Korea, Thailand and Viet Nam. 
Nigeria, by far the largest country in West Africa in terms 
of both population and surface area, and Benin have been 
most frequently cited as the origin for trafficked metham-
phetamine. Mali has reportedly also emerged as a source. 
The Republic of Korea reported that in 2011, more than 
4 kg of methamphetamine were smuggled into the country 
from Mali.104
In July 2011, Nigeria became the first and, so far, only 
country in West Africa to officially report illicit metham-
phetamine manufacture. The National Drug Law Enforce-
ment Agency seized a methamphetamine laboratory with 
a reported manufacturing capacity of between 25 and 50 
kg per manufacturing cycle near Lagos, Nigeria’s largest 
city. Several laboratories were seized in 2012. 
There is a persistent lack of data from the African region, 
which can be seen from the scarce reporting of seizures of 
ATS and their precursors due to a general lack of aware-
ness of ATS, as law enforcement authorities tend to focus 
on the interception of “traditional” drugs such as cannabis 
and cocaine. 
104 Information provided by the Supreme Prosecutors’ Office of the 
Republic of Korea at the seventeenth Asia-Pacific Operational Drug 
Enforcement Conference, Tokyo, February 2012.
Table 6. Substances frequently found in pills 
sold as “ecstasy”
Source: UNODC, data from the annual report questionnaire and 
other official sources. 
Substance Americas Asia Europe Oceania
4-MEC z
Amphetamine z
BZP z z
Caffeine z z
bk-EBDB z
Ketamine z
mCPP z
MDPBP z
Mephedrone z z
Methamphetamine z
N-ethylamphetamine z
N-ethylcathinone z
PMMA z z
TFMPP z
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G. CONCLUSIONS 
While the prevalence of people with drug dependence and 
drug use disorders has generally remained stable, there are 
many regions where evidence-based drug dependence treat-
ment and care are still not available or accessible. 
The decline in the global number of people who inject 
drugs and people who inject drugs and are living with HIV 
is in part due to the comprehensive set of interventions 
implemented by some countries. This holds the promise 
that with an increased coverage and scale up of services for 
prevention of HIV among people who inject drugs, the 
targets set out in the Political Declaration on HIV and 
AIDS: Intensifying Our Efforts to Eliminate HIV and 
AIDS adopted by the General Assembly in 2011, can be 
attained. It has to be noted, however, that to a large extent 
the decline is also due to new or revised estimates available 
from countries. 
The emergence of NPS, increasing non-medical use of 
prescription drugs and polydrug use continue to blur the 
conventional distinction between users of one or another 
illicit substances. The interdependency at the user level, 
for instance, of illicit opiates (opium, morphine and 
heroin) on the one hand, and non-medical use of prescrip-
tion opioids like painkillers and illicitly manufactured 
opioids on the other, has not been well understood. Fur-
ther research is needed to understand this phenomenon in 
order to devise comprehensive approaches to address the 
problem.
The latest drug trafficking trends show that Africa is a vul-
nerable transit continent for both cocaine and heroin. 
While West and Central Africa have already witnessed 
increased cocaine trafficking during the past few years, East 
Africa is fast emerging as a transit route for Afghan opiates 
destined for the European market. West Africa is also 
emerging as a hub for methamphetamine production. The 
spillover effect of the increased trafficking of drugs through 
Africa on drug use in African countries is a matter of con-
cern, although to study and document it remains a chal-
lenge due to weak data collection mechanisms and 
processes. 
Despite the fluctuations in opiate production in Afghani-
stan, the global opiate market remains relatively stable. 
Changes though are being observed at the regional level. 
Heroin is losing ground in Western Europe, but the recent 
information from Asia and Africa, albeit limited, indicates 
a possible increase in opiate use.
Despite the relative stability of the established cocaine mar-
kets, there are indications that cocaine is being trafficked 
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Map 6. Methamphetamine trafficking routes from Benin and Nigeria to East and South-East Asia
Source: Japan, National Police Agency, 2012; Thailand, Office of the Narcotics Control Board, 2012; and Malaysia, Royal Malaysian Police, 
2012.
Note: The boundaries shown on this map do not imply official endorsement or acceptance by the United Nations. Dashed lines represent undetermined 
boundaries. Dotted line represents approximately the Line of Control in Jammu and Kashmir agreed upon by India and Pakistan. The final status of Jammu 
and Kashmir has not yet been agreed upon by the parties. The final boundary between the Sudan and South Sudan has not yet been determined.
1. RECENT STATISTICS AND TREND ANALYSIS OF ILLICIT DRUG MARKETS 58
along new routes to cater for the growing demand from 
emerging markets. Cocaine use in Asia and Africa, which 
together account for a majority of the world population, 
has the potential to grow. Moreover, the extent of the phe-
nomenon in these regions is uncertain, possibly due in part 
to the common perception of it being a relatively small-
scale problem. In order to pre-empt an expansion of the 
cocaine market on these continents, greater attention must 
be paid to monitoring the use and the availability of this 
drug, so that appropriate and evidence-based supply and 
demand side interventions may be deployed.
The market for ATS appears to be expanding in terms of 
locations of manufacture and trafficking routes, as well as 
in terms of demand. While ATS use currently remains 
stable, this may change as a result of possible spillover of 
ATS to previously unaffected regions and countries. The 
global emergence of NPS has introduced an added layer 
of complexity to an already complex market, with an 
almost unlimited variety of substances that are being sold 
in a number of different forms. 
The manufacture of ATS is not limited by the necessity 
for cultivation of large areas of illicit crops under special 
climactic conditions, and therefore can potentially spring 
up anywhere, especially in the case of drugs such as meth-
amphetamine which are relatively easy to manufacture. 
Therefore, emerging ATS and other drug markets need to 
be monitored and addressed proactively before they are 
established and become a significant additional challenge 
for already strained national health and criminal justice 
systems.
Cannabis herb production has become more localized and 
more countries report increased domestic cultivation for 
domestic markets. The trend towards small-scale cultiva-
tion for personal consumption continues and poses a 
number of challenges for policymakers. A variety of systems 
to regulate cannabis supply exist in Member States (e.g., 
decriminalization under a certain threshold and regulation 
of supply for specific, medicinal purposes). Very little is 
known about the efficiency of these systems in terms of 
supply regulation or their impact on use trends and pat-
terns. Further research is warranted before any conclusions 
can be drawn for the international drug control system.
Maritime trafficking of drugs can be quite lucrative for 
traffickers who can invest both the time and the money 
needed to organize large, high-value shipments to lucrative 
consumer markets, either under the cover of licit, contain-
erized trade or in unregulated traffic over the open seas 
and waterways. Such shipments can be difficult to inter-
cept, but an intensified focus on this mode of transporta-
tion could result in a significant impact in terms of seizure 
quantities and interception rates, the consequent risk 
incurred by traffickers, the price of the drug and ultimately, 
its accessibility in the consumer markets. 
Gaps in availability of reliable data on all aspects of the 
drug phenomenon from many regions continue to limit 
the understanding of the drug market dynamics, posing 
further challenges for the drug control mechanisms and 
for the development of appropriate prevention and treat-
ment interventions.
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592NEW PSYCHOACTIVE SUBSTANCES
A. INTRODUCTION
The use of new psychoactive substances (NPS), i.e. psy-
choactive substances not under international control that 
pose a health threat, has grown rapidly over the past 
decade,1 in contrast to the prevalence rates for the use of 
internationally controlled drugs, which seem generally to 
have stabilized in the same time period.2 Producing and 
marketing such substances holds the promise of high 
profits without penalty. When brought under control in 
one country, production and/or the distribution centres 
of these substances are shifted to another country so that 
the sales - often conducted via the Internet - can continue. 
In other cases, the substances are modified slightly so that 
they are not covered by the respective country’s legislation. 
The number of NPS reported by Member States to 
UNODC rose from 166 at the end of 2009 to 251 by 
mid-2012. This exceeds the total number of psychoactive 
substances currently controlled by the international drug 
conventions (234 substances). 
The present chapter describes a number of approaches that 
Member States are using to tackle this issue. It has gener-
ally been observed that placing a substance under control 
reduces consumption of that substance, but the market 
quickly evolves and other NPS emerge, rapidly filling the 
void created. It is thus clear that a strategy that is compre-
hensive, proactive, dynamic and global (to prevent the 
exploitation of loopholes) is required to deal with these 
challenges.
An ever-increasing number of NPS have emerged world-
wide over the past few years, prompting responses at the 
international level (e.g. Commission on Narcotic Drugs 
resolution 48/1) as well as at the regional level, such as the 
Council of the European Union decision on the informa-
tion exchange, risk assessment and control of new psycho-
active substances.3
In 2012, in its resolution 55/1, the Commission on Nar-
cotic Drugs expressed its deep concern about “reports of 
the increased and emerging use of and trade in new psy-
choactive substances that may have effects similar to those 
of internationally controlled drugs” and about “the poten-
tial opportunities for transnational organized criminal 
groups to exploit the market for these substances”. It also 
asked UNODC to gather information and report on the 
problem. 
1 Report of the International Narcotics Control Board for 2012 (United 
Nations publication, Sales No. E.13.XI.1).
2 World Drug Report 2012 (United Nations publication, Sales No. E.12.
XI.1).
3 Council of the European Union decision 2005/387/JHA of 10 May 
2005 on information exchange, risk-assessment and control of new 
psychoactive substances (Official Journal of the European Union, L 127, 
20 May 2005). Available from http://eur-lex.europa.eu/LexUriServ/
LexUriServ.do?uri=OJ:L:2005:127:0032:0037:EN:PDF.
In 2013, in its resolution 56/4, the Commission on Nar-
cotic Drugs recognized that “the establishment of a global 
early warning system, taking advantage of existing regional 
mechanisms, as appropriate, and providing timely report-
ing on the emergence of new psychoactive substances, 
could benefit Member States’ understanding of and 
responses to the complex and changing market for these 
substances”. The Commission on Narcotic Drugs also 
urged UNODC “to continue to develop the voluntary 
electronic portal of the international collaborative exercises, 
a programme for national forensic and/or drug-testing 
laboratories to enable timely and comprehensive sharing 
of information on new psychoactive substances, including 
analytical methodologies, reference documents and mass 
spectra, as well as trend-analysis data, with a view to pro-
viding a global reference point and early warning advisory 
on new psychoactive substances”. It further requested 
UNODC to consider including within its programmes the 
provision of technical assistance in the identification and 
reporting of new psychoactive substances and for Member 
States to consider the provision of bilateral technical 
assistance. 
Well-known examples of NPS include substances such as 
synthetic cannabinoids contained in various herbal mix-
tures, piperazines (e.g. N-benzylpiperazine (BZP)), prod-
ucts sold as “bath salts” (i.e. cathinone-type substances 
such as mephedrone and methylenedioxypyrovalerone 
(MDPV)) and various phenethylamines. Ketamine was 
among the first NPS to appear. Its abuse was first recog-
nized in North America at the beginning of the 1980s. It 
became a noticeable phenomenon in Europe in the 1990s,4 
before spreading extensively in Asia and, to a lesser extent, 
in South America and Southern Africa. NPS belonging to 
the phenethylamine family appeared in the market in the 
1990s and substances belonging to the piperazine family 
at the beginning of the 2000s.5 From 2004 onwards, syn-
thetic cannabinoids such as Spice appeared in the market, 
followed by synthetic cathinones and other emerging 
groups of NPS.6
In addition to having serious health consequences, NPS 
pose a challenge to drug control systems at every level — 
national, regional and global. A number of approaches are 
4 European Monitoring Centre for Drugs and Drug Addiction, Report 
on the Risk Assessment of Ketamine in the Framework of the Joint Action 
on New Synthetic Drugs (Luxembourg, Office for Official Publications 
of the European Communities, 2002).
5 For instance, BZP was first sold commercially as an alternative to 
methamphetamine in New Zealand around 2000. T. Bassindale, “Ben-
zylpiperazine: the New Zealand legal perspective”, Drug Testing and 
Analysis, vol. 3, Nos. 7-8 (August 2011), pp. 428-429; BZP reached 
Europe around 2004, but it was placed under control in the countries 
of the European Union only in 2007.
6 United Nations Office on Drugs and Crime, The Challenge of New 
Psychoactive Substances (Vienna, March 2013).
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being tried at the national and regional levels to address 
the issue. They range from temporary and emergency drug 
control measures in response to an imminent threat to 
public health to the adoption of various pieces of legisla-
tion on consumer protection, medicines and hazardous 
substances in order to prevent the uncontrolled manufac-
ture, trafficking and harmful use of such substances. 
The issue of NPS gained in importance at the international 
level at the fifty-fifth session of the Commission on Nar-
cotic Drugs in March 2012, where the first global consen-
sus on the topic emerged, leading to the adoption of 
Commission resolution 55/1 on promoting international 
cooperation in responding to the challenges posed by new 
psychoactive substances. In its resolution, the Commission 
called on Member States to monitor emerging trends in 
the composition, production and distribution of new psy-
choactive substances and patterns of use, and to share that 
information and adopt appropriate measures aimed at 
reducing supply and demand. Also in its resolution, the 
Commission requested UNODC to provide an update to 
its 2011 report “addressing a wider range of new psycho-
active substances … and to take into consideration the 
creation of a compilation of new psychoactive substances 
encountered by Member States, to serve as an early warn-
ing advisory”. The requested report on NPS was prepared 
by UNODC and launched at the fifty-sixth session of the 
Commission, held in March 2013.7 The present chapter 
of the World Drug Report 2013 draws on the findings of 
that report and other recent reports on the topic in an 
attempt to alert an even larger audience to the issues at 
stake. It has also been prepared pursuant to Commission 
resolution 56/4, adopted in 2013, in which the Commis-
sion encouraged UNODC “to share and exchange ideas, 
efforts, good practices and experiences in adopting effec-
tive responses to address the unique challenges posed by 
new psychoactive substances, which may include, among 
other national responses, new laws, regulations and 
restrictions”.
B. NEW PSYCHOACTIVE  
SUBSTANCES: CONCEPTS AND 
DEFINITIONS 
The creation of new substances to exploit loopholes in 
drug control legislation has been a problem since the inter-
national drug control system was first established. The 
proliferation of such substances in recent decades was influ-
enced by the work done by Ann and Alexander Shulgin 
on phenethylamines8 and tryptamines9 in the 1960s and 
7 United Nations Office on Drugs and Crime, The Challenge of New 
Psychoactive Substances.
8 Alexander Shulgin and Ann Shulgin, PiHKAL (Phenethylamines I 
Have Known and Loved): A Chemical Love Story (Berkeley, California, 
Transform Press, 1991).
9 Alexander Shulgin and Ann Shulgin, TiHKAL (Tryptamines I Have 
Known and Loved): The Continuation (Berkeley, California, Transform 
the 1970s. The Shulgins reported over 230 psychoactive 
compounds that they had synthesized and evaluated for 
their psychedelic and entactogenic potential. More recently, 
a number of piperazines, synthetic cathinones and syn-
thetic cannabinoids emerged, which were marketed as 
“legal” alternatives to controlled substances. 
1. Analogues versus mimetics 
One can distinguish between chemical analogues (i.e. 
structural derivatives of a parent component that often 
differ from the original by just one or a few chemical modi-
fications) and so-called mimetics (i.e. substances that are 
chemically different but mimic the pharmacological effects 
of a particular substance, notably by acting on the same 
receptors in the brain). Most phenethylamines and 
tryptamines described in the work of the Shulgins are ana-
logues of a limited number of substances. An analogue, 
even though very similar chemically, may not have the 
same pharmacological properties as the original com-
pound. Thus, MDMA, commonly known as “ecstasy”, is 
an analogue of methamphetamine, although the pharma-
cological properties of the two are quite distinct. The syn-
thetic cannabinoids found in Spice, on the other hand, are 
mimetics of THC, the main psychoactive substance in 
cannabis. While quite different in their chemical structure, 
such substances act on the same cannabinoid receptors as 
does THC and have produced effects similar to those pro-
duced by cannabis. Over the years, Governments have 
developed various approaches to deal with such analogues 
and mimetics, which were designed to circumvent existing 
controls. 
There is a third, novel group of substances emerging, which 
interfere with the signalling pathways in the body to pro-
duce or enhance the effects associated with analogues or 
mimetics. These substances are not psychoactive per se. 
However, they prompt the body to produce the psychoac-
tive substances wanted by the users (or slow down the 
degradation of those substances in the brain, thus leading 
to their accumulation).10 Given that this is a recent phe-
nomenon, existing legislation in most countries seems 
unable to cope with such substances. 
A number of concepts and definitions for psychoactive 
substances have been developed and are marketed as a way 
to avoid legal sanctions. The past few decades have seen 
terms such as “designer drugs” (1980s and 1990s) and 
“legal highs” (the past decade) gain currency. The concept 
of “NPS” is the latest in that series. Although all these 
concepts share many characteristics, they are inherently 
different and can be distinguished from each other. 
Press, 1997).
10 For example, URB597 is a selective inhibitor of fatty acid amide 
hydrolase (FAAH), the degradatory enzyme for anandamide, an 
endogenous cannabinoid neurotransmitter. Use of URB597 causes 
the accumulation of anandamide, which plays a role in the neural 
generation of motivation and pleasure.
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2. Designer drugs and  
related concepts 
The term “designer drug” was coined in the 1980s. It origi-
nally referred to various synthetic opioids, mostly based 
on modifications of fentanyl (e.g. alpha-methylfentanyl). 
The term entered widespread use when MDMA (“ecstasy”) 
experienced a boom in the mid-1980s, first in the United 
States of America, followed by Europe in the 1990s 
and then in other parts of the world. Once MDMA was 
scheduled (in the United States in May 1985 and a year 
later at the global level), a number of chemically related 
substances appeared on the drug markets, which were 
labelled “designer drugs” because they were related to 
MDMA but fell outside the drug control system.11 Many 
more “designer drugs” were controlled at the national level. 
So, the term “designer drug” for substances already under 
control was not really appropriate. Nonetheless, use of the 
term persisted, although in some circles it was later replaced 
by the term “club drugs”. However, the term “club drugs” 
encompasses a far broader range of controlled and non-
controlled substances.12
11 Eventually, several of these “ecstasy”-type substances got scheduled 
as well (e.g. methylenedioxyamphetamine (MDA) and methylen-
edioxyethylamphetamine (MDE) at the international level in 1990). 
Etryptamine was placed under control in 1995. Alpha-Methyl-
4-methylthiophenethylamine (4-MTA) and 4-bromo-2,5-dimethoxy-
phenethylamine (2C-B), one of the designer drugs first synthesized by 
Alexander Shulgin in the 1970s, were scheduled in 2001.
12 The term refers to substances used by teenagers and young adults at 
bars, nightclubs, concerts and parties. According to the United States 
National Institute on Drug Abuse, such “club drugs” include “ecstasy” 
and related substances (both controlled and non-controlled), meth-
amphetamine (a controlled stimulant), gamma-hydroxybutyric acid 
(GHB) (a depressant), flunitrazepam (a benzodiazepine (Rohypnol)), 
Another term that emerged in the late 1990s and early 
2000s is “research chemicals”. The term was coined by 
some marketers of designer drugs, specifically, marketers 
of psychedelic drugs (i.e. drugs with hallucinogenic prop-
erties) in the tryptamine and phenethylamine families. The 
idea was that by selling the chemicals for so-called “scien-
tific research” rather than for human consumption, the 
intent clause of various analogue drug laws could be cir-
cumvented altogether. The same strategy was behind the 
marketing of some of the cathinone-related substances as 
“bath salts” not intended for human consumption. 
3. “Legal highs” 
There are a number of new - and thus non-controlled - 
synthetic substances emerging every year on the drug 
markets, which are sold as “legal highs”. Well-known 
examples in the past decade were the spread of BZP, 
mephedrone and the synthetic cannabinoids. In addition, 
a number of plant-based substances gained popularity in 
the new millennium, including kratom (leaf of Mitragyna 
speciosa, grown in South-East Asia, a mild stimulant that 
stimulates the opiate receptors in the brain and is a sedative 
at higher doses) and Salvia divinorum, a hallucinogen 
grown in Mexico. 
Substances sold as “legal highs” are mainly manufactured 
in chemical laboratories in Asia, according to the Interna-
tional Narcotics Control Board13 and the European Police 
Office (Europol),14 although some manufacture also takes 
place in Europe, the Americas and other regions.15 They 
lysergic acid diethylamide (LSD) (a hallucinogen) and ketamine.
13 Report of the International Narcotics Control Board for 2012.
14 European Monitoring Centre for Drugs and Drug Addiction and 
European Police Office, EU Drug Markets Report: A Strategic Analysis 
(Luxembourg, Publications Office of the European Union, 2013).
15 United Nations Office on Drugs and Crime, The Challenge of New 
Psychoactive Substances.
Designer drugs
“Designer drugs” have been defined by the International 
Narcotics Control Board as follows:
Substances that have been developed especially to avoid 
existing drug control measures … [and] are manufac-
tured by making a minor modification to the molecular 
structure of controlled substances, resulting in new sub-
stances with pharmacological effects similar to those of 
the controlled substances.
According to the European Monitoring Centre for Drugs 
and Drug Addiction (EMCDDA) and the European 
Police Office (Europol), such substances can be best 
defined as substances designed to mimic the effects of 
known drugs by slightly altering their chemical structure 
in order to circumvent existing controls. 
Source: Report of the International Narcotics Control Board for 
2010 (United Nations publication, Sales No. E.11.XI.1), p. vi.; 
and European Monitoring Centre for Drugs and Drug Addic-
tion (EMCDDA) and European Police Office, “EMCDDA-
Europol 2011 annual report on the implementation of Council  
decision 2005/387/JHA” (Lisbon, 2012). 
“Legal highs”
“Legal highs” is an umbrella term for unregulated (new) 
psychoactive substances or products intended to mimic 
the effects of controlled drugs. The term encompasses a 
wide range of synthetic and/or plant-derived substances 
and products, which are offered as “legal highs” (empha-
sizing the idea of legality), “research chemicals” (imply-
ing legitimate research use), “party pills” (an alternative 
to “party drugs”) and “herbal highs” (stressing the plant 
origin) etc. They are frequently sold via the Internet or 
in “smart shops” or “head shops” and in some cases are 
intentionally mislabelled, with purported ingredients 
differing from the actual composition.
Source: European Monitoring Centre for Drugs and Drug 
Addiction and European Police Office, “EMCDDA-Europol 
2011 annual report on the implementation of Council decision 
2005/387/JHA” (Lisbon, 2012), p. 25. 
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are legally imported, either as chemicals or as packaged 
products. The “legal highs” market is characterized by the 
speed with which suppliers circumvent drug controls by 
offering new alternatives to restricted products and adver-
tise them with aggressive and sophisticated marketing strat-
egies (as air fresheners, herbal incenses, bath salts, plant 
fertilizers, collectors’ items etc.).16 In fact, the term “legal 
high” is a successful marketing instrument in and of itself, 
as it implies that these substances are not as dangerous as 
controlled drugs, thus boosting their popularity and sales.
Substances presented as “legal highs” often also include 
drugs controlled in some countries.
According to Oxford Dictionaries Online,17 a “legal high” 
is “a substance with stimulant or mood-altering properties 
whose sale or use is not banned by current [national] legis-
lation”. This means, as an argumentum e contrario, that by 
controlling a substance under the national drug laws, such 
a substance ceases to be a “legal high”. As a number of coun-
tries placed substances such as BZP, mephedrone and Spice 
under control, such substances were in fact no longer “legal 
highs” in those countries, while continuing to be “legal 
highs” in others. That legislative inconsistency across juris-
dictions often hampers any meaningful international dis-
cussion on the issue, as interlocutors from different 
jurisdictions may not even be referring to the same sub-
stances when they refer to “legal highs”. 
4. New psychoactive substances 
To better serve policymaking at the regional and interna-
tional levels, the term “new psychoactive substances” or 
NPS was coined. The Commission on Narcotic Drugs 
introduced this term at the international level in its reso-
lution 55/1 of 16 March 2012.
The term “new psychoactive substances” had been legally 
defined earlier by the European Union as a new narcotic 
or psychotropic drug, in pure form or in a preparation, 
that is not scheduled under the Single Convention on Nar-
cotic Drugs of 1961 or the Convention on Psychotropic 
Substances of 1971, but which may pose a public health 
threat comparable to that posed by substances listed in 
those conventions (Council of the European Union deci-
sion 2005/387/JHA).
That legal definition is now widely used and has also been 
adopted by the EMCDDA.18 
16 European Monitoring Centre for Drugs and Drug Addiction and 
European Police Office, “EMCDDA-Europol 2011 annual report on 
the implementation of Council decision 2005/387/JHA” (Lisbon, 
2012), p. 25.
17 Oxford Dictionaries. Available from http://oxforddictionaries.com/
definition/english/legal%2Bhigh.
18 European Monitoring Centre for Drugs and Drug Addiction, 
“Responding to new psychoactive substances”, Drugs in Focus, No. 22, 
2011.
On the basis of that definition, EMCDDA identified the 
following groups of substances covered by its early warn-
ing system on NPS:19 
 s Phenethylamines, which encompass a wide range of 
substances that may exhibit stimulant, entactogenic or 
hallucinogenic effects
 s Tryptamines, which include a number of substances 
that have predominantly hallucinogenic effects
 s Piperazines, which are represented, inter alia, by m-
chlorophenylpiperazine (mCPP) and BZP, both of 
which are central nervous system stimulants
 s Synthetic cathinones, which have stimulant effects. 
The main cathinone derivatives are the semi-synthetic 
methcathinone and the synthetic compounds mephed-
rone, methylone and MDPV
 s Synthetic cannabinoids are functionally similar to THC, 
the active compound of cannabis
 s Other substances reported to the early warning system 
include various plant-derived and synthetic psychoac-
tive substances (e.g. indanes, benzodifuranyls, narcotic 
analgesics, synthetic cocaine derivatives, ketamine 
and phencyclidine derivatives), which do not strictly 
belong to any of the above-mentioned drug families. 
Also included are a number of medicinal products and 
derivatives.
In the operating guidelines on the early warning system, 
EMCDDA made it explicit that “the term ‘new’ did not 
refer to newly invented, but rather ‘newly misused’” sub-
stances as “most of the drugs in question were first created 
many years ago.”20 In fact, investigations into the potential 
use of piperazines as anthelmintic have been reported in 
scientific literature since the early 1950s.21 Yet they only 
started to emerge as a health problem in several countries 
in the decade 2001-2010. Similarly ketamine, which was 
first developed in the mid-1960s, started to emerge as a 
health problem in that decade in several countries of East 
and South-East Asia. Mephedrone was first synthesized in 
1929 but was rediscovered only in 2003 and reached the 
markets towards the end of the decade 2001-2010.22 
NPS also include plant-based substances that have existed 
for centuries. In the profiles of “new drugs”, EMCDDA 
lists plant-based substances such as Salvia divinorum and 
19 European Monitoring Centre for Drugs and Drug Addiction and 
European Police Office, “EMCDDA-Europol 2011 annual report on 
the implementation of Council decision 2005/387/JHA”, p. 27.
20 European Monitoring Centre for Drugs and Drug Addiction and 
European Police Office, Early-Warning System on New Psychoactive 
Substances: Operating Guidelines (Luxembourg, Office for Official 
Publications of the European Communities, 2007), p. 11.
21 R.H.R. White and O. Standen, “Piperazine in the treatment of thread-
worms in children”, British Medical Journal, vol. 2, No. 4839 (3 Octo-
ber 1953), pp. 755-757; O. Standen, “Activity of piperazine, in vitro, 
against Ascaris lumbricoides”, British Medical Journal, vol. 2, No. 4930 
(2 July 1955), pp. 20-22.
22 European Monitoring Centre for Drugs and Drug Addiction and 
European Police Office, Early-Warning System on New Psychoactive 
Substances: Operating Guidelines.
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khat. Khat has been known for hundreds of years in the 
countries around the Horn of Africa and the southern parts 
of the Arabian peninsula. However, it is considered to be 
a new substance in a number of European and American 
countries, as its use was barely known in those regions until 
one or two decades ago. The same applies to Salvia divi-
norum, kratom, and various hallucinogenic mushrooms, 
which are all considered to be NPS.23 Using the definition 
“newly misused on the market”, the overwhelming number 
of non-controlled psychoactive substances can be regarded 
as NPS, as there will always be some countries in which 
they have not been misused before.
UNODC has basically followed the definition and inter-
pretation of “new psychoactive substances” used by 
EMCDDA. 
Substances categorized as NPS according to the UNODC 
classification include: 
 s Synthetic cannabinoids 
 s Synthetic cathinones 
 s Phenethylamines
 s Piperazines 
 s Ketamine 
 s Plant-based psychoactive substances such as kratom 
(Mitragyna speciosa), Salvia divinorum and khat  
(Catha edulis)
 s Other substances, including 
- Tryptamines 
- Aminoindanes 
- Phencyclidine-type substances. 
However, the most widespread psychoactive substances 
worldwide - alcohol, nicotine and caffeine - are not 
included in this list. 
23 European Monitoring Centre for Drugs and Drug Addiction, “Online 
sales of new psychoactive substances/‘legal highs’: summary of results 
from the 2011 multilingual snapshots — Briefing paper” (Lisbon, 15 
November 2011), p. 6. 
5. Pharmacological properties of new  
psychoactive substances
The products under the heading of NPS include a broad 
range of substances with different chemical and pharma-
cological properties. Attempts to summarize their phar-
macological properties must be treated with caution, as 
each individual substance may have distinct properties. 
Nonetheless, some general observations can be made. The 
main health consequences of the most widespread NPS 
are described below. 
(a) Synthetic cannabinoids
The most widely used NPS are currently the synthetic can-
nabinoids, often mixed with various herbal mixtures and 
sold under the brand name Spice or other names such as 
K2, Moon Rocks, Yucatan Fire and Skunk to name just a 
few.24 Initially, the most widespread synthetic cannabinoid 
was JWH-018. After it was prohibited in some countries 
in 2010, it was immediately replaced by other, similar com-
pounds, such as JWH-073. Although the various synthetic 
cannabinoids differ,25 they tend to be more potent than 
the THC contained in the natural cannabis plant. Similar 
to cannabis, these substances tend to elevate the mood, aid 
relaxation and alter perceptions. Negative side effects 
include increased heart rate, vomiting, agitation, confusion 
and hallucinations. Synthetic cannabinoids can also raise 
blood pressure and cause reduced blood supply to the heart 
(myocardial ischemia), and have, in a few cases, been asso-
ciated with heart attacks.26 It appears that in addition to 
creating psychological disorders,27 some of these products 
may also have carcinogenic potential, sometimes related 
to metabolites of the substances contained in these 
products.28 
(b) Phenethylamines
A large number of non-controlled phenethylamines also 
fall in the category of NPS. However, the main phenethy-
lamines on the illicit markets are already under interna-
tional control, including amphetamine, methamphetamine 
and methylphenidate, as well as MDMA (“ecstasy”) and 
mescaline. In some classification schemes, the synthetic 
cathinones (see below) are also considered to be part of the 
substituted phenethylamines. The various phenethyl-
amines tend to be stimulants and/or hallucinogens and 
sometimes also have some entactogenic properties. They 
mostly affect the dopamine and serotonin systems of the 
24 United States, National Institute on Drug Abuse, “DrugFacts: Spice 
(synthetic marijuana)”, December 2012. Available from www.druga-
buse.gov/publications/drugfacts/spice-synthetic-marijuana.
25 There is a wide variety of synthetic cannabinoids; it should be noted 
that they are not limited to the JWH series.
26 National Institute on Drug Abuse, “DrugFacts: Spice (synthetic mari-
juana)”.
27 United Nations Office on Drugs and Crime, “Synthetic cannabinoids 
in herbal products” (Vienna, 2011), p. 11.
28 Ching Yu Lin and others, “Toxicity and metabolism of methylnaph-
thalenes: comparison with naphthalene and 1‐nitronaphthalene”, 
Toxicology, vol. 260, Nos. 1-3 (2009), pp. 16‐27.
United Nations Office on  
Drugs and Crime definition of 
new psychoactive substances
New psychoactive substances (NPS) are substances of 
abuse, either in a pure form or a preparation, that are not 
controlled by the 1961 Single Convention on Narcotic 
Drugs or the 1971 Convention on Psychotropic Sub-
stances, but which may pose a public health threat. In 
this context, the term “new” does not necessarily refer to 
new inventions but to substances that have recently 
become available.
Source: United Nations Office on Drugs and Crime, The Chal-
lenge of New Psychoactive Substances (Vienna, March 2013).
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brain. In low doses, phenethylamines increase alertness, 
give energy to fatigued individuals and increase endurance. 
They also tend to have some anorectic properties. In higher 
doses, they induce euphoria, stronger feelings of self-esteem 
(including diminished fear, anxiety and insecurity) but can 
also increase blood pressure, raise body temperature (hyper-
thermia), increase the heart rate, cause hallucinations and 
lead to death due to stroke, cardiac arrest and brain damage 
(starting with memory loss). Their use can entail various 
forms of drug-related psychosis and paranoia. 
The more psychedelic phenethylamines tend to bring about 
the intensification of bodily senses (hearing, touch, smell, 
vision, taste) and thus also have some aphrodisiacal effects, 
and create various hallucinogenic effects even at lower doses, 
entailing various mental, auditory and visual distortions. 
Alexander and Anne Shulgin documented the synthesis of 
some 200 phenethylamines.29 The number of phenethyl-
amines not under international control exceeds the number 
of controlled phenethylamines. They include paramethoxy- 
methamphetamine (PMMA) (street names: 4-MMA and 
methyl-MA) and a number of psychedelic phenethylamines 
such as 2,5-dimethoxy-4-iodophenethylamine (2C-I), 
2,5-dimethoxy-4-methyl-phenethylamine (2C-D) and 
2,5-dimethoxy-4-iodoamphetamine (DOI) which, in con-
trast to 4-bromo-2,5-dimethoxyphenethylamine (2C-B) 
are not controlled at the international level. PMMA and 
4-methylthioamfetamine (4-MTA) have been associated 
with more incidental deaths than other non-controlled 
phenethylamines. The former is known to have a particu-
larly high level of toxicity.30 
(c) Cathinones 
Currently, the most problematic group of NPS from the 
perspective of public safety and health seem to be the syn-
thetic cathinones, such as mephedrone or MDPV.31 Some 
of the cathinones are linked to the khat plant (Catha edulis), 
although most are synthetically manufactured. From a 
chemical and pharmacological perspective, they are stimu-
lants and similar to amphetamines and thus the pheneth-
ylamine family. Apart from the desired psychological effects 
of euphoria and increased alertness, awareness, mental stim-
ulation and increased sociability, synthetic cathinones also 
share many of the negative side effects of amphetamine-type 
stimulants, including increased heart rate, tachycardia, 
hypertension, breathing difficulties, loss of appetite, 
increased sweating, deterioration of memory, hallucina-
tions, delusions, erratic behaviour, anxiety, paranoia and 
29 Shulgin and Shulgin, PiHKAL (Phenethylamines I Have Known and 
Loved): A Chemical Love Story.
30 United Nations Office on Drugs and Crime, The Challenge of New 
Psychoactive Substances.
31 In the United Kingdom of Great Britain and Northern Ireland, for 
instance, the number of fatalities related to internationally non-
controlled synthetic cathinones were far higher than for other new 
psychoactive substances and exceeded already those related to the 
amphetamines (see Hamid Ghodse and others, Drug-related Deaths in 
the UK: Annual Report 2011 (International Centre for Drug Policy, St. 
George’s, University of London, London, 2012), pp. 95-96).
depression. The main adverse effects reported by users of 
the various synthetic cathinones include cardiac, psychiatric 
and neurological problems ranging from mild agitation to 
severe psychosis.32 A number of key cathinones are already 
under international control, including cathine, cathinone33 
and methcathinone, as well as amfepramone and pyro-
valerone.34 The most widely used non-controlled cathi-
nones at the international level include mephedrone35 
(4-methylmethcathinone, often known in the market as 
“m-cat”, “meph”, “drone” or “miaow”), methylone (“explo-
sion” or “top cat”) and MDPV. The use of MDPV was, in 
a number of cases, associated with highly bizarre 
behaviour,36 including a number of suicides, deaths associ-
ated with MDPV delirium37 and highly violent 
homicides.38
(d) Piperazines 
Piperazines are another broad group of substances that fall 
into the category of NPS. The basic molecule of this group, 
piperazine, was first introduced in medicine in 1953, for 
its anthelmintic properties. Some of the most common 
piperazines with psychoactive properties include BZP, 
1-(3-trifluoromethylphenyl)piperazine (TFMPP) and 
mCPP, which is reportedly more widespread than BZP in 
some regions.39 BZP is a drug with euphoric and stimulant 
properties, comparable to those produced by ampheta-
mines and was initially developed as a potential antidepres-
sant drug.40 In fact, users are often unable to distinguish 
the effects of BZP from those of d-amphetamine; they 
report alertness, mood escalation, euphoria and a general 
32 J. M. Prosser and L. S. Nelson, “The toxicology of bath salts: a review 
of synthetic cathinones”, Journal of Medical Toxicology, vol. 8, No. 1 
(2012), pp. 33-42. 
33 Cathinone was discovered in khat and subsequently synthesized in 
1974/1975 in the narcotics laboratory of the United Nations (see 
Kalman Szendrei, “The chemistry of khat”, Bulletin on Narcotics, vol. 
XXXII, No. 3 (1980) (United Nations publication), pp. 5-35).
34 Cathinone and methcathinone are listed in Schedule I of the Conven-
tion on Psychotropic Substances of 1971, cathine is listed in Schedule 
II and amfepramone and pyrovalerone are listed in Schedule IV of the 
same Convention.
35 For a detailed review see European Monitoring Centre for Drugs 
and Drug Addiction, Report on the Risk Assessment of Ketamine in the 
Framework of the Joint Action on New Synthetic Drugs; see also Paul I. 
Dargan and others, “The pharmacology and toxicology of the syn-
thetic cathinone mephedrone (4-methylmethcathinone)”, Drug Testing 
and Analysis, vol. 3, Nos. 7-8 (July-August 2011), pp. 454-463.
36 “Bath salts abuse”, available from http://sober.com/bath-salts.html.
37 B. L. Murray, C. M. Murphy and M. C. Beuhler, “Death following 
recreational use of designer drug “bath salts” containing 3,4-methyl-
enedioxypyrovalerone (MDPV)”, Journal of Medical Toxicology, vol. 8, 
No. 1 (2012), pp. 69-75.
38 Glenn Duncan, Hunterdon Drug Awareness Program, “3,4-methyl-
enedioxypyrovalerone (MDPV) and other synthetic cathinones”, 28 
January 2013. Available from www.slideshare.net/Guedde/mdpv-bath-
salts-emerging-drug-trends; Thomas M. Penders, “How to recognize a 
patient who’s high on ‘bath salts’”, Journal of Family Practice, vol. 61, 
No. 4 (April 2012), pp. 210-212.
39 European Monitoring Centre for Drugs and Drug Addiction, “BZP 
and other piperazines”, Drug Profiles. Available from www.emcdda.
europa.eu/publications/drug-profiles/bzp (accessed September 2012).
40 United Nations Office on Drugs and Crime, The Challenge of New 
Psychoactive Substances.
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feeling of well-being. BZP was initially marketed in some 
countries (notably New Zealand) as an alternative to meth-
amphetamine.41 If combined with TFMPP, effects similar 
to those of MDMA (“ecstasy”) are produced. Thus BZP/
TFMPP combinations have been widely used in the club 
and rave scene in many countries.42 These substances have 
been shown to have a mixed mechanism of action, acting 
both on the serotonin and the dopamine receptor systems, 
much like MDMA,43 thus showing entactogenic proper-
ties.44 In contrast to BZP, TFMPP is rarely used on its 
own. Street names of BZP include “Jax”, “A2”, “Benny 
Bear”, “Flying Angel”, “Legal E”, “Legal X”, “Pep X”, “Pep 
Love” and “Nemesis”.45 Adverse effects of BZP include 
repetitive thought patterns, increased heart rate, hyperten-
sion, dilation of pupils, nausea, flushing, slight urinary 
incontinence, chest pain, hallucinations, and - more prob-
lematically - confusion, acute psychosis, respiratory failure, 
renal toxicity and seizures. BZP produces toxic effects simi-
lar to those of amphetamines and other sympathomimet-
ics, although, according to studies on animals, its effects 
are less potent than those of amphetamines, methampheta-
mines and MDMA.46 The effects produced by mCPP are 
more like the stimulant and hallucinogenic effects pro-
duced by MDMA.47
(e) Ketamine 
Ketamine (street names: “K”, “special K”, “kit kat”, “tac”, 
“tic”, “cat valium”, “cat tranquillizer”, “vitamin K”, “ket”, 
41 M. Bowden, “Non-traditional designer substances: a new category 
of psychoactives in New Zealand”, April 2004. Available from www.
erowid.org/chemicals/bzp/bzp_info1.shtml.
42 Imogen Thompson and others, “The benzylpiperazine (BZP)/trifluo-
romethylphenylpiperazine (TFMPP) and alcohol safety study: report 
for the Ministry of Health”, 24 November 2006. Available from www.
ndp.govt.nz/moh.nsf/indexcm/ndp-publications-bzp-tfmpp-alcohol-
safety-study/$File/bzp-report-08.pdf.
43 C. Wilkins and others, Legal Party Pill Use in New Zealand: Prevalence 
of Use, Availability, Health Harms and ‘Gateway Effects’ of Benzylpipera-
zine (BZP) and Trifluorophenylmethylpiperazine (TFMPP) (Auckland, 
Massey University, 2006).
44 “Entactogens evoke mainly pleasant emotional effects of relaxation, 
feelings of happiness, increased empathy, and closeness to others” (see 
European Monitoring Centre for Drugs and Drug Addiction, “BZP 
and other piperazines”).
45 United States, Department of Justice, Drug Enforcement Administra-
tion, “N-Benzylpiperazine (street names: BZP, A2, Legal E or Legal 
X)”, Drug and Chemical Information, July 2012. Available from 
www.deadiversion.usdoj.gov/drug_chem_info/index.html; European 
Monitoring Centre for Drugs and Drug Addiction, Report on the Risk 
Assessment of BZP in the Framework of the Council Decision on New 
Psychoactive Substances, EMCDDA Risk Assessments, No. 8 (Luxem-
bourg, Office for Official Publications of the European Communi-
ties, 2009); World Health Organization, “N-benzylpiperazine (BZP): 
pre-review report”, prepared for the thirty-fifth meeting of the Expert 
Committee on Drug Dependence, Hammamet, Tunisia, 4-8 June 
2012.
46 S. Elliott, “Current awareness of piperazines: pharmacology and toxi-
cology”, Drug Testing and Analysis, vol. 3, Nos. 7-8 (2011), pp. 430-
438.
47 M. E. Tancer and C. E. Johanson, “The subjective effects of MDMA 
and mCPP in moderate MDMA users”, Drug and Alcohol Dependence, 
vol. 65, No. 1 (2001), p. 97, cited in S. Elliott, “Current awareness of 
piperazines: pharmacology and toxicology”, Drug Testing and Analysis, 
vol. 3, Nos. 7-8 (2011), pp. 430-438.
“super K”)48 is also a widespread substance falling within 
the category of NPS. It was originally developed as a deriv-
ative of phencyclidine (PCP), a drug controlled under 
Schedule II of the 1971 Convention. It is used in veteri-
nary medicine, primarily for the induction and mainte-
nance of general anaesthesia. In human medicine, it is 
sometimes used to treat depression in patients with bipolar 
disorder as well as for emergency surgery in war zones. 
However, it is also widely misused for recreational purposes 
as a club drug and in raves, notably in South-East Asia 
(often sold there as “ecstasy”, sometimes offered in pills 
containing both MDMA and ketamine) and, to a lesser 
extent, in Europe and in the Americas. It produces hallu-
cinatory effects as well as a dissociative state, characterized 
by a sense of detachment from one’s body, similar to the 
effects produced by phencyclidine. Ketamine produces 
euphoria, increased energy and a sense of calm and seren-
ity. Misuse can lead to increase in the heart rate, slurred 
speech, severe confusion, disorientation and shifts in per-
ception of reality (distortion and loss of sensory percep-
tions). In addition, hypertension and decreased heart rate 
have been associated with its use. Chronic ketamine use 
has been reported to be linked with lasting memory and 
cognitive dysfunctions.49 
(f) Tryptamines
There are a number of non-controlled tryptamines that 
are used for their psychedelic properties. They have effects 
similar to the tryptamines already controlled such as psilo-
cybin (found in “magic mushrooms”) or 3-[2-(dimethyl-
amino)ethyl]indole (DMT). Tryptamines can be 
synthesized, although they also exist in plants, fungi and 
animals.50 The work of Anne and Alexander Shulgin,51 
inter alia, provided illicit drug manufacturers with a know-
ledge base for the synthesis of a number of tryptamines. 
The use of tryptamines leads to a hallucinatory state, linked 
to auditory, visual and temporal distortions of reality. The 
intensity of the hallucinations is related to the concentra-
tion of the tryptamines in the visual cortex. The effects 
tend to vary strongly from person to person and depend 
on the setting of the “trip”. In general, use will have an 
impact on the ability for abstract thought and impair the 
ability to make sensible judgements and understand 
common dangers, thus making users susceptible to acci-
dents and injury. Their use can also cause temporary con-
fusion, dissociative fugue (a psychiatric disorder 
characterized by a reversible amnesia relating to personal 
identity) and may trigger panic attacks (“bad trips”). Use 
48 European Monitoring Centre for Drugs and Drug Addiction, Report 
on the Risk Assessment of Ketamine in the Framework of the Joint Action 
on New Synthetic Drugs.
49 T. Okon, “Ketamine: an introduction for the pain and palliative medi-
cine physician”, Pain Physician, vol. 10, No. 3 (2007), pp. 493-500.
50 M. Collins, “Some new psychoactive substances: precursor chemicals 
and synthesis-driven end-products”, Drug Testing and Analysis, vol. 3, 
Nos. 7-8 (2011), pp. 404-416.
51 Shulgin and Shulgin, TiHKAL (Tryptamines I Have Known and Loved): 
The Continuation.
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may be particularly problematic for persons already exhib-
iting symptoms of depression or schizophrenia. Interna-
tionally non-controlled tryptamines include 5-MeO-DMT 
(“alpha-O”), 5-MeO-DPT (“foxy-methoxy”), alpha-meth-
yltryptamine (AMT), 4-AcO-DMT, 4-AcO-DiPT, and 
5-HTP.52 
(g) Plant-based new psychoactive  
substances
A number of plants are also classified as NPS according to 
the broad definition. Some of the most widely used psy-
choactive plants not under international control include 
kratom (Mitragyna speciosa), Salvia divinorum and khat 
(Catha edulis).53 
a. Kratom
The cultivation and use of kratom is mostly linked to 
South-East Asia. Kratom has been used in traditional Thai 
medicine as an anti-diarrhoeal54 and it has been investi-
gated for the treatment for opioid dependence.55 However, 
it is also widely used recreationally, leading to its prohibi-
tion in Thailand as well as in other countries, including 
Malaysia, Myanmar and Australia. Kratom is a stimulant 
at low doses and a sedative at high doses. At low doses, it 
tends to increase physical energy and alertness and increases 
the ability to do monotonous physical work. At higher 
doses, it helps to reduce physical and emotional pain and 
tends to generate a feeling of well-being before eventually 
developing its sedative properties, creating a mixed state 
of wakefulness and dreaming. Withdrawal symptoms for 
chronic users of kratom may include muscle aches, irrita-
bility, crying, runny nose, diarrhoea and muscle 
jerking.56
b. Salvia divinorum
Salvia divinorum is a psychoactive plant that can induce 
dissociative effects and is a potent producer of visual and 
other hallucinatory experiences. By mass, salvinorin A, the 
psychoactive substance in the plant, appears to be the most 
potent naturally occurring hallucinogen. Its native habitat 
is the cloud forests in Mexico. It has been consumed for 
52 United Nations Office on Drugs and Crime, The Challenge of New 
Psychoactive Substances.
53 United Nations Office on Drugs and Crime, Global Smart Update 
2012, vol. 8, September 2012, pp. 4-5.
54 Karl L. R. Jansen and Colin J. Prast, “Ethnopharmacology of kratom 
and the Mitragyna alkaloids”, Journal of Ethnopharmacology, vol. 23, 
No. 1 (1988), pp. 115-119.
55 H. Takayama and others, “Studies on the synthesis and opioid ago-
nistic activities of mitragynine-related indole alkaloids: discovery of 
opioid agonists structurally different from other opioid ligands”, Jour-
nal of Medicinal Chemistry, vol. 45, No. 9 (2002), pp. 1949-1956.
56 W. C. Prozialeck, J. K. Jivan and S. V. Andurkar, “Pharmacology of 
kratom: an emerging botanical agent with stimulant, analgesic, and 
opioid-like effects”. Journal of the American Osteopathic Association, vol. 
112, No. 12 (2012), pp. 792-799; J. E. Adkins, E. W. Boyer and C. 
R. McCurdy, “Mitragyna speciosa, a psychoactive tree from Southeast 
Asia with opioid activity”, Current Topics in Medicinal Chemistry, vol. 
11, No. 9 (2011), pp. 1165-1175.
hundreds of years by local Mazatec shamans, who use it 
to facilitate visionary states of consciousness during spir-
itual healing sessions.57 It is also used in traditional medi-
cine at lower doses as a diuretic to treat ailments including 
diarrhoea, anaemia, headaches and rheumatism. Effects 
include various psychedelic experiences, including past 
memories (e.g. revisiting places from childhood memory), 
merging with objects and overlapping realities (such as the 
perception of being in several locations at the same time).58 
In contrast to other drugs, its use often prompts dysphoria, 
i.e. feelings of sadness and depression, as well as fear. 
In addition, it may prompt a decreased heart rate, slurred 
speech, lack of coordination and possibly loss of 
consciousness.59
c. Khat
Khat is a flowering plant native to the Horn of Africa and 
the Arabian peninsula. Chewing fresh khat leaves has a 
history dating back hundreds of years among the commu-
nities in those areas. The psychoactive effects resulting from 
the chewing of khat can be linked to a number of alkaloids. 
The katin alkaloid was identified first in 1887, cathine in 
193060 and cathinone in 1975.61 The stimulant effects of 
khat leaves can be linked primarily to cathinone and, to a 
lesser extent, to cathine, both of which are controlled under 
the 1971 Convention. Khat also contains norephedrine,62 
which is used, inter alia, as precursor for the manufacture 
of amphetamine63 and is thus controlled under the 1988 
Convention.64 A typical khat-chewing session results in 
the absorption of its active constituents, equivalent to the 
effects of some 5 mg of amphetamine use.65 Given the 
limited amounts of these psychoactive substances con-
tained in the khat leaf, in general, chewing khat induces 
only mild euphoria and excitement, as well as increased 
talkativeness. Withdrawal symptoms following occasional 
57 L. J. Valdés and others, “Studies of Salvia divinorum (Lamiaceae), 
an hallucinogenic mint from the Sierra Mazateca in Oaxaca, Central 
Mexico”, Economic Botany, vol. 41, No. 2 (1987), pp. 283-291.
58 D. M. Turner, Salvinorin: The Psychedelic Essence of Salvia Divinorum 
(San Francisco, Panther Press, 1996).
59 Carl Miller, “Negative effects of Salvia divinorum”. Available from 
www.ehow.com/list_6726778_negative-effects-salvia-divinorum.html.
60 “Cathinone is the principal active constituent of khat responsible 
for the stimulant effects that have led khat to be known as a ‘natural 
amphetamine’” (see J. P. Kelly, “Cathinone derivatives: a review of their 
chemistry, pharmacology and toxicology”, Drug Testing and Analysis, 
vol. 3, Nos. 7-8 (2011), pp. 439-453). 
61 Cathinone was discovered in khat and subsequently synthesized in 
1974/1975 in the narcotics laboratory of United Nations (see Szen-
drei, “The chemistry of khat”, pp. 5-35); United Nations, “Etudes sur 
la composition chimique du khat: recherches sur la fraction phényla-
lkylamine”, document MNAR/5/76.
62 Szendrei, “The chemistry of khat”.
63 WHO Expert Committee on Drug Dependence: Thirty-fourth Report, 
WHO Technical Report Series, No. 942 (Geneva, World Health 
Organization, 2006).
64 United Nations Convention against Illicit Traffic in Narcotic Drugs 
and Psychotropic Substances of 1988 (United Nations, Treaty Series, 
vol. 1582, No. 27627).
65 I. Dhaifalah and J. Santavy, “Khat habit and its health effect: a natural 
amphetamine”, Biomedical Papers, vol. 148, No. 1 (2004), pp. 11-15.
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use tend to include mild depression and irritability or, fol-
lowing prolonged use, lethargy and slight tremors. The 
physical harm related to khat use is limited as compared 
with other drugs. Khat is not considered to be a “seriously 
addictive drug” according to the World Health Organiza-
tion (WHO),66 as “its potential for dependence is low”.67 
However, the use of khat is not without problems. Khat 
affects sleep, leading to rebound effects such as late awak-
ening, day-time sleepiness and poor work performance. 
Long-term use has a negative impact on health, causing 
problems such as tooth decay, gastrointestinal disorders 
such as constipation, inflammation of the stomach, ulcers 
and upper gastrointestinal tumours; and cardiovascular 
disorders, including irregular heartbeat and myocardial 
infarction.68 Genetically predisposed people are vulnerable 
to developing psychoses. Serious socioeconomic conse-
quences have also been reported in countries where khat 
use is widespread.69 
C. THE RECENT EMERGENCE  
AND SPREAD OF NEW PSYCHO-
ACTIVE SUBSTANCES
NPS have been reported in a number of countries in recent 
years. What is actually known today, however, may be just 
the very tip of the iceberg, as systematic studies on the 
spread of NPS do not exist. The limited information avail-
able suggests that their spread is far from negligible, 
and - once cannabis is excluded from the analysis - the 
spread of NPS comes close to, or even exceeds, the spread 
of several controlled drugs.
Spread at the global level
Number of countries reporting the emer-
gence of new psychoactive substances 
Pursuant to Commission on Narcotic Drugs resolution 
55/1, entitled “Promoting international cooperation in 
responding to the challenges posed by new psychoactive 
substances”, in 2012 UNODC sent a questionnaire on 
NPS to all Member States, to which 80 countries and ter-
ritories replied. Most responses were received from coun-
tries in Europe (33), followed by countries and territories 
in Asia (23), in the Americas (12), in Africa (10) and in 
the Oceania region (2). In total 70 countries and 
territories,70 i.e. 88 per cent of all responding countries, 
66 “Khat chewing in Yemen: turning over a new leaf ”, Bulletin of the 
World Health Organization, vol. 86, No. 10 (October 2008), pp. 741-
742.
67 WHO Expert Committee on Drug Dependence: Thirty-fourth Report.
68 United States, National Institute on Drug Abuse, “DrugFacts: Khat”, 
January 2011. Available from www.drugabuse.gov/publications/drug-
facts/khat.
69 “Khat chewing in Yemen: turning over a new leaf ”, Bulletin of the 
World Health Organization, vol. 86, No. 10 (October 2008), pp. 741-
742.
70 Albania, Andorra, Angola, Argentina, Australia, Bahrain, Belgium, 
reported the emergence of NPS. Only 10 countries had 
not identified NPS in recent years.
The largest number of countries reporting NPS was in 
Europe (31 countries, or 44 per cent of all countries world-
wide reporting the spread of NPS). This may have to do 
with the creation of an early warning system under the 
auspices of EMCDDA. Within Europe, the largest number 
of countries reporting on NPS was countries in Western 
and Central Europe (22 countries). Europe’s largest coun-
try, the Russian Federation, also reported the emergence 
of NPS. The next largest number of countries was in Asia 
(19 countries, or 27 per cent), mostly in East and South-
East Asia (11 countries), and in the Near and Middle East 
(7 countries). In total, 11 countries in the Americas (16 
per cent) reported the emergence of NPS, including all of 
the countries of North America, six countries in South 
America and two in Central America. In Africa, seven 
countries (10 per cent) reported NPS, although only two 
countries could specify the category of the NPS.71
The largest proportion of countries reporting the emer-
gence of NPS, as a percentage of all respondents, was in 
the Oceania region (100 per cent, based on reports from 
two countries), Europe (94 per cent), and the Americas 
(92 per cent), followed by countries in Asia (83 per cent) 
and Africa (70 per cent). 
Groups of new psychoactive substances 
emerging between 2008 and 2012
Of the 70 countries reporting the emergence of NPS, 53 
were in a position to provide information on the main 
groups of substances concerned. Most of those countries 
reported the emergence of ketamine and of plant-based 
substances, followed by piperazines, synthetic cannabinoids 
and phenethylamines. 
The NPS markets are, however, extremely dynamic. Most 
of the ketamine, phenethylamines and piperazines emerged 
in Member States prior to 2008. In contrast, the large-scale 
entrance of new synthetic cannabinoids and synthetic 
cathinones was identified in later years. Thus, the type of 
NPS that emerges in the market changes depending on 
the period under investigation. Prior to 2008, ketamine 
dominated the market, followed by piperazines and the 
phenethylamines. In contrast, over the period 2008-2012, 
66 per cent of the 53 reporting countries identified new 
Bosnia and Herzegovina, Brazil, Brunei Darussalam, Bulgaria, Canada, 
Cape Verde, Chile, China, Colombia, Costa Rica, Croatia, Ecuador, 
Egypt, Finland, France, Georgia, Germany, Ghana, Greece, Hong 
Kong, China, Hungary, Indonesia, Ireland, Israel, Italy, Japan, Jordan, 
Latvia, Lebanon, Liechtenstein, Lithuania, Luxembourg, Malaysia, 
Malta, Mexico, Mongolia, Netherlands, New Zealand, Norway, 
Oman, Panama, Philippines, Poland, Portugal, Republic of Moldova, 
Romania, Russian Federation, Saudi Arabia, Serbia, Singapore, Slova-
kia, South Africa, Spain, Switzerland, Thailand, Togo, Turkey, United 
Arab Emirates, United States of America, Uruguay, Viet Nam and 
Zimbabwe.
71 United Nations Office on Drugs and Crime, The Challenge of New 
Psychoactive Substances.
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Map 1. Global emergence of new psychoactive substances up to July 2012
Source: United Nations Office on Drugs and Crime, The Challenge of New Psychoactive Substances (Vienna, March 2013).
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synthetic cannabinoids and 51 per cent identified new 
synthetic cathinones in their markets. This was followed 
by 40 per cent of the countries reporting non-controlled 
plant-based substances, 26 per cent piperazines, 17 per 
cent ketamine and 15 per cent phenethylamines in their 
markets. Comparing the periods prior to 2008 and from 
2008 to 2012, the most striking increases are observed for 
the number of synthetic cannabinoids and synthetic cathi-
nones entering the market.
In 2009 most of the synthetic cathinones emerged, and 
they also constituted the majority of new substances 
appearing in the market. In 2010, it was new synthetic 
cannabinoids that were most frequently spotted. In 2011, 
once again, most new substances emerging were new syn-
thetic cathinones.
Trafficking and seizure trends for  
new psychoactive substances 
Though NPS by definition are not controlled at the inter-
national level, several are controlled at the national level 
and are being seized. Of the 70 countries and territories 
that reported NPS, 61 also reported seizures of such sub-
stances. Almost half of the countries seizing NPS were 
located in Europe (48 per cent), followed - at lower levels 
- by countries in Asia (23 per cent), Africa (19 per cent), 
the Americas (16 per cent) and the Oceania region (3 per 
cent). 
Seizure trends, reflecting underlying trafficking activities, 
seem to largely confirm the patterns discussed so far. The 
overall trend for seizures of NPS between 2009 and 2012 
- based on information from 42 countries - is clearly a 
rising one. This upward trend in seizures, in addition, 
reflects the increasing number of substances that have been 
scheduled in recent years in various countries. Seizures 
show increases for synthetic cannabinoids over the period 
2009-2012 and, at least until 2011, also for the synthetic 
cathinones. In addition, the category “miscellaneous new 
psychoactive substances” showed continuing increases. In 
Fig. 2. Global emergence of new psycho-
active substances, by group, prior to 
2008 and from 2008 to 2012
Source: United Nations Office on Drugs and Crime, questionnaire 
on new psychoactive substances, 2012.
Fig. 3. Appearance of new psychoactive substance groups up to mid-2012 
Percentage of countries reporting the emergence of classes of new psychoactive substances  
from before 2008 to mid-2012
Source: United Nations Office on Drugs and Crime, The Challenge of New Psychoactive Substances (Vienna, March 2013).
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contrast, no further increases were reported for ketamine. 
The overall trends for piperazines and phenethylamines 
appear to have been rather stable over the same period. 
Some differences can be observed for plant-based sub-
stances. Seizure trends for these drugs rose until 2011 and 
then started to stabilize. 
Specific new psychoactive substances  
identified by national laboratories 
Laboratories were asked to provide detailed information 
on the specific substances they examined. An analysis of 
the responses revealed that laboratories in 40 countries 
identified a total of 251 NPS to mid-2012. This exceeds 
the total number of currently controlled psychoactive sub-
stances at the international level (234).
The number of newly identified NPS rose from 166 by 
200972 to 251 NPS by mid-2012. Thus, the total number 
of identified NPS rose by more than 50 per cent at the 
global level between 2009 and mid-2012.
The bulk of the 251 NPS identified over the period 2009 
to mid-2012 were synthetic cannabinoids (24 per cent of 
the total), phenethylamines (23 per cent) and synthetic 
cathinones (17 per cent), followed by tryptamines (10 per 
cent). These four groups accounted for almost three quar-
ters (74 per cent) of all NPS identified and reported to 
UNODC.
The main substances in each category were identified on 
the basis of the number of times they were mentioned by 
Member States. The NPS most frequently reported (more 
than 50 times) by the laboratories of Member States over 
the period 2009 to mid-2012 period were:
72 This includes new psychoactive substances identified over the 2006-
2008 period (53) and a few reports (11) from countries that could not 
identify precisely the year in which some specific new psychoactive 
substances emerged in their respective markets. A total of 102 new 
psychoactive substances were identified for the first time in 2009.
 s JWH-018 and JWH-073 among the synthetic 
cannabinoids
 s Mephedrone, MDPV and methylone among the  
synthetic cathinones
 s mCPP, BZP and TFMPP among the piperazines.
Table 1. Trend of new psychoactive substance seizures, 2009 to mid-2012a
 
Source: United Nations Office on Drugs and Crime, The Challenge of New Psychoactive Substances (Vienna, March 2013).
a Based on information from 42 countries. Respondents were asked to provide information on a yearly basis on observed seizure trends (“increasing”, 
“stable”, “decreasing”) for the above-mentioned NPS groups. When the number of respondents reporting “increasing” trends exceeded the number of 
respondents reporting “declining” or “stable” trends, an overall increase is shown in the table. Similarly, when the number of reported “declining” trends 
exceeded the “increasing” or “stable” trends an overall decline is shown. Where the largest number of respondents reported “stable” trends, an overall 
stable trend is shown.
n= Increasing, p= Decreasing, l = Stable,  unknown.
New psychoactive substance group 2009 2010 2011
First half  
of 2012
Synthetic cannabinoids n n n n
Synthetic cathinones n n n l
Ketamine l l l l
Phenethylamines l n l l
Piperazines n l l p
Plant-based substances n n n l
Miscellaneous  n n n
Fig. 4. Number of newly identified new  
psychoactive substances at the global 
level: 2009 to mid-2012 (cumulative)
Source: United Nations Office on Drugs and Crime questionnaire 
on new psychoactive substances, 2012.
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Origin and manufacture of new  
psychoactive substances
Europe was the region providing most of the information 
on the geographical origin of new psychoactive substances, 
which seem to originate primarily in Asia, notably in coun-
tries of East and South Asia that have advanced chemical 
and pharmaceutical industries.
A total of 32 countries reported information on the origin 
of new psychoactive substances (19 of them in Europe), 
and more than half of the countries cited Asia as the pri-
mary source for NPS (56 per cent) on their markets, fol-
lowed by Europe (28 per cent) and the Americas (9 per 
cent).73 All 5 reporting countries in Asia, as well as the 
73 United Nations Office on Drugs and Crime, The Challenge of New Psy-
choactive Substances. This is based on information from 32 countries. 
The sources are quoted here as reported by Member States. The results 
single largest NPS markets in North America (United 
States), Europe (United Kingdom) and the Oceania region 
(Australia) also reported Asia as the primary source region. 
In line with information from Europol74 and the Inter-
national Narcotics Control Board,75 China and India were 
most frequently named as source countries for NPS in Asia, 
are thus biased towards Europe. They have not been scientifically vali-
dated as manufacturing/production sites by the United Nations Office 
on Drugs and Crime.
74 Most of the new psychoactive substances found on the European 
market are — according to information from border seizures and law 
enforcement investigations in the European Union member States 
— imported from China and, to a lesser degree from India. Most of 
the mephedrone production, according to the European Police Office 
(Europol), takes place in Asia, particularly in China. At the same time, 
Europol also highlights that some of the new psychoactive substances 
are sourced primarily from within Europe (e.g. mCPP) (see European 
Monitoring Centre for Drugs and Drug Addiction and European 
Police Office, EU Drug Markets Report: A Strategic Analysis).
75 Report of the International Narcotics Control Board for 2012.
Fig. 5. New psychoactive substances identified in national laboratories, 2009 to mid-2012  
(number of substances and as a percentage of total (251) new psychoactive substances reported 
by 40 countries)a
Source: United Nations Office on Drugs and Crime, questionnaire on new psychoactive substances, 2012.
a Of the 40 countries responding, not all countries reported for every year.
Synthetic 
cannabinoids, 60, 23%
Phenethylamines, 
58, 23%
Synthetic cathinones, 
44, 18%
Tryptamines, 25, 10%
Plant-based 
substances, 20, 8%
Piperazines, 12, 5%
Phencyclidine-type 
substances and 
Ketamine, 5, 2%
Aminoindanes, 3, 1%
Miscellaneous, 24, 
10%
Table 2. Number of countries citing a region as the “primary source” for new psychoactive  
substancesa
Source: United Nations Office on Drugs and Crime, questionnaire on new psychoactive substances, 2012.
a Countries were asked to rank the source regions of the new psychoactive substances “reported or seized” on their territory; the replies were not scientifi-
cally validated by the United Nations Office on Drugs and Crime. 
Cited as primary source region
Reporting countries in:
Asia Europe Americas Africa Oceania Total
Europe 11 8 0 0 0 19
Asia 5 0 0 0 0 5
Americas 1 0 2 1 0 4
Africa 0 1 1 0 0 2
Oceania 1 0 0 0 1 2
Total 18 9 3 1 1 32
Primary source (percentage of total) 56 28 9 3 3 100
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though a number of European countries were also men-
tioned, including the Czech Republic, Hungary, the Neth-
erlands, Portugal, Spain, Ukraine and the United 
Kingdom.76 Among the 19 reporting countries in Europe, 
58 per cent saw Asia as their primary source region and 42 
per cent Europe. Two of the three countries reporting from 
Latin America identified other countries in the Americas 
as their primary source. The Americas were mentioned by 
one African country as its main source. Another African 
country identified Europe as its main source. 
Most of the countries providing information on the origin 
of NPS reported another country or region as the primary 
source, although they also reported some domestic produc-
tion. Of the 50 countries that provided information on 
the source of NPS detected in their country, more than 
three quarters stated that there was no NPS production on 
their territory; only 12 countries (24 per cent) reported 
that there was some domestic production, mainly serving 
the local market. Domestic manufacture was reported by 
a number of countries in Europe, in the Americas and in 
Asia. EMCDDA reported the dismantling of NPS pro-
duction-related facilities in the Netherlands as well as in 
Belgium, Ireland and Poland.77 Nonetheless, the overall 
pattern remains one of limited domestic production and 
reliance on overseas imports. This is different from the 
clandestine manufacture of controlled psychotropic sub-
stances such as amphetamine-type stimulants, which typi-
cally occurs within the same region where the consumers 
are located. 
The role of the Internet
The Internet seems to play an important role in the NPS 
business, more than it does in the illicit drug business in 
general: 88 per cent of the countries responding to a 
UNODC survey with a domestic NPS market indicated 
that the Internet was a key source for NPS detected in their 
country (35 out of 40 countries replying to this question). 
Most of the actual transport is then conducted by air and 
by mail.
The growing role of the Internet as a source for new psy-
choactive substances has been confirmed in the targeted 
EMCDDA Internet study (“snapshot”). The number of 
online shops offering to supply customers in European 
Union countries with NPS increased from 170 in January 
2010 to 314 in January 2011 and 693 in January 2012.78
Nonetheless, this key role of the Internet perceived by 
authorities worldwide was not confirmed by a Eurobarom-
eter survey conducted across the 27 European Union coun-
tries among 15- to 24-year-olds in 2011. Just 7 per cent 
76 United Nations Office on Drugs and Crime, The Challenge of New 
Psychoactive Substances.
77 European Monitoring Centre for Drugs and Drug Addiction, Annual 
Report 2012: The State of the Drugs Problem in Europe (Luxembourg, 
Publications Office of the European Union, 2012).
78 Ibid.
(range: 0-27 per cent in the various European Union coun-
tries) of the young consumers of NPS purchased the sub-
stances over the Internet, i.e. far less than the 33 per cent 
who bought it in a specialized shop, the 36 per cent who 
acquired it at a party or in a club, or the 54 per cent who 
were offered the substances by a friend.79 This indicates 
that while the import and wholesale business in NPS may 
be increasingly conducted via the Internet, more traditional 
distribution channels are still used for the retail trade.
Interest in new psychoactive substances  
as reflected in Internet searches
Data on the number of NPS abusers and on the size of the 
NPS market are very scarce. One indicator that can help 
in assessing the magnitude of the problem is the number 
of times a certain substance is searched for on the Internet. 
In the absence of global household surveys covering these 
substances, Internet searches are one of the few proxy vari-
ables that reflect interest in NPS, and thus, indirectly, their 
spread.
One can assume that there is a positive correlation between 
interest, and thus the searches for a substance, and the 
actual spread of a substance. Consumers generally wish to 
obtain information on the substances they are using or 
intend to use. Parents, teachers, the media and law enforce-
ment agencies often try to obtain information on specific 
substances once a problem is encountered in their 
communities. 
There are, of course, also some biases. Consumers of NPS 
may use the Internet to purchase such substances, a pos-
sibility that is more limited for controlled substances. 
Moreover, Internet availability plays a role. Thus, global 
Internet searches are biased towards developed countries. 
Even so, the main findings can provide an overall idea of 
reality.
When the findings are restricted to “substance abuse”, the 
most widely searched NPS globally over the period 2008-
2012 was Spice, followed by ketamine, Salvia divinorum 
and kratom. Cannabis, however, still leads the way, ahead 
of amphetamine-type stimulants, cocaine and heroin. 
Data suggest that the interest in NPS over the period 2008-
2012 (excluding Spice) was concentrated mainly on “bath 
salts” (such as mephedrone, and less so on MDPV), fol-
lowed by ketamine, khat, Salvia divinorum, kratom, 
PMMA, JWH-018 and BZP. Most of the other substances 
do not figure prominently on this list. While interest in 
amphetamine-type stimulants declined (linked to 
“ecstasy”), searches for “bath salts” increased — particularly 
in 2012 — following some serious incidents and subse-
quent discussions about controlling such substances. Inter-
net searches for “bath salts” started to approach those for 
“ecstasy” in 2012. 
79 Gallup Organization, Youth Attitudes on Drugs: Analytical Report, Flash 
Eurobarometer series No. 330 (European Commission, July 2011).
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Fig. 6. Index: Google searches made worldwide by Internet users for selected psychoactive  
substances, 2008-2012a
 
Source: Google Trends, January 2008-December 2012.
a The numbers in the figure reflect how many searches have been done for a particular term as compared to other terms over the period 2008-2012 within 
the category of “substance abuse” (in order to avoid unintended search results for Spice). The data have been normalized and are presented on a scale from 
0 to 100. The number 100 represents the peak search volume for any of the substances mentioned over the period. In this case, 100 represents the peak 
search volume for cannabis in November 2012. An overall average for each term, based on weekly data, has been calculated for the period 2008-2012 and 
is shown in the figure. 
b Amphetamine-type stimulants: “ecstasy” including the search term “MDMA”, “amphetamine”, “methamphetamine”, “jaba” and “shabu”.
Fig. 7. Index: Google searches made worldwide by Internet users for amphetamine-type stimulants 
and new psychoactive substances (excluding Spice), 2008-2012a
Source: Google Trends, January 2008-December 2012. 
a The number 100 represents the peak search volume for any of the substances mentioned over the period from 1 January 2008 to 31 December 2012. In 
this case, 100 represents the peak search volume for “bath salts” over the week of 27 May to 2 June 2012. (No filter was used for this search.) 
b “Ecstasy” including the search term “MDMA”; methamphetamine, including the search terms “jaba” and “shabu”. 
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Among Internet searches for the chemical groups of the 
main NPS, the strongest interest by far has been in syn-
thetic cannabinoids, i.e. the main psychoactive substances 
contained in Spice. This has clearly increased over the 
period 2008-2012. Interest in piperazines started to emerge 
at the global level as of 2008 and peaked in 2009 before 
declining in subsequent years. Interest in phenethylamines 
remained relatively constant. Interest in tryptamines, in 
contrast, appears to have lost momentum in recent years. 
Interest in synthetic cathinones increased in 2010, and 
again in 2012, to the extent that it was higher than for the 
other NPS groups in that year, except the synthetic 
cannabinoids. 
Spread of new psycho active  
substances at the regional level
Europe 
The most closely monitored region with regard to the 
emergence of NPS so far has been Europe, notably the 
European Union. EMCDDA, in cooperation with Euro-
pol, created the European early warning system for NPS. 
Whenever a NPS is detected in a country, information on 
its manufacture, trafficking and use is sent by the State to 
Europol and EMCDDA. The early warning system com-
prises the 27 European Union countries, as well as Norway 
and the two European Union candidate countries, Croatia 
and Turkey. Through the early warning system, a total of 
236 substances were identified over the period 2005-2012, 
equivalent to more than 90 per cent of all substances found 
globally and reported to UNODC (251). The upward 
trend has clearly gained momentum in recent years.
The monitoring activities started in June 1997 with a joint 
action covering information exchange, risk assessment and 
control of new synthetic drugs. This was subsequently 
replaced by European Union Council decision 2005/387 
on information exchange, risk assessment and control of 
NPS.80
Over 30 new synthetic drugs were reported through the 
early warning system under the 1997 joint action. The 
drugs identified were largely non-controlled phenethyl-
amines and tryptamines and, less commonly, synthetic 
cathinones and piperazines.81
In comparison, 236 new substances were formally reported 
through the early warning system over the period 2005-
2012, signalling the growing importance of NPS in Europe. 
In 2012, 73 new substances were detected,82 up from 49 
 
80 European Monitoring Centre for Drugs and Drug Addiction and 
European Police Office, Early-Warning System on New Psychoactive 
Substances: Operating Guidelines, pp. 11-15.
81 Ibid.
82 European Monitoring Centre for Drugs and Drug Addiction and 
European Police Office, EU Drug Markets Report: A Strategic Analysis.
in 2011, 41 in 2010, 24 in 200983 and, on average, 5 per 
year over the period 2000-2005.84
In contrast to the dominance of phenethylamines and 
tryptamines identified following the joint action in 1997, 
the substances identified over the period 2010-2012 fell 
mainly into the categories of synthetic cannabinoids (64), 
followed by “other new psychoactive substances” (40), syn-
thetic cathinones (28), phenethylamines (24), tryptamines 
(5) and piperazines (2).85 In 2012, the largest numbers of 
new substances identified were, for the fourth year in a 
row, synthetic cannabinoids (30 new substances), followed 
by “other new psychoactive substances” (19).86 
Comparing the number of NPS identified over the period 
2005-2008 with those identified over the period 2009-
2012, the largest increase was for synthetic cannabinoids 
and synthetic cathinones, followed by increases for “other 
new psychoactive substances” and phenethylamines. On 
the other hand, the number of newly identified tryptamines 
and piperazines declined.
83 European Monitoring Centre for Drugs and Drug Addiction, Annual 
Report 2012: The State of the Drugs Problem in Europe, p. 89.
84 United Nations Office on Drugs and Crime, Global Smart Update 
2012, vol. 8, September 2012.
85 European Monitoring Centre for Drugs and Drug Addiction, Annual 
Report 2012: The State of the Drugs Problem in Europe, p. 90.
86 European Monitoring Centre for Drugs and Drug Addiction and 
European Police Office, “EMCDDA-Europol 2011 annual report on 
the implementation of Council decision 2005/387/JHA”, p. 9.
Fig. 8. Evolution of new psychoactive  
substances reported to the early  
warning system, 2005-2011
Source: European Monitoring Centre for Drugs and Drug Addic-
tion and European Police Office, EU Drug Markets Report: A Stra-
tegic Analysis (Luxembourg, Publications Office of the European 
Union, 2013).
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A Eurobarometer survey of 12,000 randomly selected 
young people conducted across the European Union in 
2011, revealed that on average, about 2.9 million people 
or 4.8 per cent of the population between 15 and 24 years 
of age, had experimented with legal substances that imitate 
the effects of illicit drugs. This is far from negligible, equiv-
alent to about a fifth of the lifetime prevalence rate for 
cannabis in 2011 in the same age group. To put it in 
another perspective, that is about half the total number of 
people between the ages of 15 and 24 who had used illicit 
drugs other than cannabis in 2004.87
87 No data for 2011 are available.
The definition of legal substances that imitate the effects 
of illicit drugs in the Eurobarometer survey refers to psy-
choactive substances that are not controlled at the national 
level. As more substances are controlled at the national 
than at the international level, legal substances that imitate 
the effects of illicit drugs include a slightly smaller number 
of substances than NPS. The overall prevalence of NPS in 
the European Union is thus possibly greater than indicated 
by the prevalence data on legal substances that imitate the 
effects of illicit drugs. On the other hand, many of the 
substances marketed as “legal highs” may be considered 
legal by consumers even though they are under national 
control, so that in practice, the reported prevalence of legal 
Fig. 9. Number of new psychoactive substances newly reported annually through the European 
Monitoring Centre for Drugs and Drug Addiction’s early warning system, 2005-2012
 
Source: European Monitoring Centre for Drugs and Drug Addiction and European Police Office, EU Drug Markets Report: A Strategic 
Analysis (Luxembourg, Publications Office of the European Union, 2013).
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Source: United Nations Office on Drugs and Crime calculations based on European Monitoring Centre for Drugs and Drug Addiction and 
European Police Office, EU Drug Markets Report: A Strategic Analysis (Luxembourg, Publications Office of the European Union, 2013). 
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substances that imitate the effects of illicit drugs may still 
be very close to the prevalence rates for NPS.
As expected, lifetime prevalence of legal substances that 
imitate the effects of illicit drugs rises with age, from 3.6 
per cent among the European Union population aged 15 
to 18 to 5.6 per cent among those aged 19 to 21 and 22 
to 24. The increases in the lifetime prevalence with age are, 
however, less pronounced than for cannabis, probably 
reflecting the fact the legal substances that imitate the 
effects of illicit drugs have not been on the market for as 
long as cannabis.
Data from the Eurobarometer and the European School 
Survey Project on Alcohol and Other Drugs (ESPAD) sur-
veys showed a statistically significant decline in cannabis 
Fig. 11. Main groups of new psychoactive  
substances identified through the Euro-
pean Monitoring Centre for Drugs and 
Drug Addiction’s early warning system, 
2005-2008 compared to 2009-2012
 
Source: United Nations Office on Drugs and Crime calculations 
based on European Monitoring Centre for Drugs and Drug Addic-
tion and European Police Office, EU Drug Markets Report: A Stra-
tegic Analysis (Luxembourg, Publications Office of the European 
Union, 2013). 
Fig. 12. Lifetime prevalence of the use of  
illicit drugs and of legal substances 
that imitate the effects of illicit drugs 
among 15 to 24 year old persons in  
the European Union, 2002-2011
 
Source: United Nations Office on Drugs and Crime calculations 
based on European Monitoring Centre for Drugs and Drug Addic-
tion and European Police Office, EU Drug Markets Report: A Stra-
tegic Analysis (Luxembourg, Publications Office of the European 
Union, 2013). 
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Source: Gallup Organization, Youth Attitudes on Drugs: Analytical Report, Flash Eurobarometer series No. 330 (European Commission, 
July 2011).
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use and thus of drug use in general, among adolescents in 
Europe over the last decade.88 The prevalence rates for 
illicit drugs other than cannabis remained largely stable 
between 2003 and 2011, according to ESPAD. In contrast, 
the use of legal substances that imitate the effects of illicit 
drugs appears to have increased. From negligible levels a 
decade ago, the lifetime prevalence rate of legal substances 
that imitate the effects of illicit drugs rose to 3.6 per cent 
among adolescents aged 15 to 18 in 2011. In some coun-
tries (Ireland and Poland), the use of legal substances that 
imitate the effects of illicit drugs among young people is 
even greater than the use of other drugs, and in a number 
of countries, including Latvia, Lithuania, Slovenia, Sweden 
and the United Kingdom, the levels are approaching those 
of other drugs, apart from cannabis.89 
The lifetime prevalence rates for legal substances that imi-
tate the effects of illicit drugs in the European Union 
88 B. Hibell and others, The 2011 ESPAD Report: Substance Use among 
Students in 36 European Countries (Stockholm, Swedish Council for 
Information on Alcohol and Other Drugs, 2012).
89 “Approaching” has been defined here as a difference of less than 1 
percentage point in the lifetime prevalence rates between the use of 
“illicit drugs other than cannabis” (2011 ESPAD study) and the use 
of “legal substances that imitate the effects of illicit drugs” (2011 
Eurobarometer study).
appear to be slightly lower than the rates for amphetamines 
shown by the European School Survey Project on Alcohol 
and Other Drugs if adjusted to the age group 15 to 18, of 
a magnitude similar to the rate for “ecstasy” and larger than 
the corresponding rates for cocaine, LSD or heroin in 
Europe.90
As in the case of other drugs, the use of legal substances 
that imitate the effects of illicit drugs is more widespread 
among males than among females, more common in met-
ropolitan than in rural areas and more widespread among 
the unemployed population than among those working. 
Their use is slightly higher than average among those who 
have only completed primary education and lower than 
average among those having completed secondary educa-
tion, and it rises again among those who have a higher 
90 Gallup Organization, Youth Attitudes on Drugs: Analytical Report; B. 
Hibell and others, The 2011 ESPAD Report: Substance Use among 
Students in 36 European Countries (Stockholm, Swedish Council for 
Information on Alcohol and Other Drugs, 2012); B. Hibell and 
others, The ESPAD Report 2003: Alcohol and Other Drug Use Among 
Students in 35 European Countries (Stockholm, Swedish Council for 
Information on Alcohol and Other Drugs and Pompidou Group of the 
Council of Europe, 2004); and Council of Europe, Alcohol and Drug 
Use Among European 16-18 Year Old Students – Data from the ESPAD 
Project, February 2007.
Fig. 14. Lifetime prevalence of the use of illicit drugs and legal substances that imitate the effects  
of illicit drugs among adolescents in the European Union,a 2003/04-2011
 
Source: Gallup Organization, Youth Attitudes on Drugs: Analytical Report, Flash Eurobarometer series No. 330 (European Commission, 
July 2011); and Taylor Nelson Sofres, Young People and Drugs, Flash Eurobarometer series No. 158 (European Commission, June 2004); 
B. Hibell and others, The 2011 ESPAD Report: Substance Use among Students in 36 European Countries (Stockholm, Swedish Council for 
Information on Alcohol and Other Drugs, 2012).
a There are issues related to comparability due to differences in the age groups analysed (ages 15-16 in the ESPAD survey, ages 15-18 in Eurobarometer 
survey), the target groups (adolescents attending school in the ESPAD survey, school and non-school attending youth in the Eurobarometer survey), the 
sample size (ESPAD study: 103,000 students across Europe; Eurobarometer study: 12,300 young people in 27 European Union member States including 
4,600 people in the age group 15-18) and survey methodology (filling in questionnaires in school classes in the ESPAD survey; asked questions over the tel-
ephone in the Eurobarometer study. Nonetheless, the results — in broad terms — should provide some reasonable orders of magnitude. 
b Data for 2004 refer to European Union-15; data for 2011 refer to European Union-27. 
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form of education (though a higher lifetime prevalence of 
persons with a higher level of education is also a reflection 
of the fact that they are older). This represents a U-curve 
(or inverted J-curve)91 phenomenon, which is common in 
many drug markets around the world with regard to 
income and education.
Most of the users of legal substances that imitate the effects 
of illicit drugs (a) were offered such substances by a friend 
91 World Drug Report 2012, p. 89.
(54 per cent), (b) were offered them at a party or in a club 
(36 per cent), (c) bought them in specialized shops (33 per 
cent) or (d) bought them over the Internet (7 per cent).
Large proportions of such substances were sourced from 
“head shops” or “smart shops” in Italy (60 per cent), the 
Netherlands (60 per cent) and Ireland (57 per cent). The 
Internet played a clearly higher than average role as a source 
in Sweden (27 per cent), Germany (18 per cent), Denmark 
(14 per cent), Estonia (14 per cent), Finland (11 per cent), 
the Czech Republic (11 per cent) and Latvia (9 per cent).
Fig. 15. Use of legal substances that imitate the effects of illicit drugs among young people  
(aged 15-24) in the European Union-27, 2011, by sociodemographic characteristics
Source: Gallup Organization, Youth Attitudes on Drugs: Analytical Report, Flash Eurobarometer series No. 330 (European Commission, 
July 2011).
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Users of legal substances that imitate the effects of illicit 
drugs showed lower risk perceptions with regard to the 
negative health effects of illicit drugs than the general pop-
ulation. As risk perceptions often go hand in hand with 
actual use, users of legal substances that imitate the effects 
of illicit drugs appear to be more vulnerable to experimen-
tation with other drugs, including cocaine, “ecstasy” and 
cannabis. 
Use of legal substances that imitate the effects of illicit 
drugs and use of cannabis often go hand in hand. In fact, 
85 per cent of the users of legal substances that imitate the 
effects of illicit drugs in the European Union also con-
sumed cannabis, compared to a rate of 23 per cent among 
non-users of legal substances that imitate the effects of 
illicit drugs (aged 15-24). Similarly, 31 per cent of lifetime 
cannabis users in the (unweighted) sample92 experimented 
92 The sample consisted of about 500 persons in the larger countries and 250 
in the smaller countries, totalling some 12,000 persons across the Euro-
pean Union. The calculations shown here were based on the unweighted 
sample of some 12,000 persons. Once the drug users are calculated 
based on the actual size of the population (aged 15-24) in each country, 
the proportion of users of legal substances that imitate the effects of 
illicit drugs among cannabis users falls from 30 per cent to less than 
20 per cent.
with legal substances that imitate the effects of illicit drugs, 
while the proportion was negligible among non-users of 
cannabis (0.8 per cent).93
The lifetime prevalence rates for the use of legal substances 
that imitate the effects of illicit drugs in individual Euro-
pean Union countries ranged from 0.3 per cent in Malta 
to more than 16 per cent in Ireland. Levels above the Euro-
pean Union average (4.8 per cent) have been reported — 
in descending order — from Ireland, Poland, Latvia and 
the United Kingdom, followed by Luxembourg, Slovenia, 
Estonia, Portugal, Lithuania, France and Spain. 
Country results, however, must be treated with caution, 
as the individual country samples were rather small (about 
500 people in the Eurobarometer survey). Moreover, the 
authors explicitly cautioned that “the perception of sub-
stances included in the category ‘new psychoactive sub-
stances’ may have varied across countries”.94
93 UNODC calculations based on Gallup Organization, Youth Attitudes 
on Drugs: Analytical Report.
94  Gallup Organization, Youth Attitudes on Drugs: Analytical Report, p. 4.
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Map 2. Experience with legal substances that imitate the effects of illicit drugs in the European  
Union among persons aged 15-24, 2011
Source: Gallup Organization, Youth Attitudes on Drugs: Analytical Report, Flash Eurobarometer series No. 330 (European Commission, 
July 2011).
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The total number of lifetime users of legal substances that 
imitate the effects of illicit drugs among the population 
aged 15 to 24 in the European Union — as measured by 
Eurobarometer prevalence and United Nations population 
data — amounted to 2.9 million in 2011. The largest 
market for legal substances that imitate the effects of illicit 
drugs in the European Union is the United Kingdom 
(670,000 people experimenting with legal substances that 
imitate the effects of illicit drugs in the age group 15 to 
24, or 23 per cent of the European Union total), followed 
by Poland (490,000 persons, or 17 per cent), France 
(400,000, or 14 per cent), Germany (340,000, or 12 per 
cent) and Spain (230,000, or 8 per cent). Those five coun-
tries accounted for almost three quarters (73 per cent) of 
all those experimenting with legal substances that imitate 
the effects of illicit drugs in the European Union. 
Available data suggest that not only does the overall use of 
NPS differ significantly from country to country, so also 
do the specific substances. Depending on the country con-
cerned, they are either synthetic cannabinoids, mephed-
rone or even ketamine. 
Ireland: use of new psychoactive substances 
linked to several substances 
The highest prevalence rate in Europe for legal substances 
that imitate the effects of illicit drugs was identified for 
Ireland (with a lifetime prevalence of 16.3 among those 
aged 15-24 in 2011).95 The most widespread NPS in Ire-
land include Spice, various cathinone derivatives, pipera-
zines, various products sold as legal alternatives for 
“ecstasy”, LSA (products sold as legal alternatives to LSD) 
and kratom, sold as a legal alternative to opiates.96
A study among young persons aged 15 to 18 found a life-
time prevalence of “legal party pills” of 6.8 per cent among 
school attendees in 2008, which was the second highest 
after cannabis. The rate rises dramatically to 23.4 per cent97 
among school dropouts. 
A subsequent general population survey in 2010/11 iden-
tified an annual prevalence of 9.7 per cent among the 
population aged 15 to 24, which was again far higher than 
the use of most drugs other than cannabis. The annual 
prevalence of use of NPS was almost four times as high as 
the prevalence rate for cocaine, more than six times the 
95 Gallup Organization, Youth Attitudes on Drugs: Analytical Report.
96 “Legal highs and head shops: some basic facts”. Available from www.
drugs.ie/resourcesfiles/guides/Legal_highs_%26_headshops_leaflet.
pdf.
97 T. Haase and J. Pratschke, Risk and Protection Factors for Substance Use 
Among Young People: A Comparative Study of Early School-Leavers and 
School Attending Students (Dublin, National Advisory Committee on 
Drugs, 2010).
Fig. 17. Distribution of users of legal substances that imitate the effects of illicit drugs across  
European Union countries (total: 2.9 million lifetime users in the age group 15-24, based  
on a sample of 12,313 persons interviewed across the European Union in May 2011)
Source: UNODC calculations based on Gallup Organization, Youth Attitudes on Drugs: Analytical Report, Flash Eurobarometer series No. 
330 (European Commission, July 2011) and United Nations population data.
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rate for amphetamines and almost nine times the rate for 
“ecstasy” use in Ireland in this age group. The differences 
become less pronounced once older age groups are 
considered. 
The survey also showed that the annual prevalence of use 
of NPS declines with age and is more common among 
males than females. The decline with age is far more pro-
nounced than for illicit drugs in general, reflecting the fact 
that the use of NPS is still far more of a youth phenomenon 
than overall illicit drug use. 
The annual prevalence of NPS use among the general pop-
ulation aged 15 to 64 was markedly higher in the Republic 
of Ireland (3.5 per cent) than in Northern Ireland (1.1 per 
cent for mephedrone; 1.0 per cent for “legal highs” among 
those aged 15-64) or in England and Wales (1.4 per cent 
for mephedrone, 0.2 per cent for Spice, 0.2 per cent for 
khat and 0.1 per cent for BZP among those aged 16-59 in 
2010/11). 
Fig. 18. Ireland: annual prevalence of the use of new psychoactive substances compared to  
internationally controlled substances among the population aged 15 to 24, 2010/11
Source: National Advisory Committee on Drugs and Public Health Information and Research Branch, “Drug use in Ireland and Northern 
Ireland: first result from the 2010/11 drug prevalence survey”, Bulletin 1, November 2011.
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Fig. 19. Ireland: sociodemographic characteristics of the use of new psychoactive substances  
compared to illicit drugs, 2010/11
Source: National Advisory Committee on Drugs and Public Health Information and Research Branch, “Drug use in Ireland and Northern 
Ireland: first result from the 2010/11 drug prevalence survey”, Bulletin 1, November 2011. 
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The use of illicit drugs, including and excluding cannabis, 
declined in recent years in Ireland, both among students98 
and among the general population.99 More recently, there 
are signs that the use of NPS may have stabilized or even 
declined, following changes in the legal framework as well 
as increased prevention activities and a (forced) reduction 
in the number of shops selling “legal highs”. In fact, for 
2011, the authorities reported an actual decline in admis-
sions to accident and emergency services related to the 
abuse of “legal highs” for the first time in years.100
United Kingdom: use of new psychoactive  
substances linked primarily to mephedrone  
and ketamine
Europe’s largest market for NPS is the United Kingdom, 
according to the Eurobarometer survey data. The United 
Kingdom had a lifetime prevalence rate of 8.2 per cent 
among those aged 15 to 24: this amounts to 23 per cent 
of all lifetime users of NPS in the European Union in 2011. 
The United Kingdom was also the country that identified 
the maximum number of NPS in the European Union (30 
per cent of the total over the period 2005-2010).101
98 Council of Europe, 2011 ESPAD Report, Stockholm 2012.
99 General population surveys confirm the downward trend in drug 
use. Annual prevalence of cannabis use fell from 6.3 to 6.0 per cent, 
cocaine from 1.7 to 1.5 per cent and “ecstasy” from 1.2 to 0.5 per cent 
for the population aged 15-64 over the period 2006/2007-2010/2011 
(see National Advisory Committee on Drugs and Drug and Alcohol 
Information and Research Unit, cited in Health Research Board, 2011 
National Report (2010 Data) to the EMCDDA by the Reitox National 
Focal Point: Ireland — New Developments, Trends and In-depth Informa-
tion on Selected Issues (Dublin, 2011).
100 United Nations Office on Drugs and Crime, data from the annual 
report questionnaire.
101 European Commission, “Commission Staff Working Paper on the 
For the fiscal year 2010/11, the British Crime Survey found 
that the most widespread NPS was mephedrone, with an 
annual prevalence rate of 1.4 per cent among the popula-
tion aged 16 to 59 in England and Wales. This was fol-
lowed by ketamine (0.6 per cent), khat (0.2 per cent), Spice 
(0.1 per cent) and BZP (0.1 per cent). Mephedrone turned 
assessment of the functioning of Council decision 2005/387/JHA on 
information exchange, risk assessment and control of new psychoac-
tive substances”, document SEC(2011) 912 (Brussels, 11 July 2011).
Fig. 20. Annual prevalence of new psychoactive substances compared to other drugs in England  
and Wales among persons aged 16 to 24, 2010/11
Source: United Kingdom, Home Office, Drug Misuse Declared: Findings from the 2011/12 British Crime Survey for England and Wales, 
2nd ed. (London, July 2012). 
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Fig. 21. Annual prevalence of the use of new 
psychoactive substances among 
the general population aged 16 to 59 
in England and Wales, 2010/11 and 
2011/12
Source: United Kingdom, Home Office, Drug Misuse Declared: 
Findings from the 2011/12 British Crime Survey for England and 
Wales, 2nd ed. (London, July 2012).
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out to be the third most abused substance after cocaine, 
on a par with “ecstasy”. Among those aged 16 to 24, the 
use of mephedrone (4.4 per cent) was already on a par with 
that of cocaine powder, and thus the second most widely 
misused substance in 2010/11. 
Data for England and Wales suggest that the prevalence 
of NPS started to fall in 2011/12, however, following years 
of increase. Mephedrone use declined following an import 
ban and its classification as a class B substance under the 
Misuse of Drugs Act in 2010. The annual prevalence fell 
by a fifth between 2010/11 and 2011/12, to 1.1 per cent 
among the general population aged 16 to 59, so that this 
substance now ranks fourth after cannabis (6.9 per cent), 
cocaine (2.2 per cent) and “ecstasy” (1.4 per cent) among 
the general population. Marginal declines were also 
observed in the use of ketamine and of Spice.102
This was confirmed by an Internet survey undertaken on 
behalf of the United Kingdom dance and clubbing maga-
zine MixMag and the newspaper The Guardian in Novem-
102 United Kingdom, Home Office, Drug Misuse Declared: Findings 
from the 2011/12 British Crime Survey for England and Wales, 2nd ed. 
(London, July 2012).
ber and December 2011.103 That survey showed a strong 
decline in mephedrone use between 2010 and 2011 among 
those who participated.104 The same trend was observed 
for MDPV, another synthetic cathinone that was banned. 
The survey also provided some information on the use of 
a significant number of NPS that, so far have not been 
identified in national household surveys.
Poland: with new psychoactive substances  
linked to synthetic cannabinoids and synthetic 
cathinones
The second-largest market for NPS in Europe, after the 
United Kingdom, appears to have been Poland, with a 
lifetime prevalence rate of 9 per cent among those aged 15 
to 24 (the second highest in Europe after Ireland), and 
with 17 per cent of the European Union’s total number of 
lifetime users of such substances in this age group in 2011, 
according to the findings of the Eurobarometer survey.
Those findings have been reconfirmed in several national 
surveys undertaken in Poland in recent years. A question 
about the use of “dopalacze” (“legal highs”) was introduced 
for the first time in a national survey conducted in 2009. 
The study revealed that 6 per cent of the general popula-
tion aged 15 to 75 had experimented with such substances 
and 5 per cent had used them in the past year in 2009. 
The lifetime prevalence of the use of “legal highs” among 
the general population was even higher than the use of 
cannabis and all other drugs. Among those in the age group 
15 to 24, every tenth person reported having experimented 
with “legal highs”,105 which is in line with the findings of 
the 2011 Eurobarometer study.
School surveys of students aged 18 and 19 found a large 
increase in the use of such “legal highs” between 2008 
and 2010. Lifetime prevalence more than tripled, from 
3.5 per cent in 2008 to 11.4 per cent in 2010, a much 
larger increase than for any other drug group over this 
period.106
As part of “sanitary inspection checks”, more than 2,000 
samples of substances were collected from shops selling 
“legal highs” in 2010. The most frequently encountered 
substances were synthetic cathinones (15 different com-
pounds, of which MDPV — following the control of 
103 “Mixmag’s Drug Survey: the results”, March 2012. Available from 
www.mixmag.net/drugssurvey. The results of this (non-random) Inter-
net survey were based on information from some 7,700 respondents 
from the United Kingdom with a mean age of 28 (see: Patrick Butler, 
“How the Guardian/Mixmag survey was constructed”, The Guardian, 
15 March 2012).
104 “Mixmag’s Drug Survey: the results”.
105 Artur Malczewski and others, 2010 National Report (2009 Data) to the 
EMCDDA by the Reitox National Focal Point: Poland — New Devel-
opment, Trends and In-depth Information on Selected Issues (Warsaw, 
National Bureau for Drug Prevention, 2010). Available from www.
emcdda.europa.eu/attachements.cfm/att_142526_EN_PL-NR2010.
pdf.
106 Artur Malczewski, “Psychoactive substance use among school adoles-
cents: youth 2010” (Warsaw, National Bureau for Drug Prevention, 
2011).
Table 3. Drugs reported as been used by 
drug users in the United Kingdom 
responding to the MixMag-Guardian 
Internet survey, 2011
Source: “Mixmag’s Drug Survey: the results”, March 2012.  
Available from www.mixmag.net/drugssurvey.
Drugs very frequently reported
- Cannabis
- “Ecstasy”
- Cocaine
Drugs frequently reported, NPS indicated in "bold"
- Ketamine
- Mephedrone
- Valium
- Mushrooms
- Poppers
- Speed (amphetamine)
Drugs sometimes reported, NPS indicated in "bold"
- LSD
- 2C-B 
- Methotexamine
- 2 C-I
- DMT 
- Synthetic cannabis
- Benzo-Fury
- MDAI
Drugs rarely reported, NPS indicated in "bold"
- Opium 
- Ritalin
- GBL
- GHB
- Methylone
- Crack cocaine
- Heroin
- Methamphetamine
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mephedrone — was the most frequently found) and syn-
thetic cannabinoids (16 different compounds). In sum, 
they accounted for some two thirds of all “legal highs” in 
Poland, followed by amines, piperazines, psychoactive 
plants and tryptamines.107
Other countries in Europe 
Data for Latvia, the country with the third highest lifetime 
prevalence rate of use of NPS in the European Union, 
according to the 2011 Eurobarometer survey, show that 
synthetic cannabinoids are the drug of choice. The 2011 
household survey data for Latvia found a lifetime preva-
lence of the use of synthetic cannabinoids of 2.6 per cent 
among the general population (aged 15-64), which made 
it the third most widely used substance after cannabis (12.4 
per cent) and “ecstasy” (2.7 per cent) and higher than the 
rates for amphetamines (2.2 per cent), cocaine (1.5 per 
cent) or heroin (0.5 per cent).108 The lifetime prevalence 
of synthetic cannabinoids among 15- and 16-year-old stu-
dents in Latvia went as high as 10.6 per cent in 2011, 
making it the second most widely used substance after 
cannabis, more than twice as high as the prevalence of 
“ecstasy” (4.3 per cent), amphetamines (3.8 per cent), 
cocaine (3.5 per cent) or heroin (2.3 per cent). Salvia divi-
norum had a high lifetime prevalence rate of 4.4 per cent, 
107 Wioletta Żukiewicz-Sobczak and others, “Analysis of psychoactive 
and intoxicating substances in legal highs”, Annals of Agricultural and 
Environmental Medicine, vol. 19, No. 2 (2012), pp. 309-314.
108 United Nations Office on Drugs and Crime, data from the annual 
report questionnaire.
slightly higher than the corresponding rates for “ecstasy” 
or amphetamines.109
Synthetic cannabinoids also appear to be the most wide-
spread NPS in Germany, the fourth largest market for 
NPS in Europe, according to the 2011 Eurobarometer 
survey. An Internet survey conducted in 2011 among expe-
rienced drug users (average age: 24) identified synthetic 
cannabinoids as the most prevalent NPS, well exceeding 
the use of “research chemicals”110 and “other legal 
highs”.111 Synthetic cannabinoids contained in Spice have 
also been linked to an increasing number of suicides in 
Germany.112
Ketamine appears to play a significant role in other coun-
tries. Spain, Europe’s fifth largest market for NPS, accord-
ing to the 2011 Eurobarometer survey, showed a lifetime 
prevalence of 1 per cent and an annual prevalence of 0.2 
per cent for ketamine use among the population aged 15 
to 64 in its 2011 national household survey. Lifetime preva-
lence among the age group 14 to 18 was 1.1 per cent, more 
than the rates for methamphetamine or heroin.113 A study 
among 14- and 15-year-old students in 2010 suggested 
that, with a lifetime prevalence of 1.1 per cent, ketamine 
was as widespread as Spice, and almost three times as 
common as piperazines or mephedrone (0.4 per cent).114
Mephedrone plays a key role in some other countries. Data 
for Hungary reveal that 6 per cent of students aged 15 and 
16 had experimented with mephedrone in 2011 (ESPAD). 
The lifetime prevalence of mephedrone use turned out to 
be the third highest, after cannabis and tranquillizers/seda-
tives, and was higher than the use of amphetamines (5.6 
per cent), “ecstasy” (4.4 per cent), cocaine (2.5 per cent or 
heroin (1.6 per cent) in Hungary.115
The largest number of NPS identified in Europe over the 
first two quarters of 2012 was reported to UNODC by 
the Netherlands (48), surpassing the number of NPS iden-
109 2011 ESPAD study, cited in United Nations Office on Drugs and 
Crime, data from the annual report questionnaire.
110 “Research chemicals” in Germany are often understood to contain 
either synthetic cathinones (such as mephedrone) or phenethyl-
amines or piperazines (see Drogen-Information-Berlin, “Der Trend zu 
Research Chemicals verstärkt sich”. Available from www.drogen-info-
berlin.de/htm/research-chemicals.htm).
111 B. Werse and C. Morgenstern, “Online survey on the topic of ‘legal 
highs’”, short report prepared for the Centre for Drug Research, 
Goethe University, Frankfurt, Germany, 2011.
112 E. Ludger and others, “Synthetic cannabinoids in ‘spicelike’ herbal 
blends: first appearance of JWH-307 and recurrence of JWH-018 on 
the German market”, Forensic Science International, vol. 222, Nos. 1-3 
(2012), pp. 216-222.
113 Spain, Delegación del Gobierno para el Plan Nacional sobre Drogas, 
Encuesta sobre Alcohol y Drogas en Población General en España 
(EDADES) 2011-2012 (Madrid, 2013).
114 “ESTUDES” survey of drug use among secondary school students in 
Spain, cited in 2011 National Report (2010 Data) to the EMCDDA 
by the Reitox National Focal Point: Spain—New Developments, Trends 
and In-depth Information on Selected Issues (Madrid, Delegación del 
Gobierno para el Plan Nacional sobre Drogas, 2011).
115 2011 ESPAD study, cited in United Nations Office on Drugs and 
Crime, data from the annual report questionnaire.
Fig. 22. Lifetime prevalence of the use of new 
psychoactive substances among the 
general population aged 15 to 75 in 
Poland,a as compared to other drugs, 
2009
Source: Artur Malczewski and others, 2010 National Report (2009 
Data) to the EMCDDA by the Reitox National Focal Point: Poland 
— New Development, Trends and In-depth Information on 
Selected Issues (Warsaw, National Bureau for Drug Prevention, 
2010).
a Sample size: 1,001.
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tified in the United Kingdom (38) during that period. 
Most of the NPS identified in the Netherlands were new 
phenethylamines (15), followed by synthetic cannabinoids 
(9) and synthetic cathinones (7).116
North America
The market for NPS in North America is highly diversi-
fied. During the first six months of 2012, authorities in 
North America identified 82 NPS and reported them to 
UNODC.
At the same time, the overall use of NPS appears to be 
more widespread in North America than in Europe. In 
2011, the lifetime prevalence rate for the use of new sub-
stances that imitate the effects of illegal drugs amounted 
to 4.8 per cent among those aged 15 to 24 in the European 
Union, while the Monitoring the Future survey in the 
United States identified an annual prevalence rate of 11.4 
per cent among twelfth-grade students (typically aged 17 
or 18) for synthetic cannabinoids alone.117 In addition, 
Salvia divinorum (5.9 per cent) and, to a lesser extent, 
ketamine (1.7 per cent) and “bath salts” (1.3 per cent in 
2012) are also consumed in the United States. Total use 
of NPS, ranging from 11.4 per cent (including only users 
of synthetic cannabinoids) to 20.3 per cent (assuming no 
polydrug use), was thus at least twice as high as in the 
116 United Nations Office on Drugs and Crime, The Challenge of New 
Psychoactive Substances.
117 See United States, National Institute on Drug Abuse, Monitoring 
the Future: National Survey Results on Drug Use, 1975-2011, vol. 1, 
Secondary School Students 2011 (Ann Arbor, Michigan, University of 
Michigan Institute for Social Research, 2011). Available from www.
monitoringthefuture.org.
European Union (4.8 per cent lifetime prevalence) and 
higher than in all European Union countries, except per-
haps Ireland (16.3 per cent). Available data are based on 
lifetime prevalence for the European Union and annual 
prevalence for the United States. Expressing the results in 
a common metric (annual or lifetime prevalence) would 
probably result in an even more pronounced difference 
between the European Union and the United States. 
United States of America
The United States identified 62 NPS that appeared on its 
market during the first six months of 2012, the largest 
number of NPS reported by any single country to 
UNODC for this period. The most frequently reported 
substances were synthetic cathinones (25), synthetic can-
nabinoids (19) and phenethylamines (8).118 For 2012 as 
a whole, United States authorities, based on its National 
Forensic Laboratory Information System, identified 51 
new synthetic cannabinoids and 31 new synthetic cathi-
nones. In addition, 76 other compounds, including 
phenethylamines (mostly 2C compounds), tryptamines 
and piperazines, were identified. Thus, in total 158 NPS119 
were identified for the first time in the United States in 
2012, more than twice as many as in the European Union 
(73).120 
118 United Nations Office on Drugs and Crime, The Challenge of New 
Psychoactive Substances.
119 United States, Drug Enforcement Administration, National Foren-
sic Laboratory Information System, cited in a presentation at the 
side event held during the fifty-sixth session of the Commission 
on Narcotic Drugs entitled “New psychoactive substances: regional 
approaches and challenges: United States — situation and response”, 
11 March 2013.
120 European Monitoring Centre for Drugs and Drug Addiction and 
European Police Office, European Union Drug Markets Report: A Stra-
tegic Analysis.
Fig. 23. Use of new psychoactive substances among youth in the United States (aged 17-18)  
and in the European Union (aged 15-24), 2011
Source: United States, National Institute on Drug Abuse, Monitoring the Future survey; and Gallup Organization, Youth Attitudes on 
Drugs: Analytical Report, Flash Eurobarometer series No. 330 (European Commission, July 2011).
a Data for “bath salts” refer to 2012.
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The use of NPS among students in the United States is 
already more widespread than the use of all other illicit 
drugs except cannabis. This is primarily a result of the use 
of synthetic cannabinoids. The number of calls received 
by poison control centres for “synthetic marijuana” (i.e. 
synthetic cannabinoids) more than doubled, from approxi-
mately 2,900 in 2010 to almost 7,000 in 2011. However, 
the trend appears to have stabilized or declined since, fol-
lowing the “emergency scheduling” of these substances. 
Between 2011 and 2012, calls to poison control centres 
related to “synthetic marijuana” declined by approximately 
25 per cent. 
The annual prevalence of synthetic cannabinoids reached 
11.4 per cent among twelfth-grade students in 2011 and 
then declined marginally to 11.3 per cent in 2012. None-
theless, the level remains high. Other important NPS that 
have appeared on the market include Salvia divinorum (4.4 
per cent) and ketamine (1.5 per cent). “Bath salts”, con-
taining various synthetic cathinones, were used by 1.3 per 
cent of students. Their use was already more widespread 
than that of crack cocaine, methamphetamine or heroin 
among twelfth-grade students. 
At the same time, data also show that use of several of the 
NPS among twelfth-grade students declined in 2012: mar-
ginally in the case of synthetic cannabinoids, by 12 per 
cent for ketamine and by as much as 25 per cent for Salvia 
Fig. 24. Number of synthetic cannabinoids and synthetic cathinones identified in the United States 
through the National Forensic Laboratory Information System and its reports, 2009-2012
Source: United States, Drug Enforcement Administration, National Forensic Laboratory Information System, cited in a presentation at the 
side event held during the fifty-sixth session of the Commission on Narcotic Drugs entitled “New psychoactive substances: regional 
approaches and challenges: United States — situation and response”, 11 March 2013.
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divinorum. These declines did not go hand in hand with 
increased use of other drugs. In fact, most of the prevalence 
rates for the use of psychoactive substances declined mar-
ginally in 2012. 
The 2012 Monitoring the Future study revealed that, 
among twelfth-grade students, the perceived risks linked 
to the consumption of synthetic cannabinoids were con-
sidered to be higher than those for experimenting with 
marijuana, though still lower than for experimenting with 
“ecstasy”, cocaine or heroin.121 
Similar to the patterns found for other drugs, use of syn-
thetic cannabinoids continues to rise until the late teenage 
years, before declining. However, a few specific traits can 
be identified. While overall drug use is highest among 
twelfth-grade students (those aged 17-18), the prevalence 
rate for the use of synthetic cannabinoids is highest among 
those aged 19 and 20. Levels of synthetic cannabinoid use 
are still high for those aged 21 and 22, but fall rapidly 
among older age groups. This pattern is far more pro-
nounced than for drug use in general. Thus, the use of 
synthetic cannabinoids is more concentrated among youth 
and young adults than is the use of drugs in general. The 
same is true for Salvia divinorum and ketamine. 
The concentration of the use of synthetic cannabinoids 
among youth and young adults is also reflected in emer-
gency-department visits. More than three fourths (76 per 
121 See www.monitoringthefuture.org/data/12data/pr12t8.pdf.
cent) of such visits in 2010 that were related to the abuse 
of synthetic cannabinoids involved patients aged 12 to 29, 
a far larger proportion than for other substances (e.g. 57 
per cent for cannabis).122 
There were more than 11,400 visits to emergency depart-
ments resulting from the abuse of synthetic cannabinoids 
in 2010, equivalent to a rate of 3.7 per 100,000 inhabit-
ants. This was higher than the rates linked to LSD (1.3), 
GHB (0.6), ketamine (0.3) or flunitrazepam (0.2), similar 
to the rates for prescription stimulants (amphetamine/
dextroamphetamine, 4.2), though lower than for “ecstasy” 
(7.0), methamphetamine (16.7), heroin (72.6) or cocaine 
(157.8).123 
An analysis of sociodemographic characteristics reveals that 
males are more than twice as likely to use synthetic can-
nabinoids as females, a far higher ratio than for drugs in 
general. The same applies to Salvia divinorum. Emergency 
department visits also confirm this skewed sex ratio: 78 
per cent of all such visits in 2010 that were related to syn-
thetic cannabinoids among patients aged 12 to 29 were by 
122 United States, Department of Health and Human Services, Substance 
Abuse and Mental Health Services Administration, “The DAWN 
report: drug-related emergency department visits involving synthetic 
cannabinoids” (Rockville, Maryland, 4 December 2012).
123 United States, Department of Health and Human Services, Sub-
stance Abuse and Mental Health Services Administration, “Drug 
Abuse Warning Network: national estimates of drug-related emergency 
department visits, 2004-2010”. Available from www.samhsa.gov/data/
DAWN.aspx.
Fig. 26. Use of new psychoactive substances, as compared with other drugs, among twelfth-grade 
students in the United States, 2012
Source: United States, National Institute on Drug Abuse, Monitoring the Future survey.
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males.124 Overall drug-related visits to emergency depart-
ments are more gender-balanced, with males accounting 
for only 56 per cent of the total.125 
In general, drug use correlates positively with the size of a 
community, i.e. low rates in small farming communities 
and high rates in metropolitan areas. This is the case for 
cannabis, cocaine and “ecstasy”, as well as for drugs in 
general. However, the pattern is reversed when it comes to 
synthetic cannabinoids. The highest prevalence rates for 
the use of synthetic cannabinoids are found in small farm-
ing communities, while the lowest rates are encountered 
in large cities. 
More detailed information is also available for ketamine. 
Its use declines with age after the late teens, is more preva-
lent among males than females and is most prevalent in 
the west and the north-east of the country, thus showing 
patterns similar to drug use in general. The Drug Enforce-
ment Administration reported Mexico as a major source 
country. In addition, pharmaceutical companies operating 
in India were identified in several cases as the source for 
ketamine found on the United States market.126 
Another major NPS in the United States in terms of nega-
tive health consequences is methylenedioxypyrovalerone 
124 Substance Abuse and Mental Health Services Administration, “The 
DAWN report: drug-related emergency department visits involving 
synthetic cannabinoids”.
125 Substance Abuse and Mental Health Services Administration, Drug 
Abuse Warning Network, national estimates of drug-related emergency 
department visits, 2004-2010.
126 United States, Department of Justice, Drug Enforcement Administra-
tion, “Ketamine (street names: Special K, ‘K’, Kit Kat, Cat Valium)”, 
August 2011. Available from www.deadiversion.usdoj.gov/drug_
chem_info/ketamine/ketamine.pdf.
(MDPV), a synthetic cathinone.127 It was frequently sold 
as a “bath salt”, at least until it (together with mephedrone, 
another “bath salt”) became a nationally controlled sub-
stance in July 2012.128 The Monitoring the Future survey 
revealed that 33.2 per cent of twelfth-grade students in 
2012 perceived it as a “great risk” to experiment once or 
twice with such “bath salts”. Trying “bath salts” was thus 
perceived to be a greater risk than experimenting with 
Salvia divinorum (13.8 per cent), “marijuana” (14.8 per 
cent) or synthetic cannabinoids (23.5 per cent), and almost 
as risky as experimenting with amphetamines (34.3 per 
cent). Nevertheless, the risks are still perceived to be lower 
than for the use of cocaine (51.6 per cent) or “ice” (crystal 
methamphetamine (67.8 per cent)), even though “bath 
salts”, and notably MDPV, share several of the character-
istics of cocaine and methamphetamine. According to 
research undertaken by the National Institute on Drug 
Abuse, MDPV is potentially more dangerous than cocaine. 
MDPV raises brain dopamine in a manner similar to 
cocaine, but is at least 10 times as potent.129 The reward-
ing and reinforcing effects of MDPV in rats were shown 
to be nearly identical to those of methamphetamine.130 
127 United States, National Institute on Drug Abuse, “DrugFacts: synthetic 
cathinones (‘bath salts’)”, revised November 2012. Available from 
www.drugabuse.gov/publications/drugfacts/synthetic-cathinones-
bath-salts.
128 The law enumerates 31 compounds that are explicitly banned; 20 from 
the list are “synthetic marijuana” varieties and 10 are “bath salts” (see 
Patience Haggin, “Obama signs federal ban on ‘bath salt’ drugs”, Time 
NewsFeed, 10 July 2012).
129 National Institute on Drug Abuse, “DrugFacts: synthetic cathinones 
(‘bath salts’)”.
130 Ibid.
Fig. 27. Age distribution in the United States for the use of synthetic cannabinoids, as compared  
with other drugs, 2011
Source: United States, National Institute on Drug Abuse, Monitoring the Future survey, data tables and figures, 2012; and L. D. Johnston 
and others, Monitoring the Future: National Survey Results on Drug Use, 1975-2011, vol. II, College Students and Adults Ages 19-50 
(Ann Arbor, University of Michigan, Institute for Social Research, 2012). 
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Canada
NPS are also widely encountered in Canada. The authori-
ties there identified 59 NPS during the first six months of 
2012, almost as many as in the United States. Most of the 
NPS were synthetic cathinones (18), synthetic cannabi-
noids (16) and phenethylamines (11).131 
In a national school survey in 2011, widespread use of NPS 
among tenth-grade students (aged 15-16) was reported for 
Salvia divinorum (lifetime prevalence of 5.8 per cent), 
jimson weed or Datura (2.6 per cent), a hallucinogenic 
plant, and ketamine (1.6 per cent). Given the strong 
decline in ketamine use in the United States since the 
beginning of the millennium, its use among tenth-grade 
students in Canada is now slightly higher than in the 
United States (1.2 per cent in 2011). 
The general household survey for 2011 lists only Salvia 
divinorum (lifetime prevalence of 1.6 per cent) among 
NPS. Its use is more widespread than that of metham-
phetamine (0.7 per cent) or opioids (0.6 per cent), though 
less common than that of amphetamine-type stimulants, 
cocaine or cannabis.132 
Latin America and the Caribbean 
NPS have also started to emerge in the countries of Latin 
America, even though, generally speaking, levels of misuse 
of such substances in the region are lower than in North 
America or Europe. Countries reporting the emergence of 
131 United Nations Office on Drugs and Crime, The Challenge of New 
Psychoactive Substances.
132 United Nations Office on Drugs and Crime, data from the annual 
report questionnaire.
NPS included Argentina, Brazil, Chile, Colombia, Costa 
Rica, Ecuador, Mexico, Panama and Uruguay. NPS 
reported included ketamine and plant-based substances, 
followed by piperazines, synthetic cathinones, phenethyl-
amines and, to a lesser extent, synthetic cannabinoids. 
Brazil, for instance, reported the emergence of mephedrone 
and of DMMA (a phenethylamine) in its market; Chile 
Fig. 28. Sociodemographic and geographic characteristics of the use of synthetic cannabinoids  
in the United States, as compared with other drugs, ages 19-30, 2011
Source: L. D. Johnston and others, Monitoring the Future: National Survey Results on Drug Use, 1975-2011, vol. II,  
College Students and Adults Ages 19-50 (Ann Arbor, University of Michigan, Institute for Social Research, 2012). 
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Fig. 29. Lifetime use of new psychoactive  
substances compared with other drugs 
among tenth-grade students (aged  
15-16) in Canada, 2011
Source: United Nations Office on Drugs and Crime, data from the 
annual report questionnaire. 
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reported the emergence of Salvia divinorum and tryptamine; 
and Costa Rica reported the emergence of N-benzylpiper-
azine (BZP) and TFMPP, two piper azines.133 
In addition, a number of other NPS have also started to 
appear on the market. For instance, the misuse of ketamine 
has been reported in household surveys, notably in the two 
largest countries of the Southern Cone. A national house-
hold survey conducted in Argentina in 2010 found a life-
time prevalence of ketamine use of 0.3 per cent among the 
population aged 12 to 65. This was, however, still lower 
than the lifetime prevalence rates for ketamine use reported 
from the United Kingdom (2.2 per cent), Australia (1.4 
per cent) and the United States (1.0 per cent). Nonethe-
less, ketamine use in Argentina is not insignificant. The 
prevalence rate for its use was about half the reported 
domestic prevalence rate for “ecstasy” use (0.6 per cent), 
slightly higher than the rate for non-prescribed ampheta-
mines (0.2 per cent) and far higher than the lifetime preva-
lence rate for the use of crack cocaine (0.1 per cent) or 
heroin (0.1 per cent).134 
An earlier household survey conducted in Brazil in 2005 
found a lifetime prevalence rate for ketamine use of 
0.2 per cent among those aged 12 to 65. This was equiva-
lent to the lifetime use of merla, a variant of smokeable 
cocaine paste/base, and greater than the prevalence of 
heroin use (0.09 per cent). Another NPS reported in the 
133 United Nations Office on Drugs and Crime, The Challenge of New 
Psychoactive Substances.
134 United Nations Office on Drugs and Crime, data from the annual 
report questionnaire.
household survey from Brazil was “Benflogin” (benzy-
damine), with a lifetime prevalence rate of 0.4 per cent 
among the age group 12 to 65.135 This is a locally acting 
medicine with anaesthetic and analgesic properties for 
treatment of inflammatory conditions of the mouth and 
throat. Taken in high doses, it is misused in Brazil and a 
few other countries as a central nervous system stimulant 
and deliriant (special class of hallucinogens). 
An analysis, using Google Trends, of Internet searches via 
Google for the period 2005-2012 within Latin America 
revealed an interest in the terms “ketamine” or “ketamina”, 
not only in Argentina and Brazil but also in Chile, Colom-
bia, Mexico, Peru and Venezuela (Bolivarian Republic of ). 
Salvia divinorum, also known in Mexico as “ska pastora”, 
“ska María”, “hierba María” or “hierba des los dioses”, 
appears to be popular (based on Google Internet searches) 
in various Latin American countries, including Argentina, 
Brazil, Chile, Costa Rica and Mexico. Originally used by 
shamans of the Mazatec tribe of Mexico for religious pur-
poses and during spiritual healing sessions,136 Salvia divi-
norum is currently popular for reasons well beyond its 
traditional use. It has already emerged as the second most 
widely offered NPS in 2011. At the beginning of 2012 it 
was offered in online shops in the European Union.137 
135 Ibid.
136 Valdés and others, “Studies of Salvia divinorum (Lamiaceae), an hallu-
cinogenic mint from the Sierra Mazateca in Oaxaca, Central Mexico”.
137 European Monitoring Centre for Drugs and Drug Addiction, Annual 
Report 2012: The State of the Drugs Problem in Europe, p. 91.
Fig. 30. Ketamine use among the general population, 2010 (or latest year available)
Source: United Nations Office on Drugs and Crime, data from the annual report questionnaire; Home Office, Drugs Misuse Declared: 
Findings from the 2011/12 Crime Survey for England and Wales, 2nd ed. (July 2012); Australian Institute of Health and Welfare, 2010 
National Drug Strategy Household Survey Report, Drug Statistics Series No. 25 (Canberra, July 2011); United States, Department of 
Health and Human Services, Substance Abuse and Mental Health Services Administration, 2010 National Survey on Drug Use and Health. 
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The emergence of synthetic cathinones was reported by 
Brazil and Mexico.138 Again, interest in the various cathi-
none derivatives appears to be limited in Latin America. 
This may have to do with the ample availability of cocaine 
in the region.
Argentina, Brazil, Chile, Costa Rica and Mexico reported 
the emergence of piperazines on their markets. That prob-
lem also seems to be limited in scope. This may be attrib-
uted to the fact that the region is rather well supplied with 
“ecstasy”, so there is no urgent need to look for alternative 
substances. 
Oceania 
The countries in the Oceania region seem to have some of 
the highest prevalence rates in the world for the use of 
NPS. This applies to New Zealand, which for many years 
played a key role in the market for piperazines. A large 
number of NPS are also found in Australia, similar to the 
situation in Europe and North America. Overall, 44 such 
substances were identified during the first two quarters of 
2012 in the Oceania region, equivalent to more than a 
quarter of all NPS identified worldwide during this 
period.139 
In addition, a “traditional” NPS is widespread in the vari-
ous small island countries of the Oceania region, notably 
in the Western Pacific: kava, which is also exported to some 
overseas markets, including countries in Europe and the 
United States,140 where it has been marketed as an anti-
anxiety preparation. The roots of this plant are used to 
produce a drink with sedative and anaesthetic properties. 
In the Oceania region, kava is often used in combination 
with alcohol. Heavy use of kava was reported to lead to 
malnutrition, liver damage, renal dysfunctions, pulmonary 
hypertension, macrocytosis of red cells, lymphocytopenia 
and decreasing platelet volumes.141 
New Zealand
One example of a rapidly expanding market for NPS over 
the past decade has been New Zealand. The country 
reported the appearance of a number of such substances 
on its market in recent years, including several synthetic 
cannabinoids, synthetic cathinones and phenethyl-
amines.142 However, its market for NPS has been associ-
ated mostly with the spread of piperazines. By 2007/08, 
138 United Nations Office on Drugs and Crime, The Challenge of New 
Psychoactive Substances.
139 Ibid.
140 “Hepatic toxicity possibly associated with kava-containing products: 
United States, Germany, and Switzerland, 1999-2002”, Morbidity and 
Mortality Weekly Report, vol. 51, No. 47 (2002), pp. 1065-1067.
141 Peter P. Fu and others, “Toxicity of kava kava”, Journal of Environ-
mental Science and Health, Part C: Environmental Carcinogenesis and 
Ecotoxicology Review, vol. 26, No. 1 (2008), pp. 89-112.
142 United Nations Office on Drugs and Crime, The Challenge of New 
Psychoactive Substances.
i.e. prior to the classification of BZP as a class C drug143 
in April 2008, the national household survey in New Zea-
land revealed that 5.6 per cent of the population aged 15 
to 64 had used BZP in the past year, more than twice the 
rate for amphetamines (2.1 per cent) and nine times the 
rate for cocaine (0.6 per cent). These were high levels by 
international standards. For instance, in the United 
Kingdom, Europe’s largest market for such substances, the 
NPS with the highest prevalence rate (mephedrone) had 
only a 1.4 per cent prevalence rate among the general pop-
ulation in 2010/11. Beginning in 1999, BZP started 
to gain popularity as a rave drug in New Zealand, with 
such popularity later expanding to several other coun-
tries.144 BZP was marketed as a “safer legal alternative” to 
meth amphetamine.145
Following the scheduling of BZP as a class C drug in 2007, 
prevalence rates for its use declined substantially. As a con-
sequence, the overall use of “legal highs” experienced a 
clear decline between 2005 and 2010 in New Zealand,146 
in contrast to the situation in many other countries. 
143 Class C substances with a “moderate risk” of harm. For more detail, see 
discussion under “Specific legislation on new psychoactive substances” 
below. 
144 Thompson and others, “The benzylpiperazine/trifluoromethylphenyl-
piperazine and alcohol safety study: report for the Ministry of Health”.
145 Bowden, “Non-traditional designer substances: a new category of 
psychoactives in New Zealand”.
146 C. Wilkins and P. Sweetsur, “The impact of the prohibition of ben-
zylpiperazine (BZP) ‘legal highs’ on the prevalence of BZP, new legal 
highs and other drug use in New Zealand”, Drug and Alcohol Depend-
ence, vol. 127, Nos. 1-3 (2013), pp. 72-80.
Fig. 31. Annual prevalence of the use of new 
psychoactive substances, as compared 
with other drugs, among the general 
population (aged 16-64) in New Zea-
land, 2007/08
Source: Ministry of Health, Drug Use in New Zealand: Key results 
of the 2007/08 New Alcohol and Drug Use Survey, January 2010. 
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Australia 
Australia identified 33 NPS during the first six months of 
2012, fewer than the United States or Canada but similar 
to the number reported by the United Kingdom (38) and 
more than by New Zealand (15). Most of the NPS identi-
fied in Australia were synthetic cathinones (13) and 
phenethylamines (8).147 
The national household survey lists only ketamine among 
NPS. This is, however, a controlled substance in Australia. 
The survey revealed a small decline in the annual preva-
lence rate for ketamine use among the population aged 14 
and above, from 0.3 per cent in 2004 to 0.2 per cent in 
2010. It is as common as heroin, methadone or buprenor-
phine (0.2 per cent each), more common than GHB (0.1 
per cent) but less common than cocaine (2.1 per cent), 
methamphetamine (2.1 per cent) or “ecstasy” (3 per 
cent).148 
This does not, however, seem to be an accurate reflection 
of the overall spread of NPS in the country. According to 
the Australian Crime Commission, Australian drug users 
consume a broad range of substitutes for amphetamine-
type stimulants that are under control, including mephe-
drone and many other synthetic drugs. The authorities 
identified 500 different “legal highs”, advertised mostly 
through overseas “legal high” stores.149 
This perception is confirmed by studies of Australian users 
of amphetamine-type stimulants. The latest study revealed 
that 33 per cent of regular “ecstasy” and psychostimulant 
users in Australia in 2012 used an “emerging psychoactive 
substance” (excluding synthetic cannabinoids),150 up from 
28 per cent in 2011. Including synthetic cannabinoids, 
the percentage of persons using such substances rose to 40 
per cent in 2012, suggesting that about half of the users 
of synthetic cannabinoids also used other emerging psy-
choactive substances. 
The most frequently used emerging psychoactive sub-
stances in 2012 were synthetic cannabinoids, used by 15 
per cent of all regular “ecstasy” and psychostimulant users, 
up from 6 per cent in 2011. In contrast to other such sub-
stances, synthetic cannabinoids did not feature in previous 
reports. This suggests that their spread was previously very 
limited. 
147 United Nations Office on Drugs and Crime, The Challenge of New 
Psychoactive Substances.
148 Australian Institute of Health and Welfare, 2010 National Drug 
Strategy Household Survey Report, Drug Statistics Series No. 25 
(Canberra, July 2011). Available from www.aihw.gov.au/publication-
detail/?id=32212254712.
149 Australian Crime Commission, “Crime markets: illicit drug mar-
kets–drug analogues and other synthetic drugs”. Available from www.
crimecommission.gov.au/publications/organised-crime-australia/ 
2011-report/crime-markets. 
150 L. Scott and L. Burns, New South Wales Trends in Ecstasy and Related 
Drug Markets 2011: Findings from the Ecstasy and Related Drugs Report-
ing System (EDRS), Australian Drug Trends Series No. 83 (Sydney, 
University of New South Wales, National Drug and Alcohol Research 
Centre, 2011).
The two next most widely used such substances were 
dimethyltryptamine, or DMT (12 per cent), a hallucino-
genic substance, and 4-bromo-2,5-dimethoxy-phenethyl-
amine, or 2C-B (9 per cent), a psychedelic phenethylamine. 
Both substances are under international control. The use 
of these substances remained more or less stable.
The next most frequently identified substances were 
mephedrone (5 per cent among regular users of “ecstasy” 
and psychostimulants) and methylone/bk MDMA, an 
“ecstasy” derivative (5 per cent), followed by MDPV (2.5 
per cent), dextromethorphan (2.5 per cent), Salvia divi-
norum (2.5 per cent), mescaline (2 per cent), LSA, which 
is a psychedelic ergoline alkaloid related to LSD (2 per 
cent), and various psychedelic phenethylamines, notably 
2,5-dimethoxy-4-iodo-phenethylamine, or 2C-I (2 per 
cent), 2,5-dimethoxy-4-ethyl-phenethylamine, or 2C-E (2 
per cent), and BZP (1 per cent).151 
Asia
According to the UNODC survey undertaken in 2012, 
the second largest number of countries reporting the emer-
gence of NPS was in Asia. The emergence of such sub-
stances was reported from a number of countries and areas, 
mostly in East and South-East Asia (Brunei Darussalam; 
China; Hong Kong, China; Indonesia; Japan; Philippines; 
Singapore; Thailand; and Viet Nam), as well as in the 
151 University of New South Wales, National Drug and Alcohol Research 
Centre, “Australian drug trends 2012: findings from the Ecstasy and 
Related Drugs Reporting System”, Drug Trends Conference handout 
(Sydney, 2012).
Fig. 32. Use of emerging psychoactive  
substances over the past six months 
among frequent “ecstasy” and  
amphetamine users in Australia,  
2010-2012
 
Source: University of New South Wales, National Drug and Alco-
hol Research Centre, “Australian drug trends 2012: findings from 
the Ecstasy and Related Drugs Reporting System”, Drug Trends 
Conference handout (Sydney, 2012).
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Middle East (Bahrain, Israel, Jordan, Oman, Saudi Arabia 
and the United Arab Emirates). Most NPS to emerge in 
Asia during the first two quarters of 2012 were identified 
by the authorities of Israel (27), Singapore (11) and Hong 
Kong, China (7). 
Hong Kong, China, reported the emergence of a number 
of synthetic cannabinoids (such as JWH-018) and syn-
thetic cathinones (4-methylethcathinone and butylone). 
Indonesia informed UNODC of the emergence of BZP. 
Singapore saw the emergence of a number of synthetic 
cannabinoids (including JWH-018) and synthetic cathi-
nones (3-fluro-methcathinone and 4-methylethcathinone). 
Oman witnessed the emergence of synthetic cannabinoids 
(JWH- 018). Synthetic cannabinoids, as reflected in Inter-
net searches, also appear to have played a role in India, at 
least since mid-2010. Japan reported the emergence of 
phenethylamines, synthetic cathinones, piperazines, keta-
mine, synthetic cannabinoids and plant-based 
substances.152 
The two main NPS in Asia in terms of consumption seem 
to be ketamine and kratom, mostly affecting the countries 
of East and South-East Asia. Ketamine pills have been sold 
for several years as a substitute for “ecstasy” (and sometimes 
even as “ecstasy”). In addition, large-scale traditional con-
sumption of khat is present in Western Asia, notably in 
Yemen.
Ketamine
High levels of ketamine use have long been reported from 
East and South-East Asia:153
 s Hong Kong, China, and Macao, China, identified 
ketamine as the second most widely used drug  
in 2011 
 s China reported ketamine as the fourth most widely 
used substance in 2010 and the third in 2011
 s In Brunei Darussalam, ketamine was the fourth most 
widely used substance in 2011
 s In India and Myanmar, ketamine was the fifth most 
widely consumed substance in 2010 and in Japan in 
2008
 s Singapore identified ketamine as the sixth most widely 
used substance in 2011
 s Indonesia identified ketamine as the seventh most 
widely used substance in 2009.
Ketamine also plays a role in the Near and Middle East: 
 s Saudi Arabia identified ketamine as the seventh most 
widely used substance in 2010 
 s Israel reported it as the ninth most used substance in 
2011. 
Ketamine is more widely used in East and South-East Asia 
than in the Americas and Europe.
152 United Nations Office on Drugs and Crime, The Challenge of New 
Psychoactive Substances.
153 United Nations Office on Drugs and Crime, data from the annual 
report questionnaire.
The importance of ketamine is also reflected in seizure 
statistics, which showed an upward trend over the past 
decade, although the number of seizures seems to have 
stabilized or even declined in recent years. Over the period 
2001-2011, 14 Asian countries (out of 30 countries 
worldwide) reported seizures of ketamine to UNODC. 
They accounted for 95 per cent of all ketamine seized 
worldwide. 
The concentration is most pronounced in East and South-
East Asia (86 per cent of global seizures), followed by South 
Asia (9 per cent). The single largest seizures during the 
period 2001-2011 were reported from China (58 per cent 
of global ketamine seizures), followed by Taiwan Province 
of China (13 per cent), India (9 per cent), Hong Kong, 
China (5 per cent), and Malaysia (5 per cent). Smaller 
amounts were reported from Myanmar (3 per cent), Thai-
land (1 per cent), Indonesia (1 per cent) and the Philip-
pines (1 per cent), followed by Singapore; Macao, China; 
Viet Nam; Cambodia; and Brunei Darussalam. 
Fig. 33. Ketamine seizures in Asia and globally, 
2001-2011
Source: United Nations Office on Drugs and Crime, data from the 
annual report questionnaire.
a Preliminary data.
Fig. 34. Global ketamine seizures, by region, 
2001-2011
Source: United Nations Office on Drugs and Crime, data from the 
annual report questionnaire. 
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Kratom 
Another NPS widely used in East and South-East Asia, 
notably in Malaysia, Myanmar and Thailand, is kratom 
(Mitragyna speciosa). The leaves of this plant have mild 
stimulant effects, in addition to effects similar to opioids, 
as well as some hallucinogenic properties. Kratom leaves 
are used in traditional medicine as an anti-diarrhoeal and 
in the treatment of opioid dependence.154 The possession 
of kratom leaves has been illegal in Thailand since 1943; 
kratom is also controlled in a few other countries in the 
region (Malaysia and Myanmar) and outside the region 
(Australia, Bhutan, Finland and Lithuania).155 A national 
household survey conducted in Thailand in 2007 suggested 
that kratom was the second most widely used drug after 
cannabis in terms of lifetime prevalence, and the most 
widely used drug in terms of annual prevalence (0.8 per 
cent of the adult population). Use levels far above average 
were reported from southern Thailand (4.6 per cent), i.e. 
in the areas where the Mitragyna speciosa plant is native. 
Although use of kratom is very widespread, figures for 
treatment admissions for its use are rather low, accounting 
for 2,838 cases, or 2 per cent of all drug treatment admis-
sions, in Thailand in 2011.156 Consumption and related 
problems are on the rise, however. Kratom-related treat-
154 Australia, National Drugs and Poisons Schedule Committee, “Com-
ments on kratom and mitragyine”, thirty-ninth meeting, October 
2003.
155 NeuroSoup, “Kratom Mitragyna speciosa”. Available from www.neuro-
soup.com/kratom.htm.
156 Far fewer people were treated for kratom than for methamphetamine 
(165,044). Nonetheless, there were more people treated for kratom 
than for opium (2,601), heroin (2,115), “ecstasy” (172), cocaine (15) 
or ketamine (13) in 2011.
ment admissions almost tripled between 2007 and 
2011.157
Kratom seizures rose from 1.7 tons in 2005 to 23 tons in 
Thailand in 2011.158 Kratom seizures in neighbouring 
Malaysia and Myanmar reached record levels that year, at 
roughly one ton each.159 The number of seizures of kratom 
quintupled in Thailand, from 1,100 in 2005160 to 5,897 
in 2011, and was far higher than those reported for heroin 
(832), opium (480), ketamine (156), “ecstasy” (144) or 
cocaine (58).161 
Kratom-related arrests more than doubled between 2007 
and 2011 in both Myanmar and Thailand. In Myanmar, 
they increased from 89 to 211 during this period. Thailand 
reported 13,134 kratom-related arrests in 2011 (5 per cent 
of all drug-related arrests), up from 5,571 in 2007.162 
In addition to widespread consumption of kratom in 
South-East Asia, use of the substance was also reported in 
157 United Nations Office on Drugs and Crime, Patterns and Trends of 
Amphetamine-Type Stimulants and Other Drugs: Asia and the Pacific — 
2012 (Bangkok, 2012). 
158 Thailand, Office of the Narcotics Control Board, Thailand Narcotics 
Control: Annual Report 2011, No. 1-19-2555, ISSN 978-616-7187-
97-6 (Bangkok, 2012). 
159 United Nations Office on Drugs and Crime, Patterns and Trends of 
Amphetamine-Type Stimulants and Other Drugs: Asia and the Pacific — 
2012. 
160 Thailand, Office of the Narcotics Control Board, Thailand Narcotics 
Control: Annual Report 2011.
161 Thailand, Office of the Narcotics Control Board, statistics on drug 
cases throughout the country, 1 January-31 December 2011. Available 
from http://en.oncb.go.th/document/2011Arrested-s.pdf.
162 United Nations Office on Drugs and Crime, Patterns and Trends of 
Amphetamine-Type Stimulants and Other Drugs: Asia and the Pacific — 
2012 (Bangkok, 2012). 
Fig. 35. Lifetime and annual prevalence of drug use in Thailand, 2007 
Source: Thailand, Office of the Narcotics Control Board, cited in United Nations Office on Drugs and Crime, Patterns and Trends of 
Amphetamine-Type Stimulants and Other Drugs in East and South-East Asia (and Neighbouring Regions): 2009 (Bangkok, 2009). 
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the Republic of Korea163 and, in recent years, it has also 
emerged as a NPS in a number of North American, Euro-
pean and Middle Eastern countries.164 In the European 
Union, kratom was the most widely offered NPS in “online 
shops” in 2011 and at the beginning of 2012.165 
163 United Nations Office on Drugs and Crime, Patterns and Trends of 
Amphetamine-Type Stimulants and Other Drugs: Asia and the Pacific — 
2012 (Bangkok, 2012).
164 United Nations Office on Drugs and Crime, The Challenge of New 
Psychoactive Substances (Vienna, March 2013).
165 European Monitoring Centre for Drugs and Drug Addiction, 
Annual Report 2012: The State of the Drugs Problem in Europe, 
p. 91.
Khat 
Khat has been reported as a NPS in several countries in 
the Americas, Europe, the Oceania region, the Middle East 
and East Asia. It is a traditional drug in Yemen, where it 
is legal. According to a survey conducted under the aus-
pices of the World Bank, 72 per cent of Yemeni males and 
33 per cent of Yemeni females aged 12 and above reported 
the chewing of khat in 2006, with more than half of the 
users chewing it daily. The rates were even higher in areas 
where khat is cultivated. Overall, khat is used by 52 per 
cent of the Yemeni population age 12 and above.166 These 
rates are far higher than those for any other psychoactive 
substance reported by any country in the world (except for 
alcohol, tobacco or caffeine). About 70 per cent of house-
holds in Yemen reported having at least one khat user. 
The negative consequences of khat use for the individual 
may not be as severe as in the case of other drugs, as indi-
cated by the 2006 WHO Expert Committee, which con-
cluded in its critical review that no international scheduling 
was required.167 Nonetheless, some 70 per cent of Yemeni 
female users and 80 per cent of Yemini male users reported 
adverse health effects. Khat use was often found to be asso-
ciated with tooth decay, high blood pressure, sleeplessness, 
constipation and, in some cases, depression, paranoia and 
oral cancer.168 There are also negative socioeconomic 
effects. Productivity is negatively affected, at both the 
micro and the macro level, which is problematic, as Yemen 
is already a least developed country, the only one on the 
Arabian peninsula. Even though khat is legal and prices 
are thus low, some 10 per cent of the household budget, 
on average, is used for khat, increasing to more than a 
quarter among poorer families. Close to a fifth of all khat-
using households are forced to borrow money to finance 
their habit. In parallel to the rise in consumption, there 
has been a rapid increase in the area under cultivation, 
which rose 13-fold over the last three decades (from some 
8,000 ha to more than 100,000 ha), thus depleting scarce 
water resources (one third of groundwater extraction is 
linked to the cultivation of khat) and crowding out pro-
duction of essential food crops and agricultural exports.169 
Manufacture of new psychoactive substances
Asia plays a key role when it comes to the manufacture 
of NPS. In addition to khat production in West Asia 
for the local market, most of the other NPS found on mar-
kets worldwide, including most synthetic cannabinoids, 
166 World Bank, “Yemen toward qat demand reduction”, report No. 
39738-YE (June 2007).
167 World Health Organization, “Assessment of khat (Catha edulis Forsk)”, 
prepared for the thirty-fourth meeting of the Expert Committee on 
Drug Dependence (document 2006/4.4). Available from www.who.
int/medicines/areas/quality_safety/4.4KhatCritReview.pdf.
168 N. Numan, “Exploration of adverse psychological symptoms in 
Yemeni khat users by the Symptoms Checklist-90 (SCL-90)”, Addic-
tion, vol. 99, No. 1 (2004), pp. 61-65; World Bank, “Yemen: towards 
qat demand reduction”.
169 World Bank, “Yemen: towards qat demand reduction”.
Fig. 36. Kratom-related treatment  
admissions in Thailand, 2007-2011
Source: United Nations Office on Drugs and Crime, Patterns and 
Trends of Amphetamine-Type Stimulants and Other Drugs: Asia 
and the Pacific — 2012 (Bangkok, 2012).
969 1,067
2,030
2,357
2,835
0
500
1,000
1,500
2,000
2,500
3,000
2007 2008 2009 2010 2011
N
u
m
b
er
 o
f 
tr
ea
tm
en
t 
ad
m
is
si
o
n
s
13,134
1,224
211
19.0
4.3
0.4
-
5,000
10,000
15,000
Th
ai
la
nd
M
al
ay
si
a
M
ya
nm
ar
Th
ai
la
nd
M
al
ay
si
a
M
ya
nm
ar
To
ta
l n
u
m
b
er
 o
f 
ar
re
st
s
0
5
10
15
20
A
rr
es
ts
 p
er
 1
00
,0
00
 in
h
ab
it
an
ts
 
Fig. 37. Kratom-related arrests in 
South-East Asia, 2011
Source: United Nations Office on Drugs and Crime, Patterns and 
Trends of Amphetamine-Type Stimulants and Other Drugs: Asia 
and the Pacific — 2012 (Bangkok, 2012).
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cathinone derivatives and ketamine, appear to originate in 
Asia, notably in countries of East Asia and South Asia, 
which have advanced chemical and pharmaceutical indus-
tries. In fact, the UNODC survey of NPS revealed that 
Asia was the primary region of production of such sub-
stances, ahead of Europe and the Americas. NPS found on 
the markets of Asian countries appear to originate almost 
exclusively within the region. In addition, most European 
and North American countries, as well as Australia, identi-
fied Asia as the primary source for NPS. In Asia, the most 
frequently named source countries for such substances were 
China and India.170 
Africa
In total, 7 African countries (Angola, Cape Verde, Egypt, 
Ghana, South Africa, Togo and Zimbabwe) out of the 10 
that replied to the survey reported the emergence of NPS 
to UNODC. Egypt reported the emergence of not only 
plant-based substances (Salvia divinorum) but also synthetic 
cannabinoids, ketamine, piperazines (BZP) and other 
substances (2-diphenyl methylpiperidine (2-DPMP) and 
4-benzylpiperidine).171  
Nonetheless, the overall problems related to the production 
and consumption of NPS appear to be less pronounced in 
Africa. There are, however, a number of traditionally used 
substances (such as khat or ibogaine) that fall into the 
category of NPS and that, in terms of their spread, cause 
serious health problems and other social consequences. 
170 United Nations Office on Drugs and Crime, The Challenge of New 
Psychoactive Substances.
171 Ibid.
Khat 
Khat is produced and used widely in many of the countries 
along the Red Sea and the Indian Ocean, notably Djibouti, 
Ethiopia, Kenya and Somalia, and to a lesser extent Mada-
gascar, Rwanda, South Africa, the Sudan, Uganda and the 
United Republic of Tanzania. The legal status of khat dif-
fers in the various African countries. Khat is legal in Dji-
bouti, Ethiopia, Kenya and Somalia, but controlled in 
other countries, including Eritrea, Rwanda, the Sudan and 
the United Republic of Tanzania.172 The largest khat sei-
zures in Africa during the period 2005-2011 were reported 
by the United Republic of Tanzania, followed by Zambia, 
the Sudan, Eritrea and Egypt.173 
Somalia is one of the key destination countries within 
Africa. Exports to overseas markets are often destined for 
expatriate Somali communities, as well as expatriate com-
munities from neighbouring countries. The export of khat 
to overseas markets in Europe, North America, India and 
Australia originates mostly in Ethiopia, the Kenyan high-
lands and Yemen.174 
According to information provided by the United States 
State Department, khat is now the fourth-largest Ethiopian 
export, up from seventh place a few years earlier, and khat 
172 D. M. Anderson and N.C.M. Carrier, Khat: Social Harms and Legisla-
tion — A Literature Review, Occasional Paper 95 (London, Home 
Office, July 2011).
173 United Nations Office on Drugs and Crime, data from the annual 
report questionnaire.
174 Axel Klein, Pien Metaal and Martin Jelsma, “Chewing over khat 
prohibition: the globalisation of control and regulation of an ancient 
stimulant”, Series on Legislative Reform of Drug Policies No. 17 
(Transnational Institute, January 2012). 
Fig. 38. Khat use in Yemen,a 2006, as compared to drug use in England and Wales (2011/12)  
and globally (2010)
Source: World Bank, “Yemen: towards qat demand reduction”, report No. 39738-YE (June 2007); United Kingdom, Home Office, Drug 
Misuse Declared: Findings from the 2011/12 British Crime Survey for England and Wales, 2nd ed. (London, July 2012); and World Drug 
Report 2012 (United Nations publication, Sales No. E.12.XI.1).
a Based on a sample of 4,027 persons. 
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consumption, in line with rising levels of cultivation, is 
increasing. Large-scale khat cultivation also takes place in 
Kenya. This has led to rising exports, as well as increased 
domestic consumption. According to the 2010 report of 
the National Campaign Against Drug Abuse, khat (locally 
known as “miraa”) appears to have emerged as the most 
commonly consumed drug in Kenya, ahead of cannabis.175 
During the period 2008-2012, Ethiopia and Kenya, fol-
lowed by Yemen, had the largest numbers of Internet 
searches related to “khat”, “qat” or “miraa” among coun-
tries in the region, at far higher levels than found in North 
America or in Europe. 
Quantitative studies on the spread of khat in Africa are, 
however, limited. One study, done under the auspices of 
the World Bank in Djibouti, found that 28.2 per cent of 
the population aged 12 and above used khat, including 
43.7 per cent of males and 13.6 per cent of females. Almost 
half of the households (49.7 per cent) had at least one khat 
user. These are high prevalence rates, although they are 
lower than in neighbouring Yemen. Khat consumption has 
been increasing in recent decades. Khat imports from 
neighbouring Ethiopia into Djibouti rose 82 per cent in 
volume terms between 1984 and 2004. In particular, the 
number of female khat users increased during the past 15 
years, with the annual prevalence rate of 3 per cent in 1996 
more than doubling to 7 per cent in 2006, and doubling 
again to almost 14 per cent by 2011.176 
175 United States, Department of State, Bureau for International Narcotics 
and Law Enforcement Affairs, International Narcotics Control Strategy 
Report, vol. 1, Drug and Chemical Control (March 2012).
176 World Bank, Comprendre la dynamique du khat à Djibouti : aspects 
sociaux, économiques et de santé, report No. 62823-DJ (Washington, 
D.C., 2011).
The economic impact for Djibouti has also been substan-
tial. Khat accounts for one third of total agricultural 
imports into Djibouti and is the third largest import item 
in monetary terms, after food and oil. Total expenditure 
on khat in 2008 was estimated to have been equivalent to 
24 per cent of public development assistance or 66 per 
cent of foreign direct investment. The average expenditure 
by khat users was found to have been some 20 per cent of 
total household income. The typical khat user in Djibouti, 
i.e. a male between the ages of 18 and 25, consumes it 
daily and spends 40 per cent of his total income on khat.177 
Other plant-based substances 
Apart from khat, many parts of Africa are witness to wide-
spread use of a number of other psychoactive plants that 
are not under international control. One of the better-
known examples is ibogaine, a naturally occurring psycho-
active substance found in a plant known as iboga 
(Tabernanthe iboga), native to West and Central African 
rainforests. It has traditionally been used in several coun-
tries of the region (Cameroon, Congo, Gabon and in parts 
of Nigeria), often in connection with traditional spiritual 
rituals178 and administered by local shamans and 
healers.179 
The iboga tree contains ibogaine, a hallucinogen with both 
psychedelic and dissociative properties. In addition, stimu-
lant effects have been reported from chewing iboga root 
bark, thereby releasing small amounts of ibogaine into the 
body. Ibogaine also has the ability to potentiate morphine 
analgesia and has been used, outside Africa, to reduce 
addiction180 to opioids181 and, in animal experiments, to 
reduce addiction to cocaine.182 Treatment centres exist, 
inter alia, in Mexico and New Zealand. Interest in ibogaine 
outside Africa, as reflected in Internet searches catalogued 
by Google Trends, seems to be mainly in Australia, Canada, 
France, the Netherlands, the United Kingdom and the 
United States. Its use is not without problems, however. 
One of the negative side effects of ingesting large doses of 
ibogaine is ataxia, or difficulty in coordinating muscle 
motion. Other potential side effects may include xerosto-
mia, nausea and vomiting. More problematically, studies 
have suggested the possibility of adverse interaction with 
heart conditions. Ibogaine has been observed to increase 
177 Ibid.
178 Kenneth R. Alper, Howard S. Lotsof and Charles D. Kaplan, “The 
ibogaine medical subculture”, Journal of Ethnopharmacology, vol. 115, 
No. 1 (2008), pp. 9-24; Nick Sandberg, “Iboga tourism in Central 
Africa”, 21 March 2012 (see www.ibogaine.co.uk/iboga-tourism.htm).
179 Ed Platt, “The Dreaming”, Independent, 28 March 1999.
180 Kenneth R. Alper, “Ibogaine: a review”, in Ibogaine: Proceedings of the 
First International Conference, Kenneth R. Alper and Stanley D. Glick, 
eds. (San Diego, California, Academic Press, 2001).
181 S. D. Glick and others, “Effects and aftereffects of ibogaine on mor-
phine self-administration in rats”, European Journal of Pharmacology, 
vol. 195, No. 3 (1991), pp. 341-345.
182 S.L.T. Cappendijk and M. R. Dzoljic, “Inhibitory effects of ibogaine 
on cocaine self-administration in rats”, European Journal of Pharmacol-
ogy, vol. 241, Nos. 2-3 (1993), pp. 261-265.
Fig. 39. Annual prevalence of khat use in 
Djibouti,a 2011, as compared with 
Yemen,b 2006
Source: World Bank, Comprendre la dynamique du khat à Dji-
bouti: Aspects sociaux, économiques et de santé, report No. 
62823-DJ (Washington, DC, 2011); World Bank, “Yemen: towards 
qat demand reduction”, report No. 39738-YE (June 2007).
a Based on a sample of 4,309 persons. 
b Based on a sample of 4,027 persons. 
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sinus arrhythmia, leading to ventricular tachycardia. Fatali-
ties following ingestion of ibogaine have been linked to 
lethal respiratory and cardiac effects. Consequently, ibo-
gaine and its salts have been controlled in the United States 
since 1967 as a Schedule I substance, and it is also con-
trolled in Belgium and Switzerland.183 
Impact of regulations on changes in the 
use of new psychoactive substances 
It has generally been observed that when a NPS is con-
trolled, its use declines, which in turn has a positive impact 
on health-related consequences, including deaths related 
to the substance. The control system does not have a uni-
form impact on all substances and markets, however.
Data have shown that controlling a substance may have 
different impacts, for example: 
(a) The substance remains on the market, but prevalence 
of its use declines immediately. Examples include 
mephedrone in the United Kingdom, BZP in New 
Zealand, “legal highs” in Poland and mephedrone in 
Australia;
(b) Use of the substance declines after a longer interval, 
maybe a year or more (e.g. ketamine in the United 
States); 
(c) The scheduling has little or no immediate impact on 
the use of the substance, e.g. use of MDMA (“ecstasy”) 
in the United States and other countries, which did 
not decline until two decades later, following improved 
precursor controls. 
183 Multidisciplinary Association for Psychedelic Studies, “Ibogaine ther-
apy for drug addiction” (see www.maps.org/research/ibogaine).
It has also been observed that a substance can largely dis-
appear from the illicit market. This has been the case with 
the majority of the substances controlled under the 1961 
Convention and the 1971 Convention. Out of 234 sub-
stances currently under international control, only a few 
dozen are still being misused, and the bulk of the misuse 
is concentrated in a dozen such substances. 
It is clear that a holistic approach involving a number of 
factors — prevention and treatment, legal status, improv-
ing precursor controls, cracking down on trafficking rings 
— has to be applied to tackle the situation. 
A more in-depth look at various responses in terms of legal 
status is presented below.
(a) Immediate decline in the use of new psychoactive 
substances
(i) Mephedrone and the United Kingdom
Prior to the introduction of controls for the various syn-
thetic cathinones in the United Kingdom, consumption 
of mephedrone increased notably. Hardly known a few 
years earlier, by 2010/11 mephedrone had emerged as the 
third most widely used drug among the general population 
(ages 16-59) and was even the second most widely used 
drug among young persons aged 16 to 24 in England and 
Wales.184 All of this resulted in major negative health con-
sequences, including a strong rise in mephedrone-related 
deaths. By 2010, the number of such deaths had already 
exceeded the number of deaths related to the abuse of 
184 United Kingdom, Home Office, Drug Misuse Declared: Findings from 
the 2011/12 British Crime Survey for England and Wales.
Fig. 40. Number of deaths related to controlled stimulants and to new psychoactive substances  
in the United Kingdom, 2007-2010, prior to the control of synthetic cathinones 
Source: Hamid Ghodse and others, Drug-related Deaths in the United Kingdom: Annual Report 2011 (International Centre for Drug 
Policy, St. George’s, University of London, London, 2012). 
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amphetamine-type stimulants, which had declined sharply 
during the 2007-2010 period. 
The situation changed following the classification of 
mephedrone as a class B substance under the Misuse of 
Drugs Act in 2010 and an import ban on 29 March 2011. 
Between fiscal year 2010/11 and fiscal year 2011/12, 
the annual prevalence of mephedrone among the general 
population aged 16 to 59 fell by a fifth; among those 
aged 16 to 24, it fell by as much as a quarter.185 Internet 
surveys among clubgoers in the United Kingdom also con-
firmed the downward trend.186 In parallel, the 2011 
EMCDDA “snapshot” identified a major decrease in the 
number of online shops offering mephedrone in Europe, 
notably in the United Kingdom.187 
(ii) Benzylpiperazine and New Zealand
In New Zealand, the use of NPS has for years been associ-
ated mainly with the use of benzylpiperazine (BZP), which 
used to be marketed as a “safer legal alternative” to meth-
amphetamine.188 Given the massive spike in the numbers 
for both BZP use and emergency-department visits linked 
to its abuse in the first few years of the new millennium, 
BZP was recommended for scheduling in 2007 and finally 
came under national control in 2008. Following its con-
trol, annual prevalence among the population aged 13 to 
45 declined quickly, by almost 80 per cent between 2006 
185 United Kingdom, Home Office, Drug Misuse Declared: Findings from 
the 2011/12 British Crime Survey for England and Wales.
186 “Mixmag’s Drug Survey: the results”, March 2012. Available from 
www.mixmag.net/drugssurvey.
187 European Monitoring Centre for Drugs and Drug Addiction, Annual 
Report 2011: The State of the Drugs Problem in Europe (Luxembourg, 
Publications Office of the European Union, 2011).
188 M. Bowden, “Non-traditional designer substances: a new category 
of psychoactives in New Zealand”, April 2004. Available from www.
erowid.org/chemicals/bzp/bzp_info1.shtml.
and 2009. Subsequent surveys of frequent users conducted 
in 2010 confirmed this trend. As a consequence, the overall 
use of “legal highs” witnessed a clear decline between 2005 
and 2010 in New Zealand,189 in contrast to the situation 
in many other countries. 
The decline in the prevalence rate for the use of BZP in 
New Zealand is also reflected in massive declines in Inter-
net searches for BZP. Nonetheless, most BZP-related Inter-
net searches worldwide still took place in New Zealand 
during the period 2006-2012. 
(iii) “Legal highs” and Poland
Poland was characterized by massive increases in “legal 
highs” in the decade 2001-2010. The most widespread 
NPS there used to be “Tajfun”, a herbal mixture contain-
ing some synthetic cannabinoids. The rise in the use of 
“legal highs” went hand in hand with aggressive marketing 
activities. As of mid-2010, “legal highs” could be purchased 
in more than 1,100 shops across the country, up from 40 
shops in 2008 and none in 2007. The rapid rise in the use 
of “legal highs” and reports of negative health consequences 
eventually prompted the authorities to amend their control 
regime. 
Following the control of BZP and JWH-018 (a synthetic 
cannabinoid contained in herbal mixtures) in 2009, the 
list of controlled substances was extended to mephedrone 
and seven synthetic cannabinoids as of August 2010.190 
After more than 300 poisonings and 18 deaths in 2010, 
the Minister of Health ordered “in-depth checks”, result-
189 Wilkins and Sweetsur, “The impact of the prohibition of benzylpip-
erazine (BZP) ‘legal highs’ on the prevalence of BZP, new legal highs 
and other drug use in New Zealand”.
190 Lucyna Kapka-Skrzypczak and others, “Legal highs: legal aspects and 
legislative solutions”, Annals of Agricultural and Environmental Medi-
cine, vol. 18, No. 2 (2011), pp. 304-309.
Fig. 41. Annual prevalence of the use of  
mephedrone in England and Wales,  
fiscal years 2010/11 and 2011/12
Source: United Kingdom, Home Office, Drug Misuse Declared: 
Findings from the 2011/12 British Crime Survey for England and 
Wales, 2nd ed. (London, July 2012).
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BZP use in New Zealand, 2006 (prior to 
control) and 2009 (one year after control)
Source: C. Wilkins and P. Sweetsur, “The impact of the prohibition 
of benzylpiperazine (BZP) ‘legal highs’ on the prevalence of BZP, 
new legal highs and other drug use in New Zealand”, Drug and 
Alcohol Dependence, vol. 127, Nos. 1-3 (2013), pp. 72-80.
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ing in the closure in October 2010 of over 900 of the 1,100 
“legal high” shops. In particular, premises selling “Tajfun” 
were closed down.191 Subsequently, a general ban on so-
called “substitute substances” (defined as substances used 
instead of a scheduled narcotic drug or psychotropic sub-
stance) was introduced.192 
The immediate effects of this move on the prevalence rates 
for the use of “legal highs” were positive. The reported 
annual prevalence rate for the use of “legal highs” fell by 
more than 60 per cent, from 5 per cent in December 2009 
to 1.8 per cent in December 2010, according to a national 
drug use survey.193 The decline in “legal highs” was not 
compensated for by an increase in the use of other drugs. 
In fact, the use of most drugs (except tranquillizers and 
sedatives) declined as well. 
(iv) Mephedrone and Australia
From negligible levels in 2007, mephedrone use among 
users of amphetamines and “ecstasy” in Australia rose stead-
ily until 2010. In that year, the Australian authorities made 
use of the Controlled Substance Analogue Act, specifying 
that mephedrone was an analogue of methcathinone and 
191 Artur Malczewski and others, 2011 National Report (2010 Data) to the 
EMCDDA by the Reitox National Focal Point: Poland — New Devel-
opment, Trends and In-depth Information on Selected Issues (Warsaw, 
National Bureau for Drug Prevention, 2011). Available from www.
emcdda.europa.eu/attachements.cfm/att_191625_EN_Poland_2011.
pdf.
192 Artur Malczewski and others, 2010 National Report (2009 Data) to the 
EMCDDA by the Reitox National Focal Point: Poland.
193 Artur Malczewski, “Psychoactive substance use in general population 
in 2010: survey results” (Warsaw, National Bureau for Drug Preven-
tion, 2011).
thus controlled.194 Imported mephedrone was confiscated 
and the persons involved in the transactions were arrest-
ed.195 Mephedrone was subsequently added to the federal 
194 “‘Miaow’ drug seized in mail busts”, Sydney Morning Herald, 12 Feb-
ruary 2010. Available from www.smh.com.au/national/miaow-drug-
seized-in-mail-busts-20100212-nwad.html.
195 Australian Customs and Border Protection Service, “‘Legal Highs’ not 
Fig. 43. Annual prevalence of new psychoactive substances, compared with illicit drugs, among  
the general population, aged 15-75, in Poland,a 2009 and 2010
Source: Artur Malczewski, “Psychoactive substance use in general population in 2010: survey results” (Warsaw, National Bureau for Drug 
Prevention, 2011).
a Sample: 1,001 (excluding cannabis).
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Fig. 44. Use of mephedrone over the prior six 
months among regular “ecstasy” and 
psychostimulant users in Australia, 
2007-2012
Source: University of New South Wales, National Drug and Alco-
hol Research Centre, “Australian drug trends 2012: findings from 
the Ecstasy and Related Drugs Reporting System”, Drug Trends 
Conference handout (Sydney, 2012) (and previous years); and ten-
tative estimates of the United Nations Office on Drugs and Crime 
for the years 2007 and 2008, based on qualitative information 
from various sources.
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drug watch list;196 by 2011, most of the individual states 
in Australia had brought mephedrone under control. In 
parallel, the use of mephedrone declined from a peak of 
16 per cent among users of “ecstasy” and amphetamines 
in 2010 to 5 per cent in 2012. 
(v) Methylenedioxypyrovalerone and the United States
A more recent example of a substance placed under control 
in the United States is methylenedioxypyrovalerone 
(MDPV), a synthetic cathinone that has generated a great 
deal of controversy, as some of its users have been reported 
to pose a threat to local communities and to harm them-
selves by means of self-mutilation and suicide attempts.197 
The drug causes what the police have dubbed a “halluci-
natory delirium”, making the users paranoid, violent and 
unpredictable, which has led to a number of killings. 
Data on changes in the prevalence of use of MDPV are 
not available. However, data show that the number of calls 
to poison control centres concerning “bath salts” (often 
linked to MDPV) rose from 304 in 2010 to 6,134 in 2011, 
a 20-fold increase in one year.198 
Following the control of the main “bath salts”, starting 
with the “emergency scheduling” of MDPV, mephedrone 
and methylone in October 2011, calls to poison control 
centres related to “bath salts” fell by more than half in 
2012. All of this suggests that the problems related to “bath 
salts”, including MDPV, declined following the control of 
those substances. 
(b) Decline in the prevalence or use of a new psychoactive 
substance after a longer interval
Ketamine and the United States
Ketamine was scheduled under the United States Con-
trolled Substances Act in 1999. Subsequently, prevalence 
rates among twelfth-grade students fell from 2.5 per cent 
in 2000 to 1.5 per cent in 2012, a decline of 40 per cent. 
This was a remarkable success. At the same time, the per-
ceived riskiness of “ecstasy” use increased199 and the avail-
ability of “ecstasy” has declined over the past decade.200 
necessarily legal”, November 2010. Available from http://customs.gov.
au/webdata/resources/files/LegalHighsFactSheet.pdf.
196 Erowid, “4-methylmethcathinone: legal status”, 3 March 2008. Avail-
able from www.erowid.org/chemicals/4_methylmethcathinone/4_
methylmethcathinone_law.shtml.
197 E. A. Ross, M. Watson and B. Goldberger, “‘Bath salts’ intoxication”, 
New England Journal of Medicine, vol. 365, No. 10 (8 September 
2011).
198 Kevin Dolak, “‘Bath salts’: use of dangerous drug increasing across 
U.S.”, ABC News, 5 June 2012.
199 The proportion of twelfth-grade students reporting that it was a “great 
risk” to try “ecstasy” once or twice rose from 37.9 per cent in 2000 to 
49.4 per cent in 2012, equivalent to an increase of 30 per cent in the 
perceived risk during this period (see United States, National Institute 
on Drug Abuse, Monitoring the Future survey, January 2013).
200 The proportion of twelfth-grade students reporting that it was “fairly 
easy” or “very easy” to get “ecstasy” (MDMA) fell from 51.4 per cent 
in 2000 to 35.9 per cent in 2012, equivalent to a deterioration of avai 
ability of 30 per cent (see United States, National Institute on Drug 
Abuse, Monitoring the Future survey, December 2012).
All of this has contributed to a decline in the use of 
“ecstasy”. Without the introduction of appropriate control 
measures for ketamine, the decline in the availability of 
“ecstasy” could have been expected to lead to substantial 
increases in the use of ketamine, as the latter substance 
often serves as a substitute drug for the former.
(c) Legal controls that had no immediate impact on  
the use of NPS
MDMA (“ecstasy”) and the United States
The fact that a “one size fits all” solution does not work is 
best exemplified by the case of MDMA (“ecstasy”), which 
Fig. 45. Calls to United States poison control 
centres for human exposure related to 
“bath salts”, 2010-2012
Source: American Association of Poison Control Centers, “Bath 
salts data”, updated 28 February 2013. Available from https://
aapcc.s3.amazonaws.com/files/library/Bath_Salts_Data_for_Web-
site_2.282013.pdf.
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was first scheduled in the United States in 1985 and at the 
international level in 1986 and thus ceased to be an NPS. 
Despite national and international controls, “ecstasy” avail-
ability increased markedly in the United States and in sev-
eral other countries between the mid-1980s and 2000. In 
parallel, the perceived riskiness linked to the use of “ecstasy” 
declined. 
The decline in “ecstasy” use after 2000 in the United States 
was mainly the result of reduced availability, as the estab-
lished trafficking rings supplying the United States from 
the Netherlands were largely dismantled. In addition, the 
perceived riskiness linked to the use of “ecstasy” increased 
during the period 2000-2012,201 indicating progress made 
in prevention efforts. 
However, in parallel to the declining availability of “ecstasy” 
during the past decade, a number of other uncontrolled 
substances emerged, thus offsetting some of the declines 
reported.
Controlling new psychoactive  
substances: realities and challenges
New drugs of abuse and the  
international drug control system
The emergence of NPS on the drug scene is not per se a 
new phenomenon. Until recently, the control system was 
well able to cope with this phenomenon, but it is now 
reeling under the impact of the rapid proliferation of NPS. 
The emergence of new substances that are legally manu-
factured by the pharmaceutical industry, with potential for 
201 United States, National Institute on Drug Abuse, Monitoring the 
Future survey, December 2012.
abuse, started to create problems in an increasing number 
of countries in the late 1920s. As a result, a number of new 
narcotic analogues were placed under international control 
under the 1931 Convention for Limiting the Manufacture 
and Regulating the Distribution of Narcotic Drugs. The 
1931 Convention also introduced, for the first time, the 
principle of “drug scheduling”, i.e. applying different con-
trol levels based on the degree of danger and the extent to 
which a substance was required by the medical profes-
sion.202 It also enabled binding extensions of the control 
regime, based on decisions by the League of Nations 
Health Organization, the predecessor of today’s World 
Health Organization (WHO). However, that authority 
was limited to two groups, namely alkaloids linked to 
opium and to coca leaf.203 Thus, the “similarity principle” 
entered international drug control, i.e. the provisions 
applied to all drugs with similar harmful effects and abuse 
liabilities, as long as they were chemically related to the 
two groups. With the 1948 Protocol amending the Agree-
ments, Conventions and Protocols on Narcotic Drugs, this 
principle was extended to the 1925 International Opium 
Convention, authorizing WHO to extend the scope of 
control to “any narcotic drug” that WHO found to be 
“liable to similar abuse and productive of similar ill effects” 
as the substances already controlled.204 The 1931 Conven-
tion also introduced — for the first time — measures for 
“provisional control”,205 a kind of emergency scheduling 
202 Thomas Pietschmann, “A century of international drug control”, 
Bulletin on Narcotics, vol. LIV, Nos. 1 and 2 (2007) (United Nations 
publication, Sales No. 10.XI.6), p. 76.
203 Commentary on the Single Convention on Narcotic Drugs, 1961 (United 
Nations publication, Sales No. E.73.XI.1), p. 84.
204 Ibid., p. 74.
205 Symal Kuman Chatterjee, Legal Aspects of International Drug Control 
(The Hague, Martinus Nijhoff, 1981), p. 344.
Fig. 47. Perceived availabilitya and prevalence of MDMA (“ecstasy”) use among high-school students 
in the United States
Source: United States, National Institute on Drug Abuse, Monitoring the Future survey, December 2012. 
a Proportion of students reporting that it was “fairly easy” or “very easy” to get “ecstasy”. 
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system, to bridge the gap between the identification of a 
problem and the time needed by WHO to come to a con-
clusion on whether the new substance should be 
controlled.
After the Second World War, a number of new synthetic 
opioids developed during the war emerged on the market. 
Those substances were no longer opium-based and there-
fore could not be added by WHO to those controlled 
under the 1931 Convention. A new instrument had to be 
created, the Protocol bringing under International Control 
Drugs Outside the Scope of the 1931 Convention, which 
extended the controls of the 1931 Convention to synthetic 
opioids. In order to be able to react faster in the future, 
the 1948 Protocol contained a broadened “similarity prin-
ciple”. In theory, the system would work even before a 
synthetic opioid was manufactured and reached the 
market: the drug would be controlled when it was still in 
the laboratory test phase.206 In total, 14 new synthetic 
opioids came under control in 1949 (including methadone 
and pethidine) and a further 6 by 1954. It is believed that 
this control helped to prevent a massive spread of these 
substances.207 
The various international instruments (1912 Hague Con-
vention, three conventions formulated under the League 
of Nations in 1925, 1931 and 1936 and a number of drug-
related protocols, often established on an ad hoc basis) 
rendered the overall drug control system increasingly com-
plex. Thus, from 1948 to 1961, negotiations took place 
to create a “single convention”. 
With the signing of the Single Convention on Narcotic 
Drugs of 1961, 85 substances were placed under interna-
tional control, including cannabis, cocaine, opium, mor-
phine, heroin, methadone, codeine, oxycodone and 
desomorphine. Today, 119 narcotic drugs are controlled 
under the 1961 Convention.208 Most of the drugs added 
after 1961 were synthetic opioid analgesics, including fen-
tanyl (scheduled in 1964) and several of its derivatives 
(scheduled between 1988 and 1990). The last drug that 
was brought under control by the 1961 Convention in 
2007, was oripavine, an opiate and major metabolite of 
thebaine and parent compound of buprenorphine. 
Soon after the 1961 Convention was concluded, increas-
ing problems were reported with new types of synthetically 
produced psychoactive substances other than opioids, 
including barbiturates, LSD and stimulants (methampheta-
mine, amphetamine). As restrictions had already been 
introduced in several developed countries, pharmaceutical 
companies turned their attention to markets in Latin Amer-
ica, Africa and Asia, and cultivated them aggressively. The 
misuse of those substances developed into a global phe-
206 Commentary on the Single Convention on Narcotic Drugs, 1961, pp. 
76-77.
207 Pietschmann, “A century of international drug control”, p. 81.
208 International Narcotics Control Board, list of narcotic drugs under 
international control (“Yellow List”), 50th ed., December 2011.
nomenon.209 The problem lay in the fact that some of 
those substances had a broad spectrum of legitimate uses. 
It was feared that by putting them under the strict control 
regime of the 1961 Convention, their legitimate use could 
suffer. 
To tackle this new situation, the Convention on Psycho-
tropic Substances of 1971 was adopted. That Convention 
has greater flexibility in weighing the therapeutic useful-
209 United Nations Office on Drugs and Crime, A Century of International 
Drug Control (Vienna, 2009), p. 64.
Procedures foreseen to put (new) 
psychoactive substances under  
international control under the 
1961 Single Convention  
Article 3 of the 1961 Single Convention foresees that if 
either a party (i.e. a Member State) or the World Health 
Organization (WHO) has information which in its opin-
ion may require an amendment to any of the Schedules 
of the Convention, it shall notify the Secretary-General 
of the United Nations (nowadays, in his name, the Exec-
utive Director of UNODC) and furnish him with the 
information of the notification. The Secretary-General 
shall then transmit such notification and any additional 
information which he considers relevant, to the parties, 
to the Commission on Narcotic Drugs and to the WHO 
(in case the notification was made by a party). The 
WHO is to find out whether a substance is “liable to 
similar abuse and productive of similar ill effects” as 
drugs already scheduled (i.e. opium/morphine/heroin, 
cocaine and cannabis) or substances that could be con-
verted (with relative ease) into such drugs. The control of 
the Single Convention may be extended to a substance 
of any chemical structure whatsoever. The chemical 
structure of a new substance does not play a role.
Based upon the recommendations made by the WHO 
the Commission on Narcotic Drugs will decide on 
whether the substance should be controlled and in which 
schedule of the Convention it should be placed.  Art. 3 
§3 (ii) foresees an emergency scheduling procedures: 
‘provisional application’ of control measures as foreseen 
for Schedule I substances while the Commission on Nar-
cotic Drugs awaits the recommendations of the WHO. 
The Commission on Narcotic Drugs can make changes 
in the Schedules of the Single Convention only in 
accordance with recommendations of the WHO; but it 
can refuse to make changes recommended by the WHO. 
The decision by the Commission on Narcotic Drugs, 
requiring a 2/3 majority (art. 17), is still subject to review 
by the Economic and Social Council of the United 
Nations (ECOSOC) upon request of any party.  
Source: United Nations, Commentary on the Single Convention 
on Narcotic Drugs, New York 1973.
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ness against the potential social harm arising from the 
misuse of a specific substance. The 1971 Convention, like 
the 1961 Convention, has four schedules. The variation 
of controls, however, depending on the schedules is more 
nuanced: 
 s Schedule I is the strictest control regime, basically 
prohibiting a substance except for scientific and very 
limited medical purposes (art. 7). 
 s Schedule II is reserved for substances that may have a 
strong potential for abuse but that also have generally 
recognized therapeutic use. Commercial transactions 
are allowed, though they are strictly controlled. Manu-
facturers, wholesale distributors, exporters and import-
ers have to keep records, showing in detail the quanti-
ties manufactured, the acquisition and disposal, the 
date, the supplier and the recipient. Separate import 
and export authorizations are also required. 
 s For Schedule III substances, no separate import or 
export authorizations are needed. Record-keeping re-
quirements are less strict. National authorities have to 
provide the International Narcotics Control Board only 
with aggregate information on the quantities manufac-
tured, exported and imported.210 
 s Control under Schedule IV is largely limited to a 
requirement to have such substances prescribed by 
medical doctors and to have — like other schedules 
— the manufacturing, import, export and distribution 
licensed. 
210 United Nations Office on Drugs and Crime, A Century of International 
Drug Control, p. 65.
Procedures foreseen to put (new) psychoactive substances under interna-
tional control under the Convention on Psychotropic Substances of 1971
Article 2 of the Convention on Psychotropic Substances of 
1971 foresees that either a party or the World Health 
Organization (WHO) may recommend putting a sub-
stance under control. The Secretary-General has to be 
notified and the party or WHO has to furnish the infor-
mation in support of that notification. The Secretary-
General shall then transmit such notification and any 
other information he considers relevant to the parties, to 
the Commission on Narcotic Drugs and to WHO (in case 
the notification was made by a party). 
The procedures laid down in the 1971 Convention then 
deviate slightly from those in the Single Convention on 
Narcotic Drugs of 1961, giving, in theory, greater power 
to the Commission on Narcotic Drugs in the final deci-
sion. Nonetheless, without the active participation of 
WHO, notably, the elaboration of an assessment, no fur-
ther scheduling of a new substance can take place (except 
for a kind of “voluntary” emergency scheduling by the 
parties, i.e. “provisional application” of control measures as 
foreseen under Schedule I or II, according to article 2, 
paragraph 3). 
Following the notification from a party to the 1971 Con-
vention (or from the Commission on Narcotic Drugs), a 
“pre-review” is undertaken by WHO, which may make the 
recommendation for a “critical review”. This “critical 
review” or assessment by WHO is to provide answers to a 
number of questions in article 2, paragraph 4, as to whether 
(a)  ... the substance has the capacity to produce 
(i) 1. A state of dependence, 
2. Central nervous system stimulation or depres-
sion, resulting in hallucinations or disturbances 
in motor function or thinking or behaviour or 
perception or mood, or
(ii) Similar abuse and similar ill effects as substances 
in Schedule I, II, III or IV, and 
(b) ... there is sufficient evidence that the substance is be-
ing or is likely to be abused so as to constitute public 
health and social problem warranting the placing of 
the substance under international control.
WHO must communicate its assessment to the Commis-
sion on Narcotic Drugs, providing answers to the ques-
tions on “the extent or likelihood of abuse, the degree of 
seriousness of the public health and social problem and the 
degree of usefulness of the substance in medical therapy, 
together with recommendations on control measures, if 
any, that would be appropriate in the light of its assess-
ment.” 
The Commission on Narcotic Drugs, taking into account 
the assessment of WHO, which is “determinative as to 
medical and scientific matters” (art. 2, para. 5), and bear-
ing in mind the economic, social, legal, administrative and 
other factors it may consider relevant, will then decide 
whether or not the specific substance will be controlled 
and into which schedule it is to be placed. In other words, 
provided WHO has communicated its findings to the 
Commission on Narcotic Drugs, the Commission has 
some discretionary powers to deviate from the WHO rec-
ommendations on the basis of economic, social, legal or 
administrative arguments. Decisions require a two-thirds 
majority of its total membership (art. 17, para. 2). The 
Commission on Narcotic Drugs, however, cannot decide 
to control a substance if WHO has failed to find that it 
had dangerous properties. Similarly, the Commission 
cannot put a substance into Schedule I if WHO has found 
that such a substance would have more than “very limited” 
therapeutic usefulness (art. 2, para. 4 (a), (i) or (ii)). The 
decision of the Commission will then be communicated to 
the parties and the Secretary-General and will become 
effective 180 days after the date of such communication 
(art. 2, para. 7).
Source: Commentary on the Convention on Psychotropic Sub-
stances (United Nations publication, Sales No. E.76.XI.5).
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The 1971 Convention placed a number of natural, semi-
synthetic and synthetic substances under international con-
trol, including central nervous system stimulants (e.g. 
amphetamine, methamphetamine, methylphenidate, 
amfepramone), hallucinogens (e.g. LSD, mescaline, psilo-
cybine, dimethyltryptamine (DMT)) and sedative-hyp-
notics (e.g. barbiturates, methaqualone).211 It also included 
THC, the main psychoactive substance of the cannabis 
plant, and PCP, known as “angel dust”, a recreational, dis-
sociative drug causing both hallucinogenic and anaesthetic 
side effects. 
The number of substances controlled under the 1971 Con-
vention has almost quadrupled, from 32 to 115,212 since 
its adoption, a far greater increase than reported for sub-
stances controlled under the 1961 Convention over the 
same period. The largest expansion of the 1971 Convention 
took place in 1984, when 33 benzodiazepines were added 
to the substances under control. MDMA (“ecstasy”) was 
added to the list of controlled substances in 1986. In the 
same year, cathine and cathinone, the main psychoactive 
substances of the khat plant, were also controlled. Buprenor-
phine, an opioid, was added in 1989. Methcathinone came 
under control in 1995. GHB and 2C-B, a phenethylamine 
psychedelic drug, were added to the list of controlled sub-
stances in 2001. The latest addition, in 2003, was 
amineptine, an atypical tricyclic antidepressant.
Most of the NPS discussed in this chapter are synthetic 
drugs and are closely related to the substances scheduled 
211 B. Rexed and others, Guidelines for the Control of Narcotic and Psycho-
tropic Substances: In the Context of the International Treaties (Geneva, 
World Health Organization, 1984).
212 In some publications the number is given as 116, but that is because 
tetrahydrocannabinol (THC) and dronabinol (a pharmaceutical for-
mulation of THC) are counted as two different substances.
under the 1971 Convention. Thus, most of the NPS, if 
controlled at the international level, would probably be 
controlled under that Convention.
To look at the issue from a different perspective: if the 
substances under international control are classified as 
Fig. 48. Number of substances under international control, 1912-2012 
Source: I. Bayer and H. Ghodse, “Evolution of international drug control, 1945-1995”, Bulletin on Narcotics, vol. LI, Nos. 1 and 2 (1999) 
(United Nations publication) (for natural drugs until 1995 and synthetic drugs until 1948); The International Drug Control Conventions 
(United Nations publication, Sales No. E.09.XI.20); International Narcotics Control Board, list of narcotic drugs under international control 
(“Yellow List”), 50th ed., December 2011; International Narcotics Control Board, list of psychotropic substances under international con-
trol (“Green List”), 24th ed., May 2010. 
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Source: I. Bayer and H. Ghodse, “Evolution of international drug 
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trol (United Nations publication, Sales No. M.06.XI.16), Part One; 
International Narcotics Control Board, list of narcotic drugs under 
international control (“Yellow List”), 50th ed., December 2011; 
International Narcotics Control Board, list of psychotropic sub-
stances under international control (“Green List”), 24th ed., May 
2010. 
4 7
17
36
85
130
207
226 234
32 33 370
12
53
24 32 38
0 0
98
174
189 196
0
50
100
150
200
250
19
12
19
25
19
31
19
48
19
61
19
71
19
88
19
95
20
12
N
u
m
b
er
 o
f 
in
te
rn
at
io
n
al
ly
 c
o
n
tr
o
lle
d
 
su
b
st
an
ce
s 
Natural drugs Synthetic substances
2. NEW PSYCHOACTIVE SUBSTANCES 106
natural drugs and synthetic substances, irrespective of the 
convention under which they are scheduled, it becomes 
obvious that the main increases since the Second World 
War have been among the synthetic substances. Almost 84 
per cent of all substances under control in 2012 were syn-
thetic drugs, up from 33 per cent in 1948. Most of the 
synthetic drugs are under the 1971 Convention, though 
it has to be said that currently, most substances controlled 
under the 1961 Convention are also synthetic substances 
(mostly synthetic opioids). 
Overall, 234 psychoactive substances (excluding esters and 
isomers) are currently under the governance of the 1961 
Convention and the 1971 Convention. 
What is unprecedented, however, has been the accelerating 
pace at which NPS have been developed and spread around 
the globe in recent years. UNODC identified the emer-
gence of 251 NPS up to mid-2012 of which the bulk was 
identified over the 2009 - mid-2012 period.
On the other hand, an analysis of the number of substances 
controlled also shows that the upward trend in the sched-
uling of psychoactive substances has largely ground to a 
halt in recent years, even though the number of NPS 
emerging in the market is on an upward curve.213 
The WHO has found it increasingly difficult — partly for 
financial reasons — to convene meetings of the Expert 
Committee on Drug Dependence to discuss scheduling 
213 It must be taken into consideration, however, that not all NPS are 
widespread. There are discrepancies in the number of substances 
detected versus those actually used. Moreover, some of the NPS may 
not be as problematic as the substances already controlled.
Fig. 50. Internationally controlled and non- 
controlled psychoactive substances  
in 2012
Source: International Narcotics Control Board, list of narcotic 
drugs under international control (“Yellow List”), 50th ed., 
December 2011; International Narcotics Control Board, list of psy-
chotropic substances under international control (“Green List”), 
24th ed., May 2010; United Nations Office on Drugs and Crime, 
The Challenge of New Psychoactive Substances (Vienna, March 
2013).
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issues in recent years.214 In addition, ever more concerns 
were raised by experts at the Expert Committee meetings 
over the fact that the control of a substance could reduce 
its availability for medical purposes and research in the 
future, which reduced the number of positive recommen-
dations for control.215 Given the large number of emerging 
NPS, the actual number of new substances proposed 
for control has thus been extremely limited. The last time 
a psychotropic substance was scheduled was in 2003. 
The 35th meeting of the Expert Committee on Drug 
Dependence, held in June 2012, considered the control of 
ketamine and recommended against controlling it because 
it did “not appear to pose a significant global public health 
risk” while being “widely used as an anaesthetic in devel-
oping countries”.216 Substances such as mephedrone or 
MDPV, which have caused serious health problems in a 
number of countries in recent years, are yet to undergo a 
“critical review”, and it will be some time before they can 
become internationally controlled substances. 
Irrespective of the apparent shortcomings in the specific 
cases mentioned above, there are legitimate questions to 
be raised as to the capacity of Member States — and the 
associated costs — to control an ever larger number of 
substances, affecting police, customs, forensic laboratories, 
import/export authorities, health authorities, etc. 
This is also an opportunity for knowledge-sharing and 
learning from the experiences of individual Member States. 
In fact, the international drug control system has, from its 
very inception, drawn on the lessons learned by individual 
Member States and incorporated their experiences into its 
own legal framework. 
New drugs of abuse at the  
national and the regional level 
Various innovative approaches have been tried by Member 
States at the national and the regional level. They are worth 
studying for possible application at the international level. 
Early warning system 
A number of countries have introduced early warning sys-
tems in order “to provide timely information so that poli-
cymakers can make evidence-based decisions”.217 The first 
214 Such meetings used to be held every two years, but the time gap has 
widened in recent years. Following a meeting in 2006, it took six years 
for the Expert Committee on Drug Dependence to convene again, in 
June 2012.
215 WHO Expert Committee on Drug Dependence: Thirty-fifth Report, 
WHO Technical Report Series, No. 973 (Geneva, World Health 
Organization, 2012); WHO Expert Committee on Drug Dependence: 
Thirty-fourth Report, WHO Technical Report Series, No. 942 (Geneva, 
World Health Organization, 2006); WHO Expert Committee on Drug 
Dependence: Thirty-third Report, WHO Technical Report Series, No. 
915 (Geneva, World Health Organization, 2003). 
216 WHO Expert Committee on Drug Dependence: Thirty-fifth Report, 
WHO Technical Report Series, No. 973 (Geneva, World Health 
Organization, 2012).
217 Carolyn Coulson and Jonathan P. Caulkins, “Scheduling of newly 
emerging drugs: a critical review of decisions over 40 years”, Addiction, 
system at the regional level was introduced in Europe in 
1997, the early warning system on the emergence of new 
synthetic drugs.218 As of 2005, the system was broadened 
to include not only synthetic drugs, but all kinds of 
NPS.219 
The early warning system builds on the national early 
warning systems that were created in all European Union 
member States, as well as in Norway and the two European 
Union candidate countries Croatia and Turkey. The early 
warning system has been characterized by EMCDDA as a 
“low-cost mechanism to share information on new threats, 
and as a catalyst for action when this has been merited”. 
Its key task remains its function as an alert system on NPS. 
In order to remain vigilant, the early warning system 
expanded to include not only forensic science but also a 
range of health and law enforcement professionals as well 
as independent researchers.220 
When a NPS is first detected in a country (based on sei-
zures, undercover purchases, alerts by the health authori-
ties, etc.), detailed information on the manufacture, traffic 
and use, including supplementary information on possible 
medical use, is sent by the member State to Europol and 
to EMCDDA, which communicate it to their respective 
national units, the European Commission and the Euro-
pean Medicines Agency (EMA). 
If Europol and EMCDDA consider that the information 
merits further action, it is presented in the form of a 
Europol-EMCDDA joint report and submitted to the 
Council, the EMA and the Commission. The information 
contained in the joint report includes: 
 s A chemical and physical description, including the 
name under which the NPS is known
 s Frequency, circumstances and/or quantities in which a 
NPS has been encountered
 s Means and methods of manufacture of the NPS and 
the involvement of organized crime in its manufacture 
or trafficking
 s Indications of the health and social risks associated 
with the NPS, including the characteristics of its users
 s Whether the NPS is or has been under assessment by 
the United Nations system
 s Whether the NPS is already subject to control at the 
national level in a Member State
 s Chemical precursors, mode and scope of the expected 
use of the NPS.
vol. 107, No. 4 (2012), pp. 766-773.
218 Joint action 97/396/JHA of 16 June 1997, adopted by the Council 
of the European Union on the basis of Article K.3 of the Treaty on 
European Union, concerning the information exchange, risk assess-
ment and the control of new synthetic drugs (Official Journal of the 
European Communities, L 167, 25 June 1997).
219 Council of the European Union Decision 2005/387/JHA.
220 European Monitoring Centre for Drugs and Drug Addiction, Early 
Warning System: National Profiles (Luxembourg, Office for Official 
Publications of the European Communities, 2012).
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On its part, EMA submits the following information to 
Europol and EMCDDA:
 s Whether the NPS has received a marketing 
authorization
 s Whether it is the subject of an application for a mar-
keting authorization
 s Whether a marketing authorization that had been 
granted has been suspended.
The early warning system forms an integral part of the 
European Union-wide control system for NPS. In total, 
six steps221 are required in the procedures established by 
the Council Decision for submitting a NPS for control: 
1. A member State provides information on a NPS in its 
market 
2.  Europol and EMCDDA, in collaboration with EMA, 
prepare a joint report and submit it to the Council
3. The Council requests a risk assessment from 
EMCDDA
4. EMCDDA submits the risk assessment to the Council 
and the Commission
5. The Commission presents an initiative for control 
measures to the Council
6.  The Council decides on the submission of the sub-
stance to control measures and on the obligation to 
introduce criminal law measures.
The early warning system covers the first two steps on the 
list above towards controlling a NPS. The principles of the 
scheduling system developed at the European Union level 
are not so different from those at the international level. 
The main substantive difference seems to be the existence 
of the early warning system.
The evaluation of the functioning of Council Decision 
2005/387/JHA by the European Commission identified 
several critical points, notably the length of the process. 
However, the same assessment also concluded that the early 
warning system was “a useful tool for alerting member 
States to new substances detected in neighbouring coun-
tries”, even though most substances were not subsequently 
submitted for any risk assessment following the joint 
reports.222 
The early warning system prompted risk assessment for 
MBDB (1999), 4-MTA (1999), GHB (2002), ketamine 
(2002), PMMA (2003), TMA-2 (2004), 2C-l, 2C-T-2, 
2C-T-7 (2004), BZP (2009) and mephedrone (2011).223 
In addition, joint reports from EMCDDA and Europol 
have been, in recent years, prepared for 4-methylampheta-
221 European Commission, “Report from the Commission on the assess-
ment of the functioning of Council Decision 2005/387/JHA on 
information exchange, risk assessment and control of new psychoactive 
substances”, document COM(2001) 430 (Brussels, 11 July 2001), p. 4.
222 Ibid., p. 6.
223 Available from www.emcdda.europa.eu/publications/searchresults?acti
on=list&type=PUBLICATIONS&SERIES_PUB=w12.
mine (2012) and 5-(2-aminopropyl) indole (2013).224 As 
a consequence, some of the most critical NPS, in terms of 
spread and overall health consequences, are under control 
in the European Union, including BZP, PMMA (an 
amphetamine-type stimulant that has caused a number of 
deaths), several psychedelic phenethylamines (2C-I, 2C-T-
2, 2C-T-7), TMA-2 (an analogue of the phenethylamine 
cactus alkaloid mescaline, often sold as “research chemi-
cals”) and mephedrone225 which appears to have caused 
some of the most serious NPS-related health problems in 
recent years. 
Emergency scheduling
The traditional approach to drug scheduling tends to be 
very time-consuming. At the same time, decisions made 
prematurely before a scientific consensus emerges may be 
counterproductive.226 This creates a dilemma. One way 
to overcome this has been via the introduction of “emer-
gency procedures”,227 an approach taken frequently, which 
involves dealing with the problem by introducing an emer-
gency scheduling system. 
Such systems have been established in Denmark, Germany, 
the Netherlands, Spain, the United Kingdom, the United 
States228 and elsewhere. They allow for the ban of danger-
ous substances by ministerial decree.229 The systems in 
Germany, the Netherlands and the United Kingdom 
enable the authorities to place a substance under temporary 
control for a year, with the approval of a minister instead 
of parliament. If the procedure for permanent control is 
not established within that year, the restriction lapses.230 
Emergency scheduling permits quicker action than per-
manent scheduling and is used when a substance poses 
imminent danger to public health.231 At the same time, 
emergency scheduling systems help to mitigate the risk of 
making incorrect decisions by delaying the final schedul-
ing decision by, typically, 12 to 18 months. In 2011, the 
United States temporarily scheduled several synthetic can-
nabinoids (JWH-018; JWH-073; JWH-200; CP-47,497; 
224 Available from www.emcdda.europa.eu/publications/searchresults?acti
on=list&type=PUBLICATIONS&SERIES_PUB=a105.
225 European Monitoring Centre for Drugs and Drug Addiction and 
European Police Office, “EMCDDA- Europol 2011 annual report on 
the implementation of Council decision 2005/387/JHA”.
226 Coulson and Caulkins, “Scheduling of newly emerging drugs: a critical 
review of decisions over 40 years”.
227 Report of the International Narcotics Control Board for 2012.
228 Emergency scheduling was first introduced in the United States in 
1984 as part of its Comprehensive Crime Control Act of 1984 which 
in section 508 gave the Attorney General the authority to list a sub-
stance temporarily under Schedule I of the Controlled Substances Act 
(CSA).
229 Jan van Amsterdam, David Nutt and Wim van den Brink, “Generic 
legislation of new psychoactive drugs”, Journal of Psychopharmacology, 
vol. 27, No. 3 (2013), pp. 317-324.
230 European Monitoring Centre for Drugs and Drug Addiction, 
“Responding to new psychoactive substances”.
231 See http://international.drugabuse.gov/meetings/international-forum/
executive-summaries/2012-nida-international-forum.
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CP-47,497 C8 homologue)232 and some of the very prob-
lematic synthetic cathinones (mephedrone, methylone and 
MDPV),233 before putting them under regular control a 
year later. Emergency scheduling appears to have helped a 
number of countries to prevent the outbreak of drug 
epidemics. 
The “rapid procedures” or “fast-track systems” established 
by a number of other countries are different. In such sys-
tems, substances are placed under control by shortening 
defined consultation periods during the law-making pro-
cess. These accelerated scheduling decisions are then per-
manent. This may help to protect the population from 
serious health hazards in case of an emergency. Nonethe-
less, it carries an inherent risk, in that substances that do 
not require stringent control are nevertheless placed under 
it, potentially hampering the development of therapeutic 
applications.234 
Emergency scheduling, i.e. the “provisional application” 
of control measures, is, in principle, also foreseen at the 
international level in the 1961 Convention, for the period 
until WHO has made its assessment and, to a lesser extent, 
in the 1971 Convention. The application of these possi-
bilities could, in theory, reduce by several years the period 
until substances are controlled at the international level. 
However, Member States have refrained from making use 
of this system. The specific formulation of the “provisional 
application” of control measures in the 1971 Convention 
may have contributed to this. In contrast to the formula-
tion of the 1961 Convention (art. 3, para. 3 (ii)), which 
gives the Commission on Narcotic Drugs the right to 
decide on such provisional applications of control meas-
ures, the 1971 Convention only encourages the Parties to 
“examine in the light of all information available to them, 
the possibility of the provisional application to the sub-
stance of all measures of control applicable to substances 
in Schedule I or Schedule II, as appropriate” (art. 2, para. 
3). In other words, the 1971 Convention provides only 
for a voluntary, non-binding provisional application of 
scheduling procedures to be implemented by individual 
Member States. It does not give the Commission on Nar-
cotic Drugs the power to decide on such measures in a 
legally binding way. At most, the Commission on Narcotic 
Drugs could adopt a resolution asking Member States to 
implement such measures. 
232 United States, Drug Enforcement Administration, “Schedules of con-
trolled substances: temporary placement of five synthetic cannabinoids 
into Schedule I”, Final order, 21 CFR Part 1308, Docket No. DEA-
345F (www.deadiversion.usdoj.gov/fed_regs/rules/2011/fr0301.htm). 
233 United States, Drug Enforcement Administration, “Schedules of con-
trolled substances: temporary placement of three synthetic cathinones 
into Schedule I”, Final order, 21 CFR Part 1308, Docket No. DEA-
357 (www.deadiversion.usdoj.gov/fed_regs/rules/2011/fr1021_3.
htm).
234 Coulson and Caulkins, “Scheduling of newly emerging drugs: a critical 
review of decisions over 40 years”.
Analogue and generic scheduling
Most scheduling systems, including emergency scheduling, 
tend to be reactive in nature, in that they can start operat-
ing only after a substance has been found to pose a severe 
risk to public health and is already in wide circulation. In 
order to be proactive, a number of countries have intro-
duced either analogue or generic scheduling systems.235 
The basic idea in both systems is similar. Instead of requir-
ing an expensive and time-consuming scheduling process 
for each individual substance, modifications of the con-
trolled substance automatically fall under the control 
system. 
By way of illustration, the United States analogue system, 
the prototype of such systems worldwide, is explained 
below, and is subsequently compared to the generic sched-
uling system found in the United Kingdom and a few other 
countries. 
Analogue system 
The best known example of an analogue control system 
can be found in the United States, whose system served as 
a model for several other analogue systems adopted in the 
1980s, including in Canada, New Zealand and partly in 
Australia.236 
The American system, dating back to 1985/86,237 was a 
response to the proliferation of synthetic derivatives of 
controlled substances in the early 1980s, such as the spread 
of fentanyl derivatives, alphaprodine derivatives and vari-
ous phenethylamines related to MDMA, and ampheta-
mines designed to produce similar effects to those of 
controlled substances.238 
Under section 802 (32)(A) of the United States Controlled 
Substances Act (CSA), a “controlled substance analogue” 
is defined as a substance: 
(a) Whose chemical structure is substantially similar to 
that of a scheduled substance; 
(b) Whose effects (stimulant, depressant, hallucinogenic) 
are substantially similar to or greater than those of a 
controlled substance. 
Thus, the analogue system anticipates the emergence of 
NPS and controls them even before they have reached the 
market. Eventually, a court decides whether a substance 
235 Report of the International Narcotics Control Board for 2012.
236 United Nations Office on Drugs and Crime, The Challenge of New 
Psychoactive Substances.
237 United States, “Controlled Substance Analogs” Enforcement Act of 1985: 
Report of the Committee on the Judiciary — United States Senate, on S. 
1437; L. A. King and others, “Analogue controls: an imperfect law” 
(London, United Kingdom Drug Policy Commission, 19 June 2012). 
Available from www.ukdpc.org.uk/publication/analogue-controls-an-
imperfect-law. 
238 L. A. King and others, “Analogue controls: an imperfect law” (London, 
United Kingdom Drug Policy Commission, 19 June 2012). Available 
from www.ukdpc.org.uk/publication/analogue-controls-an-imperfect-
law. 
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falls under this definition. Courts in the United States have 
interpreted the law to mean that both requirements, i.e. 
similarity in structure and in effects, must be fulfilled.239 
Like traditional scheduling systems, the United States ana-
logue system thus still relies on a substance-by-substance 
analysis. The analogue system was intended to discourage 
attempts to skirt the law through molecular tinkering,240 
and it is believed to have reduced the proliferation of new 
synthetic drugs.
Nonetheless, the implementation of the analogue system 
has its own set of problems.241 From the beginning, there 
have been issues related to the clarity of the statutory defi-
nition. The issues related to “similarity” are not always 
clear-cut.242 A court judgement is required. In this context, 
it has been argued that a retrospective process undermines 
the right of a defendant to know from the outset whether 
or not an offence has been committed. This led to a court 
case in which the law on the analogue system was 
upheld.243 Nonetheless, the question as to whether a sub-
stance is “substantially similar” has repeatedly led to experts 
butting heads. The situation has been aggravated by the 
fact that no United States court has ever issued detailed 
guidelines to establish the criteria to be applied.244 
Generic system 
Generic control systems go a step further. They start from 
a core molecular structure. The law then specifies varia-
tions of the structure of this substance (defining, for 
instance, particular substituent groups in specific positions 
in the molecule), which would lead to the automatic con-
trol of such substances under the national legislation. In 
contrast to the analogue system, where all new substances 
are judged by their similarity to existing substances under 
control and are eventually dealt with individually (by the 
court), generic scheduling means that entire chemical fami-
lies of substances are controlled, i.e. many new substances 
related to one core molecule. It is not required that the 
psychoactive effects of the analogues controlled be similar 
to those of the core molecule. 
Generic legislation on drug scheduling exists in the United 
Kingdom245 and, to some extent, in Australia.246 “Generic-
239 King and others, “Analogue controls: an imperfect law”, p. 2. 
240 United States, “Controlled Substance Analogs” Enforcement Act of 1985: 
Report of the Committee on the Judiciary — United States Senate, on S. 
1437, p. 5.
241 G. Kau, “Flashback to the Federal Analogue Act of 1986: mixing rules 
and standards in the cauldron”, University of Pennsylvania Law Review, 
vol. 156, No. 4 (2008), pp. 1077-1115.
242 Alexander Shulgin, “How similar is substantially similar?”, Journal of 
Forensic Sciences, vol. 35, 1990, pp. 8-10. 
243 United States Court of Appeals, United States of America v. Allen 
McKinney, 1995 (http://law.justia.com/cases/federal/appellate-courts/
F3/79/105/555999/).
244 King and others, “Analogue controls: an imperfect law”, p. 2. 
245 European Monitoring Centre for Drugs and Drug Addiction, 
“Responding to new psychoactive substances”.
246 Section 314.1 of the Australian Criminal Code Act 1995 gives a 
detailed chemical definition of what analogue substances are in relation 
like” legislation has recently been introduced to cope with 
the problem of NPS in Austria, Belgium, Bulgaria, Cyprus, 
Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, 
Malta, Norway and Poland.247 
This approach has been around for a while — for instance, 
the application of generic definitions in the United King-
dom legislation dates back to 1971,248 even though most 
generic definitions in the Drug Misuse Act were introduced 
after 1976, covering, inter alia, barbiturates, cathinones, 
fentanyls, pethidines, phenethylamines, phenyl- and ben-
zylpiperazines, synthetic cannabinoid agonists (cannabi-
mimetics) and tryptamines.249 
A preliminary stage of the concept of generic scheduling 
has already been reached at the international level. All iso-
mers, esters, ethers and salts of the controlled drugs in 
Schedule I of the 1961 Convention, unless specifically 
excluded, are also under international control, as well as 
isomers of drugs controlled in Schedule II.250 Similarly, 
all salts of the psychoactive substances in Schedules I, II, 
III and IV of the 1971 Convention and stereoisomers, 
unless specifically excepted, of substances in Schedule I, 
whenever the existence of such stereoisomers is possible 
within the specific chemical designation, are automatically 
under international control.251 
On the surface, a generic scheduling system is extremely 
appealing. It is anticipatory instead of reactive. Its main 
advantage is that it is in line with the precautionary prin-
ciple and protects public health, because fewer people will 
be exposed to harmful substances.252 It also eliminates the 
scheduling-related costs for national authorities. 
On the downside, clandestine chemists may still be able 
to identify substances falling outside the defined cluster 
that mimic the effects of controlled substances.253 
A common feature of generic definitions is that individu-
ally controlled substances are not mentioned explicitly. 
(This also applies to the analogue approach.) Thus, in 
many of the national drug laws based on a generic defini-
tion, one may search in vain for specific substances such 
as MDMA or mephedrone even though those substances 
are controlled under such laws. Though the definitions 
to the substances explicitly controlled, stating that such substances are 
automatically also controlled, thus introducing de facto a generic drug 
control concept for Australia.
247 Van Amsterdam, Nutt and van den Brink, “Generic legislation of new 
psychoactive drugs”.
248 The United Kingdom Misuse of Drugs Act 1971 included N-alkyl 
derivatives of lysergamide (substances closely related to lysergide 
(LSD)) and cannabinols (including THC).
249 King and others, “Analogue controls: an imperfect law”, p. 3.
250 Single Convention on Narcotic Drugs of 1961 as amended by the 
1972 Protocol (United Nations, Treaty Series, vol. 976, No. 14152).
251 Convention on Psychotropic Substances of 1971 (United Nations, 
Treaty Series, vol. 1019, No. 14956).
252 Van Amsterdam, Nutt and van den Brink, “Generic legislation of new 
psychoactive drugs”.
253 Ibid.
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used are largely precise, they may be unintelligible to all 
but organic chemists.254 This creates a problem for the 
public at large. If a law is not well understood, there is a 
risk that it will not be well implemented. In fact, a number 
of examples in the present report, suggest that the use of 
a NPS, even though falling within a generic definition, 
declines only after it has been explicitly put on a list of 
controlled substances (e.g. the decline of the use of mephe-
drone in Australia following its listing in the drug laws, or 
in the United Kingdom following an explicit import ban). 
Also, most of the “legal highs” in Europe were identified 
in the United Kingdom, even though some of those sub-
stances were, officially, already under generic control there, 
perhaps indicating that many (often foreign) manufactur-
ers and consumers were not aware that they were illegal 
substances. In short, even in a generic control system, there 
is a need to identify new substances emerging on the 
market and to inform the general public and the various 
stakeholders (police, customs, etc.) that they are already 
controlled. 
An additional technical problem is that related substances 
may have very different pharmacological properties, and 
that some may well have therapeutic uses. Even though 
“control” is not equivalent to “prohibition”, it is sometimes 
feared that a generic form of legislation could hinder the 
development of new medications.255 When this was 
known ex ante, the United Kingdom authorities, for 
instance, did not exercise generic control and continued 
to list the substances to be controlled individually. 
There exists another potential problem. The legal systems 
of a number of countries are based on the concept — as 
part of the principle of legality — that any offence must 
be clearly defined. This principle is enshrined in some 
national constitutions as well as in the European Conven-
tion on Human Rights. This may pose problems both for 
generic control systems and, even more so, for analogue 
control systems. It must be noted, though, that European 
Court of Human Rights case law allows for some broader 
interpretations, and thus permits generic definitions as 
found in the drug laws of Ireland and the United 
Kingdom.256 
Application of medicines legislation 
A number of countries, faced with the rapid emergence 
of new substances, have also taken recourse to their 
national laws on medicines. European countries can 
base this approach on European Medicines Directive 
2001/83/EC, which is intended to ensure that medicinal 
products are sold and delivered in the member States only 
with proper authorization. Application of that Directive 
254 King and others, “Analogue controls: an imperfect law”, p. 3.
255 Van Amsterdam, Nutt and van den Brink, “Generic legislation of new 
psychoactive drugs”.
256 European Monitoring Centre for Drugs and Drug Addiction, 
“Responding to new psychoactive substances”.
allows a ban on unauthorized importation, trading and 
distri bution.257
An example of a country that followed this approach is 
Austria, applying the country’s medicine legislation 
(Arzneimittelgesetz)258 to fight the (legal) distribution of 
Spice and similar products containing synthetic cannabi-
noids soon after they had emerged in “head shops” in the 
local market. In late 2008 Austrian authorities temporarily 
classified Spice products, using a generic definition (herbal 
mixtures containing synthetic cannabinoids) as “medicinal 
products” under the country’s (non-criminal) medicines 
legislation before classifying them more permanently under 
this act in 2009 (prior to a subsequent reclassification of 
such substances under an act on NPS in 2012). 
The Austrian Medicinal Products Act allows for the clas-
sification of substances that have the capability to influence 
the functions of the body or mental conditions. Once Spice 
products had been established as medicines, paragraph 3 
(1) of the Act was applied, which states that it is forbidden 
to market medicines that, on the basis of current scientific 
knowledge and practical experiences, have not been proved 
not to have harmful effects beyond acceptable levels. Any 
importer of medicinal products must first obtain an 
authorization to purchase such substances. In case of vio-
lation, the importers and sellers face administrative fines 
and the confiscation of merchandise. The Act allows for 
temporary confiscations if (a) there are suspicions that such 
substances are being marketed against the rules and regu-
lations of the Act, or if (b) there is a health danger related 
to the consumption of such products. Both conditions 
applied to Spice. 
The advantage of the application of the Medicinal Prod-
ucts Act for the drug authorities has been that the import-
ers and distributors, and not the authorities, had to prove 
that the substances served a legitimate legal purpose and 
were not harmful. In contrast to the narcotics law, the users 
were not directly affected by the Act. Consumption or 
possession for personal use did not entail any penalties. 
The approach of dealing with the problem of NPS via the 
medicinal law proved effective in bringing the open mar-
keting and distribution of Spice products in the country 
to a quick halt. Though Austria was among the first coun-
tries in Europe to have been affected by a Spice epidemic, 
the 2011 Eurobarometer survey confirmed that its overall 
prevalence of NPS use was clearly below the European 
Union average (25 per cent less).259 
However, the authorities also became aware of the limita-
tion of this approach, prompting them to create a proper 
act on NPS, which became effective in 2012. 
257 Van Amsterdam, Nutt and van den Brink, “Generic legislation of new 
psychoactive drugs”.
258 Austria, Bundesgesetz vom 2. März 1983 über die Herstellung und 
das Inverkehrbringen von Arzneimitteln (Arzneimittelgesetz — AMG) 
(Medicinal Products Act), Federal Law Gazette No. 185/1983.
259 Gallup Organization, Youth Attitudes on Drugs: Analytical Report.
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Nonetheless, this remains an interesting approach for the 
large number of NPS, which rapidly change their actual 
compositions and for which the traditional scheduling 
approach may be too tedious and time-consuming. In fact, 
EMCDDA encouraged other countries to consider apply-
ing the harmonized European Union definition of a medic-
inal product to NPS so that the respective national 
medicine agencies could prohibit the unauthorized impor-
tation, marketing and distribution of such products.260 
Application of consumer protection laws 
Another approach adopted by a number of countries has 
been to apply various existing consumer protection laws 
to fight the flow of NPS into the local market.261 
For instance, under the European product safety directive, 
producers are obliged to put only safe products on the 
market. The directive states that under reasonably foresee-
able conditions of use, a product should not “present any 
risk or only the minimum risks compatible with the 
product’s use, considered to be acceptable and consistent 
with a high level of protection for the safety and health 
of persons”, taking into account its characteristics, the 
labelling, any warnings and instructions for its use. 
Under the directive, distributors must also inform the com-
petent authorities of serious risks and the distributors’ 
actions for prevention. Offences can be punishable by 
imprisonment.262 
In this context, Sweden created a separate law on goods 
that are dangerous to health. The law allows for the rapid 
classification of a substance in order to make its sale and 
possession subject to serious criminal penalties. This gives 
the authorities time to consider whether the specific sub-
stance meets the definition of a “drug” and should be 
scheduled under the law governing narcotics or psycho-
tropic substances in the country.263 
A number of countries have applied at least parts of their 
consumer protection legislation to NPS. Italy, for instance, 
made use of its labelling regulations requiring that goods 
or food on sale be clearly and accurately labelled in rela-
tion to their expected use. Italian authorities invoked this 
law to confiscate Spice products for not having been prop-
erly labelled in the Italian language.264 
Some countries have also started to apply their anti-fraud 
legislation. In Austria, e.g., piperazines used to be marketed 
as “ecstasy”. Though piperazines did not fall under the nar-
cotics and psychotropics law as of the mid-2000s, they were 
seized and the providers were convicted of consumer fraud. 
260 European Monitoring Centre for Drugs and Drug Addiction, 
“Responding to new psychoactive substances”.
261 Report of the International Narcotics Control Board for 2012.
262 European Monitoring Centre for Drugs and Drug Addiction, Annual 
Report 2011: The State of the Drugs Problem in Europe, p. 96.
263 European Monitoring Centre for Drugs and Drug Addiction, 
“Responding to new psychoactive substances”.
264 Ibid.
Specific legislation on new psychoactive 
substances 
Given the complexities related to their regulation, a few 
countries have started to implement specific legislation on 
NPS. 
Ireland, the country faced with Europe’s highest rates of 
prevalence for NPS, introduced legislation in 2010 that 
prohibits the import, export and sale of any addictive or 
harmful psychoactive substance for human consumption. 
The maximum penalty for violating the Psychoactive Sub-
stances Act265 is a prison sentence of up to five years. Initial 
results seem encouraging. The upward trend in the use of 
NPS could well be halted. 
Poland, Europe’s second largest market for NPS, prohib-
ited the marketing of “substitute drugs” (i.e. NPS) in 
2010.266 The relevant act introduced a general ban on 
manufacturing such substitute substances, on introducing 
them to trade and on advertising them. In the event of a 
reasonable suspicion that a product might be dangerous, 
it provides for the health inspector to withdraw such prod-
ucts from the market for a period of up to 18 months to 
study their harmfulness.267 Initial results, as discussed in 
this chapter, look promising. 
A similar approach was also chosen by Austria, which was 
among the first countries to pass a comprehensive law, the 
New Psychoactive Substances Act,268 which entered into 
force in 2012. This Act follows the European Union defi-
nition of NPS and applies to all NPS, except those that 
are already regulated under the Medicinal Products Act. It 
empowers the Minister of Health to issue a Verordnung 
(directive) to establish various chemical families of psycho-
active substances to be controlled, making use of broad 
generic definitions wherever deemed appropriate. NPS 
must be confiscated unless the owner can establish that the 
substance was not intended to be used for its psychoactive 
effects. The new Psychoactive Substances Act also foresees 
extensive monitoring of the market and an evaluation of 
the associated risks of NPS. Offenders who produce, 
import, export or provide other persons with NPS for their 
psychoactive properties will have to reckon with a prison 
sentence of up to two years, and in case of substance-related 
deaths, of up to 10 years. The Act shares similarities with 
the Narcotic Substances Act, except for the generic sched-
uling possibilities and overall lower penalties.269 Unlike 
265 Available from www.irishstatutebook.ie/pdf/2010/en.act.2010.0022.
PDF.
266 European Monitoring Centre for Drugs and Drug Addiction, 
“Responding to new psychoactive substances”.
267 Artur Malczewski and others, 2010 National Report (2009 Data) to the 
EMCDDA by the Reitox National Focal Point: Poland.
268 Austria, Federal Act on the Protection against Health Hazards in 
connection with New Psychoactive Substances (New Psychoactive 
Substances Act), Federal Law Gazette No. 146/2011.
269 Narcotic Substances Act: up to 5 years for traffickers, up to 20 years 
for traffickers with a leading position in organized crime (Austria, 
Bundesgesetz über Suchtgifte, psychotrope Stoffe und Drogenaus-
gangsstoffe, Federal Law Gazette No. 112/1997). 
D. Conclusions and future course of action 113
W
O
R
L
D
 D
R
U
G
 R
E
P
O
R
T
 2
01
3
the case of the Narcotic Substances Act, consumers of NPS 
do not face any penalties.
Another specific approach to NPS is evolving in New Zea-
land. Its Misuse of Drugs Act 1975 used to have three sched-
ules: class A for “very high risk” substances, class B for “high 
risk” substances and class C for substances with a “moderate 
risk” of harm. The analogue provisions of the Act state that 
substances with molecules structurally similar to those of 
controlled drugs are analogues of those drugs and are auto-
matically considered class C drugs. Nonetheless, the use of 
NPS increased. In 2005, New Zealand created an additional 
schedule for new, low-risk psychotropic drugs and put BZP 
under this schedule. Substances under this schedule pose 
“less than a moderate risk of harm”, and “regulated sale” is 
foreseen.270 Regulations refer to dosage, labelling, quality 
control, manufacturing standards, age limits and restrictions 
on advertising, i.e. how the products can be marketed.271 
Given the ongoing spread of BZP in New Zealand to the 
highest levels worldwide and related negative health conse-
quences, BZP was re-rescheduled in 2008 as a class C drug. 
Subsequently, BZP use declined significantly. 
But this did not solve the overall NPS problem, prompt-
ing the authorities to introduce new emergency scheduling 
provisions in 2011. 
Those measures, however, were considered insufficient to 
deal with the problems related to low-risk psychoactive 
substances.272  Thus, the Government agreed on the devel-
opment of new legislation in August 2012, which was 
submitted to parliament in February 2013 (Psychoactive 
Substances Bill) and is expected to enter into force in 
August 2013. This will, in general, require psychoactive 
products to be approved by a national regulator (to be 
placed in the Ministry of Health) before they can be legally 
marketed, somewhat similar to the systems in place for 
food, alcohol, medicines and hazardous substances. The 
“sponsors” of psychoactive substances (manufacturers, 
importers, etc.) will have to demonstrate that the products 
do not pose an undue risk of harm. The onus of proof is 
thus with the sellers of such products, not with the authori-
ties. The legislation also foresees measures to prevent 
attempts to market psychoactive products as incense or 
plant foods in order to skirt the regulations. Breaches of 
the rules will be subject to fines of up to $500,000 or 
imprisonment of up to two years. The unlawful personal 
possession of such substances will entail the payment of 
an infringement fee of up to $500.273 
270 “Regulatory impact statement: new regulatory regime for psychoac-
tive substances” (October 2012). Available from www.health.govt.
nz/about-ministry/legislation-and-regulation/regulatory-impact-state-
ments/new-regulatory-regime-psychoactive-substances.
271 Matt Bowden and Paul Trevorrow, “BZP and New Zealand’s alterna-
tive approach to prohibition”, Drug Testing and Analysis, vol. 3, Nos. 
7-8 (2011), pp. 426-427.
272 New Zealand, Ministry of Health, “Regulatory impact statement: new 
regulatory regime for psychoactive substances”.
273 New Zealand, Psychoactive Substances Bill, Bill No. 100-1. Available 
from www.legislation.govt.nz/bill/government/2013/0100/6.0/whole.
D. CONCLUSIONS AND FUTURE 
COURSE OF ACTION
NPS have been defined by UNODC as substances of 
abuse, either in a pure form or a preparation, that are not 
controlled by the 1961 Convention or the 1971 Conven-
tion, but that may pose a public health threat. Both psy-
choactive synthetic drugs and psychoactive plant-based 
substances thus constitute NPS. The use of the term “new” 
does not refer to the time when a substance was first iden-
tified or synthesized, but to when it emerged in the global 
market for recreational use. 
The information and findings contained in the present 
chapter allow a number of conclusions to be drawn:
1. The emergence of NPS on the drug scene is not per 
se a new phenomenon. In fact, starting from just four 
substances controlled in the 1912 Convention, the 
number increased to 85 at the time of the 1961 Con-
vention, to 130 at the time of the 1971 Convention 
and to 234 by 2012. The emergence of new substances 
in the drug markets has clearly gained pace over the 
last decade: 251 NPS had been identified by Member 
States as of mid-2012. 
2. There has been not only an increase in the number of 
NPS on the market but — in contrast to illicit drugs 
— an overall increase in their use over the last decade. 
Thus, a “free market” for NPS (as also for drugs in 
general) is most probably not the right approach. The 
present report has shown, in general, that countries 
that introduced controls could count on a decline in 
the prevalence rates of the specific NPS concerned. 
In a number of cases, however, the overall problem of 
NPS was not solved, as other, non-controlled products 
replaced those substances. 
3. The emergence of NPS is becoming a global phenom-
enon: 88 per cent of the 80 countries that replied to 
the UNODC questionnaire in 2012 had identified 
NPS on their market. The regional percentage ranged 
from 100 per cent in the Oceania region (based on 2 
countries) to 70 per cent in Africa (based on 10 coun-
tries). The largest number of countries reporting NPS 
were in Europe (31), followed by Asia (19) and the 
Americas (11). 
4. The market for NPS is extremely dynamic. Prior to 
2008, most countries reported ketamine, followed 
by piperazines and non-controlled phenethylamines 
as NPS. Over the period 2008-2012, in contrast, 
most countries identified synthetic cannabinoids (as 
contained in Spice products), followed by synthetic 
cathinones (as contained in “bath salts”). An analysis 
of Internet search terms revealed similar findings. The 
list of NPS was topped by Spice, followed by “bath 
salts”, khat and ketamine. Similarly, searches for can-
nabinoids were more common than for synthetic 
cathinones or other groups of NPS. 
html#DLM5042921.
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5. The NPS include a huge number of substances (251 at 
the global level until mid-2012). About a quarter of all 
identified NPS were synthetic cannabinoids, one fifth 
were phenethylamines, one sixth were synthetic cathi-
nones and one tenth were non-controlled tryptamines. 
The most frequently reported NPS (more than 50 
times) were JWH-018 and JWH-073 among the syn-
thetic cannabinoids; mephedrone, MDPV and methy-
lone among the synthetic cathinones; and mCPP, BZP 
and TFMPP among the piperazines. 
6. There are regional particularities. Most of the NPS 
appear to have been identified in Europe over the last 
decade. This may have been a result of the early warn-
ing system introduced among European Union coun-
tries (plus Croatia, Norway and Turkey) as of the late 
1990s. In 2012, however, the total number of newly 
identified NPS in the United States (158) turned out 
to be twice as many as in the European Union (73). 
The prevalence rates of NPS currently appear to be 
highest in North America, notably in the United 
States, ahead of Europe, where the single largest NPS 
market appears to be the United Kingdom. Close to 5 
per cent of the population aged 15 to 24 experimented 
with NPS in the European Union, equivalent to about 
one fifth of those using cannabis or half of those using 
illicit drugs other than cannabis. The prevalence rates 
of the use of NPS in the United States appear to be 
more than twice as high as in the European Union.   
Synthetic cannabinoid products currently dominate 
the NPS market in most countries where actual preva-
lence data are available, including in Germany, Latvia, 
Poland and the United States and several other coun-
tries. Mephedrone appears to be the most widespread 
NPS in Hungary and the United Kingdom. BZP was 
the most widespread NPS in New Zealand, where it 
was marketed for a long time as a legal alternative to or 
substitute for methamphetamine. Ketamine tops the 
list of NPS in several countries of South-East Asia, and 
it has also been reported by countries in the Oceania 
region, the Near and Middle East, the Americas and 
Europe. Almost 95 per cent of global ketamine seizures 
took place in Asia over the last decade. Plant-based 
NPS are most widespread in the countries of origin, 
e.g. kratom in Thailand and khat in Yemen and  
several countries around the Horn of Africa. Synthetic 
NPS in Africa appear to be most used in some of the 
more developed countries of the continent, such as 
South Africa and Egypt. 
7. Production of NPS appears to be rather concentrated. 
A number of source countries for NPS were reported, 
mostly located in East Asia and, to a lesser extent, in 
South Asia and Europe. More than half of the coun-
tries reporting NPS identified countries in Asia (56 per 
cent) as their primary source, followed by Europe (28 
per cent) and the Americas (9 per cent). 
8. The NPS trade is often associated with new media. The 
Internet seems to play a major role: 88 per cent of the 
countries with a domestic NPS market indicated that 
the Internet played a key role in supplying them NPS 
to the domestic market. Nonetheless, the individual 
consumers (as reflected in European Union survey data 
for 2011) purchased NPS primarily at a party or club 
(36 per cent) or bought them in a specialized shop (33 
per cent). Only 7 per cent bought them over the Inter-
net. Physical shipments of NPS to individual countries 
are mostly by air or by mail.
9. Large data gaps were identified, notably with regard to 
routinely measured prevalence data, both among stu-
dents and among the general population. If countries 
wish to take the issue of NPS seriously, there is clearly 
a need to improve the data on which decision-making 
is based. 
10. There are some legitimate questions to be raised as to 
the capacity of Member States to control an ever larger 
number of substances, affecting police, customs, foren-
sic laboratories, import and export authorities, health 
authorities, etc. 
11. The de facto stalemate of new controls at the inter-
national level prompted a number of countries to 
introduce new, innovative approaches at the national 
level, in line with article 23 of the 1971 Convention, 
allowing for stricter, and thus also more encompass-
ing controls than provided for by the Convention to 
protect public health and welfare. This ranged from 
the establishment of early warning systems for NPS, 
to emergency scheduling, analogue scheduling, generic 
scheduling, application of laws governing medicines 
and consumer protection to the drafting of specific 
legislation on NPS, either prohibiting their production 
and marketing or, in principle, permitting them only 
when a market regulator had investigated their health 
consequences and issued a licence. While all of these 
approaches have pros and cons, they are all valuable 
experiments. 
12. The review of the approaches taken indicates that there 
may be a need for a global early warning system in 
order to inform Member States about emerging sub-
stances on the market, notably in their neighbouring 
countries, and help to establish priorities for schedul-
ing decisions.274 
13. It has also become obvious that the traditional system 
of scheduling an ever larger number of substances is a 
time-consuming and expensive exercise, especially as 
the onus of proof lies with the authorities. Several of 
the alternative systems introduced by Member States 
attempt to remedy this situation, and most appear to 
have improved it. This is reflected in falling NPS prev-
alence rates after the introduction of such controls. 
14. The reduction in the use of specific substances due 
to control measures is not necessarily proof of suc-
cess as long as new substances emerge and supply and 
demand shift to such NPS. This risk must be kept in 
274 In fact, in resolution 56/4, adopted by the Commission on Narcotic 
Drugs at its fifty-sixth session, in March 2013, UNODC was urged to 
develop a programme for national forensic and/or drug-testing labo-
ratories to enable timely and comprehensive sharing of information 
on NPS, with a view to providing a global reference point and early 
warning advisory on NPS.
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mind when considering various options to respond to 
the problem of NPS. 
15. The current phase of innovative approaches is help-
ful for the study of the impact of the various control 
measures. At the same time, there should be no doubt 
that in the long run, some form of common approach 
at the international level would be desirable. The ap-
proaches taken by individual Member States to deal 
with NPS appear to have helped them to reduce their 
problem. But this has also contributed to the creation 
of a multitude of separate control regimes, differing 
from region to region, from country to country and 
sometimes even within countries. All of this has left 
many loopholes in the control system at the global 
level, which are regularly being exploited by drug deal-
ers worldwide. 
16. Whether the time has already come to adapt the 
international drug control system in order to better 
incorporate the NPS problematic is not clear, as several 
of the new national approaches have been established 
fairly recently. Thus, serious evaluations of their out-
come are yet to be made. Nonetheless, a process could 
still be started to systematically review, with the help 
of national experts, the outcome of the various systems 
and to study and explore, in more detail, the lessons 
learned, with a view to improving the control system 
at the international level.
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MAPS AND TABLES ON DRUG DEMAND
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Use of cocaine in 2011 (or latest year available)
Source (map 1 and 2): UNODC estimates based on annual report questionnaire data and other official sources.
Note: The boundaries shown on this map do not imply official endorsement or acceptance by the United Nations. Dashed lines represent undetermined 
boundaries. The dotted line represents approximately the Line of Control in Jammu and Kashmir agreed upon by India and Pakistan. The final status of 
Jammu and Kashmir has not yet been agreed upon by the parties. The final boundary between the Sudan and South Sudan has not yet been determined.
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a Includes heroin, opium and 
non-medical use of opioids. 
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Annual prevalence of opiatesa in 2011 (or latest year available)
Source (map 3 and 4): UNODC estimates based on annual report questionnaire data and other official sources
Note: The boundaries shown on this map do not imply official endorsement or acceptance by the United Nations. Dashed lines represent undetermined 
boundaries. The dotted line represents approximately the Line of Control in Jammu and Kashmir agreed upon by India and Pakistan. The final status of 
Jammu and Kashmir has not yet been agreed upon by the parties. The final boundary between the Sudan and South Sudan has not yet been determined.
According to the Government of Canada, data on heroin use based on the household survey is not reportable and the Government of Canada does not 
report an estimate based on indirect methods.
Use of opioidsa in 2011 (or latest year available)
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ANNEX II
MAPS AND TABLES ON DRUG SUPPLY
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Change in seizures
  Decrease
(of more than 10 per cent)
Stable
(decrease of increase of up to 10 per cent)
Increase
(of between 10 per cent and 100 per cent)
Strong increase
(of more than 100 per cent)
No data available
Changes in cannabis herb seizures between the periods 2002-2006 and 2007-2011
Source: UNODC annual report questionnaire data, supplemented by other sources.
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Afghanistan and Morocco
Afghanistan
Morocco
No data available or no annual 
report questionnaire received
Countries reporting Afghanistan and/or Morocco as the main source of cannabis resin seized  
between 2009 and 2011
Source: UNODC, data from the annual report questionnaire and other official sources.
Cannabis trafficking
WORLD DRUG REPORT 2013viii
Most frequently mentioned countries of provenancea for individual drug seizure cases,  
by drug type (all modes of transportation), 2001-2012
Source: United Nations Office on Drugs and Crime, individual drug seizure database.
a Reporting countries are asked to provide information about the country where the drugs were obtained (or, in the case of unaccompanied shipments, the 
departure country). For the purposes of the above table, this is considered as the provenance of the drug. However, countries are also asked to provide infor-
mation on the country of origin, where the drugs were produced or manufactured. In cases in which the country where the drugs were obtained is not spec-
ified, or coincides with the country that made the seizure, the country of origin is taken as the provenance. In order to reflect patterns in transnational 
trafficking, any cases where the provenance coincides with the country making the seizure are excluded. 
Rank Cannabis Cocaine (base, salts and crack) Heroin ATS
1 Morocco Brazil Afghanistan Netherlands
2 Afghanistan Colombia Pakistan Lao People’s Democratic Republic
3 Jamaica Argentina Tajikistan Germany
4 Netherlands Dominican Republic Albania United Kingdom
5 South Africa Venezuela (Bolivarian Republic of) Turkey Myanmar
6 Paraguay Peru Netherlands Cambodia
7 Ghana Jamaica Iran (Islamic Republic of) Iran (Islamic Republic of)
8 Spain Bolivia (Plurinational State of) India Belgium
9 Nepal Costa Rica Thailand China
10 Albania Netherlands Kyrgyzstan United States
11 Algeria Ecuador Belgium Hong Kong, China
12 Mozambique Mexico Bulgaria Malaysia
13 Pakistan Panama Kazakhstan Bulgaria
14 Honduras Nigeria Germany Poland
15 India Ghana Nigeria France
16 Iran (Islamic Republic of) Spain Greece Denmark
17 Kazakhstan Guinea Uzbekistan Czech Republic
18 Haiti Chile Myanmar Canada
19 United States Senegal Spain Syrian Arab Republic
20 France Trinidad and Tobago Hong Kong, China Lithuania
Most frequently mentioned countries of provenancea for individual maritime drug seizure cases, 
2001-2012
Source: United Nations Office on Drugs and Crime, individual drug seizure database.
a Reporting countries are asked to provide information about the country where the drugs were obtained (or, in the case of unaccompanied shipments, the 
departure country). For the purposes of the above table, this is considered as the provenance of the drug. However, countries are also asked to provide infor-
mation on the country of origin, where the drugs were produced or manufactured. In cases in which the country where the drugs were obtained is not spec-
ified, or coincides with the country which made the seizure, the country of origin is taken as the provenance. For that reason, the table includes countries 
that do not have access to the sea. In order to reflect patterns in transnational trafficking, any cases in which the provenance coincides with the country 
making the seizure are excluded. 
Rank Country Main drugs
1 Morocco Cannabis resin
2 Netherlands Cannabis herb, cannabis resin, cocaine, heroin
3 Colombia Cocaine
4 Ecuador Cocaine
5 Iran (Islamic Republic of) Cannabis resin, opium, heroin
6 France Cannabis resin, cannabis herb, cocaine, heroin
7 Afghanistan Heroin, cannabis resin
8 Belgium Cannabis herb, cannabis resin, cocaine, “ecstasy”, heroin
9 Spain Cannabis resin, cocaine
10 Peru Cocaine
11 Venezuela (Bolivarian Republic of) Cocaine
12 Jamaica Cannabis herb, cocaine
13 Pakistan Heroin, cannabis resin
14 Germany Cannabis herb, cannabis resin, cocaine, “ecstasy”
15 Costa Rica Cocaine
16 Brazil Cocaine
17 China Pseudoephedrine, cannabis herb, heroin, methamphetamine
18 Panama Cocaine
19 Bolivia (Plurinational State of) Cocaine
20 Chile Cocaine
Trafficking: most frequently mentioned countries of provenance
Annex II ix
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Plants and sites eradicated for selected countries, in 2011
a Calculated based on reported information on plants and sites eradicated. The reported number of sites might not directly correspond to the number of 
plants reported and there is no common, standardized definition of site or plant: plants may or may not include small plants and/or seedlings, and sites 
might be counted even if they contained no plants or seedlings at the time of dismantlement. 
b Data from 2010, as reported in the annual report questionnaire for 2011.
2011 Outdoor sites Indoor sites
Average number of plants 
per sitea
Country
Plants  
eradicated
Sites  
eradicated
Plants  
eradicated
Sites  
eradicated
Outdoors Indoors
Albania 21,267 89 239
Australia 40,879 56 18,216 223 730 82
Azerbaijan 2,961 51 58
Belgium 2,122 123 330,178 947 17 349
Brazil 1,336,182 60 22,270
Costa Rica 1,489,259 166 146 4 8,971 37
Ecuador 650 6 108
Hungary 621 13,500
Indonesia 1,839,664 40 45,992
Italy 1,005,814 2,522
Jamaica 1,053,000
Kazakhstan 79,470 228 349
Latvia 833 1 375 8 833 47
Netherlands 59 1,819,776 5,435 335
New Zealand 118,259 2,131 21,202 783 55 27
Philippines 3,955,546 129 30,663
Tajikistan 2,113,464
Uganda 20,000 5 4,000
Ukraine 1,540,000 98,000 16
United States of Americab 9,866,766 23,622 462,419 4,721 418 98
Update of information available on cannabis cultivation and production in major producing countries, 
2011
a Information from the cannabis survey conducted by United Nations Office on Drugs and Crime in Afghanistan in 2011.
b Source: United States, Department of State, Bureau for International Narcotics and Law Enforcement Affairs, International Narcotics Control Strategy 
Report, vol. 1, Drug and Chemical Control (March 2013). The Government of Mexico does not validate the estimates provided by the United States, as they 
are not part of its official figures and it does not have information on the methodology used to calculate them. The Government of Mexico has started 
implementing a monitoring system in collaboration with UNODC to estimate illicit cultivation and production, for which the first results are expected in 
2013.
c Refers to kif.
Production (tons)
Country
Area under cultivation 
(hectares)
Area eradicated 
(hectares)
Area under cultivation after 
eradication (hectares)
Cannabis 
herb
Cannabis 
resin
Afghanistana 12,000 .. .. 1,300
India .. 1,112 .. .. ..
Indonesia .. 306 .. .. ..
Jamaica .. 373 .. .. ..
Mexico 12,000b 13,430 .. 17,915 ..
Morocco .. 8,000 47,500 38,000c 760
Nigeria 918.0 918 .. .. ..
Ukraine .. 281 .. .. ..
Cannabis cultivation, production and eradication
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Net cultivation of opium poppy in selected countries, 1998-2012 (Hectares)
Source: For Afghanistan: 1998-2002: UNODC; 2003-2012: National Illicit Crop Monitoring System supported by UNODC. For Pakistan: 
annual report questionnaire, Government of Pakistan, United States Department of State. For the Lao People’s Democratic Republic: 
1998-1999: UNODC; 2000-2012: National Illicit Crop Monitoring System supported by UNODC. For Myanmar: 1998-2000: United States 
Department of State; 2001-2012: National Illicit Crop Monitoring System supported by UNODC. For Colombia: 1998-1999: various 
sources; From 2000: National Illicit Crop Monitoring System supported by UNODC. For 2008-2012, production was calculated based on 
regional yield figures and conversion ratios from the United States Department of State/DEA. For Mexico: estimates derived from United 
States Government surveys.
Note: Figures in italics are preliminary and may be revised when updated information becomes available. Information on estimation methodologies and defi-
nitions can be found in the methodology section of the online version of the present report.  
a May include areas that were eradicated after the date of the area survey.
b Owing to continuing low cultivation, figures for Viet Nam (as of 2000) and Thailand (as of 2003) were included in the category “Other countries”.
c The Government of Mexico does not validate the estimates provided by the United States, as they are not part of its official figures and it does not have 
information on the methodology used to calculate them. The Government of Mexico is in the process of implementing a monitoring system in collaboration 
with UNODC to estimate illicit cultivation and production.
d Eradication and plant seizure reports from different sources indicate that illicit opium poppy cultivation also exists in the following subregions: North Africa, 
Central Asia and Transcaucasia, Near and Middle East/South-West Asia, South Asia, East and South-East Asia, Eastern Europe, South-Eastern Europe, Central 
America and South America. Starting in 2008, a new methodology was introduced to estimate opium poppy cultivation and opium/heroin production in 
those countries. The estimates are higher than the previous figures but have a similar order of magnitude. A detailed description of the estimation methodol-
ogy is available in the online version of the present report.
1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012
SOUTH-WEST ASIA
 Afghanistan 63,674  90,583 82,171 7,606 74,100 80,000 131,000 104,000 165,000 193,000 157,000 123,000 123,000 131,000 154,000
 Pakistan 950 284 260 213 622 2,500 1,500 2,438 1,545 1,701 1,909 1,779 1,721 362 382
 Subtotal 64,624 90,867 82,431 7,819 74,722 82,500 132,500 106,438 166,545 194,701 158,909 124,779 124,721 131,362 154,382
SOUTH-EAST ASIA
 Lao People's 
Democratic 
Republic a
26,837 22,543 19,052 17,255 14,000 12,000 6,600 1,800 2,500 1,500 1,600 1,900 3,000 4,100 6,800
 Myanmar a 130,300 89,500 108,700 105,000 81,400 62,200 44,200 32,800 21,500 27,700 28,500 31,700 38,100 43,600 51,000
 Thailand b 716 702 890 820 750
 Viet Nam b 442 442
 Subtotal 158,295 113,187 128,642 123,075 96,150 74,200 50,800 34,600 24,000 29,200 30,100 33,600 41,100 47,700 57,800
LATIN AMERICA
 Colombia 7,350 6,500 6,500 4,300 4,153 4,026 3,950 1,950 1,023 715 394 356 341 338
 Mexico c 5,500 3,600 1,900 4,400 2,700 4,800 3,500 3,300 5,000 6,900 15,000 19,500 14,000 12,000
 Subtotal 12,850 10,100 8,400 8,700 6,853 8,826 7,450 5,250 6,023 7,615 15,394 19,856 14,341 12,338 12,338
OTHER
 Other  
countries d
2,050 2,050 2,479 2,500 2,500 3,074 5,190 5,212 4,432 4,184 8,600 7,700 10,500 16,100 11,800
TOTAL 237,819 216,204 221,952 142,094 180,225 168,600 195,940 151,500 201,000 235,700 213,003 185,935 190,662 207,500 236,320
Global potential production of opium and manufacture of heroin of unknown purity, 2004-2012 (Tons)
Note: The proportion of potential opium production not converted into heroin could be estimated only for Afghanistan. For the purpose of this table, for all 
other countries it is assumed that all opium potentially produced is converted into heroin. If total potential opium production in Afghanistan in 2012 were 
converted into heroin, total potential heroin production would be 529 tons (Afghanistan) and 576 tons (global).
Figures in italics are preliminary and may be revised when updated information becomes available.
2004 2005 2006 2007 2008 2009 2010 2011 2012
Total potential opium production  4,850  4,620  5,810  8,091  6,841  4,953  4,730  6,983  4,905 
Potential opium not processed into heroin  1,197  1,169  1,786  3,078  2,360  1,680  1,728  3,400  1,850 
Potential opium processed into heroin  3,653  3,451  4,024  5,012  4,481  3,273  3,002  3,583  3,055 
Total potential heroin manufacture  529  472  553  686  600  427  383  476  311 
Opium/heroin cultivation, production and eradication
WORLD DRUG REPORT 2013xii
Potential production of oven-dry opium in selected countries, 1998-2012 (Tons)
Source: For Afghanistan: 1998-2002: UNODC; 2003-2012: National Illicit Crop Monitoring System supported by UNODC. For Pakistan: 
annual report questionnaire, Government of Pakistan, United States Department of State. For the Lao People’s Democratic Republic: 
1998-1999: UNODC; 2000-2012: National Illicit Crop Monitoring System supported by UNODC. For Myanmar: 1998-2000: United States 
Department of State; 2001-2012: National Illicit Crop Monitoring System supported by UNODC. For Colombia: 1998-1999: various 
sources; From 2000: National Illicit Crop Monitoring System supported by UNODC. For 2008-2012, production was calculated based on 
regional yield figures and conversion ratios from the United States Department of State/DEA. For Mexico: estimates derived from United 
States Government surveys.
Note: Figures in italics are preliminary and may be revised when updated information becomes available. Information on estimation methodologies and defi-
nitions can be found in the methodology section of the online version of the present report. The opium production estimates for Afghanistan for 2006-2009 
were revised after data quality checks revealed an overestimation of opium yield estimates in those years. 
a Owing to continuing low cultivation, figures for Viet Nam (as of 2000) and Thailand (as of 2003) were included in the category “Other countries”.
b The Government of Mexico does not validate the estimates provided by the United States, as they are not part of its official figures and it does not have 
information on the methodology used to calculate them. The Government of Mexico is in the process of implementing a monitoring system in collaboration 
with UNODC to estimate illicit cultivation and production.
c Eradication and plant seizure reports from different sources indicate that illicit opium poppy cultivation also exists in the following subregions: North Africa, 
Central Asia and Transcaucasia, Near and Middle East/South-West Asia, South Asia, East and South-East Asia, Eastern Europe, South-Eastern Europe, Central 
America and South America. Starting in 2008, a new methodology was introduced to estimate opium poppy cultivation and opium/heroin production in 
those countries. The estimates are higher than the previous figures but have a similar order of magnitude. A detailed description of the estimation methodol-
ogy is available in the online version of the present report.
1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012
SOUTH-WEST ASIA
  Afghanistan 2,693 4,565 3,276  185 3,400 3,600 4,200 4,100 5,300 7,400 5,900 4,000 3,600 5,800 3,700 
  Pakistan  26  9  8  5  5  52 40 36 39 43 48 44 43  9  9 
  Subtotal 2,719 4,574 3,284 190 3,405 3,652 4,240 4,136 5,339 7,443 5,948 4,044 3,643 5,809 3,709
SOUTH-EAST ASIA
  Lao People's  
Democratic  
Republic
 124  124  167  134  112  120 43 14 20 9 10 11 18  25 41
  Myanmar 1,303  895 1,087 1,097  828  810 370 312 315 460 410 330 580  610 690
  Thailand a  8  8  6  6  9 
  Viet Nam a  2  2 
  Subtotal 1,437 1,029 1,260 1,237  949 930 413 326 335 469 420 341 598 635 731
LATIN AMERICA
  Colombia  100  88  88  80  52  50  49 24 13 14 10 9 8  8 
  Mexico b  60  43  21  91  58  101  73 71 108 150 325 425 300 250
  Subtotal  160  131  109  171  110 151 122 95 121 164 335 434 308 258  258 
OTHER
  Other  
countries c  30  30  38 32 56  50 75 63 16 15 139 134 181  281  207 
TOTAL 4,346 5,764 4,691 1,630 4,520 4,783 4,850 4,620 5,810 8,091 6,841 4,953 4,730 6,983 4,905
Annex II xiii
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Reported opium poppy eradication in selected countries, 2003 to 2012 (Hectares)
Source: United Nations Office on Drugs and Crime; data from the annual report questionnaire; Government reports; reports of regional 
bodies; United States, Department of State, Bureau for International Narcotics and Law Enforcement Affairs, International Narcotics Con-
trol Strategy Report, vol. 1, Drug and Chemical Control (March 2013). 
Note: Table covers only eradication reported in area units. Information on eradication reported as plant seizures can be found in the annex on seizures in the 
electronic version of the World Drug Report.
a Although eradication took place in 2004, it was not officially reported to UNODC.
 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012
Afghanistan 21,430 a 5,103 15,300 19,047 5,480 5,351 2,316 3,810 9,672
Bangladesh 8 22
Colombia 3,266 3,866 2,121 1,929 375 381 546 711 299 309
Egypt 34 65 45 50 98 121 89 222 1
Guatemala 489 720 449 536 1,345 918 1,490
India 494 167 12 247 8,000 624 2,420 3,052 5,746
Lao People’s  
Democratic Republic
4,134 3,556 2,575 1,518 779 575 651 579 662 707
Lebanon 4 67 27 8 21 4
Mexico 20,034 15,926 21,609 16,890 11,046 13,095 14,753 15,491 16,389
Myanmar 638 2,820 3,907 3,970 3,598 4,820 4,087 8,268 7,058 23,718
Nepal 19 4 1 21 35
Pakistan 4,185 5,200 391 354 614 0 105 68 1,053 592
Peru 57 98 92 88 28 23 32 21
Thailand 767 122 110 153 220 285 201 278 208 205
Ukraine 28 436
Venezuela  
(Bolivarian Republic of)
0 87 154 0 0 0
Viet Nam 100 32 38 99 31 38
Global illicit cultivation of coca bush, 2002-2011 (Hectares)
Source: For Bolivia (Plurinational State of), 2002: CICAD and United States Department of State, International Narcotics Control Strategy 
Report; since 2003: national illicit crop monitoring system supported by UNODC. For Colombia and Peru: national illicit crop monitoring 
system supported by UNODC.
Note: An account of the different concepts for different areas and their effect on comparability was presented in the World Drug Report 2012 (pp. 41 and 
42). In the continuing efforts to improve comparability of estimates between countries, for the first time the estimated net area under coca bush cultivation 
at the reference date of 31 December is presented for Peru in addition to the area under coca bush cultivation in Peru as seen on satellite imagery. The refer-
ence date of 31 December is also used for the estimated area under coca bush cultivation in Colombia. The estimates presented for the Plurinational State of 
Bolivia represent the area under coca bush cultivation as seen on satellite imagery. 
a Net area on 31 December. Estimates from 2009 were adjusted for small fields, while estimates for previous years did not require that adjustment. 
b Net area on 31 December. 
c Area interpreted from satellite imagery. 
d To maintain global comparability with past years, the global coca cultivation figure was calculated with the area interpreted from satellite imagery for Peru.
 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
Bolivia (Plurinational 
State of) 21,600 23,600 27,700 25,400 27,500 28,900 30,500 30,900 31,000 27,200
Colombia a 102,000 86,000 80,000 86,000 78,000 99,000 81,000 73,000 62,000 64,000
Peru b 62,500
Peru c 46,700 44,200 50,300 48,200 51,400 53,700 56,100 59,900 61,200 64,400
Total 170,300 153,800 158,000 159,600 156,900 181,600 167,600 163,800 154,200 155,600 d
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Potential production of sun-dried coca leaf in Bolivia (Plurinational State of) and Peru, 2005-2010 
(Tons)
Source: For Bolivia (Plurinational State of): potential production of sun-dried coca leaf available for cocaine manufacture is estimated by 
the national illicit crop monitoring system supported by UNODC. Source of estimates for leaf yield is UNODC for Yungas of La Paz and 
United States DEA for Chapare. The estimated amount of coca leaf produced on 12,000 ha in the Yungas of La Paz, where coca bush 
cultivation is authorized under national law, was deducted (range: upper and lower bounds of the 95 per cent confidence interval of the 
estimated coca leaf yield). For Peru: potential production of sun-dried coca leaf available for cocaine manufacture is estimated by the 
national illicit crop monitoring system supported by UNODC. A total of 9,000 tons of sun-dried coca leaves was deducted, which is the 
amount used for traditional purposes according to Government sources (range: upper and lower bounds of the 95 per cent confidence 
interval of the estimated coca leaf yield). To maintain comparability with past years, coca leaf production was calculated with the area 
interpreted from satellite imagery. 
Note: The ranges reflect the uncertainty associated with the estimates. For Bolivia (Plurinational State of) and Peru, the ranges are based on confidence inter-
vals and the best estimate is the mid-point between the upper and lower bounds of the range.
 2005 2006 2007 2008 2009 2010 2011
Bolivia (Plurinational 
State of) 28,200 33,200 36,400 39,400 40,100 40,900 33,500
Range 34,200-38,300 37,300-41,800 37,900-42,300  38,600-43,100  31,900-35,400 
Peru 97,000 105,100 107,800 113,300 118,000 120,500 126,100 
Range 85,400-108,600
91,000-
119,200
93,200-
122,000
97,600-
127,800
102,400-
134,200
103,000-
136,300
110,300-
142,100
Potential production of fresh coca leaf and coca leaf in oven-dried equivalent in Colombia, 2005-2011 
(Tons)
Source: National illicit crop monitoring system supported by UNODC. Due to the introduction of an adjustment factor for small fields, 
estimates for 2010 and 2011 are not directly comparable with previous years.
Note: The ranges reflect the uncertainty associated with the estimates. The range represents the two approaches taken to calculate the productive area, with 
the lower bound being closer to the estimation used in previous years. The methodology to calculate uncertainty ranges for production estimates is still 
under development and figures may be revised when more information becomes available.
2005 2006 2007 2008 2009 2010 2011
FRESH COCA LEAF
Colombia 555,400 528,300 525,300 389,600 343,600 305,300 263,800
Range 305,300-349,600
COCA LEAF IN OVEN-DRIED EQUIVALENT
Colombia 164,280 154,130 154,000 116,900 103,100 91,600 79,100
Range 91,600-104,880
Potential manufacture of cocaine with a purity of 100 per cent in Bolivia (Plurinational State of),  
Colombia and Peru, 2005-2011 (Tons)
Source: For Bolivia (Plurinational State of): Government calculations based on UNODC (Yungas of La Paz) and United States DEA scientific 
study (Chapare) coca leaf yield surveys. For Colombia: national illicit crop monitoring system supported by UNODC and DEA scientific 
studies. Due to the introduction of an adjustment factor for small fields, estimates for 2010 and 2011 are not directly comparable with 
previous years. For Peru: Government calculations based on coca leaf to cocaine conversion ratio from DEA scientific studies. Detailed 
information on the ongoing revision of conversion ratios and cocaine laboratory efficiency is available in the World Drug Report 2010, p. 
249-252.
Note: Due to the ongoing review of conversion factors, it has not been possible to provide a point estimate of the level of cocaine production since 2009. 
Because of the uncertainty surrounding the level of total potential cocaine production and concerning the comparability of the estimates between countries, 
the figures have been estimated as ranges (842-1,111 tons in 2009, 788-1,060 tons in 2010 and 776-1,051 tons in 2011). Figures in italics are under review. 
Information on estimation methodologies and definitions can be found in the section on methodology of the present report.
 2005 2006 2007 2008 2009 2010 2011
Bolivia (Plurinational State of) 80 94 104 113
Colombia 680 660 630 450 410 350 345
Range      350-400  
Peru 260 280 290 302
Total 1,020 1,034 1,024 865 
W
O
R
L
D
 D
R
U
G
 R
E
P
O
R
T
 2
01
3
xv
ANNEX III
Regional groupings
This report uses a number of regional and subregional 
designations. These are not official designations. They are 
defined as follows:
 s East Africa: Burundi, Comoros, Djibouti, Eritrea, 
Ethiopia, Kenya, Madagascar, Mauritius, Rwanda, 
Seychelles, Somalia, Uganda and United Republic of 
Tanzania. 
 s North Africa: Algeria, Egypt, Libya, Morocco, South 
Sudan, Sudan and Tunisia.
 s Southern Africa: Angola, Botswana, Lesotho, Malawi, 
Mozambique, Namibia, South Africa, Swaziland,  
Zambia and Zimbabwe.
 s West and Central Africa: Angola, Benin, Burkina Faso, 
Cameroon, Cape Verde, Central African Republic, 
Chad, Congo, Côte d’Ivoire, Democratic Republic of 
the Congo, Equatorial Guinea, Gabon, Gambia, Gha-
na, Guinea, Guinea-Bissau, Liberia, Mali, Mauritania, 
Niger, Nigeria, Sao Tome and Principe, Senegal, Sierra 
Leone and Togo. 
 s Caribbean: Antigua and Barbuda, Bahamas, Barbados, 
Bermuda, Cuba, Dominica, Dominican Republic, 
Grenada, Haiti, Jamaica, Saint Kitts and Nevis, Saint 
Lucia, Saint Vincent and the Grenadines and Trinidad 
and Tobago.
 s Central America: Belize, Costa Rica, El Salvador,  
Guatemala, Honduras, Nicaragua and Panama.
 s North America: Canada, Mexico and United States of 
America. 
 s South America: Argentina, Bolivia (Plurinational  
State of ), Brazil, Chile, Colombia, Ecuador, Guyana, 
Paraguay, Peru, Suriname, Uruguay and Venezuela  
(Bolivarian Republic of ).
 s Central Asia and Transcaucasia: Armenia, Azerbaijan, 
Georgia, Kazakhstan, Kyrgyzstan, Tajikistan, Turkmen-
istan and Uzbekistan.
 s East and South-East Asia: Brunei Darussalam, Cam-
bodia, China, Democratic People’s Republic of Korea, 
Indonesia, Japan, Lao People’s Democratic Republic, 
Malaysia, Mongolia, Myanmar, Philippines, Republic 
of Korea, Singapore, Thailand, Timor-Leste and Viet 
Nam. 
 s Near and Middle East/South-West Asia: Afghanistan, 
Bahrain, Iran (Islamic Republic of ), Iraq, Israel, Jor-
dan, Kuwait, Lebanon, Oman, Pakistan, Qatar, Saudi 
Arabia, Syrian Arab Republic, United Arab Emirates 
and Yemen. The Near and Middle East refers to a sub-
region that includes Bahrain, Israel, Jordan, Kuwait, 
Lebanon, Oman, Qatar, Saudi Arabia, the Syrian Arab 
Republic, the United Arab Emirates and Yemen.
 s South Asia: Bangladesh, Bhutan, India, Maldives,  
Nepal and Sri Lanka. 
 s Eastern Europe: Belarus, Republic of Moldova,  
Russian Federation and Ukraine.
 s South-Eastern Europe: Albania, Bosnia and Herzego-
vina, Bulgaria, Croatia, Montenegro, Romania,  
Serbia, the former Yugoslav Republic of Macedonia 
and Turkey.
 s Western and Central Europe: Andorra, Austria,  
Belgium, Cyprus, Czech Republic, Denmark, Estonia, 
Finland, France, Germany, Greece, Hungary, Iceland, 
Ireland, Italy, Latvia, Liechtenstein, Lithuania, Luxem-
bourg, Malta, Monaco, Netherlands, Norway, Poland, 
Portugal, San Marino, Slovakia, Slovenia, Spain,  
Sweden, Switzerland and United Kingdom of Great 
Britain and Northern Ireland.
 s Oceania: Australia, Fiji, Kiribati, Marshall Islands,  
Micronesia (Federated States of ), Nauru, New Zealand, 
Palau, Papua New Guinea, Samoa, Solomon Islands, 
Tonga, Tuvalu, Vanuatu and small island territories.
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GLOSSARY
amphetamine-type stimulants — a group of substances com-
prised of synthetic stimulants from the group of substances 
called amphetamines, which includes amphetamine, meth-
amphetamine, methcathinone and the “ecstasy”-group 
substances (methylenedioxymethamphetamine (MDMA) 
and its analogues) 
annual prevalence — the total number of people of a given 
age range who have used a given drug at least once in the 
past year divided by the number of people of a given age 
range
coca paste (or coca base) — an extract of the leaves of the 
coca bush. Purification of coca paste yields cocaine (base 
and hydrochloride) 
cocaine (base and salts) — coca paste, cocaine base and 
cocaine hydrochloride referred to in the aggregate
crack cocaine — cocaine base obtained from cocaine hydro-
chloride through conversion processes to make it suitable 
for smoking
new psychoactive substances — substances of abuse, either 
in a pure form or a preparation, that are not controlled by 
the Single Convention on Narcotic Drugs of 1961 or the 
Convention on Psychotropic Substances of 1971 but that 
may pose a public health threat. In this context, the term 
“new” does not necessarily refer to newly invented sub-
stances but rather to substances that have recently become 
available
opiates — a subset of opioids comprised of the various 
products derived from the opium poppy plant, including 
opium, morphine and heroin
opioids — a generic term applied to alkaloids from opium 
poppy, their synthetic analogues, and compounds synthe-
sized in the body 
poppy straw — all parts (except the seeds) of the opium 
poppy, after mowing
problem drug users — people who engage in the high-risk 
consumption of drugs, for example people who inject 
drugs, people who use drugs on a daily basis and/or people 
diagnosed as drug-dependent based on clinical criteria con-
tained in the International Classification of Diseases (tenth 
revision) of the World Health Organization and the Diag-
nostic and Statistical Manual of Mental Disorders (fourth 
edition) of the American Psychiatric Association, or any 
similar criteria or definition that may be used
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